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Résumé 
 Afin d’adresser la variabilité interindividuelle observée dans la réponse 
pharmacocinétique à de nombreux médicaments, nous avons créé un panel de génotypage 
personnalisée en utilisant des méthodes de conception et d’élaboration d’essais uniques. Celles-ci 
ont pour but  premier de capturer les variations génétiques présentent dans les gènes clés 
impliqués dans les processus d'absorption, de distribution, de métabolisme et d’excrétion 
(ADME) de nombreux agents thérapeutiques. Bien que ces gènes et voies de signalement sont 
impliqués dans plusieurs mécanismes pharmacocinétiques qui sont bien connues, il y a eu 
jusqu’à présent peu d'efforts envers l’évaluation simultanée d’un grand nombre de ces gènes 
moyennant un seul outil expérimental. La recherche pharmacogénomique peut être réalisée en 
utilisant deux approches: 1) les marqueurs fonctionnels peuvent être utilisés pour présélectionner 
ou stratifier les populations de patients en se basant sur des états métaboliques connus; 2) les 
marqueurs Tag peuvent être utilisés pour découvrir de nouvelles corrélations génotype-
phénotype. Présentement, il existe un besoin pour un outil de recherche qui englobe un grand 
nombre de gènes ADME et variantes et dont le contenu est applicable à ces deux modèles 
d'étude. Dans le cadre de cette thèse, nous avons développé un panel d’essais de génotypage de 
3,000 marqueurs génétiques ADME qui peuvent satisfaire ce besoin. Dans le cadre de ce projet, 
les gènes et marqueurs associés avec la famille ADME ont été sélectionnés en collaboration avec 
plusieurs groupes du milieu universitaire et de l'industrie pharmaceutique. Pendant trois phases 
de développement de cet essai de génotypage, le taux de conversion pour 3,000 marqueurs a été 
amélioré de 83% à 97,4% grâce à l'incorporation de nouvelles stratégies ayant pour but de 
surmonter les zones d'interférence génomiques comprenant entre autres les régions homologues 
et les polymorphismes sous-jacent les régions d’intérêt. La précision du panel de génotypage a 
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été validée par l’évaluation de plus de 200 échantillons pour lesquelles les génotypes sont connus 
pour lesquels nous avons obtenu une concordance > 98%. De plus, une comparaison croisée 
entre nos données provenant de cet essai et des données obtenues par différentes plateformes 
technologiques déjà disponibles sur le marché a révélé une concordance globale de > 99,5%. 
L'efficacité de notre stratégie de conception ont été démontrées par l'utilisation réussie de cet 
essai dans le cadre de plusieurs projets de recherche où plus de 1,000 échantillons ont été testés. 
Nous avons entre autre évalué avec succès 150 échantillons hépatiques qui ont été largement 
caractérisés pour plusieurs phénotypes. Dans ces échantillons, nous avons pu valider 13 gènes 
ADME avec cis-eQTL  précédemment rapportés et de découvrir et de 13 autres gènes ADME 
avec cis eQTLs qui n'avaient pas été observés en utilisant des méthodes standard. Enfin, à l'appui 
de ce travail, un outil logiciel a été développé, Opitimus Primer, pour aider pour aider au 
développement du test. Le logiciel a également été utilisé pour aider à l'enrichissement de cibles 
génomiques pour d'expériences séquençage. Le contenu ainsi que la conception, l’optimisation et 
la validation de notre panel le distingue largement de l’ensemble des essais commerciaux 
couramment disponibles sur le marché qui comprennent soit des marqueurs fonctionnels pour 
seulement un petit nombre de gènes, ou alors n’offre pas une couverture adéquate pour les gènes 
connus d’ADME. Nous pouvons ainsi conclure que l’essai que nous avons développé est et 
continuera certainement d’être un outil d’une grande utilité pour les futures études et essais 
cliniques dans le domaine de la pharmacocinétique, qui bénéficieraient de l'évaluation d'une 
longue liste complète de gènes d’ADME. 
Mots-clés : La pharmacogénomique, la pharmacocinétique, ADME, le génotypage, le 
développement technologique 
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Abstract 
 In order to better assess the inter-individual variability observed in a patient’s 
pharmacokinetic response to many medications, we have created a custom genotyping panel that 
uses unique assay designs to analyze variation present in key genes involved in the absorption, 
distribution, metabolism and excretion (ADME) of many therapeutic agents. These genes and 
pathways involved in most pharmacokinetic mechanisms are well known. However, as yet, there 
has been little effort to develop tools that can interrogate a large number of variations in most 
known drug metabolizing genes simultaneously within a single experimental tool. 
Pharmacogenomic research has historically been conducted using two approaches:  targeted 
studies that screen a small number of specific functional markers to identify known metabolic 
status phenotypes, and genome-wide studies that identify novel genetic correlations with drug 
response phenotypes. Thus, a gap currently exists for a targeted ADME research tool that can 
evaluate a large number of key ADME genes and variants in a format that can be applicable to 
both types of study designs. As part of this thesis, we have developed a 3000 SNP broad based 
ADME genotyping panel that can address this need. 
 Genes and markers for the genotyping panel were selected in collaboration with many 
groups from both academia and the pharmaceutical industry in an effort to capture all pertinent 
genes and metabolic pathways that have been implicated in drug metabolism. The final assay 
design was composed of over 3000 markers in 181 genes. Over three phases of iterative 
development, the assay conversion rate for the 3000 markers was improved from 83.0% to 
97.4% through the incorporation of novel design strategies to overcome areas of genomic 
interference such as regions of homology and underlying polymorphisms. Accuracy of the assay 
was validated by screening more than 200 samples of known genotype with a concordance of 
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99%. Additionally, data from the assay has also been compared to data from different 
technological platforms and has an overall concordance of 99.5%. The effectiveness of the 
design strategy was demonstrated in the successful utilization of the assay in the screening of 
over 1000 samples which identified several novel pharmacogenetic associations between ADME 
variations and adverse drug reactions in children. Another goal of this thesis was to demonstrate 
what added benefit/utility the 3000 SNP ADME panel would have when compared to currently 
available genotyping assays. Using 150 extensively investigated liver samples, the broad based 
assay was not only able to detect and validate 13 previously reported cis eQTLs in ADME genes  
but further identified an additional 13 novel ADME cis eQTLs that had never been observed 
before, doubling the number previously identified using standard methods on the same samples. 
Finally, in support of this work, a number of bioinformatic tools had to be developed to help 
expedite this research. These tools have been further refined and are currently being used to 
assist with enrichment of genomic targets for next generation sequencing experiments.  
 In conclusion, this work has led to a better understanding of ADME genetics and the 
nuances of assaying ADME genes. The content and designs of the developed assay sets it apart 
from currently available commercial assays that contain only functional markers in a small 
number of genes or do not have adequate coverage across ADME genes. The assay has the 
ability to play a significant role in pharmacogenomic studies to identify known and novel 
pharmacogenomic biomarkers. These will lead to improved biomarkers that will help better 
stratify pharmaceutical clinical trial populations or assist physicians to select better, more 
personalized, efficacious and safer therapies for their patients.  
Keywords : Pharmacogenomics, pharmacokinetics, ADME, genotyping, technology 
development 
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1 Introduction 
 The work presented in this thesis details the development, optimization, validation and 
utilization of a pharmacogenomic drug metabolism genotyping panel and its application in 
research and clinical settings to identify pharmacogenomic biomarkers for many different classes 
of therapeutic agents. Specifically, this thesis will outline the development of a broad based drug 
metabolism genotyping panel that has extensive applicability in the realm of pharmaceutical drug 
development and personalized medicine. This tool can be used for basic research, for 
investigating variability in drug response phenotypes, as well as for screening patients in clinical 
trials during the drug development process. The Introduction summarizes the rationale for the 
project and delineates the primary objectives of the work.  Additional sections of the 
Introduction have been devoted to providing relevant background information in the areas of 
pharmacology, genetics and genomic technology that are pertinent to the project.   
 
1.1  Project Rationale 
 There is a current paradox in drug development. Drugs are developed in populations but 
are used to treat individuals. The large population-based clinical trials targeted to address public 
health concerns used by pharmaceutical companies are designed to assess the efficacy and safety 
of drugs in the greater public but do not presently take into account individual patient variability 
that can have drastic effects on dosing, efficacy and adverse reactions. This variability is the 
result of different environment influences (age, sex, weight, disease status, environmental 
exposures, other concomitant medications, etc.) but is also notably influenced by genetic 
variability. By incorporating genetics into the drug development pipeline, information about 
individual patient variability becomes part of the equation and leads to a greater understanding of 
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the observed variability in response and efficacy that is seen for different pharmaceutical 
therapies
1
. Additionally, our improved understanding of genetic variability in ADME genes has 
the potential to improve the use of many drugs already on the market. Presently, genetic 
variation has already been used to improve dosing regimens for drugs such as warfarin and as 
guidance for the optimal use of drugs such as clopidogrel
2,3
.  
 There are two areas of pharmacology where genetics play a role in drug response, 
pharmacodynamics (PD) and pharmacokinetics (PK). PD involves the interaction of the drug 
with its target(s) and is directly responsible for the dose dependent pharmacologic response to 
the drug
4
. PK, determines the amount of the active drug that is available to interact with its target 
and for how long
5
. While the mechanisms of action (PD) of various drugs may differ, most drugs 
are metabolized by the products of a well-known, finite set of genes and pathways that influence 
their PK responses. Pharmacokinetic processes can be classified into four categories: Absorption, 
Distribution, Metabolism and Excretion (ADME). A genetic study involving a particular drug is 
not complete unless both PK and PD pathways are investigated; however an investigation of 
common ADME genetic pathways would be useful across many different studies or clinical trials 
involving any medication, while PD pathways are only specific to and useful for a given drug or 
treatment class.  
 In this thesis I will describe the development and validation of an ADME genotyping 
assay, including the selection of ADME content, and the testing of samples in research and 
clinical trials. Furthermore, I will also demonstrate the utility of the assay, and the added benefit 
it has over commercially available technologies in pharmacogenomic research. Finally, I will 
describe how the tools developed over the course of this project will have ongoing utility even as 
genomic technologies continue to evolve.  
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1.2  Objectives 
The objectives of this project have been organized in four parts as outlined below: 
1) ADME content selection 
a) Select genes with demonstrated involvement in drug metabolism 
b) Select markers with known and putative functional implications 
c) Standardize the description of ADME content. 
d) Select markers for maximum coverage of each gene up to space limitations of technology 
2) Assay Development 
a) Select technology platform with greatest promise for success 
b) Understand nuances and limitations of technology 
c) Identify areas of genomic interference that reduce assay functionality 
d) Develop and design technological strategies to overcome limitations in technology and 
areas genomic interference 
e)  Test and optimize design strategies 
3) Assay Validation 
a) Test samples of known genotype to validate accuracy 
b) Test samples across additional technology platforms to validate technology 
4) Assay Utilization 
a) Apply assay to research projects to demonstrate usefulness 
b) Demonstrate added value of assay compared to commercially available assays. 
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1.3 Pharmacokinetics 
 In order to make our drug metabolism genotyping assay as broadly applicable across as 
many therapeutic areas of medicine as possible, a thorough understanding of the 
pharmacokinetic pathways that are shared by many drugs was needed. By evaluating and better 
understanding these biochemical pathways, it is possible to hypothesize how genetic variation 
may disrupt the normal processes and lead to variation in the amount of active drug that reaches 
its site of action and therefore provide for the possibility to better predict what effects this 
variation might have on a patient’s drug response. Below is a detailed overview of 
biotransformation pathways and the member enzymes that can influence drug response. The 
genes that encode these enzymes will comprise the majority of the content for the drug 
metabolism genotyping panel. 
 Pharmacokinetics (PK) refers to the biological processes that act upon drugs in the body. 
It involves Absorption, Distribution, Metabolism and Excretion (ADME).  These processes are 
responsible for the length of time between administration and response, and for the duration and 
magnitude of this response. PK is dynamic, since the ADME processes all occur simultaneously 
on a given drug compound, and thus rates change over time. Several parameters can be measured 
and calculated to understand the PK of a given drug in a patient at a given time. Table 1 lists the 
common parameters that are used to characterize the PK of medical compounds. 
Table 1: Common Pharmacokinetic Parameters 
Category Parameter Formula 
Absorption 
Absorption rate 
constant 
Rate of drug absorption ÷ Amount of drug remaining to be 
absorbed 
 
Bioavailability Amount of drug absorbed ÷ Drug dose 
Distribution 
Apparent volume 
of distribution 
Amount of drug in body ÷ Plasma drug concentration 
 
Unbound fraction 
Plasma concentration of unbound drug ÷ Plasma drug 
concentration 
5 
 
 
Elimination Rate of elimination Renal excretion + Extrarenal (usually metabolic) elimination 
 
Clearance Rate of drug elimination ÷ Plasma drug concentration 
 
Renal clearance Rate of renal excretion of drug ÷ Plasma drug concentration 
 
Metabolic 
clearance 
Rate of drug metabolism ÷ Plasma drug concentration 
 
Fraction excreted 
unchanged 
Rate of renal excretion of drug ÷ Rate of drug elimination 
 
Elimination rate 
constant 
Rate of drug elimination ÷ Amount of drug in body 
 
 
Clearance ÷ Volume of distribution 
 
Biologic half-life 0.693 ÷ Elimination rate constant 
Source:  Kopacek, K.B.(2007)
5
 
 The PK of a drug depends on a patient’s phenotypic characteristics (such as age, weight 
and disease status) as well as the chemical properties of the drug (such as half-life and 
solubility). Variability in any of these factors can have profound effects on drug response. Many 
of these characteristics are well understood and are taken into account when determining the 
dose, dosing schedule and route of administration for a given medication; however, they are not 
sufficient to predict or explain a patient’s personal drug response or toxicity. 
1.3.1 Absorption 
 Absorption is the process by which the unchanged drug passes from the site of 
administration to the systemic blood circulation
6
. Absorption can be best characterized by the 
bioavailability parameter, which is the percent of administered dose that reaches the circulation 
without being modified
7
. There are several obstacles that can lower the bioavailabiliy of a drug. 
The administered drug must: be in the correct form (solid dosage forms must be dissolved), resist 
degradation, cross the physical barriers that separate the bloodstream from the site of 
administration, and for an orally delivered drug, it must resist the first-pass effect where drugs 
can be metabolized or cleared by the liver once they have entered the portal vein from the GI 
tract
7
. Drugs that are administered directly into the blood stream, intravenously, have a 
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bioavailability of nearly 100% and do not need to cross biological membranes versus those that 
are administered by other means, such as: orally, intramuscularly, transdermally, inhaled, 
sublingually, or subcutaneously that will have to pass through membrane barriers. Molecules 
may cross these membranes by three mechanisms: passive diffusion, facilitated transport, and 
endocytosis; the last of which plays little to no role in drug absorption
7
.  
 Membrane permeability is a major determinant of how well a drug is absorbed. 
Biological membranes are fluid structures composed of phospholipids and proteins in varying 
proportions
8
. The degree of fluidity, and therefore permeability, depends on the type of 
phospholipids. Short chained unsaturated phospholipids are found in fluid membranes while long 
chained saturated phospholipids are found in rigid membranes
8
. Additionally, the nature of 
membrane proteins can also affect permeability. While peripherally bound proteins play little to 
no role in permeability, integral proteins that span the membrane can function as transporters 
while ion channels can alter the permeability. The permeability of the membrane will differ by 
tissue type and therefore, the site of administration will also influence the absorption. For 
example, there is lower impedance to absorption by the capillary wall between interstitial fluid 
and the bloodstream (subcutaneous and intramuscular administration) than the epithelial lining of 
the GI tract and the bloodstream (oral administration) 
7
. 
 The chemical properties of the drug will also affect how well it can be absorbed. Small 
molecules (< 500-700 Daltons) are able to passively cross cellular membrane with relative ease, 
however as molecular size increases, the solubility properties of the drug play the most 
significant role in its absorption
9
. Lipophilic drugs will readily dissolve in the lipid membrane, 
while hydrophilic drugs will dissolve in the water that carries them throughout the body. Lipid 
soluble molecules are able to cross the membrane down the concentration gradient. Since the 
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circulating concentration is negligible, due to the large volume and constant flow, the rate of 
absorption for lipid soluble molecules is directly proportional to the concentration on the donor 
side of the membrane 
9
. In addition to solubility, molecular size, degree of ionization and the 
number of hydrogen bonds will also affect the absorption of drugs
8
. The rate of diffusion is 
inversely proportional to the size of the molecule, the ratio of ionized to unionized forms and the 
number of hydrogen bonds
8
.  
 While traditional thinking states that passive diffusion plays the largest role in drug 
absorption, it is now becoming clear that carrier mediated transport, both passive (energy 
independent down a concentration gradient) and active (energy dependant against a 
concentration gradient), plays a very important role
10
. Influx and efflux transporters are present 
in all cell types and tissues. They are able to bind reversibly to drug molecules and carry them 
across biological membranes. The overall intracellular concentration at equilibrium of a drug 
will be the result of the effects of both passive diffusion and transporters taking into account both 
influx and efflux pathways. 
1.3.2 Distribution 
 Distribution describes the process by which drugs move within the body from the blood 
to organs, tissues and back. The distribution of a drug to its site of action is the link between 
pharmacokinetics and pharmacologic activity of the drug
8
. There are four observable patterns of 
distribution that can influence the pharmacologic response of a drug (see Figure 1: Patterns of Drug 
Distribution)
7
.  
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 The pharmacokinetic parameter that best represents distribution is the volume of 
distribution which is calculated by dividing the amount of administered drug by the measured 
plasma concentration. A volume of distribution greater than the total body water indicates that 
the drug has been concentrated into tissues whereas a volume of distribution smaller than total 
body water indicates that the drug remains in the plasma
7
. Warfarin, an acidic drug, for example, 
remains largely protein bound and therefore has a small apparent volume of distribution; while a 
Figure 1: Patterns of Drug Distribution 
 
Adapted from Benedetti et al. 2009
4 
1. A drug may remain for the most part in the bloodstream; this can occur when the drug is 
largely bound to plasma proteins that inhibit its transport across plasma membranes. 2. A drug 
can be equally distributed throughout all of the body’s water; this usually occurs to small 
water soluble molecules. 3. A drug may be concentrated in a specific organ or tissue such as 
the thyroid or adipose tissue. 4. A drug may show a non-uniform distribution pattern 
consisting of a combination of the previous three distribution patterns. 
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basic drug such as amphetamine will be taken up into tissue readily and has a very large apparent 
volume of distribution
5
.  
 The drug characteristics that affect distribution are the same as those that influence 
absorption; size, solubility, and ionization status. Lipid soluble molecules may end up 
sequestered in fat tissue whereas large water soluble molecules may remain in circulation. This 
also means that a person’s body composition can influence drug distribution. A person with a 
higher percent body fat will have a greater distribution volume than a leaner person
11
.  
 Other factors that influence drug distribution include the blood perfusion of a given tissue 
which increases the availability of the drug and binding of drugs to plasma proteins, the most 
common being albumin, as only unbound drugs can cross membranes
7
.  Finally, as in absorption, 
membrane permeability plays a major role in distribution as drugs must cross the barriers 
separating the circulatory system from the various tissues and cell types. This may occur by 
simple diffusion, passive transport, or active transport. A drug cannot exert its effects unless it 
reaches its site of action, therefore variability that influences the distribution pattern of the drug 
can have profound effects on response.  
1.3.2.1 The Blood Brain Barrier 
 A unique barrier that drugs whose pharmacological action targets the brain must cross is 
the blood brain barrier (BBB).  There are three components to the BBB that make it difficult for 
drugs to cross, especially polar water soluble compounds. First, the cerebral endothelial cells 
form tight junctions with each other effectively sealing off the paracellular space
12,13
. Second, 
several membrane transporters, such as P-glycoprotein and members of the multidrug resistance 
protein family, are present in cerebral endothelial cells that regulate the transport between the 
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brain and the blood and serve as a protective efflux system to potentially harmful substances. 
Finally, the presence of metabolic enzymes, such as monoamine oxidase (MAO) and several 
cytochrome P450 enzymes, add additional metabolic activity to assist with the detoxification and 
elimination of compounds that attempt to cross the BBB
9, 10
. 
1.3.3 Metabolism 
 Drug metabolism describes the modifications involved in the biotransformation of drugs. 
It can be thought of as the body’s defense mechanism against xenobiotics. These defense 
mechanisms have been evolving for billions of years
14
. From an evolutionary standpoint, it is 
believed that through natural selection, external pressures, such as exposures to toxic 
compounds; either accidentally (such as toxic compounds in the diet)  or on purpose (such as the 
administration of drugs), have led to the selection of novel isoforms of genes with endogenous 
functions that provide a selective advantage by helping to regulate and limit the exposure and or 
accumulation of xenobiotic agents
15–17
.   
 Overall drug metabolism renders target molecules more water soluble and thus easier to 
excrete. There are four fates to the products of drug metabolism: a metabolite may have 
decreased activity compared to the administered drug, a metabolite may be more active than the 
parent compound; which is the case for a prodrug where the metabolite not the parent compound 
is responsible for the pharmacologic activity; a metabolite may be toxic, or a metabolite may 
have a physiological effect unrelated to the parent drug. Most compounds are metabolized 
through a number of pathways, either in parallel or in sequence, with each pathway having 
different outcomes with regard to drug response. The relative amount of each metabolite formed 
differs between tissues and among individuals. It depends on physiological conditions such as 
availability of enzyme, cofactors, modulators of cellular biochemistry, and transport of substrates 
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in and out of cells
18
. Metabolic enzymes are not uniformly distributed throughout the body and 
can even be induced or repressed by various stimuli (see sections 1.3.3.1, 1.3.3.2 and 1.3.6 
below). Also, with a finite number of active sites for any given enzyme in a given tissue, it is 
possible for these sites to become saturated with the drug in question or with other molecules, 
both endogenous and exogenous, that are competing for the active site. Additionally, 
demographic characteristics such as age, BMI, disease state and environmental exposures such 
concomitant medications can also influence drug metabolism
18
.  
 Metabolic reactions occur though chemical modifications that take place under normal 
physiological conditions (i.e. neutral pH, 37⁰C, atmospheric pressure etc.). In order to increase 
the rate of these reactions, enzymes are required. Enzymes facilitate these reactions in two ways, 
approximation and catalysis. Approximation involves the bringing together of two substrates in 
the proper three-dimensional orientation for the reaction to proceed. Catalysis involves the 
Figure 2: Movement of a Drug in the Body 
 
Adapted from: Thummel KE. 2007 
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reduction in activation energy required for the reaction to proceed. The enzyme interaction 
provides an alternative reaction route by stabilizing intermediates and thus increases the number 
of substrates with enough energy to pass through the transition state and form the product. The 
binding between enzymes and their substrates occurs mainly through non-covalent interactions. 
 The majority of metabolic reactions, for both endogenous chemicals such as cholesterol 
or steroid hormones and xenobiotics, occur in the liver. Compounds that are absorbed via the 
small intestine into the portal vein will pass through the liver prior to any other organ or tissue. 
This is known as the first-pass effect as many drugs are extensively metabolized or cleared from 
circulation prior to reaching any additional site in the body. Even if a portion of a drug makes it 
past the liver, or is administered in such a way to bypass the first pass effect (by IV for example), 
the subsequent passes through the liver as part of normal circulation will result in further 
metabolism of the drug (see Figure 2: Movement of a Drug in the Body )
19
. Other organs that have 
been shown to contain drug metabolizing enzymes to a smaller degree include the small 
intestine, the lungs, the nasal mucosa and kidneys. 
 Drug metabolism enzymes (DMEs) fall into two categories. Phase 1 DMEs responsible 
for the functionalization reactions that either introduce or unmask polar functional groups 
making molecules more water soluble; and phase 2 DMEs responsible for conjugation reactions 
that attach hydrophilic chemical moieties to drugs.  
1.3.3.1  Phase I Drug Metabolism Enzymes  
 Phase I drug metabolism describes the oxidation, reduction and hydrolysis reactions that 
occur to xenobiotics (see Figure 3: Phase I Drug Metabolism Reactions)
15
 . These reactions 
result in either the introduction of new polar groups (oxidation), the modification of existing 
functional groups (reduction) or the unmasking of existing polar functional groups (hydrolysis)
15
.  
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Often, the product of phase I drug metabolism will not be sufficiently polar to be excreted and 
must undergo further metabolism by either additional phase I or phase II enzymes.  
 
1.3.3.1.1 Cytochrome P450 Enzymes 
 The most abundant phase I DMEs are the cytochrome P450 (CYP) enzymes, a 
superfamily of haeme containing mono-oxygenases divided into sub-families based on amino 
acid sequence homology. The CYP superfamily contains 57 functional genes and an additional 
58 pseudogenes that play a role in endogenous compound metabolism, however only members of 
the 1,2 and 3 families play significant roles in drug metabolism
20
. Five CYPs in particular; 1A2, 
2C9, 2C19, 2D6 and 3A4, are involved in about 95% of CYP-mediated metabolism and 
metabolize about 80% of drugs currently on the market
7,20
.  The most common CYP 450 reaction 
is the mono-oxidation of a substrate (See Figure 4).   
Figure 3: Phase I Drug Metabolism Reactions 
 
Source: Nassar AF, Hollenberg PF, Scatina J. Drug Metabolism Handbook. John Wiley and Sons; 2009. 
 
14 
 
 
 The active site of all CYP enzymes contains a haeme moiety. When a substrate binds to 
the active site (1), there is a change in the electronic state of the haeme that favors reduction 
from Fe
2+
 to Fe
3+ 
with NADH or NADPH as the electron donor (2).  This is followed by the 
binding of oxygen to the haeme (3). This state is unstable and a decoupling reaction can occur 
resulting in the release of a superoxide radical. If however, a second electron is transferred to the 
moiety the reaction can continue (4). The peroxo grouped formed with the addition of the second 
electron is rapidly protonated from the surrounding solvent twice, releasing a water molecule and 
leaving an activated oxygen atom (5) that is able to react with the substrate molecule (6) that 
results in a hydroxylated substrate and the enzyme in its initial state (7)
17
. 
1.3.3.1.2 Non CYP Oxidative Metabolism 
 In addition to CYP enzymes which are the most prevalent, the products of several other 
gene families also contribute to oxidative drug metabolism, these include: flavin-containing 
Figure 4: P450 Monooxygenase Mechanism 
 
R  = any side chain 
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monooxygenases (FMO), monoamine oxidases (MAO), alcohol (ADH) and aldehyde 
dehydrogenases (ALDH), and some peroxidases (see Table 2).  
Table 2: Phase 1 Oxidation Enzymes 
Enzyme Family Oxidative Reaction 
Cytochrom P450 RH+O2+2H
+
 +2e
-
  ROH+H2O 
Flavin Containing Monooxygenase RNH+O2+2H
+
 +2e
-
  RNOH+H2O 
Monamine Oxidase RCH2NH2 + O2 + H2O  RCHO + NH3 + H2O2 
Alcohol dehydrogenase ROH + NAD
+
 RO + NADH + H+ 
Aldehyde dehydrogenase RCHO + NAD
+
 + H2O RCOOH +NADH + H
+
  
Peroxidase ROOR’ + 2H+ + 2e-  ROH + 2X′ + R’OH 
 There are five members in the FMO family (FMO1-5) with FMO3 being the most studied 
due to its association with trimethylaminuria
21
. FMO enzymes oxygenate substrates that contain 
soft-nucleophiles usually sulfur or nitrogen
22
. The biological function of FMO is poorly 
understood, however many FMOs share substrate specificity with many CYPs yet often result in 
different products. Xenobiotics that are metabolized by FMO enzymes include ketoconazole, and 
tamoxifen
23,24
.  Unlike CYP enzymes, FMOs do not require a reductase to transfer electrons from 
NAD(P)H and do not contain a haeme moiety, additionally FMO enzymes are not readily 
induced  or inhibited and therefore are not as prone to drug-drug interactions 
21
.  
 There are two members of the MAO family (A and B) that catalyze oxidative 
deamination of monoamines; most notably monoamine neurotransmitters in neurons and 
astroglia
25
. However, both MAO-A and B are also found outside the central nervous system and 
can play a role in the catabolism of ingested monoamines
25
. Some of the xenobiotics known to 
be metabolized by either MAO A or B include β-blockers such as metoprolol and propranolol 
and serotonin reuptake inhibitors such as sertraline and citalopram
24
. 
 Dehydrogenase enzymes utilize a hydride (H
-
) acceptor, usually NAD(P)
+
 to oxidize a 
substrate. ADH enzymes catalyze the conversion of alcohols to aldehydes and can be grouped 
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into five classes in humans. ADH enzymes exists as a either a homo or hetero-dimer and there 
are at least 7 different genes that encode subunits (isoenzymes) of the enzyme
24
. Class 1 ADH is 
the primary hepatic form, responsible for the conversion of ethanol to acetylaldehyde, and is 
made of three subunits encoded by the genes ADH1A, ADH1B and ADH1C
24
.  ADH has also 
been implicated as the primary metabolism pathway for several pharmaceuticals (which are also 
alcohols) such as abacavir and ethambutol
26–28
. 
 There are 17 genes that encode for members of the ALDH super-family (grouped into 10 
families and 13 subfamilies based on amino acid sequence homology) that catalyze the 
conversion of aldehydes into carboxylic acids
24
. ALDH enzymes have several very important 
endogenous functions such as the conversion of 10-formyl-tetrahydrofolate to tetrahydrofolate or 
the oxidation of retinaldehyde to retinoic acid and inborn errors in aldehyde metabolism are 
generally associated with neurological abnormalities
24,29,30
. The role of ALDH in xenobiotic 
metabolism has also been demonstrated; in addition to the conversion of acetylaldehyde to acetic 
acid in ethanol metabolism, ALDH is also responsible for the inactivation of the aminoaldehyde 
form of 4-hydroxycyclophosphamide, the active form of cyclophosphamide
31
.  
 Peroxidases are enzymes that have the unique ability to catalyze the single electron 
oxidation of substrates. The endogenous role of peroxidases such as glutathione peroxidase 
(GPX) is the detoxification of hydrogen peroxide, however, the formation of oxidized 
glutathione has been observed after the administration of certain drugs which would indicate that 
single electron oxidation is taking place resulting in radical formation and oxidized 
glutathione
32,33
.  In addition to GPX, peroxidases known to be involved in drug metabolism 
include: myeloperoxidase (MPO), which is able to oxidize chlorine containing compounds such 
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as clozapine; and prostaglandin H synthase (PHGS), involved in the oxidation of 
paracetamol
24,34,35
.  
1.3.3.1.3 Phase I Reduction Reactions 
 While oxidative processes account for the majority of phase I drug metabolism, some 
reductive reactions have been identified and may play a significant role in drug metabolism. 
Reduction reactions are carried out mainly by members of the CYP family with NADPH as a 
reductive cofactor. Several drugs are known to undergo reductive metabolism, such as the 
antifertility drugs norgesterl and norethindrone, due to the presence of the reduced metabolite in 
urine, however the exact mechanism is not always known
36
. In other cases, the reductive 
mechanism is known, as is the case with clonazapam reduction by CYP3A4
37
. 
1.3.3.1.4 Phase I Hydrolysis Reactions 
 Hydrolytic reactions are carried out by esterases that split esters into an acid and an 
alcohol. Esterases important to drug metabolism are carboxylesterases (encoded by members of 
the CES gene family), arylesterases (encoded my members of the PON gene family), and 
cholinesterases (encoded by the genes ACHE and BCHE). Drugs that undergo hydrolytic 
metabolism include procaine, and phensuximide
38,39
. 
1.3.3.2 Phase II Drug Metabolism Enzymes 
 Phase II drug metabolism reactions, or conjugation reactions, involve the transfer of 
small polar endogenous molecules to drugs. The new chemical moiety is usually activated by a 
coenzyme then transferred to a functional group, typically alcohols, amines, carboxylic acids and 
thiols, on the parent drug itself or to one introduced in the product of phase I metabolism (Table 
3). The resulting metabolites are more water soluble and thus easier to excrete and/or have 
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reduced activity. Phase II reactions that play the biggest role in drug metabolism include: 
glucuronidation, glutathione conjugation, acetylation, sulfation, methylation and amino acid 
conjugation
15
. 
Table 3: Phase II Drug Metabolism Reactions 
Functional 
Group  
Reaction  Source  Known 
Substrates  
-COOH  Amino acid 
conjugation 
glycine or glutamine  benzoic acid  
-COOH Glucuronidation uridine 5'-diphospho-glucuronic acid 
(UDPGA)  
bilirubin, 
irinotecan  
-NH2 , -OH, -
SH 
Methylation S-adenosyl methionine (SAM)  Nicotine, 
azathioprine 
-NH2 , -OH  Sulfonation 3'-phosphoadenosine-5'-phosphosulfate 
(PAPS)  
minoxidil  
-NH2 , -OH  Acetylation acetyl-CoA  isoniazid  
-Cl, -Br, -I, -F,  
-NO2, -C=C-  
Glutathione 
conjugatoin 
reduced glutathione  N-acetyl-p-
benzoquinone 
imine, thiotepa  
1.3.3.2.1 Glucuronidation 
 Glucuronidation is catalyzed by uridine diphosphate (UDP)-glucuronosyltransferases 
(UGT). UGT enzymes can be grouped into two families based on the gene location. The UGT1A 
locus, located on chromosome 2, consists of 9 genes and 4 pseudogenes in roughly a 200 kb 
region. An interesting feature of the locus is that all 13 genes share the same exons 2-5 and have 
a unique first exon (see Figure 5). The common 245 amino acid sequence at the carboxyl 
terminus, encoded by exons 2-5, determines the interaction with the common substrate, UDP-
glucuronic acid, while the amino terminal region encoded by the first exon determines substrate 
specificity
40
. 
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   Members of the UGT1A family are responsible for the glucuronidation of a wide variety 
of endogenous compounds such as thyroxine, estrone and bilirubin. UGT1A1 is the most studied 
gene of the 1A locus having the greatest bilirubin conjugating activity 
41
. Reduced function of 
UGT1A1 can lead to hyperbilirubinemic syndromes such as Gilbert’s syndrome or more severe 
forms such as Crigler-Najjar syndrome
42
.  UGT1A enzymes are also responsible for the 
glucuronidation of several xenobiotics. Of note is the chemo therapeutic irinotecan, where 
reduced function in UGT1A enzymes leads to reduced detoxification of 7-ethyl-10-
hydroxycamptothecin, an active metabolite of the drug 
43
.  
 The UGT2 family is further divided into two subfamilies, UGT2A consisting of two 
genes (2A1 and 2A2) and UGT2B consisting of seven genes. The 9 genes that encode members 
of the UGT2 family are located on chromosome 4. Endogenously, UGT2 enzymes are 
responsible for the glucuronidation of many compounds such as hyodesoxycholic acid as well as 
various steroid hormones and fatty acids. Drugs that are metabolized by UGT2 enzymes include 
morphine (UGT2B7), alizarin (UGT2B17) and oxazepam (UGT2B15) 
40,44–47
.   
1.3.3.2.2 Glutathione Conjugation 
 In addition to the antioxidant abilities of glutathione in the removal of reactive oxygen 
species; glutathione conjugation to endogenous and exogenous lipophilc compounds is an 
Figure 5:  UGT1A Locus 
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important process in reducing toxicity and increasing excretion. Glutathione conjugation is 
carried out by glutathione-S- transferase (GST) enzymes. These enzymes can be divided into 
seven classes based on amino acid identity, alpha, kappa, mu, omega, pi, theta and microsomal. 
GSTs are highly expressed and account for up to 10% of cytosolic protein in some organs. GST 
enzymes occur as a either a homo or hetero dimers with both subunits being from the same 
class
48
. GSTs are highly inducible with over 100 endogenous and exogenous compounds found 
to increase GST expression; many of the compounds that induce GSTs are themselves substrates 
for the enzymes
49
. Genes that encode GSTs in humans with the greatest amount of inter-
individual variation are members of the mu (GSTM1-5), pi (GSTP1), alpha (GSTA1-4) and theta 
(GSTT1-2) classes. Xenobiotics known to be metabolized by GST enzymes include N-acetyl-p-
benzo-quinone imine (NAPQI); the toxic metabolite of acetaminophen, thiotepa, as well as other 
chemotherapeutic agents which has led to the hypothesis that GSTs play a role in tumor drug 
resistance
44,50–52
. 
1.3.3.2.3 Acetylation 
 The phase II acetylation reaction usually involves the transfer of an acetyl group 
(CH3CO), from acetyl CoA, to a variety of nitrogen containing compounds (N-acetylation), 
however O-acetylation has also been observed
53,54
. Acetylation does not make the substrate more 
polar, rather it usually serves to either detoxify the substrate or to activate it
55
. There are two 
enzymes responsible for acetylation drug metabolism reactions, N-acetyltransferase 1 and 2 
(NAT1 and 2). NAT enzymes are among the most studied ADME enzymes and there is a vast 
amount of molecular, structural and biochemical information pertaining to them
56
. The N-
acetylation of drugs by NAT enzymes was one of the first polymorphic drug metabolism 
phenotypes observed over 50 years ago when it was recognized that there were large inter-
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individual differences in the toxic side effects of the drug isoniazid
57,58
. In addition to isoniazid, 
other drugs such as sulfur-containing antirheumatic and anti-inflammatory drugs have side effect 
profiles that are related to NAT activity
55
.  
1.3.3.2.4 Sulfonation 
 Sulfonation, catalyzed by members of the sulfotransferase (SULT) gene family of 
enzymes, involves the transfer of a sulfonate (SO3
-) group from 3’-phosphoadenosine 5’-
phosphosulfate (PAPS) to a hydroxyl or amino group of a substrate
59
. The sulfonation of 
endogenous and xenobiotics can serve to increase water solubility and thus excretion, which is 
the case for the drug acetminophen and the neurotransmitter dopamine. However, in some cases 
as is the case for the drug minoxidil, the sulfonation reaction is necessary for the drugs 
pharmacologic activity 
60
.  
 There are two types of SULT enzymes in humans, those that are bound to the golgi 
apparatus responsible predominantly for the sulfonation of peptides, proteins and lipids, and 
cytosolic SULTs that are responsible for the sulfonation of xenobiotics. There are 13 cytosolic 
SULTs that can be grouped into three families based on amino acid sequence identity: SULT1 
(A1, A2, A3, A4, B1, C2, C4, E1), SULT2 (A1, B1_v1, B1_v2) and SULT4 (A1_v1 and A1_v2) 
59
. Many SULT enzymes share substrate specificity with UGT enzymes. It has been proposed 
that the SULT system represents the low affinity high capacity pathway while the UGT system 
represents the high affinity low capacity pathway for these substrates 
59
.  
1.3.3.2.5 Amino Acid Conjugation 
 Amino acid conjugation was the first conjugation reaction characterized in humans with 
the demonstration that benzoic acid was metabolized to hippuric acid
61,62
. Despite its early 
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discovery, amino acid conjugation is not as well characterized as other drug metabolism 
reactions. The reaction is catalyzed by acyl transferase enzymes and results in the formation of 
an amide bond between a carboxyl functional group and an amino acid. Glycine is the amino 
acid most often conjugated in humans
61
. Many drugs undergo phase I metabolism that results in 
the formation of a carboxyl group that can be conjugated to glycine. These include the 
antihistamines astemizole and brompheniramine
61
.   
1.3.3.2.6  Methylation 
 Methylation involves the transfer of a methyl group (-CH3) and is involved in the 
regulation of several biological processes. This reaction is catalyzed by several different 
methyltransferase enzymes throughout the body. The most common donor of endogenous methyl 
groups is S-adenosyl methionine (SAM). The NH2, OH and SH functional groups on xenobiotics 
and on endogenous molecules such as DNA, histones, and neurotransmitters have the potential to 
be methylated.    
 The methyltransferase enzyme with the greatest amount of evidence concerning its 
involvement in drug metabolism is thiopurine S-methyltransferase (TPMT) that catalyzes the S-
methylation of aromatic and heterocyclic sulphydryl compounds such as azathioprine
63–65
. Other 
methyltansferases that have been proposed to be involved in drug metabolism include histamine 
N-methyltransferase (HNMT) and catechol-O-methyltransferase (COMT) with selective 
serotonin reuptake inhibitor response
66–68
. 
1.3.4 Excretion 
 Excretion is the process of removing a drug from the body and expelling it to the external 
environment. The drug can be excreted in the form of an unchanged molecule or as a metabolite. 
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The pharmacokinetic parameter used to quantify excretion is clearance; which is a measure of 
the volume of blood or plasma that has been irreversibly cleared of the drug per unit of time. A 
drug may undergo several routes of excretion; therefore total clearance is the sum of the 
individual excretion pathways. Since a drug or metabolite must cross biological membranes to 
exit the body, the same chemical and physical properties that influence absorption and 
distribution for a given drug also govern its excretion rates in excretory organs. Additionally, the 
same mechanisms, passive diffusion and facilitated transport, are involved in excretion. 
Excretion takes place primarily in two organs, the kidney and the liver. Renal excretion is 
controlled by three processes: Glomerular filtration in Bowman’s capsule, which is a passive 
process; tubular secretion, which is predominantly an active process involving transporters; and 
tubular reabsorption, which can occur through both passive diffusion and active transport. In the 
liver, in addition to the presence of metabolism enzymes, excretion can occur in the form of bile. 
Biliary excretion occurs primarily via active transport, as small lipophilic molecules are 
reabsorbed in the bile duct. Conjugation reactions often facilitate biliary excretion as these 
metabolites are larger in size and are not as readily reabsorbed. It is possible for drugs that enter 
the gut through the biliary system to be reabsorbed. This is known as enterohepatic recycling.  
1.3.5 Transporters 
 Transporters are membrane proteins that are able to transport both endogenous 
compounds and xenobiotics across biological membranes. Transporters are located throughout 
the body, anywhere that compounds need to cross membranes and are unable to do so by passive 
diffusion alone. Transporters are involved in drug absorption, in the intestinal lumen for 
example, in drug distribution, as part of cellular uptake or across the blood-brain barrier for 
example, and in drug elimination, in the liver and kidney for example
15
. Depending on the tissue 
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type, a given epithelial cell may have both influx and efflux transporters for the same compound, 
therefore it is the combined action of different transporter types that will determine the overall 
direction and scale of drug movement
69
. Additionally, there may be redundancy in certain 
tissues, where transporters with overlapping substrate specificities are often present together. 
From an evolutionary perspective this redundancy may be protective ensuring that toxic 
compounds are readily removed
69
. 
 Transporters can be separated into two major classes: the solute carrier (SLC) family of 
proteins and the adenosine triphosphate-binding cassette (ABC) transporter superfamily. Both 
types of transport proteins are integral membrane proteins with trans-membrane domains 
(TMDs) joined by intra- and extra- cellular chains or loops of amino acids. The substrate binding 
site can be formed by the amino acid sequence of the intracellular loop in the case of efflux 
transporters (ABC and SLC members), the extracellular loop in the case of influx transporters 
(SLC members) or the TMD in the special circumstance of some ABC transporters
70
. 
1.3.5.1 Solute Carrier Proteins 
 The SLC family is the largest superfamily of transporters with over 300 genes presently 
known to encode SLC members
70
. SLC transporters are classified by their substrate specificity 
such as organic anions (OAT), organic cations (OCT), and organic anion polypeptides (OATP). 
Not all SLC transporters however, are involved in the transport of drugs. The most important 
SLC transporters involved in drug transport are the members of the SLCO1B, SLC15A, and 
SLC22A families
69
 (see Table 4: Transporters important to Human Drug Transport). 
 SLC transporters use electro-chemical gradients as the driving force for transport
71
. They 
are generally co-transporters, transporting ions and solutes simultaneously in either the same or 
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opposite directions
70
.  The Na
+
 ion gradient is the most common source of energy in humans for 
SLC transporters; however other gradients include H
+
, glutathione, HCO3
-
 and α-ketoglutarate70. 
1.3.5.2 ATP-binding Cassette Transporters 
 Currently, 49 ABC transporters have been identified and grouped into 7 subfamilies (A 
through G). However only P-glycoprotein [ABCB1 also know as multidrug resistance 1 
(MDR1)], several members of the multidrug resistance-associated proteins (MRP1-9 or ABCC1-
9) and the breast cancer resistance protein (BCRP, ABCG2) have been shown to be efflux drug 
transporters
70,72
 (see Table 4: Transporters important to Human Drug Transport ). ABC 
transporters are highly expressed in important pharmacological barriers such as the blood-brain 
barrier (BBB), excretory sites such as the biliary canalicular membrane of hepatocytes and 
absorption barriers such as the membrane of intestinal cells
73
. ABC transport usually occurs 
against a concentration gradient and requires intracellular production of ATP as an energy 
source
7
. ABC transporters contain a cytoplasmic ATP binding domain that binds and hydrolyses 
ATP and drives drug transport
73
.  
Table 4: Transporters important to Human Drug Transport 
Gene 
name 
Transporter Name 
(synonym) 
Tissue distribution (Important to PK) Cell 
localization 
ABC:    
ABCB1 Pgp (MDR1) Blood–brain barrier, Liver, Intestine, Kidney, Apical 
ABCB11 BSEP (SPGP) Liver Apical 
ABCC1 MRP1 (MRP) Lung, Kidney, Peripheral Blood Basolateral , 
apica 
ABCC2 MRP2 (cMOAT) Blood–brain barrier, Liver, Intestine, Kidney, Apical 
ABCC3 MRP3 (MOAT-D) Intestine, Liver, Kidney Basolateral 
ABCC4 MRP4 (MOAT-B) Kidney, Lung Apical, 
basolateral 
ABCC5 MRP5 (ABC11) Liver, Brain Apical, 
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basolateral 
ABCG2 BCRP (MXR) Blood–brain barrier, Liver, Intestine Apical 
SLC:    
SLCO1B1 OATP1B1 (OATP-C) Liver Basolateral 
SLCO1B3 OATP1B3 (OATP8) Liver Basolateral 
SLC15A1 PEPT1 (HPEPT1) Intestine Apical 
SLC15A2 PEPT2 Intestine Apical 
SLC22A1 OCT1 Liver, kidney, intestine Basolateral 
SLC22A2 OCT2 Liver, kidney, intestine Basolateral 
SLC22A6 OAT1 (NKT) Liver, Kidney Basolateral 
Source:   Sugiura, Kato, and Tsuji 2006; Szakács et al. 2008; Klaassen and Aleksunes 2010  
1.3.6 Modifiers of Drug Metabolism 
 In addition to drug metabolism pathways themselves, the regulation of drug metabolism 
genes also plays a critical role in determining ones pharmacokinetic profile. Many DME and 
transporter genes share common mechanisms of transcriptional activation through various 
nuclear receptor signaling cascades. These include the aryl hydrocarbon receptor (AhR), orphan 
nuclear receptors and nuclear factor-erythoroid 2 p45-related factor 2 (Nrf2). There is a 
significant overlap in regulatory targets for most of these transcription factors. In fact, this 
overlap can account for some drug-drug interactions as the administration of one drug may 
upregulate the metabolism or excretion of another. Additionally, autoinduction, the process 
where a therapeutic agent triggers the increase in its own clearance, is also a common 
phenomenon and is the primary mechanism of pharmacokinetically mediated tolerance
74
.  
1.3.6.1 Nuclear Receptors 
 The expression of drug metabolism enzyme genes and drug transporter genes are 
regulated via similar pathways; notably by members of the nuclear receptor superfamily. There 
are 49 known members of the nuclear receptor superfamily and common to all members are 
three major protein domains categorized based on function 1) an activation function 1 domain 
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(AF-1) at the amino terminus responsible for ligand-independent activation through interaction 
with additional transcription factors. 2) A DNA binding domain (DBD) centrally located in the 
protein that interacts with DNA response elements. 3) A ligand-binding domain (LBD) located at 
the carboxy-terminus
75
. Upon binding of a drug or other ligand to the LBD in the cytoplasm, the 
receptor is dissociated from any corepressors to which it may be binding, usually a histone 
deacetylase and translocates to the nucleus to act as a transcription factor. Once inside the 
nucleus, the receptor forms either a homo or hetero complex and binds via the DBD to the 
appropriate DNA response elements in regulatory regions of target genes. The presences of the 
protein complex in the regulatory domain subsequently impact/regulate cognate gene 
transcription by interacting with the cellular transcriptional machinery (See Figure 6)
75
. 
 
Figure 6: Nuclear Receptor Activation 
 
Adapted from Urquhart et al 2007  
When a ligand binds to a nuclear receptor, it is transported to the nucleus where it can serve as a 
transcription factor and initiate transcription. 
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 Generally, when a cell is exposed to a drug, the xenobiotic substrate will interact with the 
nuclear receptors present in the cytoplasm triggering a transcription factor cascade into the 
nucleus that leads to increased expression of the enzymes and transporters that will reduce the 
exposure 
76,77
.  The most notable nuclear receptors involved in drug metabolism are the: Aryl 
hydrocarbon receptor (AhR), the orphan nuclear receptors, and nuclear factor-erythoroid 2 p45-
related factor 2 (Nrf2).  
1.3.6.2  Aryl hydrocarbon receptor 
 AhR is a highly polymorphic transcription factor that forms a dimer with the aryl 
hydrocarbon nuclear translocator (Arnt), which is not required for nuclear transport, however 
when bound together it causes a conformational change that results in greater recognition of 
enhancer sequences and thus activation of target genes
78
. AhR, when bound by polycyclic 
aromatic hydrocarbons such as dioxin, increases the expression of the CYP1 family members 
and has also been shown to up regulate UGT1A1, UGT1A6 and GSTA1 
79,80
.   
1.3.6.3  Orphan Nuclear Receptors 
 The orphan nuclear receptors responsible for the regulation of drug metabolism genes 
include: the pregnane x receptor (PXR), the constitutive androstane receptor (CAR), the 
peroxisome proliferator activated receptors (PPAR), and the retinoid x receptors (RXR). 
 PXR, encoded by the gene NR1I2, is expressed predominantly in the liver and intestine 
and to a lesser extend in the kidneys and lungs. This tissue specific expression pattern resembles 
that of CYP3A and many compounds that lead to increased expression of members of the 
CYP3A family bind to PXR. This observation is what led to the understanding of the mechanism 
of PXR mediated expression of CYP3A4
81
. Many compounds, such as rifampin, dexamethasone 
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and omeprazole lead to increased expression of CYP3A4 through the binding of PXR
82
. PXR has 
also been shown to regulate the multi-drug resistance transporter MDR1 (ABCB1) 
83
. 
 CAR (NR1I3) was originally defined as constitutively active because it can form a 
heterodimer with RXR and bind retinoic acid response elements and activate target genes in the 
absence of ligands
84
.  More recently, however, drugs such as HMG-CoA reductase inhibitors 
have been shown to activate CAR and lead to increased expression of CYP2B6
85
. 
 There are three members of the PPAR nuclear receptor family: PPARα PPARβ and 
PPARγ. All three members have overlapping physiological function and are involved in the 
regulation of fatty acid metabolism through the induction of CYP4A
86
. Peroxisome proliferator 
drugs such as clofibrate, activate PPARα, which gives rise to increased expression of CYP4A, 
which in turn metabolizes the drug and reduces the exposure
76. PPARγ can be activated by the 
thiazolidinedione class of drugs, rosiglitazone for example, that has been shown to increase the 
expression of the ABCG2 drug transporter giving rise to increase drug resistance 
87
. 
 Similar to PPAR, there are three members of the RXR family: RXRα, RXRβ and RXRγ. 
RXR is the common partner for all other orphan nuclear receptors in the formation of 
heterodimers. This heterodimer formation is a critical step for the binding and activation of all 
nuclear receptors
74
. There are two types of heterodimers, nonpermissive and permissive. RXR is 
silent in nonpermissive heterodimers and can only be activated by ligands of the partner nuclear 
receptor
74
. In permissive heterodimers, RXR can be activated by ligands of RXR or of the 
partner receptor
74
. Since RXR binds to most other nuclear receptors and affects the subsequent 
regulation of their targets, RXRs are involved in the regulation of most drug metabolism 
enzymes and transporters either directly or indirectly
77
.  
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1.3.6.4  Nuclear factor-erythoroid 2 p45-related factor 2  
 Many phase II drug metabolism enzymes contain additional cis-acting regulatory 
elements such as the anti-oxidant response element (ARE) in their 5’ regulatory region 88.  Nrf2 
is the most potent activator of ARE-mediated transcription 
88
.  During chemical or oxidative 
stress, Nrf2 has been demonstrated to upregulate several phase II DMEs including UGTs and 
GSTs
88
.   The exact mechanism of regulation of Nrf2 dependant ARE transcriptional regulation 
is unclear and likely involves multiple kinase pathways including the mitogen activated protein 
kinases (MAPKs), phosphatidylinositol 3-kinase (PI3K) and extracellular signal regulated 
kinases (ERKs)
77
. Phosphorylation leads to the dissociation of Nrf2 from Keap1, a cytosolic 
inhibitor, followed by a subsequent translocation to the nucleus where it can exert its effects
88
.  
 As part of my thesis, a thorough understanding of pharmacokinetic genes and pathways 
was undertaken in order to properly select and rank genes for inclusion in our genotyping assay. 
For the assay to be broadly applicable, genes from all of the various PK pathways described 
above were chosen, ranked and prioritized. These pathways are important for the metabolism of 
many different therapeutic classes of medications. 
1.4 Pharmacodynamics 
 Pharmacodynamics (PD), or the effects of the drug on the body, is the study of the 
mechanism and pharmacological response to a drug. This involves the binding of drugs to 
receptors, post receptor effects and chemical reactions
4
. Drugs that bind to receptors exert their 
effects by either mimicking the binding of an endogenous ligand, leading to downstream 
activation, or by inhibiting the binding of a natural ligand and preventing the downstream 
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processes. Some drugs do not bind to a receptor but rather exert their effects through chemical 
processes, such as cytotoxic drugs.  
 No study of drug response or toxicity is complete without an investigation of the drug’s 
PD profile, however in contrast to PK; PD pathways are, for the most part, unique to the drug in 
question. Thus, for a tool to be a broadly applicable across many therapeutic classes of 
medications, PK pathways are the most applicable. 
1.4.1 KRAS and Epidermal Growth Factor Receptor Inhibitors 
 An example of variation in a PD pathway that affects drug response is the relationship 
between Kirsten rat sarcoma viral oncogene homolog (KRAS) variation and epidermal growth 
factor receptor (EGFR) inhibitor response. EGFR is a transmembrane tyrosine kinase that when 
activated by a ligand, leads to the activation of a series of signaling cascades to affect gene 
transcription
89
. This in turn results in increased cell proliferation, reduced apoptosis, metastasis 
and tumor induced angiogenesis
89
. Inhibitors of EGFR such as gefitinib or monoclonal 
antibodies that bind to EGFR such as cetuximab have been shown to be effective in the treatment 
of metastatic colorectal cancer and other cancer types
89
. 
 One of the major downstream pathways activated by EGFR is the RAS-RAF-MAPK 
pathway. When variation in genes encoding members of this pathway were investigated for 
association with EGFR inhibitor response, it was found that mutations in KRAS were 
significantly associated with absence of response
90,91
.This is because mutations that 
constitutively activate KRAS (located downstream in the EGFR-RAS-RAF-MAPK pathway) 
can bypass any and all effects of inhibiting EGFR
92
. Thus, knowledge of the variability in EGFR 
and KRAS (pharmacodynamic genes) can have a profound effect on the efficacy and choice of 
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drugs for therapy. Additionally, the overall survival of patients without a KRAS mutation was 
greater than those that were carriers
90,91
.  
 While PD pharmacogenomic genetic variants are specific to specific medications and not 
generally applicable across therapeutic areas, they are still very important to measure for each 
clinical trial. In order to allow for the inclusion of project specific PD markers in the ADME 
genotyping panel, some genotyping space was purposefully left “open” in the panel design to be 
flexible. These flexible markers can be added/changed depending on the given needs of the 
project. 
1.5  Genetics of Complex Traits 
  While selecting content to be included on the ADME panel, an understanding of 
current approaches in genetic research and clinical trials was needed to establish how current 
state-of-the-art methods and technologies are being used in order to maximally design strategies 
that would have the greatest impact and utility.  
 The ADME panel has been conceptualized to have two principle uses; as a tool for 
pharmaceutical clinical trials to direct decision making and to identity novel pharmacogenomic 
biomarkers that correlates with individuals with a specific drug response phenotype. Genetic 
studies of drug response are unique in that a specific exposure to the drug is required. This is 
why family based studies in pharmacogenomics are not common as it is unlikely to find large 
families where each member has received the same drug.  
1.5.1 Candidate Gene versus Genome-wide 
 The two predominant strategies in genetic association studies are candidate gene and 
genome-wide genotyping. In the former, markers, usually single nucleotide polymorphisms 
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(SNPs) are targeted in regions in and around genes or genetic pathways that are candidates for 
association with a specific phenotype/disease being investigated. Typically, candidate gene 
studies involve the genotyping of a limited predefined number of markers (10’s to 100’s). The 
candidates are often selected based on hypotheses derived from previous studies or from 
knowledge of specific pathways. Conversely, a genome-wide approach involves the genotyping 
of  hundreds of thousands to millions of well defined SNPs that span the entire genome that have 
been selected without any bias to specific regions or genes. Genome-wide association studies 
(GWAS) are non-hypothesis methods that hope to identify regions of linkage disequilibrium 
(LD) that associate with specific phenotypes being measured. No matter the study design, the 
causal variant may not be typed (direct association) but with a well designed study there is a 
good chance of identifying a region that contains the causal variant through LD with other 
markers present on the genome-wide panel (indirect association). 
 LD is defined as the nonrandom association of alleles at two or more loci
93
. LD between 
two loci will depend on the local recombination rate, as recombination that occurs between two 
loci on the same chromosome will break up the linkage between them. Alternatively, LD may 
arise for other reasons such as selection, where a particular allele may increases reproductive 
fitness, or non-random mating, where offspring receive two copies of the same chromosome. The 
combination of alleles on the same chromosome that are transmitted together is known as a 
haplotype. When multiple markers along a chromosomal region are considered simultaneously, 
often the LD extends to several markers. This set of loci in LD with each other is known as a 
haplotype block. It is possible to graphically represent stretches of LD along a particular region 
of the chromosome as haplotype blocks (see figure7)
94
.  
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 In humans, haplotype blocks range from a few kilobases (kb) to more than 100 kb
95
. This 
discovery led to the hypothesis that testing for one marker or SNP, known as a tag SNP, within 
each LD block could be equivalent to testing every SNP in the block, thus significantly reducing 
the number of SNPs needed to interrogate the entire genome
96
. The opposite of LD is linkage 
equilibrium (LE), which implies that there is statistical independence between two or more loci. 
For LE to be reached, recombination needs to occur between two markers in LD. The shorter the 
distance between the two markers, the less likely that recombination will occur between them. 
This implies that it will take a very long time before high rates of recombination will ever be 
reached or even occur between two loci in strong LD and further supports the use of a tagging 
strategy
97
.     
 In reality, the human genome is more complex than this simple LD block model, the 
recombination rate is not constant across the entire genome, some regions do not reflect the 
Figure 7:  LD Map for a Region on Chromosome 1 Spanning the Gene DPYD in the CEU 
Population 
 
Each black line represents the position of a single SNP (475 total). The pair-wise LD is calculated for 
each pair of SNPs and the value is translated into a colour. In the above example dark red indicates a 
D’ value >0.9 and white indicated a D’ value <=0.5.  This region can be divided into 25 Haplotype 
blocks (black triangles). In order to capture the variation at all 475 SNPs using an r-squared of 0.8, 
123 tag SNPs need to be genotyped. Figure generated with Haploview (Barrett et al. 2005). 
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block-like haplotype structure and the density of SNPs varies from region to region
98
. Further 
complicating matters is that different methods of defining LD lead to different block 
boundaries
99
. Despite this, the International Haplotype Project was carried out to characterize LD 
across the entire genome and catalogue common variation in 270 samples from four distinct 
ethnic populations; African (Yoruba in Ibadan, Nigeria; YRI), Asian (Han Chinese; CHB  and 
Japanese Tokyo; JPT), and European (CEU) ancestry
100
. When phase two of the HapMap was 
released, the project contained data for more that 3.1 Million genome-wide SNPs 
101
.  More 
recently the project was expanded to include the genotyping data for an additional 1.6 million 
SNPs in 1184 individuals (the original four populations plus seven additional populations from 
around the world) that have resulted in the generation of a higher resolution map of variation 
across the genome
102
.  Analysis revealed that haplotype block sizes vary significantly between 
populations. Shorter blocks where observed in African populations when compared to Asian and 
Caucasian populations. This is consistent with the out of Africa theory that states that there are 
many more unique chromosomes present in African populations and that when our human 
ancestors moved out of Africa more than 1 million years ago and spread around the world, only a 
limited number of chromosomes left the continent to define these other non-African based 
populations.
103,104
. 
 While in the past, candidate gene studies and GWAS studies were performed 
independently, recently more and more genetic studies are starting to combine study designs into 
single experiments. There have been a number of successful examples where SNP tagging 
approaches, used predominantly in GWAS, have been successful applied to include specific 
candidate genes approaches. New analytical methods have been developed that allow for a 
focused analysis on candidate pathways even when whole genome genotyping is carried 
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out
105,106
. The statistical methods used for analysis are the same for both candidate gene and 
genome-wide association studies. Important aspects of theses analyses are detailed below.  
1.5.2 Statistics in Genetic Association Studies 
 In order to ensure that the results of the statistical analysis are robust and not statistical 
artifacts, there are preliminary quality control measures and analysis considerations that need to 
be taken into account whenever statistical genetic analysis in undertaken.  
1.5.2.1 Quality Measures 
 Data quality is very important in genetic association studies.  The first area that can 
potentially lead to spurious associations is poor quality genotype calls. Many algorithms exist to 
translate the raw signal from genotyping technologies into base calls (see section 1.7). These 
algorithms are susceptible to anything that alters the signal output including DNA quality and 
concentration, or human manipulation errors. Genotyping data should be checked for unusual 
patterns such as batch effects (differences in allele frequencies between plates or among 
recruitment sites) or unusual patterns of missing data. Depending on the number of SNPs 
genotyped in the study, it may be unfeasible to visualize the clustering of homozygous and 
heterozygous calls of the calling algorithm which makes other quality checks even more 
important. 
 Another quality measure is to assess if each SNP is in Hardy-Weinberg equilibrium 
(HWE). HWE is true when the two alleles at a locus are not statistically associated. In other 
words, the allele frequencies in a population remain constant
107
. In theory, this is only true if 
there is random mating, no mutation, no exchange of alleles between populations, no selective 
pressure and an infinitely large population size. Since it is impossible in reality for a locus to be 
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in perfect HWE, generally, the practice is to remove loci that deviate from HWE at a significance 
level of 10
-3
 or 10
-4
 prior to carrying out the analysis. This may be too conservative however, 
because deviations from HWE can also be due to an association to the phenotype being 
investigated with a particular genotype
108
.   
1.5.2.2 Testing for Association  
 There are numerous statistical tests for testing for association between a single SNP and a 
phenotype, each with specific advantages and disadvantages such as increased power for a 
particular risk model or the requirement of certain assumptions. The statistical method used to 
for association will depend on the phenotype in question. In the simplest example, where the 
study involves cases and controls, one can test the null hypothesis that the counts of the three 
genotypes (heterozygotes and the two homozygotes) for a SNP do not differ between cases and 
controls. Tests such as the Fisher exact test, the Cochran-Armitage test and the Pearson test can 
be used in this case
107
. When a continuous quantitative phenotype in involved, a regression 
model can be used to test if there is a linear relationship between the mean value of the 
phenotype and the genotype. With regression models, it is also possible to take into account 
covariates such as age and sex that may be associated with the phenotype. In addition to single 
SNP analyses, multi-marker and haplotype approaches can also be carried out. These approached 
may be more helpful in determining the location of a causal variant
109
.   
1.5.2.3 Reasons for Spurious Associations 
 Ideally, a significant association between a SNP and a phenotype will arise because there 
is strong linkage between the SNP and the phenotype or the causal locus for the phenotype. 
There are however, two important causes of spurious associations that may not be accounted for 
by pre-analysis quality control of the data.  
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 The most important cause is population structure. This will arise when a study involves 
multiple populations with a disproportional number of cases in one population. This will lead to 
any SNP with allele frequency differences between the outlying population and the others, 
becoming associated with the phenotype in question
110
. This was observed for example, with the 
association of a SNP in CYP3A4 and prostate cancer in African Americans that is no longer 
significant if population substructure is taken into account
111
.  If the population structure of study 
participants is known, it can be taken into account by performing a stratified analysis
112
. 
Additionally, methods such as principal component analysis (PCA) can be used to assess 
population structure from genotype data that can then be used as covariates in the analysis (see 
Figure 8)
113,114
. 
Figure 8: Example of Population Stratification Structure Analysis Using HapMap 
Samples 
 
Given a set of genetic markers that are not in LD, the program Structure
102
 is able to detect the 
presence of distinct populations in samples and cluster them accordingly. In the above example, 
Cluster 1 are HapMap CHB and JPT samples, Cluster 2 are HapMap CEU samples and the “All 
others” cluster is HapMap YRI samples. 
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 A second cause of false positive results is due to the large number of tests carried out. 
That is, when multiple SNPs are tested for association it is possible for the null hypothesis to be 
rejected by chance. The frequentist approach is to set a significance level α so that for any test, 
the probability of a false positive is α (usually 5%). If n SNPs are tested, assuming that the tests 
are independent, the appropriate per SNP significance threshold is approximately α/n. This is 
known as the Bonferroni correction
107
. While the Bonferroni correction is part of standard 
statistical design, this method can sometimes be too conservative if the SNPs tested are not 
independent, alternative methods such as permutation testing or the false discovery rate (FDR) 
approach can also be used to overcome the multiple testing problem
115
.  
 All the methods outlined above were utilized during various stages of the development 
process and during the analysis of genetic data for this project. 
1.5.3 Bioinformatics 
 As the size and scale of genetic association studies continues to grow, automated 
bioinformatic tools are necessary to complete most projects. They are required for assay and 
study design, to handle the vast amounts of data that is too large to manipulate by hand, and to 
perform the many types of complex statistical analysis that are required. Having a good 
understanding of what types of bioinformatics tools are available and how to automate data 
handling and analysis are becoming necessities in the present era of large scale genetic analysis. 
 For the ADME panel, two aspects of the assay design required the assistance of 
informatics tools. Firstly, a method was needed to select tagging SNPs for the hundreds of genes 
and in some cases entire loci included on the panel. There are several software packages 
designed for this process; however the algorithm we chose was LDSelect
96
.  This software takes 
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data from a reference population, in this case HapMap data, creates LD bins based on user 
defined criteria and selects one tag SNP per bin. An additional feature of the LDSelect algorithm 
is the ability to allow for input from multiple reference populations, which permits the selection 
of tag SNPs that will maximally cover LD bins in different populations
116
.  For many LD bins, 
more than one tag SNP can be selected, when possible, other design features such as the 
homology and GC content of the surrounding sequence can be evaluated to help prioritize which 
tag to select. 
 For each iteration of the ADME genotyping panel, over 9000 primers needed to be 
designed. The primary program that is used by most researchers for designing primers is 
Primer3
117
. Although the tool is generic and intended to design PCR primers, various parameters 
can be manipulated to allow for the designing of different primer types under stringent 
conditions. Use of this tool was necessary but not sufficient for the complex designs that were 
required for the creation of the ADME panel (see section 1.7.1). Our complex primer design 
requirements led to the development of a tool, Optimus Primer (OP), to assist with our primer 
design needs.  The OP tool enhances the capabilities of Primer3 and facilitates the design of 
large primer sets. This tool has broad applicability to next generation sequencing enrichment 
strategies and is being used presently by many groups (see section 5). 
 Approximately 295000 genotype calls are generated in a single run of the ADME panel 
(96 samples). As more and more runs are performed for any given study, it becomes clear that 
the amount of data generated becomes too large to handle with standard spreadsheet and text 
manipulation software. There are many data formats that have been and are being developed for 
the handling of genomic data, many of these tools, such as CASTOR-QC and MedSavant utilize 
the features of modern database software to store and manipulate data
118,119
. 
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 Once the data is generated and stored, it needs to be analyzed. Depending on the study, 
many different quality and statistical approaches may be performed (see above). Freely available 
statistical packages such as R are very good for basic statistical and graphing functionality; 
however their performance declines as the data sets become increasingly large 
120
. One utility 
that is commonly used in genetic studies of any type is PLINK
112
. PLINK is an entire tool set of 
utilities that can be used in genetic studies. Common features include: data filtering based on 
minor allele frequency (MAF) or HWE, association statistics including regression models, and 
calculations of genome-wide identity-by-state to detect relatedness in your sample set. 
 One of the most recent advances in the analysis of genetic data is the incorporation the 
method of imputation. Imputation is a method to determine allele calls for SNPs that are not 
genotyped in a given study population. Imputation expands a studies data by increasing the 
Figure 9: Overview of Imputation of Genotype Data 
 
Source: Marchini et al. 2007 
 
Genotypes for a particular locus are depicted as a 0 or 1 for the two possible alleles. The 
linkage disequilibrium pattern from a reference panel, such as the HapMap, is extrapolated to 
the study samples to fill in genotypes of untyped markers (depicted as ?).  Additional 
information such as the recombination rate along the genome can also be incorporated to 
facilitate the imputation
114
. 
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number of SNPs for analysis by including SNPs that were not directly genotyped but whose 
genotype can be imputed by accessing LD patterns from large reference population data sets. 
This method of analysis has been shown to add power to genetic studies by boosting the 
association signal obtained
121
. Some software packages that are used for imputation include 
BEAGLE and IMPUTE2 which will generate probability vectors for the three possible 
genotypes
122,123
 (see Figure 9). Certain statistical programs such as SNPTEST, allow for the 
uncertainty in probability distribution of the imputation results to be incorporated into a test for 
association
122
. 
 In the work presented within this thesis, imputation was used as a quality measure to 
strengthen association results observed.  Association results with a greater number of signals 
after imputing additional SNPs were considered to be more reliable.  
1.6 Pharmacogenetics and Pharmacogenomics 
 Pharmacogenetics has been defined as the study of individual gene variation on drug 
response while pharmacogenomics involves the investigation of the entire genome including 
downstream processes such as transcription. Often the terms are used interchangeably. 
Pharmacogenomics or pharmacogenetics, in the broadest sense of the terms, refers to the study of 
the relationship between heritable variation and inter-individual variation in drug response
124
.  
The concepts of pharmacogenetics were first introduce in 1957 by Arno Motulsky who 
suggested that drug sensitivity, to drugs such as the anti-malarial drug primaquine and the 
muscle relaxant succinylcholine, may be produced by similar genetic mechanisms, however the 
term was not coined until 1959 by Friedrich Vogel
125,126
.  Pharmacogenetics became a discipline 
on its own following Werner Kalow’s 1962 monograph which outlined the field127. 
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 Early pharmacogenetic research focused of variants with Mendelian-like effects on 
response. One of the more famous examples arose in 1977 when five members of a laboratory at 
St Mary’s Hospital Medical School in London took the drug Debrisoquine. One of the 
participants was Robert Smith, who was the head of the lab, and within hours began to feel dizzy 
and disorientated, and eventually collapsed with sever hypotension. While in most people 
debrisoquine is rapidly metabolized to an inactive metabolite and eliminated in the urine, Smith’s 
urine contained no metabolites of debrisoquine
128
. The work eventually led to the cloning of the 
gene responsible for the metabolism of debrisoquine, cytochrome P450 subfamily IID 
polypeptide 6 (CYP2D6)
129
. 
 The genes that encode for most drug metabolizing enzymes contain variants that have 
been demonstrated to influence enzymatic activity. Many of these functional variants have been 
associated to variation in drug response. When Phillips and colleagues looked at 27 different 
drugs prone to adverse drug reactions, they found that 59% of the drugs were metabolized by at 
least one drug metabolizing enzyme with known functional variants, whereas only 22% of 
randomly selected drugs satisfy this criteria
130
.  
 For many ADME genes frequently studied in pharmacogenomic studies, the star (*) 
nomenclature has been established as naming scheme for genetic variants. For example this is 
the standard used for cytochrome P450s
131
. The difficulty with this type of naming scheme is that 
this nomenclature often defines haplotypes, and while many of these haplotypes are defined by a 
single marker, in some cases they are not. Although this information is relevant, its usefulness is 
derived by its presence in a defined haplotype and often requires translation tables to define a 
specific star phenotype from a variable set of genotypes. 
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1.6.1 Pharmacogenomic Examples 
 Many pharmacogenomic examples have the necessary evidence to have real clinical 
relevance and regulatory agencies such as the US Food and Drug Administration (FDA) and 
Health Canada have made recommendations for genetic testing in patients being treated with 
these drugs (see appendix 1)
132
. With of all these mature examples (some of which are detailed 
below), knowledge of the pharmacokinetics and pharmacodynamics of the drug led to the 
eventual discovery of genetic variation that gives rise to variation in response. These examples 
demonstrate the utility of investigating genetic variation in know relevant pathways. 
Additionally, the following examples show the type of evidence needed in order to consider a 
genetic variant for clinical guidance and decision making. 
1.6.1.1 Warfarin 
 
 Perhaps one of the best known pharmacogenomic examples is the genetics of warfarin 
dosing. Warfarin has been on the market since 1954 and despite its extensive use, the mechanism 
of action was not elucidated until 1978. In 1974, Stenflo et al. showed that Vitamin K was a 
cofactor for the post translational carboxylation of specific clotting factors. Vitamin K is then 
transformed into Vitamin K epoxide
133
. The epoxide derivative is then recycled back to the 
reduced form of vitamin K by vitamin K epoxide reductase (VKOR) in what is known as the 
Vitamin K cycle
134
 (see Figure 10). Whitlon et al. showed that Warfarin exerts its effect by 
inhibiting the VKOR enzyme thus reducing the available Vitamin K to serve as a cofactor, and 
blocking the activation of Vitamin K dependant Clotting factors
135
. The gene encoding for 
VKOR was not discovered however until 2004 by Li et al.
136
 The effects of Warfarin can take up 
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to several days to elucidate as the stores of previously activated clotting factors become 
diminished
137
.  
 There are several clinical indications for when a patient should be prescribed warfarin, 
they include: atrial fibrillation, artificial heart valves, and deep vein thrombosis. Many additional 
clinic indications that are at risk of thrombolytic events use warfarin to reduce the capability to 
form a blot clot, to reduce the risk of embolism, or the spread of a thrombus. While the benefits 
of the prescribed treatment are effective, warfarin remains one of the most dangerous drugs on 
the market because it is difficult to dose correctly
138
.  This is due to the huge amount of 
variability among individuals with regard to the response to the drug
137
.  Currently, when 
Figure 10: Warfarin PK and PD 
 
Adapted from Gage et al. 2005 
Warfarin exerts it effect by blocking the conversion of oxidized vitamin K to the reduced 
form through vitamin K reductase. The reduced vitamin K is needed as a co-factor in the 
activation of many clotting factors. 
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patients are first prescribed warfarin, treatment is individualized by close monitoring of the 
patients International Normalized Ratio (INR).  The ratio measures the time it takes blood or 
plasma to form a clot after the addition of a tissue factor, otherwise known as prothrombin time 
(PT). Because the reaction can vary depending on the manufacturer of the tissue factor, the test 
has been standardized by an International Sensitivity Index (ISI) that the manufacturer assigns to 
a given tissue factor. The INR is therefore the PT of the patient divided by the PT of a “normal” 
control, raised to the power of the ISI.  This ensures that the INR of a patient is the same no 
matter what lab carries out the procedure and what tissue factor is used
139
.  The desired INR of a 
patient receiving warfarin therapy is generally between 2.0 and 3.0, which is a very small 
therapeutic range
140
. Warfarin is considered a drug with a narrow therapeutic index in that the 
minimum toxic concentration is less than twice the minimum effective dose.  In essence, 
physicians play a game of trial and error in attempting to raise the patients INR to the desired 
range.  Despite the additional monitoring of warfarin treatment, the incidence of adverse drug 
reactions is estimated to be between 7.6 and 16.5 per 100 patient years which is very high for 
such a commonly prescribed medication
134
. 
 Warfarin is comprised of two enantiomers, an R and an S form. The S form is 5 times 
more potent than the R as an inhibitor of the vitamin K reductase
141
. The S form is primarily 
metabolized by CYP2C9 and several functional variants have been identified, the two most 
important being the CYP2C9*2 and CYP2C9*3 mutations
142–145
.  Several studies have shown 
that individuals homozygous for these mutations can have as little as 5% of normal enzymatic 
activity and require a lower mean daily dose and are more prone to adverse bleeding events
146
.  
The frequency of the *2 and *3 alleles in non-Caucasian populations is low and other functional 
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variants are likely to contribute to warfarin dosing variability, these include *5, *6, *8 and 
*11
147
. 
 As mentioned above, warfarin acts by inhibiting the enzyme responsible for the recycling 
of Vitamin K in the Vitamin K cycle.  The enzyme VKOR is comprised of several subunits and 
it has been shown that sub unit 1 (VKORC1) is primarily responsible for the VKOR activity. 
Missense mutations in this gene seem to explain what is known as warfarin resistance, perhaps 
due to the fact that warfarin is unable to bind to the subunit and exert its effects
148–150
. However, 
like CYP2C9, several common SNPs in VKORC1 have been associated with warfarin 
sensitivity. Specifically, the markers that define two haplotypes (labeled A and B or H1 and H2 
or *2 and *3 depending on the study) have been associated with low and high dose requirement 
of warfarin
151–155
. It has also been shown that these haplotypes correlate with variable VKORC1 
mRNA expression levels which in turn translates to variability in VKORC1 receptor numbers 
that now sheds light on part of the mechanism responsible for warfarin sensitivity
153
. Taken 
together, in the above mentioned studies, about 40% of warfarin dose variability can be 
explained by variation in CYP2C9 and VKORC1. When other clinical factors such as age, 
weight, height and interacting drugs are also considered, over 50% of the variability in dose can 
be explained in Caucasian populations. These results are similar in Asian populations, however 
they do not explain as much of the variation in African populations
156,157
. 
 More recently, the role of CYP4F2 in the vitamin K cycle was established as the primary 
liver microsomal vitamin K oxidase that removes vitamin K from the cycle
158
. A single variant in 
CYP4F2 (V433M) has been associated with warfarin dose variation in multiple studies
159–162
. 
CYP4F2 accounts for an additional 1-4% of warfarin dose variability, however the clinical utility 
of genotyping CYP4F2 is presently unclear. 
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 The final member of the vitamin K cycle to be investigated for association with warfarin 
dose is gamma glutamyl carboxylase (GGCX). One SNP (rs11676382) has been associated with 
warfarin dose variability in Caucasians and African-Americans but it only contributes to a lesser 
extent and is not considered for most dosing algorithms
163
. Other SNPs identified in GGCX have 
conflicting data as to their effects on warfarin dose.  
 Many studies are now taking both genetic and clinical factors into account and have 
created warfarin dosing algorithms that can help guide dosing
164
. Theses algorithms are 
constantly being updated to include new findings. Several dosing algorithm are presently being 
evaluated to prove their utility in the clinical setting
165
. Epstein et al. genotyped 896 cases 
matched to 2688 historical controls and over a 6 month follow up period, prospectively found 
that genetic testing reduced hospitalizations by 31% overall and bleeding and thromboembolism 
hospitalizations were reduced by 28%
166
.  Thus, the potential for pharmacogenomics to improve 
healthcare is now becoming a reality. 
1.6.1.2  Clopidogrel 
 Clopidogrel is one of the most widely prescribe anti-platelet medications that acts to 
inhibit the formation of blood clots by inhibiting platelet aggregation and goes by the trade name 
Plavix
167
. Clopidogrel is a prodrug and must be metabolized to produce the active metabolite. 
This active metabolite selectively inhibits the binding of ADP to its platelet receptor (P2Y12) 
and prevents the ADP mediated activation of the glycoprotein complex that is the major receptor 
for fibrinogen
168
. Thus, the mechanism of action for clopidogrel ultimately inhibits the P2Y12 
platelet receptor so that fibrinogen cannot bind to platelets to cause aggregation. 
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 Several genes have been investigated for association with response to clopidogrel. These 
include: the gene coding for efflux transporter ABCB1, involved in the intestinal absorption of 
clopidogrel; the P2Y12 receptor gene; and several CYP genes involved in the metabolism of 
clopidogrel
169,170
. The only gene that consistently shows association with primary clinical 
outcomes is CYP2C19
171–175
. CYP2C19 is involved in both the formation of the active 
metabolite and the 2-oxo intermediate metabolite
167
. A number of polymorphisms in CYP2C19 
have been associated with clopidogrel response; of note are the alleles that define the *2 and *3 
loss of function haplotypes whose carriers have reduced clopidigrel response
170,171
. Another 
allele is *17 which early data indicates results in increased enzyme activity and enhanced 
metabolism of clopidigrel and therefore increased platelet inhibitor and increased risk of 
bleeding
176
. This result has not been replicated as yet.  Several cohort and post-hoc clinical trial 
studies have evaluated the effects of CYP2C19 variation on both the clopidigrel response and 
adverse events. The diminished anti-platelet response to clopidigrel for patients that are 
CYP2C19 intermediate and poor metabolizers has been observed in over 20 studies consisting of 
over 4500 subjects
177
. Adverse cardiovascular events have also been associated with the 
CYP2C19 genotype. In two studies, patients with impaired metabolized status had up to a 2.7 
fold increased risk of new cardiovascular events (death, myocardial infarction, stroke or urgent 
revascularization)
171,173
. Patients with impaired metabolizer status have also been observed to 
have a 2.1 to 2.8 fold increases risk of stent thrombosis
172–174
.   
 Interestingly, two more recent studies have led to conflicting results. The first, involving 
two large randomized placebo-controlled trials of clopidigrel for treatment of acute coronary 
syndrome (ACS) and atrial fibrillation, showed that impaired metabolizer status for CYP2C19 
had no effect on risk of cardiovascular outcomes
178
.  This may be attributed to the fact that only 
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14.5% of patients in these trials underwent percutaneous coronary intervention with stenting 
compared to 70% in previous studies. The second, a genetic substudy of a clinical trial 
comparing ticagrelor versus clopidigrel in the treatment of ACS, found that patients with 
impaired metabolizer status for CYP2C19 had increased risk for major cardiovascular events but 
only in the first 30 days of treatment
179
. Taken together these results suggest that genotyping for 
clopidigrel therapy may be only important in acute situations where patients are undergoing 
stenting.  Despite these results, two recent meta-analyses, looking at almost 20 000 patients, 
show that there is a strong association between CYP2C19 loss of function alleles and adverse 
cardiovascular events with even greater risk when stent thrombosis is analyzed separately
180,181
. 
1.6.1.3  Thiopurine Drugs 
 Thiopurine drugs, azathioprine (AZA), 6-mercaptopurine (6-MP) and 6-thioguanine (6-
TG), are purine antimetabolites used in the treatment for acute lymphoblastic leukemia and other 
hematological malignancies, autoimmune disorders such as Crohn’s disease and Rheumatoid 
arthritis, and for the prevention of organ transplant rejection. All three drugs are given as 
prodrugs and require intracellular activation via multiple metabolic pathways to give rise to their 
cytotoxic effects
182,183
. The active metabolites can exert their effects in a number of ways. They 
can be incorporated into DNA or RNA, leading to the inhibition of replication and DNA and 
RNA repair processes, they can prevent the de novo synthesis of purines and finally they can 
inhibit Rac1 which leads to apoptosis in T-cells
184
. The pathways that lead to the production of 
active metabolites are in competition with the pathways that lead to the inactivation and 
clearance of the drugs. Specifically, the inactivation is catalyzed by two enzymes, xanthine 
oxidase (XO) and thiopurine methyltransferase (TPMT)
182,185
.  
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 The catabolism reaction by XO occurs primarily in the plasma and urine following 
thiopurine administration. Xanthinuria is a rare genetic disorder that is caused by a deficiency in 
XO and leads to renal failure. Aside from this rare disorder, there is a 4 to 10 fold difference in 
inter-individual XO activity in individuals
186,187
.  To date, three small studies have looked at 
genetic variation in XO in relation to thiopurine response or adverse reactions and the results 
have been inconclusive
188–190
. One study found a weak protective effect of the C837T SNP (p 
=0.048) while another showed a trend to higher 6-MP concentrations in patients heterozygous for 
two other variants
189,190
. Further studies are required to investigate genetic variation in XO. 
 The enzyme that is most studied with established evidence of the role genetic variation as 
a contributor to inter-individual variability in thiopurine efficacy and toxicity is TPMT. 
Deficiency of TPMT was first described in 1980 when it was observed that 1 in 10 Caucasians 
have intermediate enzyme activity and 1 in 300 have deficient enzyme activity
191
. Over the next 
20 years, several studies documented the association between TPMT activity and the levels of 
cytotoxic metabolites and the relationship between TPMT activity and severe myelotoxicity
192–
195
. In general, TPMT deficiency is associated with more severe myelotoxicity, although only 
25% of all cases of thiopurine-induced myelosuppression can be explained by TPMT deficiency, 
and increased TPMT activity is associated with poor treatment response and higher risk of 
relapse
196,197
.  Recently, two meta-analyses have been carried out to summarize the relationship 
between TPMT variation and thiopurine response and toxicity. These analyses showed a 2.93 
fold increase (95% C.I. 1.68-5.09) in the incidence of patients who were homo or heterozygous 
for the TPMT *3A and *3C variants and who had thiopurine-induce adverse reactions
198
. 
Additionally, the odds ratio for leucopenia in patients that with reduced TPMT activity was 4.19 
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(95% C.I. 3.20-5.48) indicating the potential value of TPMT genotyping to reduce adverse drug 
reactions
199
.   
1.6.2 Genome wide Association Studies in Pharmacogenomics  
 There have been many genome wide association studies (GWAS) performed on drug 
toxicity and response phenotypes since 2005, when the first GWAS studies were published
200
. 
The majority of these studies have not found any statistically significant associations
201
. There 
are a number of reasons why pharmacogenomic GWAS studies have not been very successful. 
First, it is difficult to recruit the large sample sizes needed to have statistical power to detect 
small or medium sized effects. In contrast to complex-disease phenotypes, an exposure to a 
particular drug is necessary to give rise to a drug response phenotype, and patients that are non-
responders or have an adverse drug reaction are rare compared to patients that respond favorably 
to the drug. This also makes it difficult to replicate any findings that may be observed in a 
second cohort of patients. Second, the characterization of drug response phenotypes can be very 
difficult unless there is a clear quantitative measure as is the case with some drugs such as anti-
coagulants. Furthermore, many of the GWAS studies that have been conducted have been 
performed on clinical patient samples years after the trials have been completed and much of the 
phenotypic data is often incomplete or was not captured due to the fact that the trials were not 
designed as genetic studies. This gives rise to heterogeneous phenotypes that mask true 
associations. Lastly, the coverage of current genome-wide SNP arrays is not complete and 
specifically rather poor in ADME gene regions. Due to reasons such as SNP density and 
homology present in many pharmacologically relevant genes, genetic variation in most known 
ADME candidate genes is frequently not fully tested (see below). 
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 Despite the added difficulties of performing a GWAS study on pharmacogenomic 
phenotypes, there have been a number of successful examples reported to date (see table 5). 
Table 5: Published Successful Pharmacogenomic GWA Studies.  
Drug Phenotype Number 
of Cases 
Associated Gene(s) Reference(s) 
Warfarin Maintenance dose 181; 1053 VKORC1, 
CYP2C9,CYP4F2 
202,203
 
Clopidogrel Antiplatelet effect 429 CYP2C19 
204
 
Interferon-α Response in hepatitis 
C infection 
1137; 293; 
154 
IL28B 
205–207
 
Methotrexate Drug clearance 434 SLCO1B1 
208
 
Simvastain Myopathy 85 SLCO1B1 
209
 
Flucloxacillin Liver injury 51 HLA-B*5701 
210
 
   There are two interesting points to note when looking at genes associated with drug 
response and toxicity phenotypes in GWA studies: firstly, in four of the six studies, the only 
associated genes are ADME genes and secondly, in the warfarin and clopidagrel studies, the 
genome-wide approach did not add any additional information to what was already know using a 
hypothesis driven candidate gene approaches. 
1.6.3 In Vivo Probe Drugs 
 While many genetic variants have been associated with drug response, there remains 
variability in drug response that cannot be explained by genetics alone. Additionally, genetic 
variability does not account for other factors that influence drug response such as environment or 
disease status
211
.  The only method to accurately assess the in vivo activity of drug metabolism 
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enzymes and transporters is with the use probe drugs. Probe drugs are known substrates for a 
particular enzyme that are administered and following the appropriate measurement of 
pharmacokinetic parameters, are used to determine quantitatively enzyme or transporter 
activity
212
.  The most common form of in vivo probe phenotyping, involves the administration of 
a drug followed by the measurement of the drug’s metabolite in plasma or urine. The usual 
method of choice for metabolite quantification is chromatographic separation with tandem mass 
spectrometry
212
.  A number of compounds have been validated as probes for several phase 1 
metabolism enzymes. These include: caffeine for CYP1A2, warfarin for CYP2C9, omeprazole 
for CYP2C19 dextromethorphan for CYP2D6 and midazolam for CYP3A isozymes. Probe drugs 
for phase 2 metabolism enzymes and transporters are not as well developed and not as frequently 
used however include caffeine for NAT2 and digoxin for ABCB1 
213,214
. While the 
administration of a single probe drug may be useful for selective phenotyping of a single 
enzyme, efforts have been made to create combination probes, or cocktails, of probe drugs to 
simultaneously assess the activity of several metabolism enzymes. Examples of probe cocktails 
include: the Cooperstown 5+1, for cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-
acetyltransferase-2, and xanthine oxidase; and the Inje cocktail that uses probe drugs that are 
more readily available for the assessment of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A
215,216
.  There are limitations to the cocktail approach however; including the potential for 
interaction between probe drugs, side effects and toxicities of probe drugs and analytical 
complexities is assessing several metabolites concurrently which is why the maximum number of 
enzymes that can be quantified simultaneously using this method remains low
217
.  This is a why 
a genotyping approach remain the only method for broad characterization of several ADME 
pathways at once. 
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1.7 Genotyping Technologies 
 When selecting a genotyping technology for the ADME panel, it was important to 
evaluate all the technology platforms for a number of critical parameters; throughput in terms of 
number of SNPs and number of samples that can be processed simultaneously, accuracy, 
consistency of the data, ease of use, and cost. Thus, we were looking to identify the optimal 
technology and platform that is highly accurate but which balances throughput with costs. There 
are several available technologies on the market today, each with their own advantages and 
disadvantages depending on the application. However, no matter the technology, there are two 
features common to all platforms; they must have a method/technology that can differentiate 
between a minimum of two alleles and that the different alleles produce unique signal profiles 
that can be interpreted by genotyping calling algorithms
218
. 
 The most common genotyping methods commonly used to discriminate alleles are single 
primer extension, hybridization, and ligation. In single primer extension reactions, an enzymatic 
reaction involves the allele specific incorporation of dideoxy-nucleotides to extend a primer 
bound to a DNA template by one base. Generally, a unique primer is designed to bind with its 3’ 
end adjacent to the SNP being interrogated, thus the allele discrimination is determined by the 
enzymatic addition of a single labeled nucleotide. The label is incorporated into the extension 
product, the product is isolated and some sort of detection is performed. The label can be a mass 
and detection can occur by means of mass spectrometry (MassExtend iPlex arrays; Sequenom; 
San Diego, CA), or the label can be a flurophore that when excited, emits light of a certain 
wavelength that can be detected (SNPstream; Beckman Coulter, Fullerton, CA & Infinium assay; 
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Illumina, San Diego, CA). In hybridization based reactions, the reaction conditions are such that 
probes will only bind to perfectly complimentary targets. Thus, specificity is determined by the 
binding of probes to the allele in question. In this type of reaction, a probe is required for each 
possible allele of the SNP in question. Generally, the different probes will have different labels 
similar to the primer extension reactions or the probes may be anchored to a solid state such as a 
microarray (Affymetrix Genechip microarrays, Santa Clara, CA). In ligation reactions, the 
specificity is determined by both hybridization to unique DNA sequences and the specificity of 
the enzymatic activity of the ligase enzyme that can only ligate primers that are located 
proximally to each other. Typically, three probes are needed for this type of reaction; two probes 
are allele specific that are complimentary to the variant nucleotide and the third binds in the 
adjacent region to the SNP that is being queried (GoldenGate assay, Illumina, San Diego, CA). 
The ligase will then only join the probes that are perfectly complimentary creating a single 
oliognucelotide. The detection occurs in a similar fashion to the primer extension method with 
differently labeled allele specific probes.  
 The majority of assays on the market use one or a combination of the detection methods 
described above. The level of plexing (number of SNPs interrogated simultaneously) tends to be 
inversely proportional to the number of samples that can be run simultaneously in a single 
experiment. At one extreme are the whole-genome genotyping arrays, such as the Illumina 
Infinium Beadchips which use a primer extension reaction of probes anchored to beads and the 
Affymetrix GeneChip arrays that use a hybridization approach. Currently, these assays can 
interrogate millions of SNPs in a single experiment. On the lower end of the plexing spectrum 
are technologies that do not interrogate as many SNPs simultaneously; however these 
technologies are able to process hundreds of samples in a single experiment. One example is the 
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Sequenome iPlex assay that query up to 40 SNPs simultaneously in a single reaction, using a 
single primer extension reaction, in up to 384 samples in a single experiment. 
1.7.1 The Golden Gate Platform 
 The platform selected for the ADME panel development was the Illumina GoldenGate 
(GG) assay
219
. The GG assay analyzed on the Bead Station platform allows for the plexing of up 
to 3072 SNPs in a single reaction and can process 96 samples in a single experiment. An 
advantage of the GG platform is that the allele discrimination chemistry is highly accurate and 
consistent because it incorporates three levels of specificity; hybridization, primer extension and 
ligation. The reaction proceeds as follows (see Figure 11). 1. Genomic DNA is activated through 
a biotinylation reaction and is immobilized on streptavidin beads. 2. A pool of oligonucleotides 
(OPA), containing three primers per SNP, is added to the activated DNA. The three primers are 
designed as two allele specific primers (ASOs) that will only anneal to DNA that is 100 percent 
complimentary and a locus specific primer (LSO) that will anneal a few bases 3’ to the SNP in 
question. 3. A primer extension reaction is performed next that will extend the ASO that has 
successfully bound towards the LSO and a ligation reaction further joins the extended ASO to 
the LSO. Unextended primers, excess reagents and the genomic DNA are washed away leaving 
only a pool of ligated ASO-LSO oligos. 4. The ASO and LSO contain sequences that allow for 
universal PCR amplification using universal primers that incorporate one of two possible 
fluorescence labels into the amplified product. The LSO also contains a sequence (illumacode) 
which is complimentary to a probe anchored to a bead on a Sentrix array or on a GoldenGate 
chip. 5. The PCR product is then hybridized to the bead and the fluorescence is detected to 
determine genotype. 
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 Having multiple levels of specificity, along with the number of SNPs that can be included 
and run on 96 samples at a time made the GoldenGate platform ideally suited for the ADME 
panel development.      
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Figure 11: The GoldenGate Chemistry 
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 The goal of this introduction was to provide an overview of the background that was 
researched in to order design, optimize and complete the development of a broad base ADME 
genotyping panel that has broad applicability to many research and clinical studies. Furthermore, 
the introduction was also intended outlined the extensive bioinformatic and statistical genetic 
tools that were necessary to adequately interpret and analyze our large data sets. Lastly, the 
introduction gave an overview of the current state of pharmacogenomic research and 
demonstrated that there is an unmet need for the creation of a targeted broad based ADME panel 
the can be used in clinical research that can simultaneously screen known functional variants but 
at the same time identify novel pharmacogenomic biomarkers in key ADME genes. 
The following sections of this thesis are organized into 4 additional chapters. Chapter 2 
describes how the genetic content, both on the gene and SNP level, for the ADME panel was 
selected in collaboration with the PharmaADME working group; made up of members of the 
pharmaceutical industry and academia. Chapter 3 details the design, development, optimization 
and validation processes that were perform to complete the development of the 3000 SNP broad 
based ADME genotyping assay. Chapter 4 details the utilization of the assay in a research project 
involving DNA samples derived from human liver tissue in order to demonstrate the utility of the 
assay. Finally, Chapter 5 details how a bioinformatic tool that was developed in support of the 
ADME panel assay development process was further developed and made publicly available.   
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2  Development of a Consensus List of ADME Genes and Polymorphisms 
for Use in Pharmaceutical Clinical Trials: The ADME “Core” List 
This section describes the process of selecting the content for the ADME panel. In order 
to facilitate this process, in addition to extensive literature searches, the expert opinions of 7 
pharmaceutical and 3 life-science companies was sought to develop a consensus list of ADME 
genes for which there is compelling evidence of relationship between genotype and ADME 
pathways, and which could be used as a standard panel in drug development and to support 
regulatory submissions, and, if appropriate, general clinical practice. Through an iterative 
process, we identified a “Core List” of 32 ADME genes meeting these criteria, and 184 markers 
comprising all currently known alleles with utility in testing clinical samples. 
This process was unique because in addition to tapping into published resources to select 
ADME genes and variation, detailed information from the drug development programs of several 
pharmaceutical companies was incorporated. Not all of this information is available to the public 
and therefore it provided this initiative with a thorough list of ADME genes and variation, one of 
the most complete to date.  
The content described in this section formed the basis for the ADME panel development, 
described in section 3. Interestingly, three genomic technology companies have used the 
information generated in this collaboration to develop ADME genotyping assays. Being the 
curator of the data allowed me to analyze and merge the data from the various sources into a 
single universal format. Additionally, when possible, the information had to be verified either 
through resources such as the Human Cytochrome P450 (CYP) Allele Nomenclature Committee, 
dbSNP and often the original publication describing the gene or variation
220,221
. 
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Finally, a website was created to store and share everything generated in this initiative. 
Access to this website is freely-available to the entire pharmacogenomic community that can be 
accessed using the following URL: www.pharmaadme.org. Importantly, the website also serves 
as a portal for discussion so that we can keep the data up to date. 
2.1 Introduction: 
The advent of high throughput genetic analysis technologies and the ability to identify 
genes which can modify risk for disease, affect response to therapy or predict the development of 
side effects have been espoused as a means to improve drug development and ultimately 
therapeutic outcomes
222.  Many terms, such as personalized medicine, tailored therapy, or “the 
right drug into the right patient”, are often used to describe how applied genetics will benefit and 
improve health outcomes in patients.  However, as the last several years have demonstrated, the 
maturation of genomic associations into successful genomic biomarkers and then dissemination 
of these observations into general medical practice requires multiple, time consuming steps.  
Presently, one of the major goals of the clinical research community is to find ways to effectively 
translate this information into improved patient care.   
2.2 FDA Critical Path: 
In order to address documented inefficiencies associated with drug development, the 
FDA, in March 2004, outlined their proposal for the critical path initiative to accelerate the drug 
development process
223
. Among other aspects, the proposal identified some of the major 
challenges associated with the current drug development pipeline and outlined the need for better 
evaluation tools. To this end, the FDA recommended the development and implementation of 
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programs to accelerate the identification of new biomarkers that can improve clinical outcomes 
by helping to predict safety and drug response profiles
223
. With the recent advances both in our 
knowledge of the human genome and in genomic technologies, researchers are now starting to 
understand the role that genetic variation plays in a drug’s metabolism and/or mechanism of 
action
224
. One goal is to better understand how variation in genes involved in metabolism and 
transport affects how patients respond to specific drugs.  Improved predictive genomic tools may 
be used to select which patients receive a particular drug, how much of that drug is prescribed, 
and at what frequency and duration.  It is anticipated that the use of genomic biomarkers will 
have a profound effect on the way drugs are developed and subsequently utilized, by producing 
tools that identify genomic factors that can affect a drug’s efficacy and safety.  
2.3 The Pharmaceutical Company Perspective 
Many pharmaceutical companies have begun to integrate biomarker development 
programs into their pre-clinical and clinical drug development pipelines with the goal of 
improving drug development and impacting patient outcomes
224,225
. Recently, genomic 
biomarker programs have seen success in measuring DNA variation and/or changes in gene 
expression and relating that to adverse drug response or disease progression and risk
226–228
. These 
genomic approaches are becoming more widely incorporated into drug development, and have 
been facilitated by better technologies, the completion of the sequencing of the Human Genome 
and by the HapMap project
229–232
.  
Genetic biomarkers predicting improved therapeutic benefit can fall into one of three 
categories:  1) predicting likely response to therapy; 2) predicting susceptibility to an adverse 
event; or 3) predicting an altered metabolic profile.   Furthermore, the marker must be 
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sufficiently validated and the risk conferred by the marker must be sufficiently understood.  In 
addition, a validated assay, with defined sensitivity and specificity, must be generally available 
to meet the standards necessary for modern medicine. Finally, if a validated biomarker is to be 
co-developed with a drug or to be used to direct prescribing practices, regulatory approval is 
mandatory. 
Variability in individual patient response to a drug, in terms of therapeutic benefit and/or 
side effect profiles, is commonly observed for many marketed pharmaceuticals.  Genetic 
variation at the drug’s molecular target or within critical components of the target molecule’s 
pathway might be the cause of some variable responses to administered drugs.  Alternatively, 
variation in genes encoding key enzymes involved in pathways affecting pharmacokinetics (PK) 
may directly contribute to the observed variation in patient response to drug. While we 
acknowledge the potential importance of the former source of variable drug response, we are 
particularly interested in the latter, i.e. the pathways that affect how a drug is Absorbed, 
Distributed, Metabolized and Excreted (ADME). One area of genetic biomarker research where 
there has been steady flow of published information is the study of the effects of genetic 
variation on these pharmacokinetic pathways
228,233,234
.  This is of particular interest because, for 
the most part, drugs are all metabolized by the product of a well-known set of genes and 
pathways that influence their pharmacokinetic responses while the mechanisms of action and the 
therapeutic uses of the various drugs may differ.  
For example, Phillips et al. observed that 59% of the 27 drugs most frequently cited in 
Adverse Drug Reaction (ADR) studies were known to be metabolized by an ADME enzyme 
with at least one known loss of function allele
235. With the advancement of today’s technology 
platforms, expertise to develop genomic tools that can help identify variants in ADME-related 
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genes affecting pharmacokinetics, and thus efficacy, safety, and dosing of a drug has become a 
cost-effective opportunity. The current challenge for the field is to determine the set of genes and 
variants for which sufficient evidence is available to justify their examination during drug 
development on a routine basis. 
2.4 Development of an ADME list of Genes and Genetic Markers: 
The FDA recognizes that integrated multidisciplinary groups need to be formed in order 
to tackle the goals set out in the Critical Path. These goals are not achievable by one single 
company, university or government agency alone
236
.  The initiative described herein, to create a 
consensus “Core List” of ADME genes was launched by the pharmaceutical industry because it 
became clear that there was a need to develop a standardized list of “evidence based” genes with 
enabling technological tools to support drug development. Along these lines, a unique partnering  
of a group of representatives from the pharmaceutical industry and an academic center  came 
together to develop a consensus list of ADME genes and genetic variants that would be used as 
an initial tool to better understand drug disposition. The objective of the partnership was to 
assemble a diverse group of researchers and develop a consensus “Core List” of ADME genes 
and markers that could be employed in the drug development process, in support of FDA 
submissions, and ultimately in general clinical practice. Representatives from the following 
pharmaceutical companies participated in this effort: GlaxoSmithKline, Research Triangle Park, 
NC, USA; Eli Lilly and Company, Indianapolis, IN, USA; Abbott Laboratories, Abbott Park, IL, 
USA; Johnson & Johnson, Raritan, NJ, USA; Bristol-Myers Squibb, Lawrenceville, NJ, USA; F. 
Hoffmann-La Roche, Basel, Switzerland; Sanofi-Aventis, Bridgewater, NJ, USA.; Merck & Co 
Inc., Whitehouse Station, NJ. USA. Whithin these organizations, representatives from with 
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backgrounds in pharmacogenomics, biomarkers, drug development, and molecular diagnostics 
provided input to the final ADME content. 
The initiative was divided into four distinct phases: characterization and compilation of 
an ADME gene list, criteria and selection of ADME genes for a Core List, criteria and selection 
of genetic variants for the core gene list, and development of an extended list of ADME and 
ADME-related genes. 
2.4.1 Phase I: Characterization and Compilation of an ADME Gene List 
 The first step of the process was to build a global list of genes known or thought to be 
involved with metabolism and transport of pharmaceuticals.  The approach was to ask each 
participating organization to devise a list of genes of interest to them and submit their list to a 
central organizer.   A total of 9 lists (from pharmaceutical companies and an academic center) 
were received and the number of genes per list varied from as few as 10 to as many as 350.  One 
of the first major challenges encountered during this exercise was the merging and consolidation 
of the genes lists, which need to be converted into a single standardized format. This included 
mapping all genes to a unique chromosomal position on the current build of the human genome 
(NCBI 36.1), using the correct HUGO (www.genenames.org) nomenclature to describe genes, 
and using the same naming scheme to define genetic variants.  Once the lists were identically 
formatted, it was discovered that a few genes were common to most lists, but that many genes 
were unique to one or two lists. This clearly illustrated some of the challenges that were to be 
faced by the group in establishing consensus on a relevant core set of genes. 
Once the lists were consolidated, genes were grouped into four categories: 1) phase 1 
enzymes, responsible for oxidation/reduction reactions; 2) phase 2 enzymes, responsible for the 
67 
 
 
conjugation reactions; 3) transporters, responsible for the movement of drugs in and out of 
tissues or compartments; and 4) drug metabolism modifiers, that can either alter the expression 
of, or affect the biochemistry of, ADME genes. As not all the genes on the initial nine lists fell 
into these four categories, a second grouping was identified as ADME-related genes; this list 
consisted of genes involved in pharmacodynamic mechanisms. These are genes identified as 
being drug targets, receptors, ion channels or genes involved in individual drug effect 
mechanisms. While many of these genes are important for a pharmacological response of a 
specific drug, they are not broadly applicable across many therapeutic classes of medication. For 
example a gene that was common to many of the participants’ lists but that was characterized by 
the group as an ADME-related gene was the gene encoding catechol-o-methyltransferase 
(COMT) which is part of the degradative pathways for catecholamine transmitters but did not 
fulfill the required criteria of  a “drug metabolizing”237. 
The group decided that genes involved in disease predisposition and prognosis were 
ineligible due to the ethical and legal considerations involved in screening for these variations. 
For example, variations in glucose-6-phosphate dehydrogenase (G6PD) can predispose 
individuals to hemolytic anemia. Thus, even though G6PD can influence a patient’s response to 
6-mercaptopurine, it was none-the-less dropped from the list for potential ethical and legal 
reasons
238
. After normalization of the information contained within the individual lists and 
application of the criteria described above, a final master list of 295 ADME genes was obtained 
(Figure 12). It is composed of 126 genes categorized as phase I enzymes (43%); 68 genes 
categorized as phase II enzymes (23%); 77 genes categorized as transporters (26%); and 24 
genes identified as ADME gene modifiers (8%).  
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2.4.2 Phase II: Criteria and Selection of Genes for a Core List 
Although it would be of interest to sequence the comprehensive list of ADME-relevant 
genes in every patient, analyzing, classifying and housing the data would be an impossible task 
in addition to the current prohibitive cost of sequencing at this level. Therefore, the group 
decided that a key deliverable of their collaborative efforts would be an ADME Core List, 
cataloging those genes deemed most justifiable to include on a screening panel for routine use. 
Thus, genes in the “Core List” were selected to fit one or more of the following criteria: 1) genes 
listed as US-FDA validated;
239
 2) genes which had a significant body of published evidence in 
the literature indicating the gene or its variants were involved in drug disposition; or 3) key 
Figure 12: Composition of the Complete ADME List of Genes. 
 
A total of 295 genes were deemed to be directly involved in drug metabolism and/or had the 
ability to influence a drug’s pharmacokinetic profile. Of the four categories that the genes 
were placed in: 126 (43%) where categorized as phase I enzymes (Blue); 68 (23%) where 
categorized as phase II metabolic enzymes (Red); 77 (26%) where categorized as 
transporters (Green); and 24 (8%) where identified as drug metabolism modifiers (Purple). 
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opinion leaders had evidence that the gene or its variants were involved in drug disposition. The 
goal here was not to be overly restrictive, but to get a consensus list of important or ‘core’ genes. 
It was acknowledged by the group that as more data is generated, the number of genes on the 
Core List may be greater or lesser to reflect the evolving state of our knowledge of drug 
metabolism and excretion. 
Table 6: Inclusion/Exclusion Criteria for the ADME genes and markers 
 Must be involved in drug pharmacokinetics 
 Flagged by the FDA as validated 
 Supported by published literature of more than one group that the variation 
alters gene function 
 Supported by key opinion leaders in the drug metabolism field as altering 
gene function 
 Genes associated with disease have been excluded for ethical reasons 
 
Using the defined set of inclusion criteria applied to the genes in Table 6, a consensus list 
of 32 Core ADME genes was identified (Table 7). Examples of genes that made the Core List as 
US-FDA validated markers included CYP2C9, CYP2C19, CYP2D6, DPYD, NAT2, TPMT and 
UGT1A1. Examples of genes that had an extensive body of supporting published evidence were 
CYP1A1, CYP1A2, CYP2B6, NAT1, SULT1A1, ABCB1 (MDR1) and SLCO1B1 (OATPC). 
Other genes that were strongly recommended by experts working in pharmacokinetics and drug 
development included genes like CYP3A7 and the GST’s.  
Table 7: Gene Composition of the ADME Core List 
Gene 
Symbol 
Full Gene Name Class 
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 Phase I 
CYP1A2 cytochrome P450, family 1, subfamily A, polypeptide 2 Phase I 
CYP2A6 cytochrome P450, family 2, subfamily A, polypeptide 6 Phase I 
CYP2B6 cytochrome P450, family 2, subfamily B, polypeptide 6 Phase I 
CYP2C19 cytochrome P450, family 2, subfamily C, polypeptide 19 Phase I 
CYP2C8 cytochrome P450, family 2, subfamily C, polypeptide 8 Phase I 
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CYP2C9 cytochrome P450, family 2, subfamily C, polypeptide 9 Phase I 
CYP2D6 cytochrome P450, family 2, subfamily D, polypeptide 6 Phase I 
CYP2E1 cytochrome P450, family 2, subfamily E, polypeptide 1 Phase I 
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4 Phase I 
CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5 Phase I 
DPYD dihydropyrimidine dehydrogenase Phase I 
GSTM1 glutathione S-transferase M1 Phase II 
GSTP1 glutathione S-transferase pi Phase II 
GSTT1 glutathione S-transferase theta 1 Phase II 
NAT1 N-acetyltransferase 1 (arylamine N-acetyltransferase) Phase II 
NAT2 N-acetyltransferase 2 (arylamine N-acetyltransferase) Phase II 
SULT1A1 sulfotransferase family, cytosolic, 1A, member 1 Phase II 
TPMT thiopurine S-methyltransferase, Phase II 
UGT1A1 UDP glucuronosyltransferase 1 family, polypeptide A1 Phase II 
UGT2B15 UDP glucuronosyltransferase 2 family, polypeptide B15 Phase II 
UGT2B17 UDP glucuronosyltransferase 2 family, polypeptide B17 Phase II 
UGT2B7 UDP glucuronosyltransferase 2 family, polypeptide B7 Phase II 
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 Transporter 
ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Transporter 
ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 Transporter 
SLC15A2 solute carrier family 15 (H+/peptide transporter), member 2 Transporter 
SLC22A1 solute carrier family 22 (organic cation transporter), member 1 Transporter 
SLC22A2 solute carrier family 22 (organic cation transporter), member 2 Transporter 
SLC22A6 solute carrier family 22 (organic anion transporter), member 6 Transporter 
SLCO1B1 solute carrier organic anion transporter family, member 1B1 Transporter 
SLCO1B3 solute carrier organic anion transporter family, member 1B3 Transporter 
In order to facilitate data entry and maximize participant input, a website was created to 
manage the project (www.PharmaADME.org). The website is publicly available and contains all 
the gene and marker information for the ADME Core List, as well as details on the inclusion 
criteria established by the group. Further, the website allows users to provide feedback and 
suggestions on additional genes or genetic variants for inclusion on the Core List. It is important 
to note that the gene and marker lists are not static. The lists will be periodically updated as the 
body of knowledge pertaining to ADME-related genes develops. 
71 
 
 
2.4.3 Phase III: Criteria and Selection of Genetic Variants on Core Gene List 
Once the Core ADME Gene List of 32 genes was established, an accompanying set of 
genetic variants, or markers, within these genes needed to be created, since this known variation 
is what would be accessed in patient samples. Criteria for inclusion of the markers mirrored what 
the group had established for gene selection. Thus, variants had to be:  1) US-FDA validated 
variants; 2) supported by published literature from more than one group that the variation altered 
gene function; 3) supported by key opinion leaders in the drug metabolism field as altering gene 
function; or 4) one that causes an amino acid change in the protein encoded by the gene. 
In parallel with the gene lists, each of the participating groups submitted lists of genetic 
variants for their list of ADME genes. Marker identification and nomenclature assignment was 
complicated by the fact that many of the markers were not included in public databases, such as 
dbSNP, and relevant genetic variants were comprised of not only Single Nucleotide 
Polymorphisms (SNPs), but also insertions and deletions (InDels), and copy number variants 
(CNVs). Therefore, to enable the merging of the lists, a defined set of required information was 
established for each maker including at minimum: chromosome number, chromosomal position, 
variation at that position, and upstream and downstream flanking sequences (~50 bp). Having 
this information was also necessary to remove redundancy from the marker list.  
Markers were passed through a quality control (QC) process to verify their sequence and 
location by aligning the flanking sequences of the variant to the human genome using Blat 
(genome.ucsc.edu). This process was straight forward for those markers that were in present in 
curated databases such as dbSNP and Seattle SNPs (pga.gs.washington.edu). For rare functional 
markers and non-SNP variations such as CNVs, that were not present in the above mentioned 
databases, this process of QC was much more difficult. In most instances, it was necessary to 
72 
 
 
retrieve the original publication for the variant to validate the information. Often inferring 
sequence information or retrieving PCR primer designs from the original publications was 
necessary to ascertain the relevant information. This QC process was critical to standardize the 
information contained in the core variant list. 
Another challenge identified in assembling the marker list was the use of the star (*) 
nomenclature for genes where it is the established naming scheme, the standard used for the 
cytochrome P450s
131
. The difficulty with this type of naming scheme is that this nomenclature 
often defines haplotypes, and while many of these haplotypes are defined by a single marker, in 
some cases they are not. Although this information is relevant, its usefulness is derived by its 
presence in a defined haplotype and often requires translation tables to define a specific star 
phenotype from a variable set of genotypes. The group thoroughly reviewed the literature and 
websites to carefully define the minimal markers required to accurately define all star genotypes 
that were selected for the ADME core marker list (see www.PharmaADME.org). 
To help further characterize the markers, the group placed all the markers into one of 3 
categories: 1) validated functional markers, 2) potential functional markers and 3) investigative 
markers. As with the gene lists, criteria were established for a marker to be considered a 
validated functional marker (see Table 1). Those markers that met some but not all criteria were 
considered potential functional markers and the remainder were classified investigative. 
Furthermore, the group agreed that all haplotype tagging markers, that did not meet the above 
criteria would be removed from Core List because their clinical value is unclear.  
Following the inclusion criteria for genes and markers, an agreed upon consensus list of 
184 markers for the 32 genes comprises the Core ADME Variant List (Table 8). A complete list 
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of information defining the marker’s chromosomal number, chromosomal position, variation, 
and flanking sequence information can be found at www.PharmaADME.org.  
Table 8: Core ADME Marker List 
Gene Markers 
CYP1A1 *2A, *4, *3, *5, *8, *6, *7 
CYP1A2 *1K, *1C, *1F, *7 
CYP2A6 *2, *9 , *11, *17, *8, *6, *7, *5, *12, *1X2a, *1X2b, *20, *4 
CYP2B6 *8, *16, *28, *6, *4, *2 
CYP2C19 *4, *17, *8, *2, *3, *6, *7, *12, *5 
CYP2C8 *3, *4, *3, *2, *5, *7, *8 
CYP2C9 *3, *2, *9, *11, *5, *8, *10, *6, *12, *13, *15, *25, *4 
CYP2D6 *10, *2a, *2, *15 , *17, *41, *4, *6, *12, *11, *7, *3, *14, *8, *9, *18, *19, 
*20, *21, *38, *40, *42, *44, *5, *56 
CYP2E1 *2 
CYP3A4 *6, *2, *20 
CYP3A5 *6, *10, *3, *5, *7 
DPYD *9A, *8, *9B, *10, *7  
GSTM1 *B , *X2, Null 
GSTP1 V114A, V105I 
GSTT1 Null 
NAT1 *14, *11 , *15 , *19 , *17 , *22, *5 
NAT2 *12, *6, *7, *5, *13, *11, *14 , *19  
SULT1A1 *3, *2, *4, Null, XN 
TPMT *3c, *3b, *2 , *4, *8, *3a 
UGT1A1 *7, *27, *60, *6, *28 _ *36 _*37, *29 
UGT2B15 *2 
UGT2B17 *2 
UGT2B7 *2  
ABCB1 3435C>T, T1236T>C, 2677T>G,A, -129T>C 
ABCC2 V417I, I1324I, -24C>T, R768W, S789F, 1450A>T 
ABCG2 421C>A, Q126X 
SLC15A2 P409S, R509K, L350F, A284A 
SLC22A1 R61C, P341L, G465R, G220V, P283L, R287G, M420del, M408V, C88R, 
G401S 
SLC22A2 S270A, M165I, R400C, K432QP54S 
SLC22A6 R50H 
SLCO1B1 *1B, *5, *10, *11, *12, *2, *3, *3, *6, *9 
SLCO1B3 334T>G , 699G>A 
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2.4.4 Phase IV: Development of an Extended List of ADME and ADME 
Related Genes 
Genes that were not included in the Core ADME list, but listed as important to drug 
metabolism or ADME by at least one participant where included in a list identified as the ADME 
Extended list. The final Extended ADME List has 263 genes (Table 9). The list is comprised of 
the following: 114 phase 1 metabolizing enzymes, 57 phase 2 metabolizing enzymes, 68 
transporters and 24 ADME modifiers.  
Due to the large number of genes present in the Extended ADME gene list, a decision 
was made to have each of the participants prioritize and rank each of the genes within the list. 
The question posed to the participants was, “Would you be interested in including this ADME 
gene in a set of markers to be used to screen your clinical populations?” Using the 
www.PharmaADME.org web interface, all genes were defaulted as selected, so participants had 
to log-in and individually deselect genes for non-inclusion. All but one company participated in 
this exercise. Seven of the members participated in the ranking of the Extended ADME genes. 
Therefore the highest rank a gene could receive was 7. Forty-three (16%) of the genes on the list 
where given a rank of 7 (Table 9). A complete set of gene information for the Extended List can 
be found at the website, www.PharmaADME.org.  This list is also not static and will be re-
evaluated on a regular basis in order to reflect evolving functional data.   
Many of the original 399 genes submitted were of importance to various participants but 
which were not considered to be involved directly in drug metabolism or ADME. A list of 76 
genes comprises the ADME-related gene list. Some examples of genes on this list are catechol-
O-methyltransferase (COMT), as outlined above, but others include the vitamin K epoxide 
reductase complex, subunit 1 (VKORC1) involved in the pharmacodynamics of warfarin and 
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monoamine oxidase (MAO) which is the target of MAO inhibitors
240–242
. A similar ranking 
exercise was performed on the ADME-related List as was done with the ADME Extended List, 
however for this panel, as a default, the genes were not selected and a participant had to actively 
select a gene for it to be counted. Of the 76 genes on the ADME-related List, only 2 genes had a 
rank of 4 (MAO-A and MAO-B) and a total of 20 (26%) had a ranking of between 1 and 4. All 
the data on the ADME-related List can be found at www.PharmaADME.org. 
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Table 9: Genes (with rank*) of the Extended List 
Rank Gene Full Name Type 
7 ALDH4A1 aldehyde dehydrogenase 4 family, member A1 Phase I 
7 EPHX1 epoxide hydrolase 1, microsomal (xenobiotic) Phase I 
7 FMO3 flavin containing monooxygenase 3 Phase I 
7 ALDH5A1 aldehyde dehydrogenase 5 family, member A1 Phase I 
7 CYP7A1 cytochrome P450, family 7, subfamily A, polypeptide 1 Phase I 
7 CES1 carboxylesterase 1 (monocyte/macrophage serine esterase 1) Phase I 
7 CES2 carboxylesterase 2 (intestine, liver) Phase I 
7 ALDH6A1 aldehyde dehydrogenase 6 family, member A1 Phase I 
7 GSTM2 glutathione S-transferase M2 (muscle),glutathione S-transferase M4 Phase II 
7 GSTM3 glutathione S-transferase M3 (brain) Phase II 
7 GSTM4 glutathione S-transferase M4 Phase II 
7 UGT1A3 UDP glucuronosyltransferase 1 family, polypeptide A3 Phase II 
7 UGT1A6 UDP glucuronosyltransferase 1 family, polypeptide A6 Phase II 
7 UGT1A7 UDP glucuronosyltransferase 1 family, polypeptide A7 Phase II 
7 UGT1A8 UDP glucuronosyltransferase 1 family, polypeptide A8 Phase II 
7 UGT1A9 UDP glucuronosyltransferase 1 family, polypeptide A9 Phase II 
7 SULT1B1 sulfotransferase family, cytosolic, 1B, member 1 Phase II 
7 UGT2A1 UDP glucuronosyltransferase 2 family, polypeptide A1 Phase II 
7 UGT2B11 UDP glucuronosyltransferase 2 family, polypeptide B11 Phase II 
7 UGT2B28 UDP glucuronosyltransferase 2 family, polypeptide B28 Phase II 
7 UGT2B4 UDP glucuronosyltransferase 2 family, polypeptide B4 Phase II 
7 GSTA1 glutathione S-transferase A1 Phase II 
7 GSTA2 glutathione S-transferase A2 Phase II 
7 GSTA3 glutathione S-transferase A3 Phase II 
7 GSTA4 glutathione S-transferase A4 Phase II 
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*Table 4 contains only the 43 genes of the extended list that had the highest rank of 7 out of 7. The remainder of the list can be found 
on www.PharmaADME.org. The gens are divided into four classes: phase I metabolizing enzymes (Blue), phase II metabolic enzymes (Red), 
transporters (Green), and ADME modifiers (Purple). 
 
  
7 GSTA5 glutathione S-transferase A5 Phase II 
7 GSTO1 glutathione S-transferase omega 1,glutathione S-transferase omega 2 Phase II 
7 GSTO2 glutathione S-transferase omega 2 Phase II 
7 SULT1A2 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2 Phase II 
7 SULT1A3 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 Phase II 
7 GSTT2 glutathione S-transferase theta 2 Phase II 
7 ABCB8 ATP-binding cassette, sub-family B (MDR/TAP), member 8 Transporter 
7 SLC22A11 solute carrier family 22 (organic anion/cation transporter), member 11 Transporter 
7 SLC22A8 solute carrier family 22 (organic anion transporter), member 8 Transporter 
7 SLCO2B1 solute carrier organic anion transporter family, member 2B1 Transporter 
7 SLCO1A2 solute carrier organic anion transporter family, member 1A2 Transporter 
7 ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Transporter 
7 SLC15A1 solute carrier family 15 (oligopeptide transporter), member 1 Transporter 
7 SLC10A1 solute carrier family 10 (sodium/bile acid cotransporter family), member 1 Transporter 
7 ABCC12 ATP-binding cassette, sub-family C (CFTR/MRP), member 12 Transporter 
7 SLC7A5 solute carrier family 7 (cationic amino acid transporter,), member 5 Transporter 
7 ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 Transporter 
7 AHR aryl hydrocarbon receptor Modifier 
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2.5 Discussion: 
 The process of defining a Core List of ADME gene was developed as a successful 
collaboration between pharmaceutical companies and an academic center. The result is an 
industry directed evidence-based consensus Core List of ADME genes that has been well vetted 
and agreed upon by all participants. Remarkably, despite very different directed research 
programs, the diverse group was able to come to agreement on a concrete set of genes using a 
pre-defined set of criteria. This ADME Core List will now form the basis for a minimal set of 
genes and related markers that could be used to screen clinical populations involved in drug 
development by the agreed parties. As a second objective for the ADME Core List, the group 
also had the goal of using the list to provide a framework for the various technology platform 
providers to create standardized products that will be broadly applicable across many therapeutic 
classes of drugs. This has been accomplished with the development of three commercially 
available assays: the Affymetrix DMET Plus Premier Pack 
243–245
 , the Sequenom iPLEX
®
 
ADME PGx panel
246
  and the Illumina VeraCode ADME Core Panel
247
. While the VeraCode 
product consists solely of markers on the Core List, the DMET chip and iPLEX ADME PGx 
panel contain additional markers in genes from the extended ADME list (Table 10). 
Table 10:  Contents of Three Commercially Available ADME Genotyping Products Based 
on Content Derived by the PharmaADME Working Group. 
 
Company Assay 
Number 
of Genes 
Number of 
Markers 
Design Criteria 
Affymetrix
®
 
DMET™ Plus 
Premier Pack 
225 1936 
90 % of ADME core list plus 
additional putative functional 
variants in other ADME genes. 
Sequenom
®
 
iPLEX
®
 ADME 
PGx panel 
36 192 
99 % of ADME core list plus 
additional functional haplotypes 
Illumina
®
 VeraCode ADME 34 184 Known functional variants 
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Core Panel including deletion and 
duplications in ADME genes as 
defined by the ADME Core List 
 
While the ADME Core List can be applied to drug development in several ways, it was 
not conceived to be only limited to drug development uses.  The group intended the list to be 
used in any application where knowledge of variability in metabolism or transport could aid 
decision making. Public access to the lists through www.PharmaADME.org and the sharing of 
the selection criteria was deemed the most reliable way for dissemination to the broadest 
audience. 
 In generating the ADME Core List, which contained the genes with documented effect on 
drug disposition, the group also compiled a list of additional ADME genes, the ADME Extended 
list, which does not have the same evidence base as the ADME Core List.  It is reasonable to 
assume that some of the genes in this extended list will ultimately be found to have a significant 
role in the metabolism or transport of new or existing compounds. Thus, both the Core and 
Extended Lists are to be updated on a regular basis.  
Throughout the process of defining the ADME gene and variant lists, several prescribed 
uses became evident as to how this information will be used in practice. The two predominant 
models are the evidence based approach and the broader hypothesis free screening approach. In 
the evidence based approach only a limited group of genes, the ADME Core list, would be 
useful. This would be the case for pharmaceutical driven clinical studies because this list was 
founded on compiled, known functional evidence.  The purpose of the Core List was to have an 
agreed upon list of variants, summarizing all current knowledge, that would be useful for 
evidence based decision making in clinical trials. In the hypothesis free screening approach the 
80 
 
 
Extended List would be more useful, where it would be necessary to cast a broader, more 
inclusive net for additional genes potentially involved in metabolism or transport to identify 
correlations between genotype and observed outcomes of the trial. An added rationale for using 
the broader ADME list was to enable the identification of new pathways that might be involved 
in the metabolism of a compound of interest where the technology was not previously available. 
A good example of the latter design was the recent finding of the involvement of CYP4F2 in 
warfarin metabolism.
248
 
To address the evolution of our knowledge with respect to variation in drug metabolism 
pathways, the group has agreed to meet on an annual or bi-annual basis to review, update and 
discuss the information in the respective lists. The www.PharmaADME.org  website is intended 
to be a public portal for this information.  It is important to note that the gene and marker lists are 
thought of as moving targets. Hence, the lists will be updated as the body of knowledge 
pertaining to ADME continues to grow. The website is also intended to be a point of access 
where individual researchers can make suggestions for the inclusion of additional genes and 
variants to either list. 
 The information established by this unique collaboration of academic and pharmaceutical 
partners could be used as a working model for future collaborations with the purpose of 
addressing the FDA’s Critical Path initiative. Efforts like this can only help advance the 
integration of genomic biomarkers into the drug development process and clinical practice. As 
new research in the areas of drug efficacy and toxicity continues, the prioritization of genes and 
markers will evolve. Nonetheless, the necessary framework has been established to incorporate 
new knowledge. In the future, we anticipate the participation of even more parties who will share 
the same goal of applying genetics to improving patient outcomes.  
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3  The Development of a Broad Based  ADME Panel for use in 
Pharmacogenomic Studies 
 This section describes the development and testing of a broad based ADME genotyping 
assay. The assay has gone through three design iterations where over 27 000 oligonucleotides 
have been tested to interrogate functional and tag SNPs in ADME genes. The assay was 
developed to address the gap in commercially available ADME genotyping assays that either 
contain a small number of functional variants or do not have sufficient coverage of ADME 
genes. Genes and markers for the genotyping panel were selected in collaboration with many 
groups from both academia and the pharmaceutical industry in an effort to capture all pertinent 
genes and metabolic pathways that have been implicated in drug metabolism. The final assay 
design was composed of just over 3,000 markers in 181 genes. Over three phases of iterative 
development, the assay conversion rate for the 3,000 markers was improved from 83% to 97.4% 
through the incorporation of novel design strategies to overcome areas of genomic interference 
such as regions of homology and underlying polymorphisms. Accuracy of the assay was 
validated by screening more than 200 samples of known genotype with a concordance >98%. 
Additionally, data from the assay has also been compared to data from different technological 
platforms and has an overall concordance of >99.5%. The effectiveness of the design strategy 
was demonstrated in the successful utilization of the assay in the screening of over 1000 samples 
in various pharmacogenomic studies. Of particular interest are the novel associations with 
ADME gene variation and two different adverse drug reactions in children uncovered using the 
assay.  
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3.1 Abstract 
In order to optimally address the inter-individual variability observed in pharmacokinetic 
drug response, we have created a custom genotyping panel that interrogates most of the key 
genetic variations present in a set of 181 prioritized genes responsible for the Absorption, 
Distribution, Metabolism and Excretion (ADME) of many therapeutic agents. This consensus list 
of genes and variants was based on the ADME Core and Extended gene lists compiled by a 
group of Pharmaceutical companies as having relevance (PharmaADME.org). These 
pharmacokinetic genes and pathways are well known; however there has been little effort to 
develop tools that can interrogate a large number of these genes simultaneously within a single 
experiment. Using novel technical design strategies, an optimized and validated ADME 
genotyping panel, encompassing ~3,000 variants, has been developed that has broad applicability 
to any study or clinical trial that would benefit from the evaluation of an extensive list of ADME 
genes. 
 
 
 
KEY Words: pharmacogenomics, drug metabolism, ADME, genotyping, SNPs 
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3.2 Introduction  
 Many medications show clear patient variability in terms of efficacy and undesired 
adverse side effects
249,250
. This variability can have significant impact on medical outcomes and 
the success or failure of drug development programs. While a portion of this variability can be 
attributed to patient characteristics such as age, sex and disease state, a substantial amount of the 
variability in drug response in patients is due to genetic variation
250
. Genetic variation in drug 
response can be divided into two major areas pharmacodynamics (PD) and pharmacokinetics 
(PK). Pharmacodynamics involves the interaction of the drug with its target and is directly 
responsible for a patient’s pharmacologic dose dependent response4. Pharmakinetics, or drug 
metabolism, determines the amount of the active drug that is available to interact with its target 
and for how long it remains active in the body
251
. There is a substantial amount of literature 
outlining a well understood set of genes and pathways responsible for the metabolism and 
mechanisms of action for many drugs
73,252–254
.  Of particular relevance are the PK 
pharmacogenetic biomarkers that are responsible for the Absorption, Distribution, Metabolism 
and Excretion (ADME) of drugs and their metabolites. PK genes are applicable to almost all 
medical compounds; while PD genes are primarily involved with a specific drug target and are 
most often only specific to a particular medical compound and its mechanism of action. Thus, 
when developing tools to help integrate genetics into healthcare and drug development programs, 
a focused PK derived pharmacogenetic biomarker tool will have greater utility and application 
across many therapeutic areas than a set of PD derived genetic biomarkers which will only be 
applicable to a single medical compound or class of drugs.  While the concept of applying 
pharmacogenetics to the drug development process has been debated for over a decade, 
consensus on exactly how it can be applied is still being developed
255
.  
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 Genetic variation observed in ADME genes can be grouped into two categories; 
functional and those having unknown functional consequence. Evidence based biomarkers, or 
known functional variants, have been experimentally demonstrated to alter drug response
239
. 
Only with evidence based/functional biomarkers can a physician make actionable decisions in 
the treatment of patients. Moreover, only functional biomarkers can be used to help stratify 
pharmaceutical clinical trials to improve efficacy and safety profiles
256,257
. For example, several 
CYP2C19 based biomarkers/variants have been shown to reduce CYP2C19 activity which is 
necessary for the activation of the drug clopidogrel (Plavix) in both retrospective and prospective 
studies
171–175
. Thus, patients possessing loss of function polymorphisms in the CYP2C19 gene 
will have reduced efficacy of Plavix and be at a higher risk of thrombolytic events. These types 
of well documented observations are now becoming routinely incorporated into the labels of 
many drugs by the FDA 
239
. If an ADME genetic variation has yet to be functionally 
characterized, it falls into the category of variations with unknown functional consequence. 
Theses hypothesis generating variants have the potential to be functional but must first be tested 
for association with drug response in well phenotyped patients. An example of this type of 
variation includes the variants in TPMT and COMT that have recently been identified and 
associated with ototoxicity in children receiving cisplatin
258
. This observation is presently being 
validated in additional patient populations. 
 The full implication of the influence of genetic variation on drug response is presently 
poorly understood for many drugs and requires a broader investigation of both PK and PD 
pathways; however, a tool that interrogates evidence based and hypothesis generating variation 
in ADME genes would have significant application to clinical trials involving any medication. 
Such a tool could be used to identify metabolism status phenotypes, to assist with patient 
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decision making either as: a covariate in a statistical analysis, exclusion criteria in a clinical trial, 
a predictor of drug response and toxicity, or as guidance of dose selection. Moreover, when there 
appears to be no evidence for functional variants affecting response, haplotype tagging variants 
in ADME genes can be used to uncover new correlations between response or toxicity and 
genetic variation (see Figure 13). It is for these reasons that we set out to create a genotyping 
assay that not only includes known functional variation in ADME genes, but also encompasses 
tag SNPs that account for blocks of Linkage Disequilibrium (LD) across many ADME genes. 
Such an assay will have application for both the evidence based functional characterization of 
patient populations as well as have the ability to identify and discover new genetic biomarkers in 
ADME genes.  
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3.3 Selection of the Genotyping Platform 
 As outlined above, there is a need for a comprehensive ADME panel that can query both 
functional and tagging SNPs. To address this deficiency, we have embarked on developing an 
optimized and validated broad based ADME panel that can be used to screen a significant 
Figure 13: The Uses of ADME Pharmacogenomics in Research and Drug Development 
 
The design of the ADME panel allows for two different yet complimentary applications. 1) 
Validated functional variants able to identify metabolism status phenotypes that can assist 
with patient decision making either as: a covariate in a statistical analysis, exclusion criteria 
in a clinical trial, a predictor of drug response and toxicity, or as guidance of dose selection. 
2) Haplotype tagging variants in ADME genes can be used to uncover new correlations 
between response or toxicity and genetic variation.   
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number of drug metabolism (PK pathway) genes for use in pharmacogenomic studies. A 
genotyping tool of this nature would be complimentary to most currently available commercial 
ADME genotyping assays that are primarily focused on a small number genes and functional 
variants
243,246,247,259–262
 (see Table 11). Moreover, whole genome SNP arrays often lack key 
markers in most ADME loci due to complexities in theses genomic regions and the tagging SNP 
coverage of ADME genes is often poor in these commercial products (see Table 12)
263
. Recently, 
it was demonstrated that even whole genome arrays with more than 2.5 million SNPs still cover 
no more than 85% of 253 ADME genes
264
. There have been many pharmacogenomic genome 
wide association studies (GWAS) and save a few examples 
202–210
, most have been largely 
unsuccessful in identifying genes that are predictive of response or toxicity
201
.  Interestingly a 
number pharmacogenomic GWAS studies failed to identify significant associations in genes that 
were not already known from previous ADME candidate gene studies
202–210
. 
Table 11: Content of Commercially Available ADME Genotyping Products Compared too 
Developed Panel. 
Company Assay Number 
of Genes 
Number of 
Markers 
Design Criteria 
NA ADME Panel ~180 
3000 (plus 
the ability to 
spike in an 
additional 72) 
known and putative functional 
variation in ADME genes as 
well as tag SNPs that account 
for blocks of Linkage 
Disequilibrium (LD) across 
ADME genes 
Affymetrix
®
 
DMET™ Plus 
Premier Pack 
225 1936 
Known functional and putative 
functional variants in ADME 
genes. 
Sequenom
®
 
iPLEX
®
 ADME 
PGx panel 
36 192 
99 % of ADME core list plus 
additional functional haplotypes 
Illumina
®
 
VeraCode ADME 
Core Panel 
34 184 
Known functional variants 
including deletion and 
duplications in ADME genes as 
89 
 
 
defined by the PharmaADME 
working group 
Roche
®
 
AmpliChip™ 
CYP450 Test 
2 ~22 
Known functional variants 
including deletion and 
duplications in CYP2D6 and 
CYP2C19 
Progenika
®
 PHARMAchip 36 ~90 
Known functional variants 
including deletion and 
duplications in PK and PD 
genes. 
 
Table 12: Content Unique to the ADME Panel in Comparison to Several Commercially 
Available Assays. 
Assay: Affymetrix 
DMET plus 
Affymetrix 
500K 
Illumina 
HumanHap550 
Affymetrix 6.0 Illumina 
OmniQuad 
Number of SNPs  1936 500,000 550,000 907,000 1,000,000 
ADME Panel SNPs  
Included on Assay  
225 405 1038 1017 2088 
ADME Proxy (r2 >0.8)  66 1446 495 702 168 
Unique to ADME Panel 
Content  
90.3% 
(2709 SNPs) 
38.3% 
(1149 SNPs) 
48.9% 
(1467 SNPs) 
42.7% 
(1281 SNPs) 
24.8% 
(744 SNPs) 
 
 For the development of this ADME genotyping tool, Illumina’s GoldenGate genotyping 
technology was selected as the preferred platform for its multiplexing capabilities (up to 1536 
SNPs in a single oligo pool array (OPA)), high throughput capability (96 samples in a single 
experiment), and ease of use
219
.  An additional advantage of the Illumina GoldenGate technology 
versus other genotyping technologies is its proven consistency and accuracy. GoldenGate 
chemistry involves three levels of specificity; independent hybridization, primer extension and 
ligation steps all combine to increase the precision of allele discrimination of the assay. 
Furthermore, highly reproducible results are achieved because each genotyping data point is a 
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result of an average of ~30 independent measures
219
. A further benefit of selecting the 
GoldenGate chemistry for this development was that this was the primary technology used to 
generate much of the HapMap data and successful validated designs were already available for 
many of the selected SNPs
101
. 
3.4 ADME Content: The PharmADME Core List  
 An industry initiated effort was launched to develop a consensus, “Core List” of 
standardized “evidence based” drug metabolizing (ADME) genetic biomarkers that are broadly 
applicable to many pharmaceutical clinical trials and FDA drug submissions. The effort was 
driven by a unique multidisciplinary group of representatives from the pharmaceutical industry 
(see section 2.4). Our goal was to develop a list of genes and genetic biomarkers that could be 
screened using today’s technology platforms to identify predictors of pharmacokinetic variability 
that could impact drug safety and efficacy in the current drug development process. Through a 
phased process and using pre-defined criteria, we identified a “Core List” of 32 ADME genes, 
which includes 184 markers that can be used to screen subjects in clinical trials (see section 2). 
Thus, genes and markers in the “Core List” were selected to fit one or more of the following 
criteria: 1) genes listed as US-FDA validated;
239
 2) genes which had a significant body of 
published evidence in the literature indicating the gene or its variants were involved in drug 
disposition; or 3) key opinion leaders had evidence that the gene or its variants were involved in 
drug disposition. The goal here was not to be overly restrictive, but to get a consensus list of 
important or ‘core’ genes. Additionally, we ranked a further 300 ADME genes that are likely 
involved in a patient’s pharmacokinetic response but have not been thoroughly investigated yet.  
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 The ADME Core genes can be grouped into four categories: Phase I drug metabolism 
enzymes, such as members of the cytochrome P450 superfamily responsible for non synthetic 
oxidation and reduction reactions that render drugs more polar or water soluble; phase II drug 
metabolism enzymes, responsible for the conjugation with endogenous moieties such as 
glucuronidation (uridine diphosphate-glucuronosyltransferases) or sulfonation 
(sulfotransferases); transporters, responsible for the uptake and excretion of drugs in and out of 
cells, such as the solute carrier (SLC) family; and modifiers, that can either alter the expression 
of ADME genes or affect the biochemistry of ADME enzymes, such as the retinoid X receptor 
77
.  
 As a second objective for the ADME Core List, the group also had the goal of using the 
lists to provide a framework for various technology platform providers to create standardized 
products that could be broadly applicable across many therapeutic classes of drugs. This has 
been accomplished with the development of three commercially available assays: the Affymetrix 
DMET Plus Premier Pack 
243–245
 , the Sequenom iPLEX
®
 ADME PGx panel
246
  and the Illumina 
VeraCode ADME Core Panel
247
. 
 The results of this collaboration are available on the web at www.pharmaADME.org. The 
website is intended to be a public portal for this information and the lists will be updated as the 
body of knowledge pertaining to ADME continues to grow. 
3.4.1 Gene and SNP Selection 
 With the comprehensive gene and SNP lists established for the ADME Core and 
Expanded gene categories, a SNP selection approach was initiated to incorporate both functional 
and tagging SNPs for all genes. The primary focus of the panel was to incorporate markers from 
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the ADME Core list and annotated functional markers from the highest ranked Expanded panel 
genes (~320 function SNPs were identified in the literature). Based on our strategy, the 
remaining SNP selection was to be filled with SNPs that tag haplotype blocks in our genes of 
interest.  Our tagging strategy takes into consideration the entire gene locus and not just coding 
regions. Using data from the International HapMap project
101
, SNPs were selected that account 
for blocks of linkage disequilibrium (LD) that span each ADME gene plus or minus 10kb of the 
gene. LD-Select
265
 was used to generate bins of tag SNPs (r
2
 = 0.9) for each of the three original 
HapMap populations (CEU,YRI and JPT/CHB). Tag SNPs were first selected that accounted for 
bins of LD in two or all three populations, followed by the selection of bins unique to a single 
population, with a priority for the CEU population, until the space limitation of the list was 
fulfilled. When possible, putative functional variants were prioritized and selected as the tag for a 
given bin. Examples of these include SNPs from the Human Cytochrome P450 Allele 
Nomenclature Committee website that either affect transcription, splicing, translation, 
posttranscriptional or posttranslational modifications or result in at least one amino acid 
change
220
. Our strategy was tailored to allow for the inclusion of the maximal content while 
respecting the limitation of having space within 2 Illumina GoldenGate OPA’s for only 3,072 
SNPs.  The final assay designs also incorporated 50 SNPs with known minor allele frequencies 
that differ greatly in different populations to be used as ancestry informative markers. These 
ancestry informative markers are valuable for use in population stratification of study subjects.  
Finally, in the final assay design, some genotyping space was purposefully left “open” and not 
assigned a SNP for the inclusion of 72 flexible markers that could have the ability to be 
added/changed depending on the given needs of the project. The final assay includes 3000 
variants in 181 ADME genes (see Appendix 3 Gene and SNP list). 
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3.5 Panel Development 
 The design of the broad-based ADME genotyping assay required that we develop 2 
independent oligo pooled arrays (OPA’s; consisting of 1536 SNPs per OPA) using an Illumina 
GoldenGate design. In order to make the majority of our identified SNP assays convert to 
functioning assays and to fully optimize the overall genotyping assay, three iterations of the 
GoldenGate ADME panel were necessary. During each phase of assay development, specific 
assay failure modes were addressed and different approaches were taken to improve the quality 
and robustness of the overall assay (see table 3). Data from each phase gave rise to insight into 
the subtleties and limitations of the technology and allowed for the development of novel 
strategies and modifications to the standard process to continually improve assay conversion 
rates.  In addition to the testing and the validation of the assay on standardized DNA samples 
from the Coriell institute (www.coriell.org) and HapMap samples, each iteration of the ADME 
panel was used to genotype research samples of unknown genotype from several research studies 
during all phases of development. The three phases of development and summary results from 
the many applications are outlined in detail below.  
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Table 13: Objectives and Results of Each Assay Development Phase. 
3.5.1 Phase 1 
 The primary goal of the first phase of assay development was to benchmark the 
technology, to determine what would and would not work. As all of the content on the ADME 
panel was selected for a defined purpose, it was imperative that the majority of the markers 
selected performed accurately and robustly. A marker was considered converted or functioning 
well when it has passed QC clustering using Illumina’s Genome Studio software. A SNP has 
passed QC when its data points have consistent signal intensity and display tight clustering 
patterns for the homo and heterozygous calls.  
The assay design for phase 1 consisted of two OPAs. One primarily composed of tag SNPs while 
the other contained functional and putative functional variants. An overlap of 93 SNPs between 
OPAs was also included in the design to access reproducibility. Preliminary testing of the phase 
Development 
Phase 
Objective Results %Conversion 
Phase 1 
 Benchmark 
Technology 
 Evaluate assay 
conversion 
 Identified three areas 
of genomic 
interference that 
disrupt assay 
conversion 
 Identified errors in 
industrial process 
83% 
Phase 2 
 Test strategies 
to improve 
assay 
conversion 
 
 Validated assay 
design strategies 
 Identified oligo 
synthesis 
inefficiencies 
 
93.5% 
Phase 3 
 Finalize content 
and design 
 Pool oligo 
synthesis 
 Final Content and 
Design for use in 
research and clinical 
trials  
 
97.4% 
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1 designs revealed that the tag OPA and the functional OPA had marker conversion rates of 96% 
and 70% respectfully. This was expected as many of the tag SNPs had been previously validated 
on the GoldenGate platform as part of the HapMap project and when possible, the SNP with the 
highest design score from Illumina’s assay design tool was selected for LD bins with more than 
one tag SNP. 
 
Furthermore, many of the SNPs included in the functional SNP OPA were 
included despite having low design scores. This was done purposefully as this was a 
benchmarking exercise and we wanted to assess and establish failure modes for “must have” 
functional content. 
3.5.2 Phase 2 
 After the analysis of the phase 1 genotyping results, two interesting observations were 
evident. First was the frequent appearance of unusual clustering patterns, which deviated from 
the usual three cluster patterns showing two homozygous and one heterozygous allele calls, and 
the second was that some of the SNPs duplicated in both OPA assays worked well in only one 
instance (see figure 3). This led to the identification of three consistent failure modes exhibited 
by the GoldenGate technology (see figure 13): underlying polymorphisms, falling within the 
regions of oligo binding which disrupt the binding affinity; SNP assays in close proximity, where 
adjacent oligos interfere with one another; and markers that lie within regions of homology that 
reduce the binding specificity of the oligos. 
 In phase 2 of development, several new design strategies were incorporated in an attempt 
to compensate for the above mentioned failure modes. These strategies fell outside the standard 
Illumina design process, and required that many of the new oligos be manually designed or 
synthesized separately and then added back into the OPA pools.  
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In order to adjust for underlying SNPs disrupting the binding affinity of oligos, degenerate bases 
were incorporated in the oligos. That is, oligos were designed for all possible allele combinations 
of the SNP being interrogated plus incorporating different combinations of the underlying SNP.  
In order to adjust for regions of high SNP density that generate assays that fail due to close 
proximity, two strategies were developed, first the distance between the allele specific and locus 
specific oligos was increased to limit possible interactions with adjacent oligos, however if this 
was not possible, we developed a method of splitting SNPs into separate OPA pools thus 
avoiding the interaction of adjacent oligos. The separated OPA pools could be merged back into 
the GoldenGate process after the binding and extension steps in order to read all markers 
simultaneously on a single array. Finally, in order to adjust for regions of high homology leading 
to a loss of specificity of the bind of the oligos, we developed a method where we could spike in 
PCR products in place of genomic DNA for the desired SNP containing regions of interest to 
increase the specificity of the assaying oligos. This strategy also allowed for specific PCR 
designs that were able to detect gene deletions and duplications (see Appendix 4). For example, 
we were able to design PCR primers that only produced a product if the CYP2D6 locus was 
either deleted or duplicated (see Appendix 4).  Figure 14 shows successful examples of the 
incorporation of these strategies into the overall process recovering markers that had previously 
not worked. The integration of the above mentioned design strategies had the result of increasing 
the overall marker conversion rate from 83% to 93.5%. 
 As a further strategic part of the second iteration of the ADME panel, we duplicated the 
synthesis of one of the OPAs to test for consistency in assay conversion rates in assays that 
essentially should be identical. The outcome of this experiment was to assess the accuracy and 
consistence of the oligo synthesis process. We observed a non-overlapping SNP failure rate of 
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7% and 5%, respectively, in the duplicate OPA syntheses in SNPs that did not fail in the prior 
version of the assay.  Due to the large number of oligos needed for this assay (4608 oligos per 
1536 SNPs assay) it is very difficult to have 100 percent efficiency in synthesis of every oligo. In 
an attempt to recover these markers that were failing from apparent oligo synthesis 
inefficiencies, oligos from the duplicate OPA syntheses were pooled together. In the resulting 
pooled assay, most of the failed markers were recovered and converted successfully (see figure 
14D). We observed on average 4% of markers had a pattern indicating oligo synthesis issues. In 
theory, if synthesis inefficiencies are random, there is a 0.16% chance that the same oligo would 
fail synthesis in two separate syntheses. This would indicate that we would still expect to observe 
7 or 8 SNPs per 1536 SNP OPA to have synthesis issues. 
  
98 
 
 
 
  
Figure 14: Depiction of Three Identified Means of Genomic Interference 
 
This figure depicts the three modes of genomic interference that give rise to aberrant genotyping 
calls A) When a polymorphism is located under an oligonucleotide, it will alter binding affinity, 
hence reducing the signal intensity. A spectrum of affinities is possible which makes the spread of 
genotyping clusters greater. B) When the assays for two SNPs are in close proximity, the oligos will 
overlap and interfere with each other. C) Homology in the genome to the region of interest will 
cause a reduction in specificity for the oligos. This can cause incorrect binding and amplification and 
disrupt the signal for the desired region. 
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Figure 15: Examples of Genotyping Results Before and After the Incorporation of 
Novel Design Strategies.  
 
 
A) Degenerate Base strategy: 1) shows the clustering with standard design. Circled are 
data points with lower signal intensity due to a SNP underlying the red labeled 
oligo. 2) shows clustering after inclusion of degenerate bases into oligo design 
B) Genotyping results generated from spiking in PCR product in place of genomic 
DNA for regions of homology. 1) SNP in CYP2C9 from PCR product 2) the 
detection of the presence of a deleted copy of CYP2D6, three samples circled are 
positive for the deletion. 
C) Separate OPA (read on single array) 1) and 2) show performance of SNPs when 
assayed in the same pool for two SNPs in close proximity to each other. 3) and 4) 
show performance when hybridization and ligation occur in separate reactions. 
D) Multiple Syntheses. 1) and 2) shows clustering for the same SNP from two different 
oligo syntheses. 1) all of the signal is coming from the red labeled oligo, 2) all of 
the signal is coming from the blue labeled oligo. 3) Show clustering from pooled 
synthesis. 
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3.5.3 Phase 3 
 To adapt to the observations made in the second phase of the study and to continue with 
our ADME development strategy, the final assay design not only integrated our previous design 
strategies, but also incorporated a double synthesis of each of the OPA oligo pools to compensate 
for random oligo synthesis failures. Currently, we have used the third version of the assay on 
three clinical sample sets totaling more than 300 samples. The average marker conversion rate on 
these samples is 97.6%. The improved SNP assay conversion rates observed for this latest panel 
design are generating a more complete set of informative ADME markers and thus resulting in a 
more complete data set that gives improved detection power for the ADME assay.  
The 3
rd
 design iteration of the ADME panel fills in many of the gaps in coverage, present on 
currently available commercial genotyping assays. As much as 90% of the final content of the 
ADME panel is unique to the panel in comparison to commercially available whole genome 
products (see Table 3).    
3.6 Validation 
3.6.1 Genotype Concordance 
 Forty-two samples from the international HapMap project were run on the final iteration 
of the ADME panel (7 CEU trios and 7 YRI trios) in order to test for concordance. There are 
2953 markers on the ADME panel which are also present in HapMap database (release #2). The 
individual sample call rates for each SNP were ~96% within the ADME panel data where as the 
HapMap data is only ~83% complete for the same samples. Thus, the HapMap data has 
significant gaps in these key ADME genes. After removing missing genotypes, markers that fail 
hardy-weinberg equilibrium (p-value > 0.05) the concordance between our data and that of the 
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HapMap is 99%. In 2606 of the 2953 SNPs (88.3%), the concordance is 100%. After the initial 
analysis, we took a closer look at the discordant SNPs (from the comparison between our ADME 
panel data and the HapMap data), we observed a significant increase in the number of 
homozygous allele calls in that HapMap SNPS and have concluded that this is due to a 
significant allelic dropout (error) in the HapMap data (p-value = 0.02). It appears that other 
discordant SNPs calls are due to erroneous SNP calls in the HapMap database. This may be due 
to limitations in the various technology platforms that were used to generate the HapMap data as 
the majority of discordant SNPs were run on different platforms than the Illumina GoldenGate 
platform. For example, when we remove the Perlegen data from the overall HapMap data, the 
concordance goes up to 99.3%. 
 As a further validation of the ADME panel, an additional 149 samples that had 
previously been genotyped for 34 of the key functional markers were tested individually using 
various technologies to definitively determine the accuracy of our multiplexed broad based 
ADME panel. After analysis, the panel was shown to have a concordance of 99% for 5066 
independent genotype calls. These samples had also been genotyped using the Illumina 
HumanHap300 whole genome array and the concordance of overlapping markers between the 
two arrays was >99% for ~17,000 genotypes compared. 
3.6.2 Cross Technology Comparison 
 Data from the broad based ADME panel has also been cross validated by comparing it 
against validated ADME panels developed on two different technological platforms: the 
Affymetrix DMET Plus Premier Pack
26
 and the Illumina VeraCode ADME Core Panel
247
. In 
total, 85 SNPs are present on all three assays and the concordance between all three assays is 
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>99.5% in 24 samples screened on all three assays. 
3.7 Discussion 
 Over three phases of assay development, we have developed a broad based ADME 
genotyping panel that incorporates multiple strategies that successfully overcome several sources 
of genomic interference inherent to the GoldenGate assay; underlying polymorphism, SNPs in 
close proximity and regions of high genomic homology. This improved assay design has 
permitted the genotyping of SNPs within many ADME regions that were previously very 
difficult or impossible to genotype. Additionally, SNP genotyping space has been left open 
within the assays giving researchers the flexibility to spike in additional markers or PCR product 
in place of genomic DNA. This gives the assay flexibility to be tailored to the needs of a specific 
study. The consecutive improvements integrated into each iteration of the ADME panel have 
increased the overall assay conversion rate from 83% using the standard designs and methods to 
97% using our modified designs. This increase in marker conversion rate directly impacts SNP 
coverage and thus improves the panel’s power for detection and analysis266. 
 After the first phase of ADME panel design, the assay had an overall marker conversion 
rate of 83%. Even with this lower, non-optimal, number of working assays, Visscher et al. 
demonstrated that the content of the assay was sufficient to be used in principal component 
analysis to stratify samples by geographic origin (see Figure 16) 
267
. Additionally, the first 
iteration of the broad based ADME assay was also used in an effort to identify genetic causes of 
adverse drug reactions in children. In an initial cohort of 54 children treated in pediatric 
oncology units, with replication in a second cohort of 112 children, genetic variants in TPMT 
(rs12201199, P value = 0.00022, OR = 17.0, 95% CI 2.3-125.9) and COMT (rs9332377, P value 
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= 0.00018, OR = 5.5, 95% CI 1.9-15.9) were associated with cisplatin-induced hearing loss in 
children (see table 14) 
258
. The results of this study demonstrate that the content and design of the 
assay were successful in identifying novel observations in pharmacogenomic research studies.  
 
 
Figure 16: Use of Principal Component Analysis with the ADME panel  
 
A plot of the 1st vs 2nd principal component based on genotype data generated using the ADME panel 
on a set of worldwide reference samples from the Coriell Institute (Camden, New Jersey). As 
expected, the pattern resembles the geographic map locations of the typed populations . 
Source: Visscher, H. et al. 2009 
104 
 
 
 During the second phase of development, we integrated several assay optimization 
strategies in the new improved design that addressed multiple failure modes present in the first 
version of the ADME panel assay. The new version of the ADME assay increased conversion 
rate from 83% to 93.5%.  The utility of the assay design and content was further validated in a 
study of 156 anthracycline-treated patients, with replication in  two additional cohorts of 188 and 
96 patients for the identification of significant association of a synonymous coding variant 
rs7853758 (L461L) within the SLC28A3 gene with anthracycline-induced cardiotoxicity (odds 
ratio, 0.35; P = 1.8 × 10
-5
 for all cohorts combined) (see table 15)
268
. When combined with 
additional clinical characteristic, patients could be successfully stratified into low and high risk 
groups 
268
. Once again, the ADME candidate gene approach and our functional plus tagging SNP 
design proved to be successful at identifying novel genetic biomarkers for this clinical study. 
Table 14: Genetic Variants Associated with Cisplatin-Induced Hearing Loss. 
 
Source: Ross et al. 2009 
 
Table 15: Risk and Protective Variants for Anthracycline-Induced Cardiotoxicity 
          Single marker test   Multi marker model 
SNP rs-ID Gene Chr Positiona   OR (95% CI) P-value   OR (95% CI) P-value 
Risk variants 
        rs6759892 UGT1A6 2 234,383,669 
 
1.77 (1.20 - 2.61) 0.0038 
 
2.93 (1.74 - 4.94) 0.000022 
rs1149222 ABCB4 7 86,718,426
 
1.87 (1.20 - 2.92) 0.0054
 
2.31 (1.34 - 4.00) 0.0023 
rs4148350 ABCC1 16 16,077,978
 
3.44 (1.65 - 7.15) 0.0012
 
3.77 (1.46 - 9.75) 0.0051 
rs17583889 HNMT 2 138,579,771
 
1.91 (1.21 - 3.02) 0.0057
 
2.21 (1.22 - 4.01) 0.0088 
         
Geno- Ototox. Controls Ototox. Controls Ototox. Controls
Gene SNP type (n= 33) (n= 20) OR (95%CI) (n= 73) (n= 36) OR (95%CI) (n= 106) (n= 56) OR (95%CI) p-value
 †
TPMT rs12201199 A/A 1 0 2.51 (0.1, 65.00) 2 0 3.09 (0.14, 66.17) 3 0 4.77 (0.24, 94.11) 0.277
A/T 8 0 14.22 (0.77, 261.62) 14 1 8.60 (1.08, 68.26) 22 1 14.94 (1.96, 114.09) 0.000607
A/- 9 0 15.90 (0.87, 290.02) 16 1 9.82 (1.25, 77.37) 25 1 16.98 (2.23, 128.99) 0.000181
T/T 24 20 1 57 35 1 81 55 1
COMT rs4646316 G/G 20 10 21.48 (1.08, 426.70) 51 15 6.80 (0.58, 80.28) 71 25 19.88 (2.33, 169.70) 0.000982
G/A 13 5 27.00 (1.27, 575.95) 21 19 2.21 (0.19, 26.38) 34 24 9.92 (1.14, 85.95) 0.0215
G/- 33 15 23.77 (1.24, 457.45) 72 34 4.24 (0.37, 48.34) 105 49 15.00 (1.80, 125.29) 0.00263
A/A 0 5 1 1 2 1 1 7 1
Discovery (n=53) Replication (n=109)         Combined (n=162)
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Protective variants 
      
 
rs7853758 SLC28A3 9 84,130,480
 
0.31 (0.16 - 0.60) 0.00010
 
0.20 (0.09 - 0.45) 0.0000071 
rs2020870 FMO2 1 167,886,617
 
0.14 (0.03 - 0.59) 0.00042
 
0.09 (0.02 - 0.46) 0.00021 
rs2019604 SPG7 16 88,143,266
 
0.39 (0.20 - 0.76) 0.0021
 
0.33 (0.15 - 0.73) 0.0026 
rs9514091 SLC10A2 13 102,512,255
 
0.43 (0.23 - 0.78) 0.0033
 
0.41 (0.21 - 0.82) 0.0074 
rs4877847 SLC28A3 9 84,175,971  0.60 (0.41 - 0.89) 0.0092  0.54 (0.33 - 0.87) 0.0097 
Both single and multi marker regression models included important clinical covariates and the first two principal components 
using an additive genetic model. Odds ratios are per copy of the minor allele. Results shown are for the combined Canadian 
cohort. Only variants included in the final multi-marker model are shown.  
OR Odds Ratio; CI Confidence Interval 
Source: Visscher et al. 2011 
 
 The second iteration of the assay was also used to screen two pharmaceutical clinical 
populations. The first involved acute coronary syndrome in 348 patients taking part in the 
Rosuva-Atorva ACS trial, CENTAURUS with the aim of identifying genetic variation that can 
be predictive of the inter-individual variability observed in response to rosuvastatin and 
atorvastatin. The second involved the use of a novel 5-Lipoxygenase inhibitor in the prevention 
of atherosclerosis in 187 patients. Interesting results have emerged from each of these studies 
and the data is presently being finalized for future publication. 
 The successful identification of novel pharmacogenomic association with the use of our 
broad based ADME panel reaffirms that our panel design, the ADME gene content and our SNP 
selection methodology of including both tag and functional variants has been proven to be 
effective. After having screened more than 1,000 samples in the research and clinical setting, and 
the validation of genotype calls in more than 200 samples, it can be concluded that the assay we 
have developed has and will continue to be a valuable tool for use in future pharmacogenomic 
studies. The content and design of the assay sets it apart from currently available commercial 
assays that contain only functional markers in a small number of genes or do not have adequate 
coverage across ADME genes. 
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 Having included two types of variation; known and putative functional markers that can 
be used in an evidence-based approach and haplotype tagging markers that can be used to 
discover novel associations, we have created a tool with broad applicability in research and drug 
development. In the future, we plan to utilize the ADME panel in parallel with commercially 
available whole genome assays to demonstrate the added utility of having a more complete set of 
ADME genetic variation when evaluating drug related genotype phenotype correlations.  
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4 Uncovering Drug Metabolism Genotype Phenotype correlations in 
Human Liver Samples 
4.1 Introduction 
 There are 2 main types of genotyping experimental designs that predominate in drug 
metabolism (ADME) pharmacogenomic research: functional/evidence based experiments where 
definitive decisions must be made based on genotype outcome, and investigative research where 
candidate gene or genome wide SNPs are studied to identify novel biomarkers of efficacy and/or 
safety. To support this research, two distinctly different types of commercial genotyping assays 
have been developed by various technology platform providers. For targeted studies, robust 
genotyping assays with a small number of very specific functional markers have been developed 
based on the ADME Cole list of genes (see chapters 1 & 2 above for more detail). Two examples 
include the Illumina VeraCode ADME Core Panel
247
 and the Sequenom iPLEX
®
 ADME PGx 
panel
246
. These panels can be used to identify known metabolic status phenotypes and stratify 
patient populations in clinical trials. Currently the only way to perform investigative biomarker 
identification on a genome wide basis is to use whole genome genotyping arrays. These assays 
can be used to identify novel genetic correlations with drug response phenotypes in a hypothesis 
free manner. However, genome wide arrays are often missing many key markers in many of the 
drug metabolism genes due to areas of genomic interference that we have overcome with the 
ADME panel (see tables 12 and 13 above).   
 In order to address these analysis gaps, we developed a broad based ADME genotyping 
assay that encompassed both known functional markers and tag markers across 181 ADME 
genes (comprised of 3072 SNPs) which could be applicable to both functional and investigative 
types of studies mentioned above. This assay has been optimized to a conversion rate close to 
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100%. Its accuracy and consistency has been demonstrated in over 1000 samples screened to 
date. Additionally, the assay has been successfully utilized to identify and validate novel drug 
response genotype/phenotype correlations in multiple studies
258,268
. After development of this 
panel, the main challenge remaining was to establish what added value, if any, does this ~3000 
SNP broad based ADME panel have in relation to the commercial focused core panels and the 
genome wide assays. Thus, one of the main questions that we wished to answer as part of this 
chapter was what advantages does this tool have to make discoveries over others? Also, where 
does this ADME panel fit in relation to other genotyping tools and how can it most optimally be 
used? 
 To this end, 150 well characterized liver samples from the Institut für klinische 
Pharmakologie (IKP) in Stuttgart were screened against our 3000 SNP ADME panel. The livers 
have been previously tested using several genomic approaches such as whole-genome analysis 
(318 237 SNPs on the Illumina HumanHap300 Genotyping BeadChip) and candidate SNP 
genotyping (with a limited number of key SNPs), mRNA gene expression (44 800 mRNA probes 
with the Illumina Human-WG6v2 Expression BeadChip) and protein expression (using selected 
antibodies) for selected ADME genes as well as measures of enzymatic activity for a number of 
ADME enzymes. Additionally, there is also clinical and demographic information available for 
each sample including disease status at time of surgery and concomitant medications. Liver 
samples are ideally suited for testing with the ADME panel because this is the organ that is 
primarily responsible for drug metabolism (see section 1.3.3 above) and therefore, genetic 
variation in ADME genes that affect gene expression may have a more profound effect in the 
liver than in other organs and tissue types. Identifying genetic variation associated with gene 
expression in the liver, will be helpful in elucidating any functional associations that might be 
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discovered between SNPs and drug response phenotypes. The Stuttgart liver samples represent 
one of the best collections of characterized liver samples in the world as many previously 
identified ADME genotype/phenotype observations have already been discovered using these 
samples
269–271
. In order to determine the added value of our 3000 SNP panel, our strategy was to 
see to what extent our panel could identify previous genotype/phenotype observations as well as, 
what additional discoveries, if any, could be made. Uncovering additional genotype/phenotype 
correlations in the liver samples that have already been extensively tested will show that our 
ADME panel design strategy and content have added value over currently available commercial 
assays. 
 Testing for molecular phenotypes such as gene expression has gained substantial interest 
recently with the hope of identifying genetic variation with functional consequence that may help 
explain a greater proportion of the heritability of disease. Several groups have performed large 
genome-wide studies of gene expression in various tissue and cell types
272–275
.  The identification 
of loci associated with gene expression (expression quantitative trait loci or eQTL) in these 
studies may help to explain the functionality of association results between SNPs and disease 
phenotypes. Interestingly, one group found that as many as 30% of eQTLs identified with 
stringent criteria, failed to replicate in a different cohort of samples
276
.  This may partially be 
explained by variability in experimental protocol and data collection; however it is more likely 
due to unknown or unmeasured confounding variables
276,277
. This suggests that a significant 
portion of eQTLs may not be globally informative across studies and cell types. Thus, we 
decided to perform an eQTL analysis with our ADME panel on these characterized liver cells to 
see how accurately the data could be reproduced and if any additional observations could be 
made. 
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 To date, a comprehensive eQTL analysis of ADME gene liver expression with an ADME 
focused genotyping assay has not yet been performed. Studies have investigated the role of 
external stimuli such as various drugs on gene expression; others have looked for association 
between gene expression and drug response phenotypes.
278–280
 More recently, the correlation 
between hepatic expression of certain ADME genes was shown not to be correlated with the 
expression in blood
281
. Schadt et al.
272
 and Innocenti et al.
276
, have each performed a large 
genome-wide study of gene expression in liver cells using commercially available genome wide 
SNP arrays and have identified 1229 and 1787 genome wide cis eQTLS respectively. 
Additionally, Schröder et al.
271
  used a genome wide SNP array to look for eQTLs in these very 
samples and identified 979 significant associations, 200 of which were validated based on a 
comparison to the two previous studies. 89 of the significant cis eQTLs were in ADME genes.  
 While it is possible to extract ADME variation data, after the fact, from these datasets, as 
described above, the ADME content on the whole-genome arrays is not very complete (see 
section 3.3). This is why the application of the ADME panel to the liver samples has the 
potential to generate a unique dataset of liver ADME eQTLs and will demonstrate the utility our 
broad based ADME genotyping assay for future studies even when other genotyping efforts have 
been performed. 
4.2 Methods 
4.2.1 Samples 
 DNA derived from 150 liver surgical samples of Caucasian ethnicity (71 male and 79 
female) was obtained in collaboration with IKP in Stuttgart
271
. The average age of the samples is 
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58 ± 14 years. Only non tumor tissue, as determined by a pathologist, was used. Demographic 
data for the samples, including diagnosis, age and sex, is listed in Table 14.  
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Table 16: IKP Liver Sample Demographics 
Sample 
Sex    
1=female 
2=male 
Age 
Smoki
ng 
Status 
1=non 
2=smo
ker 
Alcohol 
Use 
1=no 
2=yes 
Ethnicity 
1=German 2= 
Turkish/Greek 
3=Unknown 
Drugs 1=none 
2=P450 
Inducer 
3=other 
Cholestasis
* 
Diagnosis** 
IKP148-
016 
1 36 1 1 2 1 0 2b 
IKP148-
018 
2 77 2 2 1 3 0 3a 
IKP148-
019 
2 59 1 2 1 3 0 3a 
IKP148-
021 
1 53 na na 1 3 0 2a 
IKP148-
022 
2 76 1 1 1 3 0 2a 
IKP148-
025 
2 69 1 2 1 3 0 3b 
IKP148-
028 
2 68 1 1 1 3 0 3a 
IKP148-
029 
1 58 2 2 1 2 0 3b 
IKP148-
036 
1 56 1 2 1 2 0 3b 
IKP148-
038 
2 48 1 1 1 3 0 3b 
IKP148-
039 
2 70 1 1 1 3 0 3a 
IKP148-
040 
2 57 1 2 1 3 0 2b 
IKP148-
041 
2 59 2 2 1 3 0 2d 
IKP148-
042 
1 55 2 1 1 3 0 3a 
IKP148-
043 
2 70 1 1 1 1 0 3b 
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IKP148-
044 
1 56 1 na 1 3 0 2a 
IKP148-
047 
1 61 2 3 1 3 1 1 
IKP148-
054 
2 57 1 1 1 3 0 3a 
IKP148-
058 
1 54 1 3 1 3 0 3a 
IKP148-
059 
2 57 2 2 1 2 0 2c 
IKP148-
061 
1 71 1 1 1 2 1 3b 
IKP148-
063 
2 73 2 na 1 2 1 2c 
IKP148-
064 
2 63 1 1 1 1 0 3a 
IKP148-
069 
2 85 1 2 1 2 1 3a 
IKP148-
070 
2 71 2 1 1 3 0 2a 
IKP148-
072 
1 59 1 2 1 2 1 2c 
IKP148-
076 
2 66 2 1 1 3 0 3b 
IKP148-
079 
2 7 1 1 1 2 1 2b 
IKP148-
080 
2 74 1 2 1 3 0 3a 
IKP148-
081 
1 74 
 
3 1 3 1 2d 
IKP148-
082 
2 57 1 2 1 1 0 3a 
IKP148-
085 
2 63 1 1 1 3 0 2b 
IKP148-
087 
1 50 1 3 1 3 0 3a 
IKP148-
096 
2 60 1 2 1 2 0 2b 
114 
 
 
IKP148-
098 
1 58 2 1 1 1 0 3a 
IKP148-
102 
1 58 1 2 1 3 0 3b 
IKP148-
103 
1 38 1 2 1 1 0 3a 
IKP148-
104 
2 48 na na 1 3 0 2b 
IKP148-
106 
2 50 1 1 1 1 1 3a 
IKP148-
118 
1 52 2 2 1 1 0 3a 
IKP148-
120 
2 67 1 1 1 3 0 3a 
IKP148-
121 
2 35 2 1 1 1 0 3a 
IKP148-
122 
2 41 1 1 2 1 0 2b 
IKP148-
123 
2 69 1 1 1 2 1 2b 
IKP148-
124 
1 66 2 3 1 3 0 3a 
IKP148-
126 
1 52 1 1 1 3 0 2c 
IKP148-
127 
1 76 2 3 1 2 0 2a 
IKP148-
129 
1 59 1 1 1 1 0 3a 
IKP148-
132 
1 71 2 2 1 2 0 3a 
IKP148-
133 
1 61 1 1 1 1 0 3a 
IKP148-
134 
2 48 1 1 1 3 0 2b 
IKP148-
135 
2 28 1 1 2 3 0 1 
IKP148-
136 
2 77 1 1 1 2 1 2c 
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IKP148-
137 
1 50 1 2 1 3 1 2d 
IKP148-
139 
1 74 1 1 1 3 0 2b 
IKP148-
140 
2 39 1 2 1 1 0 2a 
IKP148-
143 
2 72 2 1 1 2 0 3a 
IKP148-
144 
2 54 1 1 1 3 0 2b 
IKP148-
145 
1 52 2 2 1 3 0 3a 
IKP148-
150 
1 59 1 3 1 3 0 3a 
IKP148-
153 
2 44 2 2 2 1 0 3a 
IKP148-
156 
1 53 1 2 1 3 0 3a 
IKP148-
157 
2 54 1 1 1 1 0 3a 
IKP148-
159 
2 56 1 2 1 1 0 2a 
IKP148-
163 
2 69 1 1 1 3 0 3a 
IKP148-
164 
1 43 2 2 3 1 0 2b 
IKP148-
165 
1 47 2 2 1 1 0 3b 
IKP148-
166 
1 70 1 1 1 3 0 3a 
IKP148-
168 
2 77 1 1 1 2 0 3a 
IKP148-
169 
1 67 2 2 1 3 0 3b 
IKP148-
170 
1 15 1 1 1 1 1 1 
IKP148-
171 
1 58 1 1 1 3 0 3a 
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IKP148-
178 
1 62 1 2 1 2 1 2b 
IKP148-
179 
2 70 1 1 1 3 1 3b 
IKP148-
181 
2 64 1 2 1 3 0 3a 
IKP148-
182 
2 62 1 2 1 2 0 2a 
IKP148-
183 
1 65 1 1 1 3 0 3a 
IKP148-
186 
2 51 1 1 1 3 0 2a 
IKP148-
187 
2 60 2 2 1 2 0 2a 
IKP148-
188 
2 76 1 1 1 3 0 2a 
IKP148-
189 
1 58 2 1 1 2 0 2a 
IKP148-
190 
2 42 1 2 1 1 0 3b 
IKP148-
191 
2 68 1 2 1 2 0 2b 
IKP148-
192 
1 47 1 1 1 3 0 3a 
IKP148-
193 
2 66 1 1 1 3 0 3b 
IKP148-
194 
2 56 1 1 1 2 0 3b 
IKP148-
195 
1 79 1 3 1 3 0 2a 
IKP148-
199 
1 36 1 2 1 3 0 3a 
IKP148-
202 
2 55 1 2 1 2 1 2c 
IKP148-
205 
1 69 1 3 1 3 0 3a 
IKP148-
209 
2 45 1 2 1 1 0 2b 
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IKP148-
210 
2 66 1 1 1 1 0 3a 
IKP148-
212 
1 55 2 2 1 2 1 2c 
IKP148-
213 
1 67 1 2 1 1 0 3a 
IKP148-
214 
1 59 1 2 1 3 0 3a 
IKP148-
218 
2 56 2 3 1 1 0 2b 
IKP148-
221 
2 68 1 1 2 2 0 2b 
IKP148-
222 
2 45 1 1 1 1 0 2a 
IKP148-
223 
2 37 1 1 1 1 0 2b 
IKP148-
224 
1 59 1 1 1 2 0 3a 
IKP148-
225 
1 55 1 1 1 1 0 3a 
IKP148-
226 
2 52 1 1 1 1 1 2b 
IKP148-
227 
2 47 1 1 1 3 0 3b 
IKP148-
229 
1 26 1 1 2 3 1 2b 
IKP148-
230 
2 67 1 1 1 1 0 2b 
IKP148-
231 
2 64 1 1 1 3 0 2d 
IKP148-
232 
2 64 1 1 1 2 0 3a 
IKP148-
234 
1 56 na na 1 1 1 2c 
IKP148-
235 
2 58 1 1 1 2 1 2c 
IKP148-
236 
2 46 1 1 1 1 0 3a 
118 
 
 
IKP148-
237 
1 69 1 na 1 2 
 
2b 
IKP148-
238 
2 75 1 1 1 2 0 2a 
IKP148-
239 
1 54 1 1 1 1 0 3a 
IKP148-
240 
2 42 1 1 1 3 0 3b 
IKP148-
242 
1 51 2 1 1 1 0 2b 
IKP148-
243 
1 69 1 1 1 3 0 2a 
IKP148-
244 
2 74 1 1 1 2 0 3a 
IKP148-
246 
1 45 1 1 1 3 0 3a 
IKP148-
248 
2 48 1 1 1 2 1 2c 
IKP148-
249 
2 72 1 1 1 3 0 3a 
IKP148-
250 
1 57 2 1 1 3 0 2a 
IKP148-
251 
2 50 1 1 1 1 0 3a 
IKP148-
254 
1 72 1 1 1 2 0 3a 
IKP148-
255 
1 60 1 1 1 3 0 3a 
IKP148-
259 
1 70 1 1 1 1 0 3a 
IKP148-
260 
2 74 1 1 1 2 
 
3a 
IKP148-
261 
1 71 1 1 1 3 0 3a 
IKP148-
264 
1 70 1 1 1 1 0 2a 
IKP148-
266 
2 52 1 1 1 3 1 3a 
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IKP148-
268 
1 61 1 1 1 2 
 
2c 
IKP148-
269 
1 62 1 1 1 1 0 3a 
IKP148-
270 
2 47 1 1 1 3 0 2b 
IKP148-
271 
2 36 2 1 1 3 0 3b 
IKP148-
272 
2 62 1 1 1 1 0 3a 
IKP148-
273 
1 57 1 1 1 3 0 3a 
IKP148-
274 
1 69 1 1 1 3 
 
2a 
IKP148-
275 
1 62 1 1 1 2 0 3a 
IKP148-
279 
2 40 1 1 1 3 0 2d 
IKP148-
281 
1 57 1 1 1 3 0 2c 
IKP148-
282 
1 32 1 1 1 2 1 2b 
IKP148-
283 
1 65 1 1 1 2 0 3a 
IKP148-
285 
1 43 1 1 1 1 0 3a 
IKP148-
288 
2 72 1 1 1 2 0 2a 
IKP148-
293 
2 80 1 1 1 2 1 2c 
IKP148-
295 
2 75 1 1 1 2 0 3a 
IKP148-
296 
1 72 1 1 1 3 1 2d 
IKP148-
297 
1 52 2 1 1 3 0 3a 
IKP148-
298 
2 32 1 1 1 3 0 2b 
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IKP148-
299 
1 56 1 1 1 1 0 3a 
IKP148-
300 
1 63 1 1 1 3 0 3a 
*cholestasis as described in Nies et al., Hepatology 2009; 50:1227-1240; 
**Diagnosis: 1=no tumor 2=primary tumor of liver (2a=HCC, 2b=liver tumor, 2c=klatskin, 2d=gallbladder), 3=metastasis 
(3a=colorectal, 3b other) 
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 4.2.2 Genotyping Data 
 DNA from the 150 liver samples, described above, was obtained from IKP Stuttgart and 
was genotyped using our broad based ADME panel (see Appendix 2 for ADME panel protocol). 
Due to limitations in the quantity of liver sample DNA, only the pooled OPAs were used to 
screen the samples, and thus, no spike-in experiments where performed with these samples 
because this requires substantially more DNA. Using the final iteration of the ADME panel 
design (outlined above), each sample was screened for 3000 ADME SNPs.   
4.2.2.1 Genotyping Quality Control 
 The genotype clusters were visually inspected using GenomeStudio v2010.1(Illlumina). 
77 SNPs were removed from further analysis due to poor clustering. Additionally, 193 SNPs 
were excluded from the analysis for deviating from HWE (p –value <0.05) and 237 SNPs were 
removed for having a minor allele frequency < 0.05. In total 2496 SNPs remained for further 
analysis. The breakdown of theses SNPs is as follows: 41 Core Functional SNPs, 320 Putative 
Functional / Tag SNPs, and 2135 Tag SNPs. 
4.2.3 Liver Gene Expression Data 
 The mRNA expression levels for the liver cells were determined as described in Schroder 
et al. 
271
 In summary, genome wide mRNA expression was assessed in the liver samples using 
the Illumina HumanWG-6 V2 array. The array consists of 48 701 probes spanning the genome. 
The data was preprocessed using Illumina BeadStudio version 3.0 and signal intensities were 
calculated. The expression intensity data was then quantile normalized and log2 transformed.  
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4.2.3.1 Gene Expression Quality Control 
 In order to test for probes with outlier expression data across all samples, principal 
component analysis (PCA) was performed on the expression data for all 150 samples (see Figure 
17). No samples were excluded based on results of the PCA. 
 
 In order to increase the confidence in the association analysis, two additional quality 
control steps were performed on the expression probes to remove potentially bad data. The first 
step involved making sure that probes mapped uniquely to their target gene. Probes without a 
“perfect” mapping score in the ReMOAT database were removed 282. Secondly, all probes with a 
potential underlying SNP (dbSNP130) were removed from the data set (see Table 12).  After 
processing the data for these QC steps, 17 971 probes were removed because they did not 
perfectly map to their target gene and 4 412 probes were removed because they contained 
potentially underlying SNPs. Thus, after data clean-up, 26 320 probes remained for analysis. 
Figure 17: Plot of the 1
st
 vs 2
nd
 principal component for expression data from 48701 
probes on the 150 samples. 
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Table 17: Summary of Probe QC 
 Total Non Perfect Probes Perfect Probes with 
Underlying SNPs 
Number of Probes 48 703 17 971 4 412 
Probes Remaining 
for Analysis 
48 703 30 732 26 320 
4.2.4 Additional Phenotypes 
In addition to mRNA expression data several other phenotypes were available for analysis. 
Additional clinical data is listed in Table 18. No additional clinical information impacted the 
association results when used as covariates in the analysis. 
Table 18: IKP Liver Sample; Additional Clinical Data 
Sample Bilirubin 
(mg/dl) 
alkaline 
phosphatase 
(IU/L) 
gamma-
glutamyl 
transferase 
(IU/L) 
Aspartate 
aminotransferase 
(IU/L) 
Alanine 
aminotransferase 
(IU/L) 
Albumin 
(g/dl) 
CRP 
(mg/dl) 
IKP148-
016 
0.6 58 19 8 17 4.9 0.6 
IKP148-
018 
0.9 227 na 28 33 na 2.3 
IKP148-
019 
0.4 95 13 11 8 4.8 0.8 
IKP148-
021 
0.4 112 59 16 6 4.7 0.5 
IKP148-
022 
0.3 346 130 19 11 4.2 0.5 
IKP148-
025 
0.9 479 455 34 36 3.8 1.1 
IKP148-
028 
0.4 110 10 6 4 4.1 0.5 
IKP148-
029 
0.3 136 34 17 6 3.8 7.2 
IKP148-
036 
0.6 116 32 11 6 4.9 0.5 
IKP148-
038 
0.5 114 11 12 16 4.9 0.5 
IKP148-
039 
0.6 221 37 17 21 4.8 0.5 
IKP148-
040 
0.6 97 9 14 18 4.6 0.5 
IKP148-
041 
1.3 177 22 21 45 5.2 0.7 
IKP148-
042 
0.65 129 37 7 4 4.5 0.6 
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IKP148-
043 
0.4 194 7 9 4 4.7 0.5 
IKP148-
044 
1.9 112 42 31.5 54 5 0.9 
IKP148-
047 
3.3 157 35 7 7 4.1 19.3 
IKP148-
054 
0.6 202 16 10 1 4.5 0.5 
IKP148-
058 
0.5 106 33 11 19 4.9 0.5 
IKP148-
059 
0.9 331 101 28 37 4.3 0.8 
IKP148-
061 
1.6 227 73 118 111 4.4 0.95 
IKP148-
063 
1.2 877 427 29 82 4.1 0.8 
IKP148-
064 
0.3 115 22 12 15 4.2 0.5 
IKP148-
069 
0.5 921 213 44 84 3.7 12.5 
IKP148-
070 
0.4 92 18 11 5 3.5 0.5 
IKP148-
072 
3.2 445 258 24 49 4 4 
IKP148-
076 
0.2 187 38 14 17 3.9 0.4 
IKP148-
079 
8 977 93 69 44 2.7 21.1 
IKP148-
080 
0.6 139 11 24 31 4.6 0.1 
IKP148-
081 
0.7 851 605 62 109 4 10.8 
IKP148-
082 
0.5 230 49 10 8 3.7 6.4 
IKP148-
085 
0.4 202 42 13 20 4.5 1 
IKP148-
087 
0.6 134 53 22 44 4.4 0.3 
IKP148-
096 
0.9 98 6 8 7 4.4 0.3 
IKP148-
098 
1.05 198 33 15 16 4.2 1.05 
IKP148-
102 
0.7 127 27 17 38 4.3 0.4 
IKP148-
103 
0.9 62 10 10 7 4.5 0.1 
IKP148-
104 
0.8 111 26 9 15 4.9 0.2 
IKP148- 0.8 775 239 62 79 4.4 1.7 
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106 
IKP148-
118 
0.4 201 29 14.5 14 4.6 2.6 
IKP148-
120 
0.3 176 na 11 5 na 2.2 
IKP148-
121 
0.5 127 10 8 6 3.9 1.2 
IKP148-
122 
0.5 89 7 6 4 4 0.1 
IKP148-
123 
1.7 269 80 52 25 2.8 31.1 
IKP148-
124 
0.2 132 15 12 9 4.3 0.1 
IKP148-
126 
0.4 143 177 15 27 4.5 0.1 
IKP148-
127 
0.7 134 39 17 14.5 3.9 1.85 
IKP148-
129 
0.3 123 16 11 12 4.2 1.1 
IKP148-
132 
0.4 175 19 7 6 3.2 1.9 
IKP148-
133 
0.7 141 24 12 11 4.2 1.2 
IKP148-
134 
0.45 72.5 7 10 11 3.8 0.1 
IKP148-
135 
0.8 73 9 19.5 46 4.4 0.1 
IKP148-
136 
6.6 1680 1550 152 206 3.4 5 
IKP148-
137 
41.55 407 140 21.5 30.5 na 4.55 
IKP148-
139 
0.65 100 53 10.5 7.5 4.5 0.1 
IKP148-
140 
0.7 144 18 10 7 4.5 0.4 
IKP148-
143 
0.4 85 11 9 5 4.2 0.9 
IKP148-
144 
0.4 126 74 12 10 4.7 1 
IKP148-
145 
0.6 180 63 7 7 4.1 3.2 
IKP148-
150 
1.4 231 79 16 21 4.5 0.1 
IKP148-
153 
0.5 111 19 12 19 4.3 0.1 
IKP148-
156 
1 230 137 14 15 4.2 1.5 
IKP148-
157 
0.9 122 20 13 20 4.5 0.1 
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IKP148-
159 
0.6 121 57 11 16 4.4 0.9 
IKP148-
163 
0.4 171 60 12 11 4.4 0.3 
IKP148-
164 
0.9 92 15 10 9 4.3 0.1 
IKP148-
165 
0.5 88 21 11 14 4.3 0.1 
IKP148-
166 
0.8 93 12 11 8 4.3 0.25 
IKP148-
168 
0.2 168 54 10 10 3.6 6.1 
IKP148-
169 
0.45 271 140 8 8 3.7 2.6 
IKP148-
170 
0.9 242 29 65 104 4.6 3.5 
IKP148-
171 
0.3 407 105 16 28 3.6 4.1 
IKP148-
178 
3.1 376 246 38 77 3.6 4.2 
IKP148-
179 
3.45 1381.5 245 24.5 16 2.4 5.2 
IKP148-
181 
1.3 81 13 8 6 4.4 0.1 
IKP148-
182 
0.5 148 59 16 42 3.6 3.4 
IKP148-
183 
0.4 155 65 10 8 4.6 0.1 
IKP148-
186 
0.3 325 54 21.5 41 4.6 0.4 
IKP148-
187 
0.8 623 155 74 60 3.7 4.8 
IKP148-
188 
1 286 100 26 17 3.4 1.7 
IKP148-
189 
0.4 117 35 10 11 3.2 1.2 
IKP148-
190 
0.4 86 14 9 6 4.7 0.1 
IKP148-
191 
0.3 287 120 17 20 3.4 7.6 
IKP148-
192 
0.9 71 25 12 12 3.9 0.1 
IKP148-
193 
0.55 219 46 13 11.5 4.3 0.5 
IKP148-
194 
0.9 75 9 14 22 4.1 0.1 
IKP148-
195 
0.7 295 72 12 21 4 0.2 
IKP148- 0.5 159 67 16 26 4.5 0.1 
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199 
IKP148-
202 
1.2 1080 136 19 21 3.2 6.6 
IKP148-
205 
0.5 91 23 18 29 4.4 0.1 
IKP148-
209 
0.75 63 8 7.5 7 4.5 0.1 
IKP148-
210 
0.8 171 20 13 10 4.3 1.3 
IKP148-
212 
2.8 163 16 11 6 4.4 1 
IKP148-
213 
0.3 100 32 6 6 4 2.8 
IKP148-
214 
0.4 206 33 9 9 3.9 2.1 
IKP148-
218 
0.7 585 332 19 29 4.5 4.2 
IKP148-
221 
0.5 197 19 10 10 4.3 1.6 
IKP148-
222 
0.8 208 61 60 55 3.9 0.3 
IKP148-
223 
0.6 89 12 10 5 4.6 0.1 
IKP148-
224 
0.6 196 28 15 18 4.6 0.5 
IKP148-
225 
1.1 103 21 8 3 4 0.1 
IKP148-
226 
1.8 400 168 24 116 3.6 0.2 
IKP148-
227 
0.9 125 10 13 18 4.3 0.1 
IKP148-
229 
0.8 157 136 66 134 4.7 0.1 
IKP148-
230 
0.7 171 20 13 10 4.3 0.1 
IKP148-
231 
0.5 451 40 27 41 3.7 2.3 
IKP148-
232 
0.8 434 120 21.5 21 20.8 13.6 
IKP148-
234 
4.4 649 740 22 19 3.3 10.1 
IKP148-
235 
3.7 467 112 36 51 3.8 0.1 
IKP148-
236 
0.7 127 11 14 11 4.7 0.1 
IKP148-
237 
na na na 21 Na na na 
IKP148-
238 
1.1 232 154 37 26 3.8 1 
128 
 
 
IKP148-
239 
0.4 89 24 10 10 4.5 0.1 
IKP148-
240 
0.2 111 11 9 6 3.9 0.6 
IKP148-
242 
0.4 124 10 12 14 3.7 0.1 
IKP148-
243 
0.5 141 30 14 15 4.3 0.5 
IKP148-
244 
0.2 92 18 7 5 4.1 1.4 
IKP148-
246 
1 122 na 15 10 na 0.1 
IKP148-
248 
0.4 259 108 75 190 3.9 2.7 
IKP148-
249 
1 177 16 8 2 3.8 0.1 
IKP148-
250 
0.6 124 39 7 5 4.2 0.1 
IKP148-
251 
0.2 104 9 10 8 3.9 0.3 
IKP148-
254 
0.6 146 20 15 10 4.4 0.1 
IKP148-
255 
0.5 201 33 9 12 4.7 0.3 
IKP148-
259 
0.5 94 40 13 16 4.1 0.1 
IKP148-
260 
na na na 12 Na na 0.1 
IKP148-
261 
0.5 106 22 9 9 3.7 0.3 
IKP148-
264 
0.9 91 39 23 43 4.6 0.1 
IKP148-
266 
1.7 na na 135 184 na na 
IKP148-
268 
2.4 1043 230 31 Na 3 0.6 
IKP148-
269 
4 122 51 38 54 4.2 0.8 
IKP148-
270 
0.5 173 44 8 6 4.4 0.1 
IKP148-
271 
0.4 122 19 8 9 4.2 0.7 
IKP148-
272 
0.7 129 13 17 24 4.1 0.1 
IKP148-
273 
0.4 108 8 7 6 4.1 0.1 
IKP148-
274 
na na na 33 Na na na 
IKP148- 0.3 202 78 16 23 3.7 4.9 
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275 
IKP148-
279 
0.4 589 56 15 20 3.9 1 
IKP148-
281 
0.6 103 7 8 8 4.2 0.1 
IKP148-
282 
2.1 847 191 85 97 3.8 0.9 
IKP148-
283 
1 261 96 35 15 4.4 2.1 
IKP148-
285 
0.4 201 30 12 19 4.3 1.9 
IKP148-
288 
0.6 103 20 10 7 4 0.1 
IKP148-
293 
1.1 1068 661 42 82 3.7 4 
IKP148-
295 
0.9 199 137 12 13 4 0.1 
IKP148-
296 
5 449 51 27 39 3.4 0.1 
IKP148-
297 
0.3 119 15 11 18 4.6 0.1 
IKP148-
298 
0.6 125 64 14 16 4.6 0.1 
IKP148-
299 
0.6 231 114 12 19 4.2 1 
IKP148-
300 
0.9 118 18 12 8 4.9 0.1 
 
4.2.5 Population Stratification 
 Two independent methods were used to assess if there was any underlying population 
stratification in the Stuttgart liver samples; the software program Structure and PCA (see Figure 
18) were used to assess the population structure in the liver samples using ~600 SNPs in linkage 
equilibrium (r-squared <0.2) from the ADME panel that were also common to the HapMap 
project
283,284
. HapMap samples of known ancestry (CEU, YRI and JPT/CHB) were used as 
reference populations. Both methods identified two individuals (IKP148-016 and IKP148-168) 
that were phenotypically labeled as CEU but which fell outside the CEU cluster. These two 
individuals were excluded from future analysis. 
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4.2.6 Statistical Analysis 
 Plink v1.06 was used to test for association between each SNP and each probe (2496 
SNPs x 2632 probes = 6 569 472 tests).  Linear regression using additive model was performed 
using age and sex as covariates. Analysis was restricted to 3 data sets: 
1. All probes vs all SNPs 
2. All SNPs vs probes within +- 100 kb 
3. All SNPs vs probe in the same ADME annotated gene 
4.2.7 Multiple Testing Correction 
 Two methods were used to account for false positives that may arise by chance due to the 
number of tests.  P value significance thresholds were set using a Bonferroni correction that takes 
into account the number of SNPs (p-value 2.0e-5 for 3000 SNPs) and the number of tests (p-
value 7.611e-10 for ~66 million tests)  being performed, and the false discovery rate calculation 
Figure 18: Results from STRUCTURE and PCA analysis of Liver Samples 
 
On the left CEU samples are in blue, YRI samples are in red, JPT/CHB samples are in green and 
IKP samples are in yellow. On the right, CEU samples are in green, YRI samples are in red, 
JPT/CHB samples are in blue and IKP samples are in purple. Using both methods two individuals 
fall outside the CEU cluster. 
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(FDR) was used (10% FDR p-value 2.158e-07, 5% FDR p-value 6.635e-08, 1% FDR p-value 
8.053e-09). 
4.2.8 Imputation as Quality Control 
 
 SNPs from HapMap3 and the 1000 genome project (CEU population) were imputed for 
regions spanning 20 kb upstream and downstream of each gene included on the ADME panel 
using Impute2
285
. The genotype/phenotype associations were calculated with the imputation data 
using SNPTEST
122
. The imputation association data was used to prioritize the original 
association results. When a lone spike was observed in the imputed data the association was 
determined to be reliable (see Figure 19).Using imputation and association data, the following 
probes (5700477, 50392 and 4540424) were flagged as being erroneous because of unusual 
patterns using this method of analysis and were subsequently removed from the final data set 
(see Figure 20 and Table 19). 
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Figure 19: Examples of Good Imputation Association Results 
 
Genotyped SNP with smallest p value is indicated in red. For probe 380441 the imputed SNPs 
have more significant p values, for probe 4860441 a genotyped SNP has the most significant 
p value. Horizontal lines indicate p values of 2.0e-5 and 7.611e-10 
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Table 19: Flagged Association Data based on Imputation Data 
PROBE GENE CHR SNP P Previously Identified 
5700477 DDT 22 rs575959 3.24E-46  
5700477 DDT 22 rs113413 9.07E-29 Zeller et al. (2010) 
50392 SULT2A1 19 rs296381  6.23E-22  
50392 SULT2A1 19 rs188440  3.65E-10   
4540424 EPHX2 8 rs1042064 2.13E-07  
Figure 20: Example of Flagged Imputation Data 
 
The association for probes 50392 and 5770047 were flagged after observing the imputation 
data. Upon further investigation the expression of these probes was not normally distributed 
which gave rise to the spurious associations. 
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4.3 Results 
4.3.1 Cis eQTLs 
 The data analysis was focused primarily on cis associations as trans associations are 
difficult to prove; however future analysis will more thoroughly investigate this data. Cis acting 
associations were defined as SNPs and gene probes being within 100 kb of each other. Using a 
Bonferroni significance threshold of 7.611 e-10, there were 22 significant cis associations. At a 
1% FDR there remained 25 significant cis associations. There are 68 cis associations with a p 
value smaller that 2.0r-05 (Bonferroni correction for 3000 SNPs). These 68 associations equate 
to 60 SNPs that correlate with eQTLS for 32 genes (See Table 20). 15 of the cis eQTLs, 
including the top association, had previously been identified on a different set of samples in one 
or multiple previously published eQTL studies (highlighted in red Table 20) giving further 
evidence to the validity of the results.     
Table 20: Significant cis eQTLs (p-value <2.0e-05)  
SNPs that are lower than the 1%FDR cutoff (8.053e-09) have a green background, 5%FDR 
cutoff (6.635e-08) have a blue background and 10% FDR cutoff (2.158e-07) have an orange 
background. 
 
PROBE GENE CHR SNP P Previously Identified 
6330037 CHURC1 14 rs7143764 2.30E-62 
Veyrieras et al. (2008) 
Stranger et al. (2007) 
5700477 DDT 22 rs575959 3.24E-46  
6330037 CHURC1 14 rs1886506 2.16E-41 
Veyrieras et al. (2008) 
Stranger et al. (2007) 
6840497 GSTT1 22 rs113413 5.78E-30 Zeller et al. (2010) 
380441 ABCC11 16 rs16945988 6.74E-29  
5700477 DDT 22 rs113413 9.07E-29 Zeller et al. (2010) 
6330037 CHURC1 14 rs8016174 2.05E-25 
Veyrieras et al. (2008) 
Stranger et al. (2007) 
4860441 SLC22A10 11 rs502642 6.48E-23  
50392 SULT2A1 19 rs296381 6.23E-22  
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1340653 SLC22A10 11 rs502642 5.14E-20 
 6840497 GSTT1 22 rs575959 1.38E-19 Stranger et al. (2007) 
3830538 GPX7 1 rs835344 8.49E-19 Zeller et al. (2010) 
620280 ARNT 1 rs11204735 6.02E-15 Stranger et al. (2007) 
620280 ARNT 1 rs10888395 2.00E-14 Schadt et al. (2007) 
6590689 GSTO2 10 rs568526 2.21E-14  
6330037 CHURC1 14 rs2296327 9.29E-14 Stranger et al. (2007) 
4860441 SLC22A10 11 rs556730 1.96E-13  
1050035 GSTA3 6 rs10948726 3.98E-13  
3830538 GPX7 1 rs946154 1.40E-12  
1340653 SLC22A10 11 rs556730 4.82E-12  
3930189 SLC22A3 6 rs641990 4.72E-11  
6130669 PSMB9 6 rs1383268 1.09E-10 Zeller et al. (2010) 
50392 SULT2A1 19 rs188440 3.65E-10  
380441 ABCC11 16 rs17743256 4.55E-10  
380441 ABCC11 16 rs8050120 5.56E-09  
7320632 SLC25A27 6 rs953062 3.50E-08  
6130669 PSMB9 6 rs4148882 3.72E-08 Zeller et al. (2010) 
6590343 PERLD1 17 rs1053651 9.12E-08  
6590689 GSTO2 10 rs966645 9.27E-08  
7320632 SLC25A27 6 rs12192544 1.17E-07 Schadt et al. (2007) 
5670722 FMO4 1 rs6662297 1.18E-07  
5670722 FMO4 1 rs714839 1.69E-07  
4540424 EPHX2 8 rs1042064 2.13E-07  
6040754 ENTPD5 14 rs7153587 2.60E-07  
4050008 TDRD6 6 rs9472817 3.63E-07  
3370300 CYP3A7 7 rs4646450 5.56E-07  
6060390 CDA 1 rs1689924 7.95E-07  
1050035 GSTA3 6 rs9395826 1.06E-06  
6370497 ULK3 15 rs2470890 1.31E-06 Zeller et al. (2010) 
6040754 ENTPD5 14 rs1536 1.37E-06  
6130669 PSMB9 6 rs1383266 1.43E-06  
6370382 IQCB1 3 rs2293616 1.47E-06  
1340653 SLC22A10 11 rs4570581 2.13E-06  
1470050 GSTZ1 14 rs7972 2.14E-06  
6550328 PON1 7 rs854552 2.54E-06 
 6370382 IQCB1 3 rs1143672 2.89E-06 
6370382 IQCB1 3 rs2257212 3.34E-06  
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3830538 GPX7 1 rs835337 3.72E-06 Zeller et al. (2010) 
6130669 PSMB9 6 rs6912492 4.41E-06  
1470050 GSTZ1 14 rs2287398 4.45E-06  
3830538 GPX7 1 rs7529595 4.98E-06  
4050008 TDRD6 6 rs953062 5.58E-06  
5670722 FMO4 1 rs2294482 5.76E-06  
6940133 UGT1A3 2 rs6725478 5.97E-06  
4860441 SLC22A10 11 rs4570581 6.58E-06  
6370382 IQCB1 3 rs866926 7.19E-06  
6370497 ULK3 15 rs762551 9.32E-06  
6940133 UGT1A3 2 rs4294999 9.63E-06  
1260470 LONP2 16 rs16945988 9.71E-06  
4180050 FMO1 1 rs714839 1.12E-05  
3780717 UGT2A1 4 rs1432329 1.12E-05  
3930189 SLC22A3 6 rs569919 1.23E-05  
5700477 DDT 22 rs2858908 1.34E-05 
 7320632 SLC25A27 6 rs12215229 1.36E-05 
 5810598 GNAI3 1 rs542338 1.67E-05 Zeller et al. (2010) 
2710575 GPX2 14 rs7143764 1.69E-05 
 7210017 CYP21A2 6 rs433061 1.79E-05 
 3420632 DOPEY2 21 rs2835286 1.92E-05 
  
4.3.2 Trans Associations 
  A trans eQTL was defined as any association where the SNP and probe were on different 
chromosomes. There are 23 significant trans eQTLs using a 10% FDR significance threshold 
(see Table 21). None of these trans eQTLs had been previously identified and none were in 
ADME genes. 
Table 21:  Significant trans eQTLs (p-value <= 2.11E-07) 
GENE CHR SNP P 
KCNG1 20 rs575959 4.19E-18 
KCNG1 20 rs113413 5.08E-12 
TSN 2 rs6068810 9.22E-10 
PGCP 8 rs6068810 1.08E-09 
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MLANA 9 rs6068810 2.23E-09 
TYRP1 9 rs6068810 3.96E-09 
SFRS12 5 rs6068810 5.99E-09 
AKT1 14 rs17578180 1.85E-08 
LOC347376 X rs6068810 5.60E-08 
PSMA7 20 rs2239566 8.03E-08 
RIMS2 8 rs6068810 9.43E-08 
RPLP1 15 rs6068810 9.69E-08 
FAM98A 2 rs952499 9.75E-08 
SFRS11 1 rs12562630 9.81E-08 
HTN3 4 rs6068810 1.01E-07 
WDSOF1 8 rs2239566 1.05E-07 
CARS 11 rs12543000 1.24E-07 
TFAP2A 6 rs543613 1.25E-07 
GDI2 10 rs2817227 1.33E-07 
RPS28 19 rs12553329 1.36E-07 
SUMO2 17 rs512077 1.43E-07 
ATG16L1 2 rs11635541 1.57E-07 
RNF121 11 rs2027055 2.11E-07 
 
4.3.3 ADME Gene Analysis 
 As we are primarily interested in ADME gene associations, the analysis was further 
refined to examine only association between SNPs on the ADME panel and probes annotated to 
be in the same ADME gene. Some SNPs were annotated for an entire loci rather than a single 
gene due to short inter-genic distances or strong LD (eg UGT1A, and CYP3A). At significance 
thresholds of 1.32 E-04 (1% FDR) and 9.37E-04 (5% FDR) there are 57 and 79 significant 
eQTLs respectively, when looking only at ADME genes and SNPs (see Table 22). This 
corresponds to eQTLS for 24 ADME genes/loci. Of these ADME eQTLs, only four have 
previously been reported in studies within different sets of samples and only three were 
previously identified in the same 150 liver samples using a whole genome genotyping array
276
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Table 22: Significant ADME Gene Associations  
Previously identified associations from any study are indicated in red. Gene associations 
previously identified in the IKP150 liver samples are bolded and underlined. 1%FDR: 1.32 E-04 
(have a green background) and 5%FDR: 9.37E-04 (have a blue background). 
SNP SNP Gene/Locus Probe Probe Gene P-value 
rs16945988 ABCC11/12 380441 ABCC11 6.74E-29 
rs502642 SLC22A9/10 4860441 SLC22A10 6.48E-23 
rs502642 SLC22A9/10 1340653 SLC22A10 5.14E-20 
rs835344 GPX7 3830538 GPX7 8.49E-19 
rs11204735 ARNT 620280 ARNT 6.016E-15 
rs10888395 ARNT 620280 ARNT 2.003E-14 
rs568526 GSTO1/O2 6590689 GSTO2 2.21E-14 
rs556730 SLC22A9/10 4860441 SLC22A10 1.955E-13 
rs10948726 GSTA1/2/3/4/5 1050035 GSTA3 3.979E-13 
rs946154 GPX7 3830538 GPX7 1.399E-12 
rs2144698 GSTA1/2/3/4/5 1050035 GSTA3 2.306E-12 
rs556730 SLC22A9/10 1340653 SLC22A10 4.817E-12 
rs2608632 GSTA1/2/3/4/5 1050035 GSTA3 2.306E-11 
rs641990 SLC22A3 3930189 SLC22A3 4.718E-11 
rs17743256 ABCC11/12 380441 ABCC11 4.554E-10 
rs4715326 GSTA1/2/3/4/5 1050035 GSTA3 7.654E-10 
rs2608624 GSTA1/2/3/4/5 1050035 GSTA3 9.125E-10 
rs8050120 ABCC11/12 380441 ABCC11 5.558E-09 
rs966645 GSTO1/O2 6590689 GSTO2 9.272E-08 
rs6662297 FMO 5670722 FMO4 1.183E-07 
rs714839 FMO 5670722 FMO4 1.694E-07 
rs1042064 EPHX2 4540424 EPHX2 2.129E-07 
rs2180314 GSTA1/2/3/4/5 1050035 GSTA3 4.597E-07 
rs4646450 CYP3A 3370300 CYP3A7 5.556E-07 
rs1689924 CDA 6060390 CDA 7.946E-07 
rs9395826 GSTA1/2/3/4/5 1050035 GSTA3 1.06E-06 
rs2741023 UGT1A 6940133 UGT1A1 1.09E-06 
rs4570581 SLC22A10 1340653 SLC22A10 2.13E-06 
rs7972 GSTZ1 1470050 GSTZ1 2.14E-06 
rs2741019 UGT1A 6940133 UGT1A1 2.27E-06 
rs854552 PON1 6550328 PON1 2.54E-06 
rs835337 GPX7 3830538 GPX7 3.72E-06 
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rs2287398 GSTZ1 1470050 GSTZ1 4.45E-06 
rs7529595 GPX7 3830538 GPX7 4.98E-06 
rs2294482 FMO 5670722 FMO4 5.76E-06 
rs6725478 UGT1A 6940133 UGT1A1 5.97E-06 
rs4570581 SLC22A10 4860441 SLC22A10 6.58E-06 
rs4294999 UGT1A 6940133 UGT1A1 9.63E-06 
rs714839 FMO 4180050 FMO1 1.12E-05 
rs1432329 UGT2A1/2B4 3780717 UGT2A1 1.12E-05 
rs569919 SLC22A3 3930189 SLC22A3 1.23E-05 
rs7143764 GPX2 2710575 GPX2 1.69E-05 
rs433061 CYP21A2 7210017 CYP21A2 1.79E-05 
rs718016 FMO 5670722 FMO4 2.79E-05 
rs3820170 FMO 5670722 FMO4 2.99E-05 
rs7877 FMO 5670722 FMO4 3.03E-05 
rs4124874 UGT1A1 6940133 UGT1A1 3.26E-05 
rs3820170 FMO 4180050 FMO1 4.00E-05 
rs13269963 EPHX2 4540424 EPHX2 5.97E-05 
rs757158 PON1 6550328 PON1 8.37E-05 
rs1319811 UGT2A1/2B4 3780717 UGT2A1 9.74E-05 
rs10916827 CDA 6060390 CDA 9.98E-05 
rs1569343 UGT2A1/2B4 3780717 UGT2A1 1.08E-04 
rs2292334 SLC22A3 3930189 SLC22A3 1.32E-04 
rs43047 PON2/3 6450753 PON2 0.0001885 
rs2231142 ABCG2 2320711 ABCG2 0.0002369 
rs16945874 ABCC11/12 380441 ABCC11 0.0002532 
rs43037 PON2/3 6450753 PON2 0.0002767 
rs854573 PON1 6550328 PON1 0.000277 
rs1886506 GPX2 2710575 GPX2 0.0002772 
rs2760139 ALDH5A1 3780524 ALDH5A1 0.0003145 
rs2180312 GSTA1/2/3/4/5 1050035 GSTA3 0.0003346 
rs2272365 PON1 6550328 PON1 0.0003595 
rs17147507 UGT2A1/2B4 3780717 UGT2A1 0.0003925 
rs7527068 GPX7 3830538 GPX7 0.000429 
rs17863787 UGT1A 6940133 UGT1A1 0.0004464 
rs2835286 CBR3 1470132 CBR3 0.0004709 
rs6662297 FMO 4180050 FMO1 0.0005119 
rs818194 CDA 6060390 CDA 0.0005143 
rs2076317 ALDH5A1 3780524 ALDH5A1 0.0005243 
rs1823803 UGT1A 6940133 UGT1A1 0.0006196 
rs4787456 SULT1A1/2 5270477 SULT1A1 0.0006907 
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rs2239566 CBR3 1470132 CBR3 0.0008067 
rs3091344 CYB5R3 2490678 CYB5R3 0.0008437 
rs10499314 SLC22A3 3930189 SLC22A3 0.0008658 
rs2288740 UGT2A1 3780717 UGT2A1 0.0009367 
 
  When examining eQTL data from the Schadt et al. paper, there are 27 cis eQTLs that 
appear in ADME genes that overlap with genes present on our 3000 SNP ADME panel. Of the 
27 genes identified in the Schadt et al. data, we identified at least one significant cis eQTL in 8 
of these genes in this study: CBR3, GSTO2, PON2, SULT2A1, UGT2A1, ARNT, GSTA3, and 
FMO1. For comparison, the  Schadt et al. data was generated using almost 3 times the number of 
human liver samples (427) as our study of 150 while also using whole genome SNP arrays with 
more than 780 000 SNPs. Of the remaining 19 genes in the Schadt et al. data that did not have 
cis eQTLs in our data, the average p value 0.06, trending toward significance. Moreover, our 
study identified an additional 17 cis eQTLs in key ADME genes that are unique to our liver data 
set, and for which no pervious observations have been made: ABCC11, FMO4, UGT1A1, 
ABCG2, GPX2, ALDH5A1, GPX7, CDA, GSTZ1, CYB5R3, PON1, CYP3A7, SLC22A10, 
EPHX2, SLC22A3, CYP21A2, and SULT1A1. In the Schadt et al. data, there are three SNPs 
that are present on our ADME panel that are significantly associated with cis eQTLs that we did 
not see in our data because probes in these genes were removed as part of our stringent QC 
process. 
 While the Schadt et al. data was generated on a different set of human liver samples, the 
Schröder et al. eQTL data was generate on the same 150 human liver samples using the Illumina 
330 whole genome array.  Comparison of both data sets identified ADME cis eQTLS, in the 
same six ADME genes: ARNT, FMO4, GPX7, GSTO2, SLC22A10 and UGT1A1
271
; however 
there are an additional 13 ADME genes with cis eQTLs that are unique to our data set: ABCC11, 
141 
 
 
ABCG2, GPX2, ALDH5A1, CDA, GSTZ1, CYB5R3, PON1, CYP3A7, EPHX2, SLC22A3, 
CYP21A2, and SULT1A1. Therefore, in a straight comparison study using the same liver 
samples, our ADME panel had the same ability to detect an equal number of eQTLs (5) as the 
commercial whole genome arrays while having additional content that increased its sensitivity to 
discover an additional 13 eQTLs that were not detected using conventional tools.   
 In addition to mRNA expression, twenty-two additional phenotypes were tested for 
association with ADME genotype (see Appendix 5). The additional phenotypes include twelve 
protein expression phenotypes measured by Western blot analysis (CYP2B6, CYP2C8, 
CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, P450, POR, UGT1A1, and 
UGT1A3) and ten enzymatic activities measured using probe drugs (CYP1A2, CYP2A6, 
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and POR). The protein 
level of three genes (UGT1A3, CYP3A5 and UGT1A1) had 23 significant associations with 
ADME SNPs. For some of these associations, the same SNP was also associated with mRNA 
expression (See Table 23). 
Table 23: Additional Phenotype Associations 
Phenotype SNP SNP 
Gene 
P-value eQTL P-value 
UGT1A3 rs4294999 UGT1A 3.73E-19 UGT1A1 0.000009634 
UGT1A3 rs6725478 UGT1A 1.08E-18 UGT1A1 0.000005967 
UGT1A3 rs4124874 UGT1A1 6.71E-17 UGT1A1 0.00003261 
UGT1A3 rs2741023 UGT1A 4.01E-15 UGT1A1 0.000001092 
UGT1A3 rs2741019 UGT1A 3.66E-12 UGT1A1 0.000002269 
UGT1A3 rs17863787 UGT1A 3.03E-11 UGT1A1 0.0004464 
UGT1A3 rs2602378 UGT1A 1.90E-09   
UGT1A3 rs28946889 UGT1A 1.23E-08   
CYP3A5 rs2242480 CYP3A 1.65E-08   
CYP3A5 rs2687079 CYP3A 4.54E-08   
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UGT1A3 rs1823803 UGT1A 5.52E-08 UGT1A1 0.0006196 
CYP3A5 rs4646450 CYP3A 1.67E-07 CYP3A7 5.556E-07 
UGT1A3 rs6431558 UGT1A 3.53E-07   
UGT1A3 rs4148328 UGT1A 5.25E-07   
UGT1A1 rs17863787 UGT1A 5.32E-07 UGT1A1 0.0004464 
CYP3A5 rs6945984 CYP3A 6.30E-07   
UGT1A3 rs4281899 UGT1A 7.52E-07   
UGT1A1 rs4294999 UGT1A 1.39E-06 UGT1A1 0.000009634 
UGT1A1 rs4124874 UGT1A1 2.51E-06 UGT1A1 0.00003261 
UGT1A1 rs6725478 UGT1A 6.21E-06 UGT1A1 0.000005967 
UGT1A1 rs2741019 UGT1A 8.86E-06 UGT1A1 0.000002269 
CYP3A5 rs472660 CYP3A 8.99E-06   
UGT1A1 rs2602378 UGT1A 1.49E-05   
 
No significant associations were observed between our ADME SNP genotypes and any other 
protein expression or enzymatic activity phenotype when treated as continuous or dichotomous 
trait. 
4.4 Discussion 
 We have completed a thorough investigation of ADME gene eQTLs in samples derived 
from Human liver tissue. The use of very stringent quality control measures, such as strict HWE 
and the removal of gene expression probes without perfect mapping scores, may be too 
conservative and may have resulted in the inadvertent removal of true positive results, however, 
with such stringent quality metrics we are confident in these observations. Interestingly, eQTLs 
were observed for three SNPs in the Schadt et al. data that are present on the ADME panel, 
however were not observed in our analysis because the probes in these genes did not pass our 
QC criteria. If these three probes are kept in the analysis, we also observe the same three 
significant results. While these may be true associations, it has been demonstrated that the 
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reasons for probe removal during our QC process, i.e. underlying SNPs and non perfect mapping 
to their target gene, do cause inaccurate gene expression data
286–289
.   
 The number of significant eQTLs in ADME genes observed in this study, 57 and 79, 
respectively for significance thresholds of 1.32 E-04 (1% FDR) and 9.37E-04 (5% FDR) is 
similar in number to studies using whole genome approaches, 65 and 89 for Schadt et al. and 
Schroder et al.  There are two reasons to explain these findings. First, the testing of only 3000 
SNPs on the ADME panel does not suffer the same multiple testing penalty, and therefore has a 
lower p-value threshold, than experienced when using a whole genome genotyping approach. 
Secondly, as mentioned above (see Table 12), much of the content of the ADME panel is not 
included on commercial whole genome arrays. Of the 70 significantly associated ADME SNPs, 
30% and 20% of the them, are not accounted for on the whole genome arrays used in the 
Schroder et al. and Schadt et al. studies respectively even when accounting for proxy SNPs. 
 The design and content of the ADME panel has been validated by the fact that we 
replicated the findings of several other groups by identifying many of the same eQTLs in liver 
samples and other tissues using a much smaller but targeted set of ADME SNP markers
226,273,275
. 
These results also validate the replicated eQTLs. More importantly, our ADME panel shows 
increased sensitivity to identify novel pharmacogenomic biomarkers as it was able to identify an 
additional 13 novel ADME eQTLs using the same liver samples which had been previously 
investigated using whole genome genotyping approaches. While these results must be considered 
tentative until they can be validated in an additional cohort of liver samples; this clearly 
demonstrates the added value of this assay when compared to commercial whole genome arrays. 
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 This list of ADME eQTLs produced by this analysis has identified a number of 
genotype/phenotype correlations that needs to be further investigated to determine what impact 
any of these SNPs has on gene function and altered gene expression. For example, a SNP in a 
gene encoding a drug metabolism enzyme may be significantly associated with an adverse 
response to a drug. It may turn out that this SNP is an eQTL for the same drug metabolism gene 
and carriers of a certain allele have reduced expression. It may then be inferred that the reason 
for the association with the adverse event is that these people have reduced expression of the 
gene and therefore reduced metabolism. The generation of the ADME eQLT list will serve a 
valuable tool for future pharmacogenomic studies.   
 In addition to ADME eQTLs, associations were identified between ADME protein 
expression and ADME genotype. While these correlations require future validation, it is 
interesting that many of the associated SNPs are also ADME eQTLs for the same gene. These 
results show a potential link between mRNA expression and protein expression via genetic 
variation. Additionally, one of the SNPs associated with CYP3A5 protein expression, rs6945984, 
has also been associated with olanzapine clearance, thus implicating a possible mechanism for 
the association
290
. 
 Finally, many CYP enzymes are known to be highly polymorphic with regard to gene 
and protein expression and yet none were detected in this analysis. For CYP2D6, CYP2C9 and 
2C19, this is due to the fact that the 3000 SNP panel does not include any markers for these 
genes. The SNPs in these genes require additional PCR enrichment of the targets which are 
spiked into the reaction (see above). We did not have enough DNA from the liver samples to add 
the PCR spike in genes. For other genes, such as CYP2A6 and CYP2B6, the mechanism of 
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expression differences, may involve complicated mechanisms such alternative splicing that may 
not be well detected using micro arrays
291
. 
4.5 Conclusion 
  The result of the application of the broad based ADME panel to identify novel 
genotype/phenotype correlation, described above, has demonstrated the usefulness of our ADME 
panel design. Not only were we able to identify previously reported cis eQTLs but we were able 
to show the added sensitivity and added value of our panel over the other commercially available 
genome-wide SNP arrays, by identifying eQTLs in ADME gene that had not previously been 
reported using the very same samples. This is most likely due to the poor coverage of ADME 
gene on whole genome arrays or to the difficulty in generating good quality genotyping data due 
to area of genomic interference (discussed above) in areas surrounding many ADME genes. 
These results strongly suggest that our ADME panel would have broad applicability to most 
pharmacogenomic clinical trials and would have greater sensitivity to detect novel 
genotype/phenotype observations over current commercially available tools. Any study 
investigating the role of genetic variation on drug response could benefit from the use of our 
assay in their study. 
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5 Optimus Primer: A PCR enrichment primer design program for next-
generation sequencing of human exonic regions. 
 
 Over the course of the ADME panel development, several bioinformatic tools were 
developed to assist with assay and primer design. In this section, the further development of one 
of these tools into a utility for next-generation sequencing enrichment experiments is described. 
Sequencing experiments are becoming more prevalent however, costs for the whole genome 
sequencing of a large number of samples is still prohibitive. This is why many groups are 
enriching for certain regions of the genome prior to sequencing experiments. 
 To facilitate with primer design during the ADME panel development, an automated 
primer design pipeline was developed. This pipeline was modified to be able to automate the 
design of exon specific primers for PCR enrichment in sequencing experiments. It was our 
intention during the ADME panel development, to make bioinformatic tools that could be 
manipulated with very little effort so that they could have applicability in several areas of genetic 
research.  
 As the cost associated with sequencing experiments continues to drop, it may one day be 
cost effective to do large scale sequencing experiments on thousands of samples rather than 
genotyping. In this case, the content developed for the ADME genotyping assay could be 
translated into an ADME sequencing panel and a tool like the one described in this section would 
help with this process. 
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5.1 Abstract 
5.1.1 Background 
Polymerase chain reaction (PCR) remains a simple, flexible, and inexpensive method for 
enriching genomic regions of interest for next-generation sequencing. In order to utilize PCR in 
this context, a major challenge facing researchers is how to generate a very large number of 
functional PCR primers that will successfully generate useable amplicons. For instance, in an 
exon-only re-sequencing project targeting 100 genes, each with 10 exons, 1,000 pairs of primers 
are required. In fact, the reality is often more complex as each gene might have several isoforms 
and large exons need to be divided to maintain the desired amplicon size. With only a list of gene 
names, our program Optimus Primer (OP) automatically takes into account all these variables, 
and can generate primers with no need to provide genome coordinates. More importantly 
however, OP, unlike other primer design programs, uniquely utilizes Primer3 in an iterative 
manner that allows the user to progressively design up to four iterations of primer designs. 
Through a single interface, the user can specify up to four different design parameters with 
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different stringencies, thus increasing the probability that a functional PCR primer pair will be 
designed for all regions of interest in a single pass of the pipeline.  
5.1.2 Findings 
To demonstrate the effectiveness of the program, we designed PCR primers against 77 genes 
located in loci associated with ulcerative colitis as part of a candidate gene re-sequencing 
experiment. We achieved an experimental success rate of 93% or 472 out of 508 amplicons 
spanning the exonic regions of the 77 genes. Moreover, by automatically passing amplicons that 
failed primer design through three additional iterations of design parameters, we achieved an 
additional 170 successful primer pairs or 34% more in a single pass of OP than by conventional 
methods. 
5.1.3 Conclusion 
With only a gene list and PCR parameters, a user can produce hundreds of PCR primer designs 
for regions of interest with a high probability of success in a very short amount of time. Optimus 
Primer is an essential tool for researchers who want to pursue PCR-based enrichment strategies 
for next-generation re-sequencing applications. The program can be accessed via website at 
http://op.pgx.ca. 
5.2 Findings 
The development of next-generation sequencing (NGS) technologies has dramatically increased 
the size and scale of sequencing experiments. It is now possible to produce several gigabases of 
DNA sequence in a short period of time
292
.  To date, the cost of whole human genome 
sequencing remains prohibitive. Focusing NGS experiments to specific genomic regions is an 
alternative, cost-effective approach to whole genome sequencing but it requires the enrichment 
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of the targeted regions before library construction. Several hybridization-based methods – each 
with its own strengths and weaknesses – have been developed293. While these DNA enrichment 
methods continue to be developed and improved, a simple and inexpensive alternative is PCR. 
PCR is a robust, well-understood, very accessible and flexible strategy for DNA enrichment. It 
also allows for the very specific amplification of targeted regions without the high background 
found in hybridization-based methods. Hundreds or even thousands of PCR amplicons that span 
selected genomic regions of interest can be pooled together and used as input material for the 
sequencing reaction. PCR has been traditionally used for classic Sanger chemistry-based 
sequencing of few genes. However, the throughput of next-generation DNA re-sequencing is 
such that new tools need to be developed to facilitate the implementation of PCR as enrichment 
strategy for these new sequencing methods.  
Enrichment of exonic regions is of particular interest as the functionality of variations within 
these regions can be more easily inferred than variations in non-coding DNA. Surveying genetic 
variation by NGS for all exons in candidate genes, such as those identified in genome wide 
association studies (GWAS), may contribute to the identification of the causal genes and 
variants, and therefore the underlying biology of the disease.  
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In order to utilize PCR in the context of NGS, where hundreds of genes are resequencd, a major 
challenge facing researchers is how to generate a very large number of functional PCR primers 
that will successfully generate useable amplicons. For instance, in order to target the re-
sequencing of 100 genes, each with 10 exons, this requires 1,000 pairs of PCR primers. In fact, 
the reality is often more complex as each gene might have several isoforms and the enrichment 
strategy must accommodate large exons that require overlapping PCR products to maintain the 
desired amplicon size. Thus, to address this significant bioinformatic need in setting up robust 
NGS enrichment pipelines, we have developed the Optimus Primer (OP) website 
(http://op.pgx.ca) where users can import a gene list with no need to provide genome coordinates 
to generate a complete list of PCR primer pairs (see Figure 21 and Table 24 for example). 
Table 24:  Example PCR Primer Pairs Designed After Submitting TCF7L2 
Region Name Forward Primer Reverse Primer 
TCF7L2_chr10_exon1-3_1 CTGTTTATTTATGCACACGTCACTG gTACTCACCTTCTTCCAAACTTTCC 
TCF7L2_chr10_exon1-3_2 GATTCTTTTTCTCCCCCTTCTC AGCCAGCAATCTCCACTAGAAAG 
TCF7L2_chr10_exon4_1 TCCCTGTATGCTTATTGAATAGGTG CCCAGAAAAGAAGTCATGGAATAAC 
TCF7L2_chr10_exon5_1 GGCTAGTTGTTCTGCATTTACTTTC AGCTCCAAAATAAGGAGGCAGTTAG 
TCF7L2_chr10_exon6_1 AATAGGAGAGTTCTGATTTGTGCTG GACTTATTCCACATTTTGTCTCTCC 
TCF7L2_chr10_exon7_1 CATCTTAGAAAATCCAGGTGAGAGG AACAACTGGGATAAAAAGGGGATG 
TCF7L2_chr10_exon8_1 ATGAGATGAAACCTACCAACAACTC TGTTGTTCAGAGTACAGATCACTGG 
TCF7L2_chr10_exon9_1 CTTACTGTGCAGAGAGAACTTTTCC ATTAGCGACTAAAACATACTGCTGC 
TCF7L2_chr10_exon10-12_1 ACGATTTACACAGCTTTCTGTCTTC CTATGTCATTCTGTCATTTGCTCAC 
TCF7L2_chr10_exon10-12_2 CTGAGTGCACGTTGAAAGAAAG AGAGAGGACTAGGCAGATCCTGTAG 
TCF7L2_chr10_exon13-14_1 CAGACACTCTTCTCACATCTGTTTC GGAGGTTTATTACTGAATTCCTTCC 
TCF7L2_chr10_exon15-16_1 CTCGCTTCTCTCTTGAACTCATTC CTTCTCCATGTGTCTCGACTCTAAG 
TCF7L2_chr10_exon17_1 TATTCACAGATAACTCTCTCCCCTG TCTATTAAGTGTTGAGTAGCGTCCC 
TCF7L2_chr10_exon17_2 ACATCTGGTTTTTAAACCGTAAGGG GAGCATAAAACGGAACAGTAACATC 
TCF7L2_chr10_exon17_3 CATATTACATACGAGTAGGCAGCAG CGATACTGTGGTCACCTTAAGAAAC 
After having only submitted the gene name (TCF7L2) Optimus Primer was able to 
successfully design PCR primers to amplify all exons (see figure 1 for amplicons position). 
Note that exon in close proximity to each other were merged into single amplicons (exons 1-
3 for example) and that large exons were divided into several amplicons to maintain 
consistent amplicons size (exon 17 for example). 
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Other groups have developed pipelines to facilitate PCR primer design
294–296
. These programs 
often cannot accommodate primer design from the gene names alone and require significant 
background research to obtain sequence information. Furthermore, most of these programs are 
only capable of processing a limited list of genes at a time and lastly, all of these programs do 
not possess the ability to handle multiple design criteria to design multiple iterations of the same 
amplicon in a single run, thus maximizing the likelihood that a successful primer pair will be 
designed. Therefore these algorithms are not suitable for the large number of PCR primers 
required for NGS enrichment. In contrast, OP is able to handle many genes simultaneously and 
requires only the gene name as input. The user of the program has the ability to set the design 
criteria for up to four iterations of primer designing parameters that allows the user to 
progressively modify the design iterations to make them less stringent in order to design primers 
for all submitted genes or regions. This makes this program especially useful for the rapid design 
of the large number of primers needed in targeted resequencing experiments.   
Figure 21: Example of Exon Coverage of Optimus Primer Designed Amplicons 
 
Image from the UCSC genome browser (genome.ucsc.edu) showing Optimus Primer design 
results for the gene TCF7L2. The black boxes (highlighted by the red arrow) indicate the 
positions of all isPCR validated amplicons designed by OP. Note that only the gene name, 
TCF7L2, was submitted into the pipeline yet amplicons were designed spanning the exons 
(indicated by blue boxed) for all 6 known isoforms of the gene. 
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5.3 Implementation 
Optimus Primer (OP) is a web-based automated pipeline that requires the user to submit only a 
gene list, or list of regions of interest, and primer design parameters. The pipeline consists of 
four steps. First, all exons for all known isoforms for each gene submitted are identified using the 
RefSeq database
297
. This step is skipped if regions of interest are submitted. A list of all unique 
exons for each gene is then generated with exons/regions that are in close proximity to each other 
(<25 base pairs for example) merged into a single element in the list. Second, the pipeline 
extracts the desired genomic sequences from the current build of the human genome (currently 
hg18/ NCBI36), plus additional flanking sequence at a length defined by the user to facilitate the 
design of the PCR primers. OP will prioritize the design of the primers to these flanking regions 
to ensure complete coverage of the specific exonic regions. The user has the option of including 
or excluding sequence that has been masked with RepeatMasker
298
. Additionally, 
polymorphisms from the current build of dbSNP (currently build 130) can be masked to ensure 
that primers are not designed to locations with underlying SNPs
221
. Primer3 has been integrated 
into the pipeline to design PCR primers using user defined parameters
117
. Exons/regions that are 
larger than the specified amplicon size will be automatically split into smaller amplicons, with a 
minimum 25 bp overlap to ensure that every base can be amplified and sequenced. Exons for 
which no PCR primer design is possible using the initial parameters are passed on to a second 
iteration of Primer3 with modified design criteria defined by the user. 
Currently, the pipeline allows the user to define up to four iterations of Primer3 design criteria in 
a single pass to attempt to design PCR primers for all amplicons with up to 5 primer pairs for 
each amplicon. The final step of the pipeline is to run all designed PCR primers through the 
UCSC Genome Browser in-silico PCR (isPCR) utility as a validation step for the primer pairs 
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selected
299
. The isPCR utility allows the user to check the human genome for the presence of 
unique primer pairs, ensures that they are designed correctly on opposite strands, that they are 
the correct distance apart and generates a report of the theoretical amplicons produced by the 
primer pair. OP then uses this data to generate a report for all primer designs as well as the 
percent coverage for each exon/region for each gene for all isPCR validated primer pairs. 
Primers designed with OP can then be used to amplify genes of interest as the enrichment step 
prior to library construction for NGS experiments. In particular, because PCR is flexible and 
easily implementable, OP will be ideal to target for NGS genes that are difficult to enrich using 
solid- or liquid-based capture reagents and for genes that are very polymorphic. Additionally, for 
genes whose annotation is dynamic from one build of the human genome to the other, PCR can 
be easily adapted whereas probes-based capture reagents will need to be re-synthesized.  
5.4 Results 
As part of a high-throughput DNA re-sequencing project to identify genetic risk factors for 
ulcerative colitis, we targeted 77 genes for NGS. PCR amplification was selected as enrichment 
strategy and we opted for pooled sequencing. This corresponds to 867 unique exons and a total 
of 237 kb of sequence.  OP divided the exons into 993 amplicons (average size of 586 bp). After 
a single pass of OP, primer pairs were designed for 861 (87%) of amplicons using our stringent 
design parameters (see Table 25). 
Table 25:  Primer Design Parameters Used in the Four Passes of Primer3.  
 First Pass Second Pass Third Pass Fourth Pass 
Optimum Size (BP) 25 25 25 25 
Minimum Size (BP) 20 20 18 20 
Maximum Size (BP) 30 30 33 30 
OptimumTM (⁰C) 60 60 60 60 
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Minimum TM (⁰C) 55 55 50 55 
Maximum TM (⁰C) 65 65 70 65 
Optimum GC% 50 50 50 50 
Minimum GC% 40 40 35 40 
Maximum GC% 60 60 65 60 
GC CLAMP Yes No No Yes 
NUM RETURN 1 1 1 1 
PRODUCT SIZE RANGE (BP) 400-600 400-600 400-600 400-600 
Repeat Masking Yes Yes Yes No 
SNP Masking Yes Yes Yes Yes 
 
PCR primers could not be designed for all desired amplicons for reasons such as low complexity 
DNA and underlying variation. However with additional effort, it is possible to modify (loosen) 
Primer3 parameters to allow for the design of PCR primers in these regions. 714 of the OP 
designed primer designs (861) passed our isPCR evaluation and validation process (representing 
72.5% of desired exons).  In the lab, we tested 508 of the isPCR validated primer pairs using 7 
different genomic DNA samples. We demonstrated successful PCR products for 472 amplicons 
(92.9% success rate) using agarose gel electrophoresis and/or PicoGreen quantification. Of the 
508 primer pairs tested, 338, 18, 80 and 72 were designed in the first, second, third and fourth 
iterations of Primer3 respectively. By including three additional design iterations with different 
design parameters with different stringencies, it resulted in an additional 170 successful primer 
pairs or an increase of 34% more designs in a single pass of OP than by conventional methods. 
The success rates were 93%, 84%, 99% and 97% for the four iterations. Therefore, we feel that 
our approach of using multiple design iterations with progressively looser design parameters is a 
valid approach to successful primer design. In our specific experiment, amplicons were pooled 
and libraries were constructed according to Illumina’s recommendations. We re-sequenced the 
targeted exons using a single-end 36-base pair protocol on our Genome Analyzer II. We 
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generated 4.5 gigabases of DNA sequences, 89% of which was on target. This allowed us to 
generate 40X coverage and identify over 700 coding DNA sequence variants. Specific details 
from genetic risk factors for UC will be presented elsewhere. 
5.5 Conclusion 
PCR is currently the cheapest, simplest, most flexible approach for sample enrichment prior to 
NGS experiments. It also has some distinctive advantages over the less specific enrichment 
methodologies currently used for targeted next generation resequencing. In order to capitalize on 
PCR-based methodologies, hundreds if not thousands of PCR primers need to be designed. To 
address this gap in bioinformatic tools, we have developed Optimus Primer (OP), a web-based 
automated PCR design pipeline that facilitates the simultaneous design of PCR primers for the 
enrichment of exonic regions in multiple genes. This tool can be useful not only for the 
enrichment of exonic regions for NGS experiments, but it also has much more general 
applicability to other experiments that require the rapid design of PCR primers for multiple 
regions of interest such as genotyping, Sanger sequencing and real time PCR. With only a gene 
list and PCR parameters, a user can design hundreds of PCR primers in a very short timeframe. 
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6  Summary & Perspectives 
 The work presented within this thesis describes the development and utilization of the 
types of tools needed to continue to expand the field of pharmacogenomics. To date 
pharmacogenomic research has predominantly focused on improving the use of drugs that 
already have regulatory approval; however the data that is being generated such as that 
presented,  is gradually changing the drug development process and a future of drugs developed 
in parallel with a companion genetic test is not too far off. 
6.1  Future of Pharmacogenomics 
 The extent to which genomic personalized medicine becomes part of routine medical 
practice depends on how the ethical, legal, economic and medical issues that surround the 
various stakeholders are accounted for. These stakeholders include: the patients, the doctors, the 
diagnostic test providers, the pharmaceutical companies and the payers, either governments or 
insurance companies.  
 Patients want a drug that will work for them without adverse reactions. They also want 
their genetic information kept secure and do not want it to affect them in a negative way such as 
being refused insurance or employment
300
. Doctors require genetic testing that is accessible and 
easy to interpret and understand. Additionally, alternative treatments are necessary to make 
pharmacogenetic testing viable as it will be difficult for physicians to not treat a patient with a 
given drug if a patient’s genetic profile indicates that there is a probability that they will not 
respond. What does one do if there is no alternative treatment available? The education of 
physicians also needs to be updated to include the advances being made in pharmacogenomics. 
In a recent survey of Canadian physicians, the majority of respondents felt that genetic testing 
will have a positive effect on the treatment of patients; however half of theses respondents 
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thought that there is currently not enough evidence to support the incorporation of genetic testing 
into routine care
301
. Finally, informatics infrastructure needs to be established to assist with the 
interpretation, transfer and storage of genetic data in the clinic. The companies that produce the 
genetic tests need to be reimbursed for the time and money spent developing and getting 
regulatory approval tests that are accurate and interpretable 
302
. Pharmaceutical companies do not 
want to have their market share reduced if they are to continue to spend billions of dollars on the 
development of new drugs. Healthcare payers do not want to pay for unnecessary medical testing 
and want the results of genomics medicine to be conclusive and must help to lower costs in the 
long run. The potential to do so is there. Finally, regulatory bodies, such as Health Canada and 
the FDA need to adapt to the rush of new technologies and biomarker testing in order to take 
advantage of all facets of personalized medicine. Specifically, regulatory agencies will need to 
adapt their current processes to incorporate new drugs that have been developed using genomic 
based clinical trial designs which have companion diagnostic tests that must accompany the 
launch of the drug
303
. 
 It is clear that there is support from all parties mentioned above for personalized medicine 
to become a reality, and as mentioned earlier, there are several examples of its utilization 
currently. As we continue to grow the body of knowledge surrounding genetic variation and its 
effects on drug response, gradually, the use of genetic information in the prescribing of drugs 
will become more widespread and accessible. 
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7  Conclusion 
 The goal of the work presented in this thesis was broken down into four areas. The first 
was to establish consensus within academia and the pharmaceutical industry on a set of ADME 
genes and markers that should become the basis for pharmacogenomic studies involving any 
medication. The second was to develop and validate a genotyping assay that could be used to 
screen this set of ADME variation. Third was to demonstrate the utility of this assay in research 
and clinical studies to validate its effectiveness. Finally, to show that there is added benefit of the 
assay even in studies where standard genomic analysis methods are used. 
 The first goal was accomplished through collaboration with the PharmaADME working 
group, where a Core and Extended list of ADME genes and variation was established to identify 
a consensus list of key functional ADME variants that can be used to make clinical decisions in 
drug development and the clinical setting. This list has become the basis for several 
commercially available assays and it can be argued that no pharmacogenomic study is complete 
unless these genes and markers are investigated. The PharmaADME.org website has become one 
of the main resources for this information. The genotyping assay itself was developed in an 
iterative manner that led to a better understanding of the types of genomic interference that has 
hindered the analysis of ADME variation in the past. The resulting assay, that utilizes novel 
design strategies to overcome genomic interference has been optimized and validated. 
Bioinformatic tools created during this process were also further developed and made publically 
available to assist with the design of any genetic study. As next generation sequencing is 
becoming more integrated into research and clinical studies, the same difficulties assaying 
ADME genes that were seen over the course of this work will be evident and the insight gained 
in this study will assist with future assay designs. The effectiveness of our design strategies were also 
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demonstrated in the successful utilization of the assay in the screening of over 1000 samples which has 
led to novel associations with ADME gene variation and adverse drug reactions in children; specifically, 
the role of TPMT and COMT with cisplatin-induced hearing loss in children 
258
 and SLC28A3 
with anthracycline-induced cardiotoxicity
268
. Furthermore, the added utility of the assay compared to 
currently available commercial assays was demonstrated by screening 150 liver samples that have been 
extensively investigated using many different “omic” approaches. In these samples we were able to 
validate previously reported cis eQTLs in 13 ADME genes and uncover an additional 13 ADME genes 
with novel cis eQTLs, doubling the number previously identified using standard methods on these 
samples. 
 The success of a pharmacogenomic study depends heavily on the quality of the clinical 
information that is obtained and the analytical tools which are used to carry out the study.  It can 
be very difficult and time consuming to recruit a quality set of patients for a pharmacogenomic 
phenotype, therefore it is important to have high quality tools available to test these patients with 
in order to maximize the return on your efforts. We have gone to great lengths to develop, 
optimize and validate a targeted ADME genotyping tool, with broad applicability to both 
pharmacogenomic research studies and clinical trials, in order to provide the pharmacogenomic 
community with the type of high quality tool needed to conduct their research. It will be 
necessary now to continue to find ways to utilize these tools in well phenotyped clinical 
populations. In the end, this will lead to a better understanding of how genetic variation affects 
drug response, and will change the way drugs are developed and used. 
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Appendix 1: Table of FDA Approved Drugs with Pharmacogenomic Information in Their Label   
Drug Therapeutic 
Area 
Biomarker Label Sections 
Abacavir Antivirals HLA-B*5701 Boxed Warning, 
Contradindications, Warnings 
and Precautions, Patient 
Counseling Information 
Aripiprazole Psychiatry CYP2D6 Clinical Pharmacology, Dosage 
and Administration 
Arsenic Trioxide Oncology PML/RAR? Boxed Warning, Clinical 
Pharmacology, Indications and 
Usage, Warnings 
Atomoxetine Psychiatry CYP2D6 Dosage and Administration, 
Warnings and Precautions, Drug 
Interactions, Clinical 
Pharmacology 
Atorvastatin Metabolic and 
Endocrinology 
LDL receptor Indications and Usage, Dosage 
and Administration, Warnings 
and Precautions, Clinical 
Pharmacology, Clinical Studies 
Azathioprine Rheumatology TPMT Dosage and Administration, 
Warnings and Precautions, Drug 
Interactions, Adverse Reactions, 
Clinical Pharmacology 
Boceprevir Antivirals IL28B Clinical Pharmacology 
Brentuximab 
Vedotin0 
Oncology CD30 Indications and Usage, 
Description, Clinical 
Pharmacology 
Busulfan Oncology Ph Chromosome Clinical Studies 
Capecitabine Oncology DPD Contraindications, Precautions, 
Patient Information 
Carbamazepine Neurology HLA-B*1502 Boxed Warning, Warnings and 
Precautions 
Carisoprodol Musculoskeletal CYP2C9 Clinical Pharmacology, Special 
Populations 
Carvedilol Cardiovascular CYP2D6 Drug Interactions, Clinical 
Pharmacology 
Celecoxib Analgesics CYP2C9 Dosage and Administration, Drug 
Interactions, Use in Specific 
Populations, Clinical 
Pharmacology 
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Cetuximab Oncology EGFR Indications and Usage, Warnings 
and Precautions, Description, 
Clinical Pharmacology, Clinical 
Studies 
Cetuximab Oncology KRAS Indications and Usage, Clinical 
Pharmacology, Clinical Studies 
Cevimeline Dermatology 
and Dental 
CYP2D6 Drug Interactions 
Chlordiazepoxide 
and Amitriptyline0 
Psychiatry CYP2D6 Precautions 
Chloroquine Antiinfectives G6PD Precautions 
Citalopram Psychiatry CYP2C19 Drug Interactions, Warnings 
Citalopram Psychiatry CYP2D6 Drug Interactions 
Clobazam Neurology CYP2C19 Clinical Pharmacology, Dosage 
and Administration, Use in 
Specific Populations 
Clomiphene Reproductive 
and Urologic 
Rh genotype Precautions 
Clomipramine Psychiatry CYP2D6 Drug Interactions 
Clopidogrel Cardiovascular CYP2C19 Boxed Warning, Dosage and 
Administration, Warnings and 
Precautions, Drug Interactions, 
Clinical Pharmacology 
Clozapine Psychiatry CYP2D6 Drug Interactions, Clinical 
Pharmacology 
Codeine Analgesics CYP2D6 Warnings and Precautions, Use 
in Specific Populations, Clinical 
Pharmacology 
Crizotinib Oncology ALK Indications and Usage, Warnings 
and Precautions, Adverse 
Reactions, Clinical 
Pharmacology, Clinical Studies 
Dapsone Dermatology 
and Dental 
G6PD Indications and Usage, 
Precautions, Adverse Reactions, 
Patient Counseling Information 
Dasatinib Oncology Ph Chromosome Indications and Usage, Clinical 
Studies, Patient Counseling 
Information 
Desipramine Psychiatry CYP2D6 Drug Interactions 
Desloratadine and 
Pseudoephedrine 
Allergy CYP2D6 Clinical Pharmacology 
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Dexlansoprazole Gastroenterology CYP2C19 Clinical Pharmacology, Drug 
Interactions 
Dexlansoprazole Gastroenterology CYP1A2 Clinical Pharmacology 
Dextromethorphan 
and Quinidine 
Neurology CYP2D6 Clinical Pharmacology, 
Warnings and Precautions 
Diazepam Psychiatry CYP2C19 Drug Interactions, Clinical 
Pharmacology 
Doxepin Psychiatry CYP2D6 Precautions 
Drospirenone and 
Ethinyl Estradiol 
Reproductive CYP2C19 Precautions, Drug Interactions 
Erlotinib Oncology EGFR Clinical Pharmacology 
Esomeprazole Gastroenterology CYP2C19 Drug Interactions, Clinical 
Pharmacology 
Fluorouracil Dermatology 
and Dental 
DPD Contraindications, Warnings 
Fluoxetine Psychiatry CYP2D6 Warnings, Precautions, Clinical 
Pharmacology 
Fluoxetine and 
Olanzapine 
Psychiatry CYP2D6 Drug Interactions, Clinical 
Pharmacology 
Flurbiprofen Rheumatology CYP2C9 Clinical Pharmacology, Special 
Populations 
Fluvoxamine Psychiatry CYP2C9 Drug Interactions 
Fluvoxamine Psychiatry CYP2C19 Drug Interactions 
Fluvoxamine Psychiatry CYP2D6 Drug Interactions 
Fulvestrant Oncology ER receptor Indications and Usage, Patient 
Counseling Information 
Galantamine Neurology CYP2D6 Special Populations 
Gefitinib Oncology CYP2D6 Drug Interactions 
Gefitinib Oncology EGFR Clinical Pharmacology 
Iloperidone Psychiatry CYP2D6 Clinical Pharmacology, Dosage 
and Administration, Drug 
Interactions, Specific 
Populations, Warnings and 
Precautions 
Imatinib Oncology C-Kit Indications and Usage, Dosage 
and Administration Clinical 
Pharmacology, Clinical Studies 
Imatinib Oncology Ph Chromosome Indications and Usage, Dosage 
and Administration, Clinical 
Pharmacology, Clinical Studies 
Imatinib Oncology PDGFR Indications and Usage, Dosage 
and Administration, Clincal 
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Studies 
Imatinib Oncology FIP1L1-PDGFR? Indications and Usage, Dosage 
and Administration, Clinical 
Studies 
Imipramine Psychiatry CYP2D6 Drug Interactions 
Indacaterol Pulmonary UGT1A1 Clinical Pharmacology 
Irinotecan Oncology UGT1A1 Dosage and Administration, 
Warnings, Clinical 
Pharmacology 
Isosorbide and 
Hydralazine 
Cardiovascular NAT1; NAT2 Clinical Pharmacology 
Lapatinib Oncology Her2/neu Indications and Usage, Clinical 
Pharmacology, Patient 
Counseling Information 
Lenalidomide Hematology Chromosome 5q Boxed Warning, Indications and 
Usage, Clinical Studies, Patient 
Counseling 
Maraviroc Antivirals CCR5 Indications and Usage, Warnings 
and Precautions, Clinical 
Pharmacology, Clinical Studies, 
Patient Counseling Information 
Mercaptopurine Oncology TPMT Dosage and Administration, 
Contraindications, Precautions, 
Adverse Reactions, Clinical 
Pharmacology 
Metoprolol Cardiovascular CYP2D6 Precautions, Clinical 
Pharmacology 
Mivacurium Musculoskeletal Plasma 
Cholinesterase gene 
(BCHE) 
Pseudocholinestrase 
deficiency 
Clinical Pharmacology, Special 
Populations, Precautions, 
Warnings 
Modafinil Psychiatry CYP2C19 Drug Interactions 
Modafinil  Psychiatry CYP2D6 Drug Interactions 
Nefazodone Psychiatry CYP2D6 Drug Interactions 
Nelfinavir Antivirals CYP2C19 Drug Interactions, Clinical 
Pharmacology 
Nilotinib Oncology Ph Chromosome Indications and Usage, Patient 
Counseling Information 
Nilotinib Oncology UGT1A1 Warnings and Precautions, 
Clinical Pharmacology 
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Nortriptyline Psychiatry CYP2D6 Drug Interactions 
Omeprazole Gastroenterology CYP2C19 Dosage and Administration, 
Warnings and Precautions, Drug 
Interactions 
Panitumumab Oncology EGFR Indications and Usage, Warnings 
and Precautions, Clinical 
Pharmacology, Clinical Studies 
Panitumumab Oncology KRAS Indications and Usage, Clinical 
Pharmacology, Clinical Studies 
Pantoprazole Gastroenterology CYP2C19 Clinical Pharmacology, Drug 
Interactions, Special Populations 
Paroxetine Psychiatry CYP2D6 Clinical Pharmacology, Drug 
Interactions 
Peginterferon alfa-b Antivirals IL28B Clinical Pharmacology 
Perphenazine Psychiatry CYP2D6 Clinical Pharmacology, Drug 
Interactions 
Phenytoin Neurology HLA-B*1502 Warnings 
Pimozide Psychiatry CYP2D6 Warnings, Precautions, 
Contraindications, Dosage and 
Administration 
Prasugrel Cardiovascular CYP2C19 Use in Specific Populations, 
Clinical Pharmacology, Clinical 
Studies 
Pravastatin Cardiovascular Genotype ApoE2/E2 
in Fredrickson Type 
III; Other 
Hyperlipidemias 
Clinical Studies, Use in Specific 
Populations 
Propafenone Cardiovascular CYP2D6 Clinical Pharmacology 
Propranolol Cardiovascular CYP2D6 Precautions, Drug Interactions, 
Clinical Pharmacology 
Protriptyline Psychiatry CYP2D6 Precautions 
Quinidine Antiarrhythmics CYP2D6 Precautions 
Rabeprazole Gastroenterology CYP2C19 Drug Interactions, Clinical 
Pharmacology 
Rasburicase Oncology G6PD Boxed Warning, 
Contraindications 
Rifampin, Isoniazid, 
and Pyrazinamide 
Antiinfectives NAT1; NAT2 Adverse Reactions, Clinical 
Pharmacology 
Risperidone Psychiatry CYP2D6 Drug Interactions, Clinical 
Pharmacology 
Sodium 
Phenylacetate and 
Gastroenterology UCD (NAGS; CPS; 
ASS; OTC; ASL; 
Indications and Usage, 
Description, Clinical 
192 
 
 
Sodium Benzoate ARG) Pharmacology 
Sodium 
Phenylbutyrate 
Gastroenterology UCD (NAGS; CPS; 
ASS; OTC; ASL; 
ARG) 
Indications and Usage, Dosage 
and Administration, Nutritional 
Management 
Tamoxifen Oncology ER receptor Indications and Usage, 
Precautions, Medication Guide 
Telaprevir Antivirals IL28B Clinical Pharmacology 
Terbinafine Antifungals CYP2D6 Drug Interactions 
Tetrabenazine Neurology CYP2D6 Dosage and Administration, 
Warnings, Clinical 
Pharmacology 
Thioguanine Oncology TPMT Dosage and Administration, 
Precautions, Warnings 
Thioridazine Psychiatry CYP2D6 Precautions, Warnings, 
Contraindications 
Ticagrelor Cardiovascular CYP2C19 Clinical Studies 
Timolol Opththalmology CYP2D6 Clinical Pharmacology 
Tiotropium Pulmonary CYP2D6 Clinical Pharmacology 
Tolterodine Reproductive 
and Urologic 
CYP2D6 Clinical Pharmacology, Drug 
Interactions, Warnings and 
Precautions 
Tositumomab Oncology CD20 antigen Indications and Usage, Clinical 
Pharmacology 
Tramadol and 
Acetaminophen 
Analgesics CYP2D6 Clinical Pharmacology 
Trastuzumab Oncology Her2/neu Indications and Usage, 
Precautions, Clinical 
Pharmacology 
Tretinoin Dermatology 
and Dental 
PML/RAR? Boxed Warning, Dosage and 
Administration, Precautions 
Trimipramine Psychiatry CYP2D6 Drug Interactions 
Valproic Acid Psychiatry UCD (NAGS; CPS; 
ASS; OTC; ASL; 
ARG) 
Contraindications, Precautions, 
Adverse Reactions 
Vemurafenib Oncology BRAF Indications and Usage, Warning 
and Precautions, Clinical 
Pharmacology, Clinical Studies, 
Patient Counseling Information 
Venlafaxine Psychiatry CYP2D6 Drug Interactions 
Voriconazole Antifungals CYP2C19 Clinical Pharmacology, Drug 
Interactions 
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Warfarin Hematology CYP2C9 Dosage and Administration, 
Precautions, Clinical 
Pharmacology 
Warfarin Hematology VKORC1 Dosage and Administration, 
Precautions, Clinical 
Pharmacology 
Source : (http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.html  
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Appendix 2: ADME Panel Modified Golden Gate Method 
 
The following is the Golden Gate method used for the custom ADME panel. Sections that are 
underligned are deviations from the standard Illumina method. 
 
Required Equipment  
- Heat block (Illumina, with 96-well insert for 0,2ml plate)  
- Plate shaker (Illumina)  
- Raised bar magnetic plate (Illumina, Dynal catalog # MPC®-96S)  
- Plate Centrifuge  
- Hybridization Oven (Illumina)  
- 8-channel or 12-channel Multi-pipette (P20 and P200)  
- Heat sealer  
- Single channel (P200) Pipette  
- Single channel (P1000) Pipette  
- Autoloader (Illumina)  
- iScan (Illumina)  
- Tube vortexer  
- 96-well thermal cycler with heated lid  
- BeadChip Hyb Cartridge (Illumina)  
- Grip n’ Strip Tool (Illumina)  
- BeadChip Coverslips (Illumina)  
- Filter plate adaptor (Millipore catalog #MACF 09604)  
- OmniTray (Nunc, catalog # 242811)  
 
Consumables  
- 96-well 0.2 mL skirted microplates (AB gene, cat no: AB-0800 or equivalent)  
- 96-well cap mat (ABgene, cat no: AB-0566)  
- Foil Heating Seal (ABgene, cat no AB-0559)  
- 50 mL reservoir basin  
- Centrifuge tubes (50 mL)  
- Microseal™ “F” film  
- Microplate heat seals  
- Adhesive films (Phenix Research, cat no. 100SEALPLT)  
- Filter plates MultiScreen Filter Plates, 0.45 μM, clear, Styrene, Millipore (catalog #MAHV-
N45 10/50)  
- 96-well V-bottom plates Costar* Brand 96-Well Plates, Polypropylene  
- Vbottom plate (VWR International catalog # 29444-102)  
- 96-well storage mats (VWR International, catalog # 29445-122)  
- Canned air  
- Hyb Chambers (X2, Illumina )  
- Hyb Chambers gaskets (X2, Illumina )  
- Hyb Chambers inserts (X8, Illumina )  
- Multi-Sample BeadChip Alignment Fixture  
- BeadChips (12x1, Illumina) 
- Illumina pre-printed Barcodes labels for chips, Plates, Reagents (etc)  
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Chemicals  
- DNA plate (min 50 ng/μL)  
- GS#-MS1 (1 tubes, Illumina)  
- 100% 2-propanol (2 mL)  
- GS#-PS1 (1 mL, Illumina)  
- GS#-RS1 (1.2 mL, Illumina)  
- GS#-OPA (1 tubes, Illumina)  
- GS#-OB1 (1 tubes, Illumina)  
- GS#-AM1 (11 mL, Illumina)  
- GS#-UB1 (6ml and 11 mL, Illumina)  
- GS#-MEL (1 tubes, Illumina)  
- Illumina-recommended DNA Polymerase (64 μL)  
- UDG Uracil DNA Glycosylase (OPTIONAL) (50 μL, Illumina )  
- GS#-IP1 (1 tubes, Illumina)  
- GS#-MPB (1 tubes, Illumina)  
- 0.1N NaOH (16 mL)  
- GS#-UB2 (16 mL, Illumina)  
- GS#-MH1 (3.84 mL, Illumina)  
- GS#-CHB (2 tubes, 1tube per 48 samples, Illumina)  
- GS#-XC4 (1 bottle, Illumina)  
 
If two oligo pools (either standard or PCR product) are being processed simultaneously that are 
to be merged and read on a singly array it is during step 6. Inoc PCR, that this will occur. The 
plates for the two pools should be processed at the same time during this step. In order not to 
confuse which plates are to be merged, it is useful to label the plates that are to be merged with 
the same number except for an additional 1 and 2 for each step of the protocol. For example: 
ASE-9999-1 and ASE-9999-2. 
 
1. Make SUD (Pre-PCR Area)  
This process activates sufficient DNA of each individual sample to be used ONCE in the 
GoldenGate genotyping assay.  
1.1 Preheat the heat block(s) to 95°C (may take up to 45 minutes).  
1.2 Thaw GS#-MS1 to room temperature.  
1.3 Vortex to fully mix tube contents and pour into a sterile trough.  
1.4 Apply a GS#-SUD barcode label to a 96-well 0.2 mL plate.  
1.5 Add 5 μL GS#-MS1 reagent to each well of GS#-SUD plate. 
 
If genomic DNA is being activated follow step 1.6a. If PCR product is being activated follow 
step 1.6b.  
 Genomic DNA 
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 1.6a Transfer 5 μL normalized DNA sample to each well of the GS#-SUD plate. 
 
 PCR Product 
 1.6b Pool 5 μL from each PCR reaction that is to be assayed be the same OPA. Transfer 5 
μL of the pool to each well of the GS#-SUD plate.    
 
1.7 Apply microplate foil seal, heat-seal the GS#-SUD plate, and pulse-centrifuge to 250 Xg. 
1.8 Vortex at 2300 rpm for 20 seconds.  
1.9 Pulse-centrifuge sealed plate to 250 Xg to prevent wells from drying out during the 
incubation.  
1.11Heat GS#-SUD plate at 95°C for 30 min in preheated heat block, covering plate with heat 
block cover to reduce condensation (95°C incubation must not exceed 30 minutes).  
1.12 Remove GS#-SUD plate from heat block and pulse-centrifuge to 250 Xg  
(if proceeding to Make ASE immediately after DNA preparation, immediately switch heat block 
to 70°C).  
 
2. Precip SUD (Pre-PCR Area)  
This process precipitates the DNA in the GS#-SUD plate and removes excess DNA activation 
reagent GS#-MS1.  
2.1. Carefully remove heat seal from GS#-SUD plate -- do not splash (use optional foil stripper).  
2.2. Add 5 μL GS#-PS1 reagent to each well of the GS#-SUD plate, and seal plate with adhesive 
film.  
2.3. Pulse-centrifuge GS#-SUD plate to 250 Xg, then vortex at 2300 rpm for 20 seconds. 
2.4. Remove adhesive film and add 15 μL 2-propanol to each well of GS#-SUD plate.  
2.5. Seal GS#-SUD plate with adhesive film and vortex at 1600 rpm for 20 seconds.  
2.6. Inspect wells for uniform blue color, and re-vortex if non-uniform appearance is observed.  
2.7. Centrifuge sealed GS#-SUD plate at 3000 Xg for 20 minutes.  
2.8. Remove GS#-SUD plate from centrifuge, remove plate seal, and decant supernatant by 
inversion onto an absorbent pad. Blot off excess supernatant.  
2.9. Invert GS#-SUD plate on absorbent pad and centrifuge at 8 Xg for 1 minute. Do not spin the 
inverted plate at more than 8 Xg.  
2.10.Allow plate to dry at room temperature for 15 minutes.  
 
3. Resuspend SUD (Pre-PCR Area)  
In this process, the DNA in the GS#-SUD plate is resuspended.  
3.1. Pour 1.2 mL GS#-RS1 into a sterile trough.  
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3.2. Add 10 μL GS#-RS1 reagent to each well of GS#-SUD plate.  
3.3. Seal GS#-SUD plate with adhesive film, pulse centrifuge to 250 Xg.  
3.4. Vortex at 2300 rpm for 1 minute to resuspend blue pellet.  
3.5. Verify that all blue pellets have been dissolved back into solution. If not, repeat vortex.  
3.6. Either heat-seal the plate and store at 4°C, or proceed immediately to Make ASE.  
 
N.B. For long-term storage, the activated DNA may be frozen at -20°C. If the activated DNA is 
stored frozen, thaw completely and vortex to mix contents before use in assay.  
 
4. Make ASE (Pre-PCR Area)  
 
This process combines the activated DNAs with SNP query oligos, hybridization reagents, and 
paramagnetic particles in an Allele Specific Extension (ASE) plate. The plate is then placed in a 
heat block and the allele specific and locus specific oligos for each SNP locus of interest are 
allowed to anneal to the activated DNA samples. The activated DNA is simultaneously captured 
by paramagnetic particles. The resulting GS#-ASE plate is ready for the extension and ligation of 
the hybridized oligos on the bound DNAs. 
4.1. Remove GS#-AM1 and GS#-UB1 from refrigerator and thaw GS#-MEL to room 
temperature.  
4.2. Pour 11 mL (+10 mL for each additional plate) GS#-AM1 into sterile trough.  
4.3. Pour 11 mL GS#-UB1 into another sterile trough.  
4.4. Centrifuge GS#-ASE plate to 250 Xg.  
4.5. Place GS#-ASE plate on magnetic plate for ~ 2 minutes, or until beads are completely 
captured.  
4.6. Remove heat seal from GS#-ASE plate; remove all liquid (~50 μL) from wells and discard 
liquid (leave beads in wells).  
4.7.With GS#-ASE plate on magnetic plate, use new pipet tips and add 50 μL GS#-AM1 to each 
well of GS#-ASE plate.  
4.8.Seal GS#-ASE plate with adhesive film.  
4.9.Vortex GS#-ASE plate at 1600 rpm for 20 seconds or until all beads are resuspended.  
4.10.Place GS#-ASE plate on magnetic plate for ~2 minutes, or until beads are completely 
captured.  
4.11.Using the same 8-channel pipet with the same tips, remove all GS#-AM1 from each well.  
4.12.Repeat addition of 50 μL GS#-AM1, vortexing, and removal of buffer.  
4.13.Remove GS#-ASE plate from magnetic plate and, using new tips, add 50 μL GS#-UB1 to 
each well.  
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4.14.Place GS#-ASE plate onto magnetic plate for ~2 minutes, or until beads are completely 
captured.  
4.15.Remove all GS#-UB1 from each well (using same tips).  
4.16.Repeat addition of 50 μL GS#-UB1 and removal of buffer.  
4.17.Pour thawed GS#-MEL reagent into a new sterile trough.  
4.18.Using new pipet tips, add 37 μL GS#-MEL to each well of GS#-ASE plate.  
4.19.Seal plate with adhesive film, and vortex plate at 1600 rpm for 1 minute.  
4.20.Incubate GS#-ASE plate on preheated 45°C heat block for 15 minutes.  
 
5. Make PCR (Pre-PCR Area)  
This process adds the Illumina-recommended DNA Polymerase and Uracil DNA Glycosylase 
(UDG -- OPTIONAL) to the master mix for PCR (GS#-MMP reagent) and creates a 96-sample 
plate for use in the Inoc PCR process.  
5.1. Thaw one tube GS#-MMP to room temperature.  
5.2. Add 64 μL Illumina-recommended DNA Polymerase to GS#-MMP tube.  
5.3. Add 50 μL UDG to GS#-MMP tube (OPTIONAL). 
5.4. Invert GS#-MMP tube several times to mix contents, and pour into a sterile trough.  
5.5. Apply a GS#-PCR barcode label to a new 96-well 0.2 mL microplate.  
5.6. Aliquot 30 μL of mixture into each well of GS#-PCR plate.  
5.7. Seal GS#-PCR plate with clear adhesive film and pulse centrifuge to 250 Xg.  
 
6. Inoc PCR (Pre-PCR Area)  
This process uses the template formed in the extension and ligation process in a PCR reaction. 
This PCR reaction uses three universal primers: two are labeled with fluorescent dyes and 
the third is biotinylated. The biotinylated primer allows capture of the PCR product and 
elution of the strand containing the fluorescent signal.  
 
6.1.Remove GS#-ASE plate from heat block  
N.B. Do not transfer the plate to the 95°C heat block until all washes are completed!  
6.2. Immediately preheat the heat block to 95°C.  
6.3. Pour 6 mL GS#-UB1 into a sterile trough.  
6.4. Pour entire contents of GS#-IP1 tube into another sterile trough.  
6.5. Place GS#-ASE plate on magnetic plate for ~2 minutes, or until beads are captured.  
 6.6. Remove clear adhesive film from GS#-ASE plate.  
6.7. Remove and discard supernatant (~50 μL) from all wells of the GS#-ASE plate (leave beads 
in wells).  
6.8. Leave GS#-ASE plate on magnetic plate.  
6.9. With new pipet tips, add 50 μL GS#-UB1 to each well of the GS#-ASE plate, and allow 
plate to rest on magnetic plate for at least 2 minutes.  
6.10. Remove and discard all supernatant (~50 μL) from all wells of GS#-ASE plate (leave 
beads in wells).  
6.11. Discard pipet tips. 
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If the normal GoldenGate protocol is being followed for a standard OPA than follow steps 6.12a-
6.17a. If two standard oligo pools are to be merged follow steps 6.12b-6.17b. If a standard oligo 
pool is being merged with PCR product pools than follow steps 6.12c-6.17c. 
  
GoldenGate Procedrue for a single OPA 
 
6.12a. Add 35 μL GS#-IP1 to each column of GS#-ASE plate and seal with adhesive film.  
6.13a. Vortex at 1800 rpm for 1 minute, or until all beads are resuspended.  
6.14a. Place the plate on 95°C heat block for 1 minute.  
6.15a. Remove plate from heat block and place onto magnetic plate for 2 minutes, or until beads 
have settled completely.  
6.16a. Transfer 30 μL supernatant from first column of GS#-ASE plate into first column of GS#-
PCR plate, and discard pipet tips. 
6.17a. Repeat transfer for each column of the GS#-ASE plate, using new pipet tips for each 
column.  
 
Merging two Standard GoldengGate Oligo Pools 
 
6.12b. Add 35 μL GS#-IP1 to each column of GS#-ASE-1 and GS#-ASE-2 plates and seal with 
adhesive film.   
6.13b. Vortex at 1800 rpm for 1 minute, or until all beads are resuspended.  
6.14b. Place the plates on 95°C heat block for 1 minute.  
6.15b. Remove plates from heat block and place onto magnetic plate for 2 minutes, or until beads 
have settled completely.  
6.16b. Transfer 15 μL supernatant from first column of GS#-ASE-1 plate into first column of 
GS#-PCR plate, and discard pipet tips. Transfer 15 μL supernatant from first column of 
GS#-ASE-2 plate into first column of GS#-PCR plate, and discard pipet tips. 
6.17b. Repeat transfer for each column of the GS#-ASE-1 and GS#-ASE-2 plates, using new 
pipet tips for each column.  
 
Merging a standard oligo pool and a PCR product pool 
 
6.12c. Add 35 μL GS#-IP1 to each column of GS#-ASE-1 (standard) and GS#-ASE-2 (PCR) 
plate and seal with adhesive film.  
6.13c. Vortex at 1800 rpm for 1 minute, or until all beads are resuspended.  
6.14c. Place the plates on 95°C heat block for 1 minute.  
6.15c. Remove plates from heat block and place onto magnetic plate for 2 minutes, or until beads 
have settled completely.  
6.16c. Transfer 25 μL supernatant from first column of GS#-ASE-1 plate into first column of 
GS#-PCR plate, and discard pipet tips. Transfer 5 μL supernatant from first column of 
GS#-ASE-2 plate into first column of GS#-PCR plate, and discard pipet tips.   
 
N.B. If there is more than one PCR ASE plate, than pool 30 μL of supernatant from each plate 
for each sample prior to transferring 5 μL to the GS#-PCR plate.   
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6.17c. Repeat transfer for each column of the GS#-ASE-1 and GS#-ASE-2 plates, using new 
pipet tips for each column.  
 
6.18. Seal GS#-PCR plate with Microseal "A" PCR plate sealing film.  
6.19. Immediately transfer GS#-PCR plate to the thermal cycler immediately.  
6.20. GS#-ASE plate may be discarded. 
7.Complete PCR Steps -- Cycle PCR (Post-PCR Area)  
This process thermal cycles the GS#-PCR plate to fluorescently label and amplify the templates 
generated in the pre-PCR process.  
 
7.1.Place sealed plate into thermal cycler and run thermal cycler program (see Table 1)  
Table 1. Thermal cycler program for GoldenGate  
Temperature Time at Temperature  
37⁰C 10 minutes  
95⁰C 3 minutes  
95⁰C 35 seconds  
56⁰C 35 seconds 34 cycles 
72⁰C 2 minutes  
72⁰C 10 minutes  
4⁰C 5 minutes  
 
7.2. Proceed immediately to Bind PCR, or seal and store GS#-PCR plate at -20°C. 
 
 
8.Bind PCR (Post-PCR Area)  
 
In this step, the double-stranded PCR products are immobilized by binding the biotinylated 
strand to paramagnetic particles. Solution is transferred to a Filter plate and incubated at 
room temperature so that the PCR product may bind to the paramagnetic particles.  
8.1.Vortex GS#-MPB tube until beads are completely resuspended.  
8.2.Pour GS#-MPB into a sterile trough.  
8.3.Write the PCR plate barcode number in the space provided on a  
 
8.4.Apply the Filter Plate: GS_________-PCR label to the top surface of the Filter plate 
adjacent to column 12.  
8.5.Pulse centrifuge GS#-PCR plate to 250 Xg.  
8.6.Using new tips on a multi-channel pipet (5-50 μL), pipet 20 μL resuspended GS#-MPB from 
trough into each column of GS#-PCR plate. It is not necessary to change pipet tips again 
until liquid has been transferred to all 12 columns.  
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N.B. To avoid tip contamination, place the tips against the top edge of the wells. If you suspect 
the tips are contaminated with the contents of the well, discard the tips and use new tips.  
8.7.Discard pipet tips.  
8.8.Using new tips on a multi-channel pipet (50-300 μL) set to 85 μL, pipet solution in the first 
column of the GS#-PCR plate up and down several times to mix the beads with PCR 
product, then transfer the mixed solution to the first column of the Filter plate.  
8.9.Using new pipet tips for each column, repeat the pipet mix and transfer step for the 
remaining columns of the GS#-PCR plate.  
8.10. Discard the empty GS#-PCR plate.  
8.11. Cover the Filter plate with its cover.  
8.12. Store at room temperature, protected from light, for 60 minutes.  
 
9.Make INT (Post-PCR Area)  
 
In this step, the single-stranded fluor-labeled PCR product from the filter plate is washed and 
then eluted into an intermediate (INT) plate. The product from this plate is hybridized to the 
BeadChip.  
9.1.Apply a GS#-INT barcode label to a new 96-well V-bottom plate.  
9.2.Using a serological pipet, transfer 6 mL GS#-UB2 into a sterile trough.  
9.3.Pour 4 mL 0.1N NaOH into another sterile trough.  
 
N.B. If you plan to proceed to hybridization immediately after making the INT plate, then 
begin resuspending the XC4 reagent now (see appendix 2: Resuspend XC4 Reagent). 
 
9.4.When processing 8 BeadChips (96 samples), pour the GS#-MH1 tube’s entire contents into a 
sterile trough. When any other combination of BeadChips are processed, aliquot 30 μL 
from the GS#-MH1 tube into each well.  
9.5.Place Filter plate adapter on a new 96-well V-bottom Waste plate.  
9.6.Place Filter plate containing the bound PCR products onto Filter plate adapter.  
9.7.Centrifuge at 1000 Xg for 5 minutes at 25°C.  
9.8.Remove Filter plate lid.  
9.9.Using new pipet tips, add 50 μL GS#-UB2 from sterile trough to appropriate columns of the 
Filter plate.  
 
N.B. To avoid disturbing the pellet or contaminating the tips, place the tips against the top edge 
of the wells.  
9.10. Re-lid the Filter plate and centrifuge at 1000 Xg for 5 minutes at 25°C.  
9.11. Usinga multichannel pipette with new tips, add 30 μl MH1 to each well containing sample 
of the INT plate.  
9.12. Replace the waste plate with the INT plate. Orient the INT plate so that well A1 of the filter 
plate matches well A1 of the INT plate.  
9.13. Discard the waste plate.  
9.14. Using a multichannel pipette with new tips, add 30 μl 0.1N NaOH to each occupied well of 
the filter plate.  
9.15. Replace the filter plate lid.  
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N.B. To avoid tip contamination, place the tips against the top edge of the wells. If you suspect 
the tips are contaminated with the contents of the well, discard the tips and use new tips.  
9.16. Centrifuge immediately to 1000 xg for 5 minutes at 25°C. At the end, no beads should be 
visible in the wells of the INT plate. 
 
9.17. Discard the filter plate. Save the adapter for later use in other protocols.  
9.18. Gently mix the contents of the INT plate by moving it from side to side without splashing.  
9.19. Seal the INT plate with a 96-well cap mat. Store the plate in the dark until ready to 
dispense sample onto a BeadChip.  
 
10.Make HYB BeadChip (Post-PCR Area)  
In this process, DNA samples from the INT plate are dispensed onto the BeadChips. The 
BeadChips are hybridized using the Hyb Chamber. After the Hyb Chamber has been 
assembled, the DNA-loaded BeadChips are placed into the Hyb Chamber and the samples 
are ready for hybridization. The BeadChip is hybridized overnight in the Illumina 
Hybridization Oven, with a temperature ramp-down from 60°C to 45°C.  
 
10.1.Preheat oven to 60°C and allow oven to equilibrate.  
10.2.Place the following items on the bench top:  
• BeadChip Hyb Chamber (1 per 4 BeadChips)  
• BeadChip Hyb Chamber gasket (1 per Hyb Chamber)  
• BeadChip Hyb Chamber inserts (4 per Hyb Chamber)  
 
10.3.Place the Hyb Chamber Gasket into the Hyb Chamber. 
  10.3.1 Match the wider edge of the Hyb Chamber gasket to the barcode-ridge side of the 
Hyb Chamber. 
 10.3.2 Lay the gasket into the Hyb Chamber and then press it down all around  
 10.3.3 Make sure the Hyb Chamber gasket is properly seated.   
10.4.Add 200 μl CHB into each of the eight humidifying buffer reservoirs in the Hyb Chamber. 
If you are hybridizing fewer than four BeadChips, only fill the reservoirs of sections that will 
contain BeadChips. 
 
10.5. Close and lock the BeadChip Hyb Chamber lid 
 10.5.1 Seat the lid securely on the bottom plate 
10.5.2 Snap two clamps shut, diagonally across from each other.  
10.5.3 Snap the other two clamps.  
10.6.Leave the closed Hyb Chamber on the bench at room temperature (22°C) until the 
BeadChips are loaded with DNA sample.  
 
11. Prepare BeadChip for HYB (Post-PCR Area)  
11.1.Remove all the BeadChips from their packages.  
11.2.Place each BeadChip in a Hyb Chamber Insert, orienting the barcode end so that it matches 
the barcode symbol on the Hyb Chamber Insert.  
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12.Load Sample (Post-PCR Area)  
12.1.Pipette samples up and down in the INT plate to mix.  
12.2.Using a single or multi-channel precision pipette, add 15 μl sample from the INT plate onto 
the center of each inlet port.  
12.3.Visually inspect all sections. Ensure sample covers all of the sections of the stripe. Record 
any sections that are not covered on the lab tracking worksheet.  
12.4.Open the Hyb Chamber. 
 
12.5. Load four Hyb Chamber Inserts containing sample-laden BeadChips into each Hyb 
Chamber  
12.6.Position the barcode end over the ridges indicated on the Hyb Chamber and ensure the 
inserts are securely seated.  
12.7.Close and lock the BeadChip Hyb Chamber lid. 
 12.7.1 Seat the lid securely on the bottom plate 
 12.7.2 Snap two clamps shut, diagonally across from each other.  
 12.7.3 Snap the other two clamps.  
13.Hybridize BeadChips(Post-PCR Area)  
 
13.1. Place the Hyb Chamber into the 60°C Illumina Hybridization Oven so that the clamps face 
the left and right sides of the oven. The Illumina logo on top of the Hyb Chamber should 
face you.  
13.2.Incubate for exactly 30 minutes at 60ºC.  
13.3.After 30 minutes, reset the temperature to 45ºC.  
13.4.Incubate for at least 14 hours but no more than 20 hours at 45°C. 
 
 
14. Wash and Coat BeadChip (Post-PCR Area)  
In this process, the BeadChips are removed from the Hyb Chamber and washed three times with 
UB2 and XC4 reagents. There are two separate UB2 washes and one XC4 wash. To process 
multiple BeadChips in parallel, set up a group of wash stations for each wash rack filled with 
BeadChips. Start washing subsequent BeadChips while the previous ones are incubating in UB2 
or XC4.  
 
14.1. Set up three top-loading wash dishes, labeled UB2, UB2 and XC4. 
 
14.2.Submerge the unloaded wash rack into the first UB2 wash dish with the locking arms facing 
you. This orients the wash rack so that you can safely remove the BeadChips.  
14.3.With a hand on top of the Hyb Chamber, un-snap the four clips one at a time. Start with the 
first clip, then un-snap the clip that is diagonally across from it and so on. Lift the lid 
straight up and off. Set the lid to the side on the bench.  
14.4.Remove each Hyb Chamber from the Illumina Hybridization Oven.  
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14.5.Remove the first BeadChip from a Hyb Chamber insert.  
14.6.Remove the IntelliHyb Seal from the BeadChip:  
 14.6.1 Wearing powder-free gloves, hold the BeadChip in one hand with your thumb and 
forefinger on opposing edges of the BeadChip. Do not touch the sample inlets. The 
barcode should face up and be closest to you, and the top side of the BeadChip should be 
angled slightly away from you.  
 14.6.2 Remove the entire seal in a single, rapid motion by pulling it off in a diagonal 
direction. Start with a corner on the barcode end and pull with a continuous upward motion away 
from you and towards the opposite corner on the top side of the BeadChip. Do not stop and start 
the pulling action. Do not touch the exposed active areas. 
 14.6.3 Discard the seal.  
 
14.7.Holding the BeadChip by the barcode end, immediately and carefully slide the BeadChip 
into the wash rack while it is submerged in UB2.  
14.8.Ensure that the BeadChip barcodes are correctly positioned in the wash rack, with the labels 
facing up and away from you. This is essential for proper handling and coating.  
14.9.Repeat steps 14. 5–14.8 until all BeadChips are transferred to the submerged wash rack. 
Load the wash rack with up to 8 BeadChips. Put four BeadChips above the wash rack 
handle and four below.  
14.10. Once all BeadChips are in the wash rack, move the wash rack up and down ten times, 
breaking the surface of the UB2 with gentle, slow agitation.  
14.11. Transfer the wash rack to the second UB2 wash dish and let it soak for five minutes.  
14.12 Transfer the wash rack to the XC4 wash dish and slowly move the wash rack up and down 
ten times. Let it soak for five minutes. The barcode labels on the BeadChips must face 
away from you, while the locking arms on the handle face towards you, for proper 
handling and coating. 
 
15. Dry BeadChips (Post-PCR Area)  
 
15.1.Prepare a clean tube rack for the wash rack by placing two folded Kimwipes under the tube 
rack.  
15.2.Prepare one additional tube rack per 8 BeadChips that fits the internal dimensions of the 
vacuum desiccator.  
15.3.Remove the wash rack in one smooth, rapid motion and place it directly on the prepared 
tube rack, making sure the barcodes face up and the locking arms and tab face down. 
 
15.4.For the top four BeadChips, working top to bottom:  
 15.4.1 Continuing to hold the wash rack handle, carefully grip each BeadChip at its 
barcode end with self-locking tweezers. 
 15.4.2 Place the BeadChip on a tube rack with the barcode facing up and towards you. 
 
15.5.Holding the top of the wash rack in position, gently remove the wash rack handle by 
grasping the handle between the thumb and forefinger. Push the tab up with your thumb 
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and push the handle away from you (unlocking the handle), then pull up the handle and 
remove.  
15.6.Place any remaining BeadChips on the tube rack with six BeadChips on top of the rack and 
two BeadChips on the bottom. The barcode ends should be towards you, and the 
BeadChips should be completely horizontal.  
15.7.Place the tube rack in the vacuum desiccator. Each dessicator can hold one tube rack (8 
BeadChips).  
15.8.Ensure the vacuum valve is seated tightly and securely.  
15.9.Start the vacuum, using at least 508 mm Hg (0.68 bar).  
15.10. To ensure that the dessicator is properly sealed, gently lift the lid of the vacuum 
desiccator. It should not lift off the desiccator base.  
15.11. Dry under vacuum for 50–55 minutes. ( Drying times may vary according to room 
temperature and humidity)  
15.12. Release the vacuum by turning the handle very slowly.  
15.13. Touch the borders of the chips (do not touch the stripes) to ensure that the etched, bar-
coded side of the BeadChips are dry to the touch.  
15.14. If the underside feels tacky, manually clean the underside of the BeadChip to remove any 
excess XC4. The bottom two BeadChips are the most likely to have some excess.  
 15.14.1 Wrap a pre-saturated Prostat EtOH Wipe around your index finger.  
 15.14.2 Wipe along the underside of the BeadChip five or six times, until the surface is 
clean and smooth.  
15.15. Clean the Hyb Chambers: 
 15.15.1 Remove the rubber gaskets from the Hyb Chambers.  
 15.15.2 Rinse all Hyb Chamber components with DI water.  
 15.15.3 Thoroughly rinse the eight humidifying buffer reservoirs.  
 
15.16. Clean and dry the wash dishes:  
 15.16.1 Rinse the UB2 wash dishes with DI water.  
 15.16.2 Rinse the XC4 wash dish with ethanol.  
 15.16.3 Air dry all wash dishes.  
 
15.17. Discard unused reagents in accordance with facility standards.  
15.18. Proceed to Image BeadChip on the iScan System.  
 
16.BeadChips Imaging  
The iScan Reader uses a laser to excite the fluor of the single-base extension product on the 
beads of the BeadChip sections. Light emissions from these fluors are then recorded in 
high-resolution images of the BeadChip sections. Data from these images are analyzed 
using Illumina’s GenomeScan software.  
16.1.Turn on the iScan Reader, boot up the iScan PC, and start the GenomeScan application.  
 
N.B. Turn on the iScan Reader before launching the GenomeScan software. If the software is 
launched when the instrument is turned off, an error message will alert you that the 
hardware is missing.  
16.2.Load the BeadChips to be scanned, and copy their decode data into the Input Path.  
16.3.Check the scan settings and input/output paths, making modifications if necessary.  
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16.4.If you wish, remove BeadChip sections or entire BeadChips from the scan.  
16.5.Start the scan and monitor its progress.  
16.6.Review the scan metrics.  
 
 
17. Reference Documents  
 
17.1. Illumina, BeadStation500G, Experienced User Cards, Rev B  
 
17.2. Illumina, BeadStation500G, System Manual, RevB  
 
17.3. Illumina, Universal 12 BeadChip, Booklet, Rev A1  
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Appendix 3: Final Gene and SNP list for the ADME Panel: 
OPA 1 
   
OPA 2 
   Gene/Loci RS Chr Coordinate Gene/Loci RS Chr Coordinate 
ALDH4A1 rs9117 1 19071482   rs10864327 1 8077134 
ALDH4A1 rs6664725 1 19075814 CYP4B1 rs7540241 1 47030806 
ALDH4A1 rs7365362 1 19083403 CYP4B1 rs6659627 1 47094286 
ALDH4A1 rs4912075 1 19088005 GPX7 rs7527068 1 52849213 
ALDH4A1 rs1009971 1 19094607 CYP2J2 rs12092576 1 60082886 
ALDH4A1 rs4912044 1 19102850 CYP2J2 rs2294950 1 60087084 
ALDH4A1 rs6673711 1 19108104 CYP2J2 rs3754203 1 60096541 
ALDH4A1 rs16862355 1 19108245   rs11162555 1 79032440 
ALDH4A1 rs16862363 1 19111529 ABCA4 rs7518454 1 94235954 
CDA rs635479 1 20785381 ABCA4 rs10874828 1 94242161 
CDA rs603412 1 20788005 ABCA4 rs3789387 1 94247549 
CDA rs818202 1 20789378 ABCA4 rs1801574 1 94248976 
CDA rs471760 1 20789793 ABCA4 rs537831 1 94249143 
CDA rs10916824 1 20791499 ABCA4 rs11165063 1 94250237 
CDA rs818196 1 20799218 ABCA4 rs945067 1 94250481 
CDA rs517483 1 20802622 ABCA4 rs17391542 1 94250523 
CDA rs818194 1 20804415 ABCA4 rs12083701 1 94252313 
CDA rs10916827 1 20805928 ABCA4 rs915200 1 94254492 
CDA rs580032 1 20806480 ABCA4 rs17110858 1 94258943 
CDA rs1689924 1 20807383 ABCA4 rs2282229 1 94260914 
CDA rs12404655 1 20815782 ABCA4 rs17110885 1 94265819 
CDA rs1614627 1 20819343 ABCA4 rs17392369 1 94284948 
CDA rs10916837 1 20827770 ABCA4 rs12123388 1 94285689 
CDA rs10916843 1 20850724 ABCA4 rs6658767 1 94302483 
CYP4B1 rs863915 1 47031725 ABCA4 rs10493868 1 94304146 
CYP4B1 rs632233 1 47036792 ABCA4 rs7366102 1 94304850 
CYP4B1 rs3766209 1 47037860 ABCA4 rs2151848 1 94310148 
CYP4B1 rs837398 1 47039009 ABCA4 rs17461953 1 94324038 
CYP4B1 rs837395 1 47041925 ABCA4 rs12088309 1 94336504 
CYP4B1 rs4646481 1 47044125 ABCA4 rs548122 1 94338018 
CYP4B1 rs4646485 1 47051426 ABCA4 rs35146614 1 94342777 
CYP4B1 rs4646486 1 47051584 ABCA4 rs1191236 1 94344858 
CYP4B1 rs13373822 1 47062500 ABCA4 rs4147798 1 94357597 
GPX7 rs835344 1 52823608 ABCA4 rs11165081 1 94366668 
GPX7 rs835337 1 52831694 DPYD RS1801268 1 97317215 
GPX7 rs6588431 1 52840174 DPYD RS1801267 1 97336742 
GPX7 rs946154 1 52845915 DPYD rs1801266 1 97929920 
GPX7 rs7529595 1 52849251 GSTM1/2/3/4/5 rs542338 1 109994289 
GPX7 rs6671552 1 52854173 GSTM1/2/3/4/5 rs1010167 1 110000250 
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GPX7 rs11581211 1 52863509 GSTM1/2/3/4/5 rs625456 1 110012194 
CYP2J2 rs11207530 1 60111364 GSTM1/2/3/4/5 rs673151 1 110014981 
CYP2J2 rs10789082 1 60130557 GSTM1/2/3/4/5 rs574344 1 110015037 
CYP2J2 rs1155002 1 60146363 GSTM1/2/3/4/5 rs655315 1 110016701 
CYP2J2 rs10493270 1 60161262 GSTM1/2/3/4/5 rs12024479 1 110021609 
CYP2J2 rs12731852 1 60181563 GSTM1/2/3/4/5 rs366732 1 110024530 
ABCA4 rs1889547 1 94222719 GSTM1/2/3/4/5 rs412543 1 110031467 
ABCA4 rs3747961 1 94231009 GSTM1 rs1065411 1 110034661 
ABCA4 rs1932016 1 94232931 GSTM1/2/3/4/5 rs1292099 1 110048687 
ABCA4 rs6666652 1 94234305 GSTM1/2/3/4/5 rs11579576 1 110050699 
ABCA4 rs3789375 1 94237720 GSTM1/2/3/4/5 rs674787 1 110055434 
ABCA4 rs4147871 1 94238049 GSTM1/2/3/4/5 rs1758104 1 110056201 
ABCA4 rs4847195 1 94241396 GSTM1/2/3/4/5 rs12736389 1 110056690 
ABCA4 rs7537325 1 94242219 GSTM1/2/3/4/5 rs886177 1 110058030 
ABCA4 rs2275031 1 94246484 GSTM1/2/3/4/5 rs12743015 1 110058454 
ABCA4 rs1191234 1 94246608 GSTM1/2/3/4/5 rs3768490 1 110060539 
ABCA4 rs17110808 1 94247460 GSTM1/2/3/4/5 rs4970776 1 110072980 
ABCA4 rs12085639 1 94250881 GSTM1/2/3/4/5 rs12059276 1 110075064 
ABCA4 rs2275033 1 94252625 GSTM1/2/3/4/5 rs15864 1 110094379 
ABCA4 rs3818778 1 94253117 SLC16A1 rs12727968 1 113253807 
ABCA4 rs914958 1 94253656 SLC16A1 rs4839273 1 113304075 
ABCA4 rs915199 1 94254517 SLC16A1 rs17494145 1 113348865 
ABCA4 rs17110850 1 94258079 SLC22A15 rs10733105 1 116313417 
ABCA4 rs10493867 1 94258994 SLC22A15 rs1281693 1 116319842 
ABCA4 rs4147848 1 94259175 SLC22A15 rs2486081 1 116338170 
ABCA4 rs472908 1 94259942 SLC22A15 rs6667257 1 116348182 
ABCA4 rs1932014 1 94261085 SLC22A15 rs12023924 1 116367313 
ABCA4 rs11165065 1 94264056 SLC22A15 rs12562630 1 116372348 
ABCA4 rs4147844 1 94268075 SLC22A15 rs17515267 1 116407661 
ABCA4 rs3789395 1 94274182 SLC22A15 rs12410137 1 116421214 
ABCA4 rs1889548 1 94275785 FMO5 rs10900321 1 145096540 
ABCA4 rs11165069 1 94277133 FMO5 rs12401360 1 145127071 
ABCA4 rs4147839 1 94281814 FMO5 rs718369 1 145135518 
ABCA4 rs484110 1 94287545 FMO5 rs10494242 1 145137254 
ABCA4 rs497511 1 94295701 FMO5 rs17159924 1 145137668 
ABCA4 rs549848 1 94297444 FMO5 rs894469 1 145139530 
ABCA4 rs1007347 1 94303106 FMO5 rs2297753 1 145150755 
ABCA4 rs1191232 1 94303780 FMO5 rs2354432 1 145159853 
ABCA4 rs3789407 1 94304194 FMO5 rs12140294 1 145175208 
ABCA4 rs1931575 1 94305602 FMO5 rs7537483 1 145176501 
ABCA4 rs549114 1 94306942 ARNT rs10888395 1 149028795 
ABCA4 rs4612636 1 94308277 ARNT rs4379678 1 149047206 
ABCA4 rs3789412 1 94308655 ARNT rs10305724 1 149061989 
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ABCA4 rs12759306 1 94310230 ARNT rs10305710 1 149069651 
ABCA4 rs524322 1 94313912 ARNT rs10305695 1 149075740 
ABCA4 rs17111003 1 94314437 NR1I3 rs5082 1 159460307 
ABCA4 rs3120133 1 94315358 NR1I3 rs11265571 1 159478523 
ABCA4 rs4147830 1 94316864 ALDH9A1 rs7527279 1 163888214 
ABCA4 rs560426 1 94326026 ALDH9A1 rs4147602 1 163888402 
ABCA4 rs4847196 1 94327041 FMO3 rs10910879 1 169319777 
ABCA4 rs1191238 1 94329482 FMO3 rs16863990 1 169322194 
ABCA4 rs554931 1 94329945 FMO3 rs1736560 1 169325774 
ABCA4 rs952499 1 94331013 FMO3 rs2075992 1 169347109 
ABCA4 rs2068334 1 94332303 FMO3 rs12080672 1 169354339 
ABCA4 rs4147825 1 94333526 FMO3 rs742057 1 169357608 
ABCA4 rs4147822 1 94334077 FMO3 rs2064080 1 169369865 
ABCA4 rs4147820 1 94334672 FMO1/2 rs2307492 1 169435169 
ABCA4 rs3789421 1 94338165   rs11587539 1 185181800 
ABCA4 rs950283 1 94339811 EPHX1 rs17571067 1 224070785 
ABCA4 rs570926 1 94342806 EPHX1 rs10753410 1 224074724 
ABCA4 rs4147815 1 94347396 EPHX1 rs2854450 1 224079200 
ABCA4 rs3789433 1 94348028 EPHX1 rs1051740 1 224086256 
ABCA4 rs2297634 1 94349556 EPHX1 rs2260863 1 224086397 
ABCA4 rs1889404 1 94350011 EPHX1 rs2740168 1 224087611 
ABCA4 rs4147807 1 94351641 EPHX1 rs10915884 1 224090498 
ABCA4 rs10782976 1 94353713 EPHX1 rs2671267 1 224092313 
ABCA4 rs3789441 1 94353972 EPHX1 rs6965 1 224100099 
ABCA4 rs3761906 1 94359950 CYP1B1 rs4670235 2 38126032 
ABCA4 rs3789452 1 94360089 CYP1B1 rs162561 2 38152381 
ABCA4 rs2151846 1 94360275   rs2900805 2 71311975 
ABCA4 rs1105123 1 94364878   rs10189601 2 104568129 
ABCA4 rs17111122 1 94369052 SULT1C1 rs2305485 2 108271480 
DPYD rs10875044 1 97291251 SULT1C1 rs12998619 2 108272846 
DPYD rs17430460 1 97315067 SULT1C1 rs2198466 2 108293399 
DPYD rs1042482 1 97316547 SULT1C1 rs752273 2 108297537 
DPYD rs1023244 1 97318788 SULT1C2 rs13021399 2 108373097 
DPYD rs290852 1 97322779   rs4988235 2 136325116 
DPYD rs17471125 1 97325716   rs13395686 2 136571458 
DPYD rs2056048 1 97330750   rs3911925 2 162116176 
DPYD rs10449721 1 97332311   rs2389550 2 162166647 
DPYD rs11165779 1 97337238 ABCB11 rs504393 2 169439579 
DPYD rs11165783 1 97342132 ABCB11 rs569805 2 169491126 
DPYD rs17471577 1 97352799 ABCB11 rs16823014 2 169525959 
DPYD rs6681958 1 97356749 ABCB11 rs4148794 2 169529894 
DPYD rs9437663 1 97358525 ABCB11 rs4233823 2 169599137 
DPYD rs4950021 1 97366648 ABCB11 rs7577650 2 169599456 
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DPYD rs17431828 1 97372898   rs12624292 2 172533589 
DPYD rs1709409 1 97375314   rs1011584 2 190606463 
DPYD rs7552825 1 97379352   rs10084389 2 213834442 
DPYD rs6667550 1 97379808   rs691968 2 219382394 
DPYD rs17702702 1 97380425 ABCB6 rs4674367 2 219781096 
DPYD rs828053 1 97381914 ABCB6 rs17783626 2 219782686 
DPYD rs828054 1 97382614 ABCB6 rs908196 2 219796492 
DPYD rs1760215 1 97384103 UGT1A rs12467878 2 234145095 
DPYD rs1514495 1 97390377 UGT1A rs2741019 2 234175427 
DPYD rs12133667 1 97409312 UGT1A rs4402757 2 234181194 
DPYD rs11165798 1 97411138 UGT1A rs6431558 2 234194382 
DPYD rs12035560 1 97414359 UGT1A rs1597942 2 234200589 
DPYD rs6661442 1 97416050 UGT1A rs4663871 2 234246326 
DPYD rs6656660 1 97421797 UGT1A rs28948388 2 234251257 
DPYD rs11587873 1 97425658 UGT1A rs6751673 2 234269642 
DPYD rs1413228 1 97433280 UGT1A rs6715829 2 234270901 
DPYD rs6593639 1 97442913 UGT1A rs4233633 2 234284676 
DPYD rs12120068 1 97452904 UGT1A rs6755571 2 234292275 
DPYD rs1333727 1 97453930 UGT1A rs2011404 2 234292676 
DPYD rs12046655 1 97454964 UGT1A rs4663964 2 234314975 
DPYD rs4415625 1 97461419 UGT1A rs13009407 2 234317086 
DPYD rs885622 1 97463593 UGT1A1 rs35350960 2 234334358 
DPYD rs676686 1 97471225 UGT1A rs28946889 2 234336201 
DPYD rs11165814 1 97480849 UGT1A1 rs55750087 2 234341619 
DPYD rs12124488 1 97481641 UGT1A1 rs34993780 2 234345798 
DPYD rs12758854 1 97484149 UGT1A rs10203853 2 234352157 
DPYD rs10875057 1 97487253 UGT1A rs6431632 2 234355284 
DPYD rs12069661 1 97487743 UGT1A rs6431633 2 234355530 
DPYD rs12735722 1 97492522 PPARG rs2920502 3 12304195 
DPYD rs1413241 1 97495260 PPARG rs12493718 3 12338637 
DPYD rs2027055 1 97495652 PPARG rs17793951 3 12345737 
DPYD rs2027056 1 97496189 PPARG rs10510418 3 12363563 
DPYD rs12140120 1 97496597 PPARG rs12497191 3 12365135 
DPYD rs11165823 1 97498267 PPARG rs1801282 3 12368125 
DPYD rs499009 1 97503990 PPARG rs4135247 3 12371588 
DPYD rs12048612 1 97506520 PPARG rs2938392 3 12409608 
DPYD rs7539889 1 97513711 PPARG rs4135268 3 12412237 
DPYD rs667565 1 97521836 PPARG rs4135284 3 12424866 
DPYD rs11165837 1 97531608 PPARG rs4135292 3 12440956 
DPYD rs4264037 1 97536661 PPARG rs6782475 3 12446330 
DPYD rs7555294 1 97572133 PPARG rs1152003 3 12452055 
DPYD rs9782950 1 97576312 PPARG rs9833097 3 12453817 
DPYD rs11588048 1 97584162 PPARG rs709159 3 12456203 
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DPYD rs7414210 1 97585200 PPARG rs1184332 3 12461421 
DPYD rs6685859 1 97595357 SLC22A13/14 rs169196 3 38274808 
DPYD rs12564011 1 97603134 SLC22A13/14 rs2298421 3 38298293 
DPYD rs867261 1 97605427 SLC22A13/14 rs4679029 3 38317718 
DPYD rs1879372 1 97606506 SLC22A13/14 rs11129785 3 38325079 
DPYD rs1890138 1 97611604 SLC22A13/14 rs2070491 3 38325138 
DPYD rs10875079 1 97614467 SLC22A13/14 rs818821 3 38325230 
DPYD rs10875080 1 97621884 SLC22A13/14 rs818811 3 38327454 
DPYD rs2152878 1 97626031 SLC22A13/14 rs194706 3 38330921 
DPYD rs1577897 1 97639786 SLC22A13/14 rs240033 3 38332965 
DPYD rs12725266 1 97641787 SLC22A13/14 rs151619 3 38343974 
DPYD rs11165863 1 97645010   rs267267 3 45564706 
DPYD rs4492658 1 97649111 NR1I2 rs9821892 3 120974639 
DPYD rs4949952 1 97658759 NR1I2 rs7643645 3 121008187 
DPYD rs11165869 1 97659722 NR1I2 rs3732359 3 121019119 
DPYD rs4950033 1 97662935 NR1I2 rs2037547 3 121027305 
DPYD rs12123121 1 97663749 SLC15A2 rs9289180 3 123090599 
DPYD rs12031561 1 97676171 SLC15A2 rs1881997 3 123097179 
DPYD rs7517899 1 97680341 SLC15A2 rs2700424 3 123132167 
DPYD rs17376848 1 97688212 SLC15A2 rs1920309 3 123148169 
DPYD rs3897854 1 97690894   rs4677996 3 124376655 
DPYD rs7523116 1 97697641 SLCO2A1 rs6773481 3 135139080 
DPYD rs6696976 1 97701564 SLCO2A1 rs6439448 3 135139123 
DPYD rs12136186 1 97704844 SLCO2A1 rs11709172 3 135164968 
DPYD rs11165877 1 97705803 SLCO2A1 rs11714164 3 135180454 
DPYD rs11811087 1 97712758 SLCO2A1 rs3924290 3 135182035 
DPYD rs11165879 1 97714073 SLCO2A1 rs9870646 3 135184376 
DPYD rs945881 1 97717880 SLCO2A1 rs7613393 3 135194419 
DPYD rs7545712 1 97722622 SLCO2A1 rs9861729 3 135197691 
DPYD rs4520446 1 97738793 SLCO2A1 rs7653639 3 135212950 
DPYD rs868184 1 97748288 SLCO2A1 rs7617777 3 135213693 
DPYD rs1556795 1 97751905 SLCO2A1 rs6791704 3 135219286 
DPYD rs1556796 1 97752263 SLCO2A1 rs4854790 3 135221689 
DPYD rs17368837 1 97764194 SLCO2A1 rs9834727 3 135230094 
DPYD rs2786518 1 97769385 SLCO2A1 rs4241366 3 135232860 
DPYD rs12756513 1 97778810 ABCC5 rs7647281 3 185118474 
DPYD rs2811170 1 97780163 ABCC5 rs9838667 3 185147372 
DPYD rs12060391 1 97792585   rs896120 4 21398623 
DPYD rs17100624 1 97793543 UGT2B17 rs7671342 4 69086425 
DPYD rs17377638 1 97798405 UGT2B17 rs7442348 4 69107786 
DPYD rs2811219 1 97799389 UGT2B15 rs1902023 4 69570689 
DPYD rs2248658 1 97810679 UGT2B10 rs4694358 4 69731237 
DPYD rs3790384 1 97832793 UGT2B7 rs4694169 4 69988740 
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DPYD rs10783070 1 97836951 UGT2B7 rs7439366 4 69998927 
DPYD rs12144462 1 97845998 UGT2B7 rs3924194 4 70005681 
DPYD rs2811196 1 97851581 UGT2B7 rs4348159 4 70007541 
DPYD rs7533902 1 97851816 UGT2B11 rs4342251 4 70092703 
DPYD rs17369442 1 97858158 UGT2B11 rs13123057 4 70095992 
DPYD rs10518636 1 97871467 UGT2B11 rs4283741 4 70111108 
DPYD rs6663670 1 97878026 UGT2B11 rs4280807 4 70118306 
DPYD rs2786507 1 97890908 UGT2A1 rs17681080 4 70555132 
DPYD rs2780851 1 97922716 SULT1B1 rs4694235 4 70585986 
DPYD rs10875102 1 97932146 SULT1B1 rs6824108 4 70615547 
DPYD rs12119882 1 97934950 SULT1B1 rs7696239 4 70621199 
DPYD rs2297595 1 97937679 SULT1B1 rs13133166 4 70634788 
DPYD rs4304627 1 97960343 SULT1B1 rs2089075 4 70639207 
DPYD rs4554755 1 97970794 SULT1B1 rs7689180 4 70643778 
DPYD rs6683957 1 97973307 SULT1B1 rs11569731 4 70655663 
DPYD rs17378539 1 97981698 SULT1B1 rs12644878 4 70699964 
DPYD rs4537601 1 98006118 SULT1E1 rs13145571 4 70729758 
DPYD rs12725934 1 98038842 SULT1E1 rs1354362 4 70737168 
DPYD rs12568335 1 98046720 SULT1E1 rs1220703 4 70746750 
DPYD rs12134028 1 98062826 SULT1E1 rs1534672 4 70760287 
DPYD rs4246514 1 98070319   rs1816184 4 79919620 
DPYD rs7412142 1 98105779 ADH7 rs284793 4 100549317 
DPYD rs11165922 1 98109411   rs10003981 4 110673755 
DPYD rs17379561 1 98112727   rs10023955 4 169237869 
DPYD rs1801265 1 98121473 SLCO4C1 rs7721254 5 101579741 
DPYD rs11165924 1 98148036 SLCO4C1 rs10043044 5 101590759 
GSTM1/2/3/4/5 rs560018 1 110001883 SLCO4C1 rs6877943 5 101591585 
GSTM1/2/3/4/5 rs650985 1 110003103 SLCO4C1 rs391828 5 101591854 
GSTM1/2/3/4/5 rs638820 1 110011429 SLCO4C1 rs10074392 5 101624311 
GSTM1/2/3/4/5 rs366631 1 110053995 SLCO4C1 rs2113092 5 101628736 
GSTM1/2/3/4/5 rs1292096 1 110054903 SLCO4C1 rs10463973 5 101664129 
GSTM1/2/3/4/5 rs4970773 1 110057119 SLCO4C1 rs7708494 5 101665063 
GSTM1/2/3/4/5 rs11101992 1 110068277 SLCO6A1 rs17332107 5 101687004 
GSTM1/2/3/4/5 rs1537234 1 110081344 SLCO6A1 rs1901512 5 101751774 
SLC22A15 rs4046190 1 116336375 SLCO6A1 rs2060834 5 101772811 
SLC22A15 rs17035127 1 116369555 SLCO6A1 rs13358778 5 101773876 
SLC22A15 rs1146353 1 116447280 SLCO6A1 rs12658397 5 101779552 
ARNT rs11204735 1 149108291 SLCO6A1 rs10044561 5 101835612 
ARNT rs2292166 1 149151400 SLCO6A1 rs17151033 5 101844068 
NR1I3 rs11421 1 159455560 SLCO6A1 rs6891115 5 101845027 
NR1I3 rs4489574 1 159456337 SLCO6A1 rs13190449 5 101862368 
NR1I3 rs12721035 1 159457963 ALDH7A1 rs3736174 5 125959236 
NR1I3 rs6413453 1 159458940 SLC22A4/5 rs162901 5 131648265 
213 
 
 
NR1I3 rs4233368 1 159463868 SLC22A4/5 rs381870 5 131650200 
NR1I3 rs2307418 1 159467210 SLC22A4/5 rs162892 5 131651149 
NR1I3 rs2501873 1 159471162 SLC22A4/5 rs157572 5 131654011 
NR1I3 rs2502805 1 159476465 SLC22A4/5 rs272885 5 131695635 
NR1I3 rs2502807 1 159484317 SLC22A4/5 rs10515456 5 131727568 
ALDH9A1 rs7549511 1 163888227 SLC22A4/5 rs7731390 5 131749648 
ALDH9A1 rs10918228 1 163888431 SLC22A4/5 rs17689550 5 131750964 
ALDH9A1 rs2297765 1 163888831 SLC22A4/5 rs2073645 5 131752713 
ALDH9A1 rs3795540 1 163889191 TPMT rs56161402 6 18238972 
ALDH9A1 rs2297763 1 163889286 TPMT rs1800460 6 18247207 
ALDH9A1 rs10800125 1 163895545 TPMT rs12663332 6 18249287 
ALDH9A1 rs11506 1 163898130 TPMT rs1800462 6 18251934 
ALDH9A1 rs3820362 1 163901049 ALDH5A1 rs12199914 6 24639398 
ALDH9A1 rs12080699 1 163905667 TAP1 rs241426 6 32912531 
ALDH9A1 rs6690818 1 163909491 TAP1 rs1871665 6 32912857 
ALDH9A1 rs10800127 1 163911966 PPARD rs9470001 6 35441719 
ALDH9A1 rs4578194 1 163917240 PPARD rs9380506 6 35474868 
ALDH9A1 rs1913844 1 163918126 PPARD rs1040436 6 35475887 
ALDH9A1 rs12408101 1 163934405 PPARD rs6906237 6 35483504 
ALDH9A1 rs4657468 1 163934917 PPARD rs1053046 6 35503556 
ALDH9A1 rs1547725 1 163937582 PPARD rs2206030 6 35512332 
ALDH9A1 rs10800135 1 163942110 ABCC10 rs1214763 6 43468239 
ALDH9A1 rs2090281 1 163943230 ABCC10 rs6907066 6 43496032 
ALDH9A1 rs9919190 1 163943408 ABCC10 rs4714684 6 43504834 
ALDH9A1 rs10918256 1 163943637 ABCC10 rs3734688 6 43531757 
ALDH9A1 rs12143472 1 163943865 GSTA1/2/3/4/5 rs6577 6 52723374 
ALDH9A1 rs12044709 1 163944355 GSTA1/2/3/4/5 rs1986661 6 52760299 
FMO3 rs17350502 1 169320930 GSTA1/2/3/4/5 rs10948726 6 52803420 
FMO3 rs17564210 1 169324860 GSTA1/2/3/4/5 rs9370155 6 52806206 
FMO3 rs12404183 1 169325570 GSTA1/2/3/4/5 rs2397118 6 52809102 
FMO3 rs2266782 1 169343590 GSTA1/2/3/4/5 rs4715352 6 52811355 
FMO3 rs2066534 1 169343996 GSTA1/2/3/4/5 rs12202200 6 52887166 
FMO3 rs1736557 1 169346704 GSTA1/2/3/4/5 rs1032418 6 52942916 
FMO3 rs4916390 1 169364185 GSTA1/2/3/4/5 rs17608261 6 52944656 
FMO3 rs6608452 1 169383737 GSTA1/2/3/4/5 rs400804 6 52945049 
FMO1/2 rs2421707 1 169399875 GSTA1/2/3/4/5 rs378775 6 52949438 
FMO1/2 rs11806405 1 169404022 GSTA1/2/3/4/5 rs17614751 6 52950808 
FMO1/2 rs4916414 1 169418414 GSTA1/2/3/4/5 rs543613 6 52951483 
FMO1/2 rs926268 1 169418615 GSTA1/2/3/4/5 rs16883343 6 52968334 
FMO1/2 rs2020862 1 169435208 GSTA1/2/3/4/5 rs6909523 6 52968367 
FMO1/2 rs7542361 1 169435317 GSTA1/2/3/4/5 rs182623 6 52969817 
FMO1/2 rs6692347 1 169436171 SLC22A16 rs17071648 6 110851455 
FMO1/2 rs7527478 1 169438771 SLC22A16 rs3823447 6 110852512 
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FMO1/2 rs2020863 1 169441155 SLC22A16 rs9487404 6 110857172 
FMO1/2 rs7512785 1 169445911 SLC22A16 rs9320332 6 110857487 
FMO1/2 rs17568302 1 169448465 SLC22A16 rs1033572 6 110858982 
FMO1/2 rs981460 1 169458207 SLC22A16 rs7765849 6 110863701 
FMO1/2 rs4631734 1 169486860 SLC22A16 rs12210538 6 110866701 
FMO1/2 rs7533889 1 169487645 SLC22A16 rs12195708 6 110883423 
FMO1/2 rs4073692 1 169488541 SLC22A16 rs2428191 6 110898957 
FMO1/2 rs10912669 1 169489639 SLC22A16 rs7763591 6 110905478 
FMO1/2 rs4916273 1 169489758 SLC22A16 rs6928183 6 110905894 
FMO1/2 rs12567338 1 169490371 SLC22A16 rs9400393 6 110910707 
FMO1/2 rs4433435 1 169490575 SLC22A16 rs2494543 6 110910763 
FMO1/2 rs10798294 1 169490711 SLC22A16 rs9386904 6 110912518 
FMO1/2 rs17581251 1 169499070   rs4897215 6 127899445 
FMO1/2 rs16864296 1 169502950 SLC22A1/2 rs2282140 6 160414511 
FMO1/2 rs10912698 1 169505410 SLC22A1 rs12208357 6 160463138 
FMO1/2 rs12022278 1 169505610 SLC22A1 rs55918055 6 160463219 
FMO1/2 rs16864302 1 169511535 SLC22A1/2 rs461473 6 160463552 
FMO1/2 rs17642661 1 169515708 SLC22A1 rs36103319 6 160473397 
FMO1/2 rs12049309 1 169518637 SLC22A1 rs4646277 6 160477250 
FMO1/2 rs7877 1 169521514 SLC22A1 rs2282143 6 160477633 
FMO4 rs714839 1 169565564 SLC22A1 rs34130495 6 160480814 
FMO4 rs718016 1 169565639 SLC22A1/2 rs662138 6 160484466 
FMO4 rs12089574 1 169566795 SLC22A1/2 rs644992 6 160485993 
FMO4 rs2294482 1 169567583 SLC22A1/2 rs619598 6 160492269 
FMO4 rs3820170 1 169570549 SLC22A1 rs34059508 6 160495827 
FMO4 rs7541966 1 169573779 SLC22A1/2 rs609468 6 160498904 
FMO4 rs11576306 1 169579132 SLC22A1/2 rs10455864 6 160505388 
FMO4 rs6662297 1 169585105 SLC22A1/2 rs7773429 6 160509481 
EPHX1 rs4653436 1 224061834 SLC22A1/2 rs3127593 6 160557993 
EPHX1 rs868966 1 224072721 SLC22A1/2 rs13195185 6 160558986 
EPHX1 rs3753658 1 224079309 SLC22A1/2 rs316002 6 160563809 
EPHX1 rs1877724 1 224079978 SLC22A1/2 rs315980 6 160573971 
EPHX1 rs3738043 1 224081922 SLC22A1/2 rs17588242 6 160583220 
EPHX1 rs2292566 1 224086276 SLC22A1/2 rs315996 6 160586355 
EPHX1 rs2740170 1 224091420 SLC22A1/2 rs316019 6 160590272 
EPHX1 rs2234922 1 224093029 SLC22A1/2 rs3798156 6 160596206 
EPHX1 rs360063 1 224102932 SLC22A2 rs8177507 6 160597659 
EPHX1 rs1009668 1 224107027 SLC22A1/2 rs624249 6 160599390 
CYP1B1 rs163077 2 38139109 SLC22A2 rs8177504 6 160599620 
CYP1B1 rs163078 2 38140449 SLC22A1/2 rs316025 6 160603371 
CYP1B1 rs10916 2 38150674 SLC22A1/2 rs316033 6 160609720 
CYP1B1 rs1800440 2 38151643 SLC22A3 rs425983 6 160663887 
CYP1B1 rs162556 2 38159958 SLC22A3 rs3004079 6 160690210 
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CYP1B1 rs4646429 2 38160439 SLC22A3 rs641990 6 160699124 
CYP1B1 rs162555 2 38161013 SLC22A3 rs10499314 6 160735700 
SULT1C1 rs1116927 2 108257182 SLC22A3 rs1397168 6 160775011 
SULT1C1 rs11684742 2 108265720   rs998341 7 14401174 
SULT1C1 rs7568215 2 108269150 ABCB5 rs12700224 7 20623921 
SULT1C1 rs2305484 2 108271462 ABCB5 rs6461510 7 20645238 
SULT1C1 rs17821152 2 108272927 ABCB5 rs6967789 7 20645370 
SULT1C1 rs4149422 2 108281695 ABCB5 rs1004060 7 20646532 
SULT1C1 rs17036104 2 108288468 ABCB5 rs11772341 7 20646847 
SULT1C1 rs11689841 2 108292004 ABCB5 rs10216013 7 20648846 
SULT1C2 rs10173535 2 108332126   rs2074000 7 20652009 
SULT1C2 rs1402464 2 108337783 ABCB5 rs6950237 7 20654660 
SULT1C2 rs1402467 2 108361240 ABCB5 rs7812159 7 20689587 
ABCB11 rs10497346 2 169479442 ABCB5 rs17817117 7 20691351 
ABCB11 rs496550 2 169487958 ABCB5 rs17817152 7 20692185 
ABCB11 rs483234 2 169490820 ABCB5 rs2190410 7 20695474 
ABCB11 rs17540154 2 169492739 ABCB5 rs11974407 7 20695644 
ABCB11 rs3755157 2 169500417 ABCB5 rs2024046 7 20703791 
ABCB11 rs853774 2 169521642 ABCB5 rs9655200 7 20707510 
ABCB11 rs853773 2 169522593 ABCB5 rs2158855 7 20711068 
ABCB11 rs3821120 2 169525182 ABCB5 rs7781446 7 20720627 
ABCB11 rs4148797 2 169526281 ABCB5 rs10277477 7 20736060 
ABCB11 rs3770582 2 169528070 ABCB5 rs6960186 7 20740520 
ABCB11 rs17267869 2 169531654 ABCB5 rs17819195 7 20742816 
ABCB11 rs3770585 2 169532113 ABCB5 rs10267176 7 20755065 
ABCB11 rs2287621 2 169538761 ABCB5 rs13225659 7 20759957 
ABCB11 rs2058996 2 169542195 ABCB5 rs1029595 7 20781877 
ABCB11 rs3770589 2 169545574 POR rs12537282 7 75382148 
ABCB11 rs6433102 2 169561879 POR rs1966363 7 75414873 
ABCB11 rs3770599 2 169563353 POR rs6949454 7 75433357 
ABCB11 rs7605199 2 169564700 POR rs7804806 7 75433618 
ABCB11 rs3815676 2 169578625 POR rs10954724 7 75435481 
ABCB11 rs3770603 2 169591464 POR rs11764251 7 75450120 
ABCB11 rs4668115 2 169592894 ABCB4 rs7785206 7 86858959 
ABCB11 rs2161037 2 169601665 ABCB4 rs1558376 7 86917039 
ABCB11 rs6433103 2 169619435 ABCB1 rs6979885 7 86975397 
AOX1 rs11677893 2 201149674 ABCB1 rs2032583 7 86998497 
AOX1 rs4674194 2 201153397 ABCB1 rs2032582 7 86998554 
AOX1 rs17448345 2 201161996 ABCB1 rs1922241 7 87023830 
AOX1 rs1405984 2 201170602 ABCB1 rs1211152 7 87053050 
AOX1 rs2463492 2 201173963 ABCB1 rs3213619 7 87068129 
AOX1 rs1405986 2 201174341 ABCB1 rs7810499 7 87124382 
AOX1 rs4337457 2 201174580 CYP3A rs3735453 7 99067371 
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AOX1 rs2248130 2 201175199 CYP3A5 rs41279854 7 99085708 
AOX1 rs2293524 2 201175476 CYP3A5 rs41303343 7 99088358 
AOX1 rs2470902 2 201181919 CYP3A5 rs55965422 7 99102509 
AOX1 rs10497853 2 201183402 CYP3A rs2014764 7 99185442 
AOX1 rs2002957 2 201189757 CYP3A rs6945984 7 99186264 
AOX1 rs16833889 2 201192170 CYP3A rs2242480 7 99199402 
AOX1 rs4672866 2 201193894 CYP3A4 rs55785340 7 99203919 
AOX1 rs6761375 2 201194075 CYP3A rs559239 7 99304934 
AOX1 rs1986415 2 201199805 CYP3A rs2572010 7 99326479 
AOX1 rs2254576 2 201204356   rs10226470 7 112954174 
AOX1 rs2465661 2 201208876   rs12705915 7 113260505 
AOX1 rs2470900 2 201211143 SLC13A1 rs10500090 7 122533104 
AOX1 rs4541241 2 201212649 SLC13A1 rs11772595 7 122548427 
AOX1 rs7587871 2 201213514 SLC13A1 rs2470983 7 122561839 
AOX1 rs2348023 2 201223550 SLC13A1 rs17541728 7 122574202 
AOX1 rs2348024 2 201224930 SLC13A1 rs6953295 7 122595153 
AOX1 rs2540069 2 201228843 SLC13A1 rs3824025 7 122629265 
AOX1 rs2287011 2 201229717 ABCB8 rs3763486 7 150354198 
AOX1 rs2348025 2 201231000 ABCB8 rs6944935 7 150357853 
AOX1 rs7562507 2 201231429 ABCB8 rs2303928 7 150370263 
AOX1 rs3769833 2 201234127 ABCB8 rs891507 7 150382999 
AOX1 rs2881811 2 201234991 ABCB8 rs1549760 7 150386772 
AOX1 rs2241080 2 201235484   rs10260295 7 151838242 
AOX1 rs4674311 2 201240089   rs10903321 8 10106895 
AOX1 rs2540066 2 201243320 NAT1 rs4298522 8 18112962 
AOX1 rs2540064 2 201246326 NAT1 rs11203943 8 18115207 
AOX1 rs16834021 2 201249233 NAT1 rs4921580 8 18115280 
AOX1 rs6731511 2 201264139 NAT1 rs13253389 8 18116187 
CYP20A1 rs11693128 2 203824146 NAT1 rs9325827 8 18117462 
CYP20A1 rs4673253 2 203828459 NAT1 rs6586714 8 18118222 
CYP20A1 rs11690137 2 203852705 NAT1 rs8190845 8 18122908 
CYP20A1 rs11888559 2 203873416 NAT1 rs56318881 8 18123933 
CYP27A1 rs7594289 2 219360530 NAT1 rs56379106 8 18124026 
CYP27A1 rs12623740 2 219373959 NAT1 rs4986782 8 18124396 
CYP27A1 rs11677711 2 219377619 NAT1 rs4986783 8 18124476 
CYP27A1 rs647952 2 219389845 NAT1 rs56172717 8 18124588 
CYP27A1 rs645163 2 219390501 NAT1 rs55793712 8 18124720 
CYP27A1 rs6436094 2 219395841 NAT1 rs4986993 8 18125027 
ABCB6 rs10799 2 219793182 NAT1 rs13270034 8 18126634 
ABCB6 rs2276635 2 219795685 NAT1 rs7837181 8 18132472 
UGT1A rs4129945 2 234157787 NAT2 rs17595174 8 18283118 
UGT1A rs2741023 2 234181453 NAT2 rs34546534 8 18286051 
UGT1A rs17862837 2 234181538 NAT2 rs11780884 8 18290333 
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UGT1A rs4281899 2 234185408 NAT2 rs2410556 8 18298747 
UGT1A rs1377460 2 234201376 NAT2 rs1961456 8 18299989 
UGT1A rs1823803 2 234203850 NAT2 rs1801279 8 18301984 
UGT1A rs10929251 2 234210968 NAT2 rs1041983 8 18302075 
UGT1A rs10176426 2 234244654 NAT2 rs1208 8 18302596 
UGT1A rs2602378 2 234247243 NAT2 rs12674710 8 18307943 
UGT1A rs17862859 2 234262581   rs10103620 8 49773976 
UGT1A rs12988520 2 234272133 SLCO5A1 rs16936254 8 70740986 
UGT1A rs17863787 2 234275833 SLCO5A1 rs1138541 8 70747182 
UGT1A rs6725478 2 234280139 SLCO5A1 rs9298151 8 70752856 
UGT1A rs3806591 2 234290938 SLCO5A1 rs10448013 8 70753303 
UGT1A rs4294999 2 234300206 SLCO5A1 rs2959590 8 70757708 
UGT1A1 rs4124874 2 234330398 SLCO5A1 rs11995058 8 70766296 
UGT1A1 rs4148323 2 234333883 SLCO5A1 rs2380563 8 70767626 
UGT1A rs3771342 2 234337402 SLCO5A1 rs2933062 8 70768729 
UGT1A rs2302538 2 234341152 SLCO5A1 rs2380573 8 70780464 
UGT1A rs4148328 2 234342398 SLCO5A1 rs11987225 8 70783027 
UGT1A rs11888492 2 234344713 SLCO5A1 rs2959566 8 70785651 
UGT1A rs6717546 2 234346858 SLCO5A1 rs2380582 8 70790665 
UGT1A rs6719561 2 234348502 SLCO5A1 rs2380581 8 70790781 
UGT1A rs4663335 2 234353829 SLCO5A1 rs6472483 8 70791920 
PPARG rs2920500 3 12298413 SLCO5A1 rs11782475 8 70798423 
PPARG rs13077495 3 12302751 SLCO5A1 rs17729816 8 70801068 
PPARG rs2120825 3 12388339 SLCO5A1 rs11785641 8 70812132 
PPARG rs4135275 3 12418844 SLCO5A1 rs2380566 8 70820792 
PPARG rs7626560 3 12450088 SLCO5A1 rs10096246 8 70823413 
PPARG rs3856806 3 12450557 SLCO5A1 rs10097419 8 70827418 
PPARG rs4498025 3 12456375 SLCO5A1 rs16936450 8 70885969 
PPARG rs1152004 3 12458104 SLCO5A1 rs3829899 8 70911751 
PPARG rs4684104 3 12459849 SLCO5A1 rs4236976 8 70915421 
PPARG rs13090265 3 12459985 SLCO5A1 rs7012009 8 70916427 
SLC22A13/14 rs6599079 3 38246885 SLCO5A1 rs7845711 8 70917498 
SLC22A13/14 rs4679028 3 38302296   rs10101451 8 91733759 
SLC22A13/14 rs4679032 3 38318008 ALDH1A1 rs647880 9 74749638 
SLC22A13/14 rs697331 3 38321783   rs10988717 9 100928606 
SLC22A13/14 rs818816 3 38326298   rs3739798 9 100954633 
SLC22A13/14 rs151635 3 38337399 ABCA1 rs10117535 9 106576842 
NR1I2 rs1523127 3 120983729 ABCA1 rs2482432 9 106582993 
NR1I2 rs1403527 3 120989570 ABCA1 rs2482433 9 106586722 
NR1I2 rs1357459 3 120997246 ABCA1 rs11789818 9 106587051 
NR1I2 rs2461823 3 121002815 ABCA1 rs2777797 9 106588196 
NR1I2 rs2461818 3 121006562 ABCA1 rs2066882 9 106588283 
NR1I2 rs3732357 3 121013548 ABCA1 rs2740481 9 106596238 
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NR1I2 rs6784598 3 121015946 ABCA1 rs2777801 9 106606698 
NR1I2 rs3732360 3 121019271 ABCA1 rs12338782 9 106620480 
NR1I2 rs1054190 3 121019408 ABCA1 rs13291863 9 106627146 
SLC15A2 rs1344279 3 123098369 ABCA1 rs4743763 9 106633003 
SLC15A2 rs1881995 3 123098641 ABCA1 rs2472448 9 106644328 
SLC15A2 rs1523519 3 123114531 ABCA1 rs12002265 9 106644778 
SLC15A2 rs866926 3 123114951 ABCA1 rs1175293 9 106653704 
SLC15A2 rs2293616 3 123124383 ABCA1 rs11789603 9 106686840 
SLC15A2 rs2257212 3 123126494 ABCA1 rs3847302 9 106688416 
SLC15A2 rs1143671 3 123129976 ABCA1 rs1883025 9 106704122 
SLC15A2 rs1143672 3 123130858 ABCA1 rs3758294 9 106704636 
SLC15A2 rs9871743 3 123153095 ABCA1 rs2740487 9 106704782 
SLC15A2 rs4602434 3 123171325 ABCA1 rs1800978 9 106705799 
SLCO2A1 rs6439445 3 135119256 ABCA1 rs2777794 9 106708707 
SLCO2A1 rs6763132 3 135126859 ABCA1 rs13284054 9 106708894 
SLCO2A1 rs7623757 3 135127583 ABCA1 rs10820744 9 106711756 
SLCO2A1 rs11915399 3 135132598 ABCA1 rs34165419 9 106715847 
SLCO2A1 rs9819520 3 135133686 ABCA1 rs12344687 9 106718461 
SLCO2A1 rs1131598 3 135135012 ABCA1 rs10991408 9 106718737 
SLCO2A1 rs7616492 3 135137536 ABCA1 rs2515617 9 106720736 
SLCO2A1 rs4502579 3 135137691 ABCA1 rs2791952 9 106722338 
SLCO2A1 rs11710021 3 135141256 ABCA1 rs10991413 9 106724240 
SLCO2A1 rs9818609 3 135146371 ABCA1 rs12343571 9 106724447 
SLCO2A1 rs11720811 3 135147233 ABCA1 rs10991414 9 106725410 
SLCO2A1 rs4854769 3 135153081 ABCA1 rs2043664 9 106734066 
SLCO2A1 rs7340717 3 135157585 ABCA1 rs12553329 9 106738143 
SLCO2A1 rs4854776 3 135170554 RXRA rs12006542 9 136335453 
SLCO2A1 rs13319548 3 135172728 RXRA rs11794220 9 136335950 
SLCO2A1 rs13093879 3 135173066 RXRA rs12006409 9 136370190 
SLCO2A1 rs4854778 3 135173865 RXRA rs12347354 9 136385354 
SLCO2A1 rs6795214 3 135176549 RXRA rs11103473 9 136427450 
SLCO2A1 rs4241363 3 135178975 RXRA rs11103482 9 136427681 
SLCO2A1 rs10935090 3 135181039 RXRA rs2266677 9 136433582 
SLCO2A1 rs7646392 3 135182265 RXRA rs875444 9 136435125 
SLCO2A1 rs7627477 3 135186855 RXRA rs1536474 9 136437917 
SLCO2A1 rs13069549 3 135187589 RXRA rs3132297 9 136441687 
SLCO2A1 rs4331673 3 135192213 RXRA rs7038018 9 136449780 
SLCO2A1 rs7636169 3 135194886 RXRA rs6537944 9 136452649 
SLCO2A1 rs4854785 3 135200638 RXRA rs748964 9 136473910 
SLCO2A1 rs4306855 3 135201105 RXRA rs1007971 9 136475735 
SLCO2A1 rs13074733 3 135201309 RXRA rs3132288 9 136481319 
SLCO2A1 rs13320795 3 135202496 RXRA rs11103603 9 136481421 
SLCO2A1 rs4854786 3 135203499   rs7924176 10 75965795 
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SLCO2A1 rs9790150 3 135205718 CYP2C8 rs1934954 10 96782192 
SLCO2A1 rs7428024 3 135208282 CYP2C8 rs11188147 10 96783810 
SLCO2A1 rs7625035 3 135210556 CYP2C8 rs11572181 10 96785036 
SLCO2A1 rs4854787 3 135213298 CYP2C8 rs10509681 10 96788739 
SLCO2A1 rs7629416 3 135213622 CYP2C8 rs11572127 10 96804679 
SLCO2A1 rs4241365 3 135221235 CYP2C8 rs11572103 10 96808096 
SLCO2A1 rs9816473 3 135238792 CYP2C8 rs1557044 10 96821379 
ABCC5 rs11716770 3 185111279 ABCC2 rs717620 10 101532568 
ABCC5 rs2176825 3 185117286 ABCC2 rs56199535 10 101568567 
ABCC5 rs13066518 3 185118192 ABCC2 rs56220353 10 101568631 
ABCC5 rs4912515 3 185136412 ABCC2 rs7476245 10 101584719 
ABCC5 rs2139560 3 185136563 ABCC2 rs3740066 10 101594197 
ABCC5 rs12054261 3 185141012 ABCC2 rs56296335 10 101600383 
ABCC5 rs2280392 3 185148436 GSTO1/O2 rs12769390 10 105996508 
ABCC5 rs3817404 3 185153366 CYP2E1 rs10857726 10 135149008 
ABCC5 rs1879257 3 185165591 CYP2E1 rs2026047 10 135179606 
ABCC5 rs3805111 3 185172683 CYP2E1 rs10857735 10 135186220 
ABCC5 rs4148568 3 185205715 CYP2E1 rs915907 10 135196917 
ABCC5 rs939335 3 185228357 CYP2E1 rs2987795 10 135228646 
UGT2B10 rs11737566 4 69735656 SLC22A18 rs2283230 11 2873035 
UGT2B10 rs1379809 4 69738116 SLC22A18 rs2283232 11 2875709 
UGT2B10 rs6836520 4 69745204 SLC22A18 rs10741735 11 2876859 
UGT2B7 rs7677996 4 69975780 SLC22A18 rs4930027 11 2879069 
UGT2B7 rs10028494 4 70005526 SLC22A18 rs418439 11 2879178 
UGT2B11 rs4400059 4 70102440 SLC22A18 rs450208 11 2888557 
UGT2B28 rs4260604 4 70183419 SLC22A18 rs10832897 11 2889111 
UGT2B28 rs4235126 4 70190735 SLC22A18 rs3782066 11 2891787 
UGT2B28 rs10002503 4 70191593 SLC22A18 rs12419420 11 2892857 
UGT2B28 rs7437560 4 70195383 SLC22A18 rs11024558 11 2892942 
UGT2B28 rs4580710 4 70196118 SLC22A18 rs440150 11 2893233 
UGT2B4 rs2642859 4 70355118 SLC22A18 rs443193 11 2893422 
UGT2B4 rs2642849 4 70372914 SLC22A18 rs11024580 11 2895702 
UGT2B4 rs1569343 4 70376052 SLC22A18 rs11024581 11 2896281 
UGT2B4 rs1131878 4 70380493 SLC22A18 rs444198 11 2896812 
UGT2B4 rs1966151 4 70380716 SLC22A18 rs3782068 11 2897851 
UGT2B4 rs1389930 4 70381761 SLC22A18 rs1129782 11 2900247 
UGT2B4 rs11249442 4 70384946 SLC22A18 rs3847646 11 2910299 
UGT2B4 rs2013573 4 70389067 ABCC8 rs1002227 11 17361923 
UGT2B4 rs1845556 4 70389473 ABCC8 rs1800467 11 17365407 
UGT2B4 rs3822179 4 70390784 ABCC8 rs7124355 11 17369536 
UGT2B4 rs17671289 4 70393434 ABCC8 rs2073583 11 17383912 
UGT2B4 rs13145834 4 70393657 ABCC8 rs4757517 11 17398404 
UGT2B4 rs1835827 4 70406635 ABCC8 rs916827 11 17401602 
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UGT2B4 rs1432323 4 70426575 ABCC8 rs10832786 11 17403538 
UGT2B4 rs17672601 4 70442088 ABCC8 rs2283262 11 17407567 
UGT2A1 rs6847823 4 70446126 ABCC8 rs6486370 11 17429289 
UGT2A1 rs7696068 4 70471828 ABCC8 rs2283255 11 17451627 
UGT2A1 rs2288740 4 70490168 ABCC8 rs11024300 11 17452549 
UGT2A1 rs1835826 4 70492831 ABCC8 rs985572 11 17458327 
UGT2A1 rs4148301 4 70496631 ABCC8 rs11603988 11 17466995 
UGT2A1 rs1319811 4 70497482 SLC22A6/8 rs10750977 11 62490185 
UGT2A1 rs1432313 4 70501399 SLC22A6/8 rs11231287 11 62490781 
UGT2A1 rs7671313 4 70502666 SLC22A6/8 rs3017670 11 62501475 
UGT2A1 rs6832167 4 70508899 SLC22A6/8 rs11568621 11 62506166 
UGT2A1 rs10026988 4 70509964 SLC22A6 rs11568626 11 62508590 
UGT2A1 rs17147507 4 70511177 SLC22A6/8 rs10792367 11 62515375 
UGT2A1 rs4401516 4 70511312 SLC22A6/8 rs4963326 11 62537153 
UGT2A1 rs7670819 4 70516469 SLC22A6/8 rs3809069 11 62540348 
UGT2A1 rs13120401 4 70516599 SLC22A6/8 rs3948869 11 62542574 
UGT2A1 rs4148291 4 70517912 SLC22A6/8 rs11231308 11 62544845 
UGT2A1 rs4694027 4 70528582 SLC22A6/8 rs10792372 11 62549021 
UGT2A1 rs10011630 4 70529573 SLC22A10 rs4570581 11 62806704 
UGT2A1 rs17680131 4 70531824 SLC22A9 rs502642 11 62907363 
UGT2A1 rs17147521 4 70532754 SLC22A9 rs554212 11 62921976 
UGT2A1 rs11249454 4 70533823 SLC22A9 rs11231454 11 62927311 
UGT2A1 rs988672 4 70541107 SLC22A9 rs7940738 11 62927410 
UGT2A1 rs1560605 4 70546016 SLC22A9 rs11231464 11 62941416 
UGT2A1 rs1432329 4 70548299 SLC22A9 rs7935983 11 62942668 
UGT2A1 rs4148279 4 70548947 SLC22A11 rs4930426 11 64072490 
UGT2A1 rs7668703 4 70552541 SLC22A12 rs528211 11 64108297 
UGT2A1 rs2163659 4 70553332 SLC22A12 rs3802947 11 64132883 
UGT2A1 rs4280808 4 70554049 GSTP1 rs6591252 11 67102153 
UGT2A1 rs10033854 4 70554493 GSTP1 rs1138272 11 67110155 
UGT2A1 rs11729544 4 70554983 GSTP1 rs11227844 11 67116840 
UGT2A1 rs10518065 4 70555186 GSTP1 rs12790798 11 67125217 
UGT2A1 rs13134357 4 70555419 SLCO2B1 rs12279394 11 74520484 
SULT1B1 rs2292092 4 70627379 SLCO2B1 rs2851064 11 74537709 
SULT1B1 rs3775781 4 70630226 SLCO2B1 rs2851109 11 74555724 
SULT1B1 rs1847359 4 70664002 SLCO2B1 rs7125268 11 74558504 
SULT1E1 rs7669593 4 70698560 SLCO2B1 rs1612859 11 74564688 
SULT1E1 rs2014777 4 70706332 SLCO2B1 rs1789693 11 74564813 
SULT1E1 rs1910465 4 70739131 SLCO2B1 rs7117473 11 74565201 
SULT1E1 rs1220702 4 70748109 SLCO2B1 rs1676882 11 74565910 
SULT1E1 rs4149535 4 70748760 SLCO2B1 rs11236366 11 74566069 
SULT1E1 rs3775775 4 70752871 SLCO2B1 rs1077858 11 74579249 
SULT1E1 rs3822173 4 70758404 SLCO2B1 rs7118873 11 74580510 
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SULT1E1 rs4149525 4 70760988 SLCO2B1 rs1676885 11 74582926 
SULT1E1 rs1590128 4 70768648 SLCO2B1 rs1789690 11 74603176 
ABCG2 rs2725215 4 89180595 NNMT rs11214942 11 113695587 
ABCG2 rs2725270 4 89226945 NNMT rs2852439 11 113697310 
ABCG2 rs2231164 4 89234881 SLCO1B3/1C1 rs7975334 12 20731118 
ABCG2 rs2622610 4 89246566 SLCO1B3/1C1 rs35653399 12 20767250 
ABCG2 rs2231148 4 89247502 SLCO1B3/1C1 rs12820079 12 20767494 
ABCG2 rs12505410 4 89249865 SLCO1B3/1C1 rs7310077 12 20788391 
ABCG2 rs2622621 4 89249944 SLCO1B3/1C1 rs4581504 12 20790983 
ABCG2 rs11931123 4 89269132 SLCO1B3/1C1 rs972507 12 20794787 
ABCG2 rs2231142 4 89271347 SLCO1B3/1C1 rs7977213 12 20872067 
ABCG2 rs1564481 4 89280289 SLCO1B3/1C1 rs11045577 12 20920465 
ABCG2 rs2725252 4 89280934 SLCO1B3/1C1 rs10841697 12 20947477 
ABCG2 rs13137622 4 89281537 SLCO1B3/1C1 rs1865159 12 20962526 
ABCG2 rs3114018 4 89283605 SLCO1B3/1C1 rs11045611 12 20990539 
ABCG2 rs2622626 4 89285739 SLCO1B1/1A2 rs16923519 12 21202985 
ABCG2 rs6532049 4 89286550 SLCO1B1/1A2 rs7138177 12 21204191 
ABCG2 rs2622624 4 89288430 SLCO1B1/1A2 rs7953338 12 21205839 
ABCG2 rs9999111 4 89292221 SLCO1B1/1A2 rs4149032 12 21209058 
ABCG2 rs2622604 4 89297948 SLCO1B1 rs56101265 12 21216983 
ADH4/5 rs1238741 4 100202335 SLCO1B1 rs56061388 12 21218796 
ADH4/5 rs17595186 4 100207736 SLCO1B1 RS4149056 12 21222816 
ADH4/5 rs4699699 4 100216202 SLCO1B1/1A2 rs4149058 12 21224481 
ADH4/5 rs1154412 4 100220270 SLCO1B1/1A2 rs991262 12 21225481 
ADH4/5 rs17216887 4 100229296 SLCO1B1 rs55901008 12 21244796 
ADH4/5 rs1312200 4 100231380 SLCO1B1 rs59502379 12 21250200 
ADH4/5 rs2602884 4 100260026 SLCO1B1/1A2 rs4149070 12 21261150 
ADH4/5 rs1800759 4 100284532 SLCO1B1/1A2 rs7137060 12 21274097 
ADH4/5 rs3762894 4 100285107 SLCO1B1 rs56199088 12 21283278 
ADH4/5 rs4148884 4 100285310 SLCO1B1/1A2 rs7960688 12 21287136 
ADH4/5 rs10032099 4 100292048 SLCO1B1/1A2 rs11045906 12 21300112 
ADH4/5 rs4699720 4 100292284 SLCO1B1/1A2 rs7966334 12 21358482 
ADH6 rs1540053 4 100301177 SLCO1B1/1A2 rs11045975 12 21370057 
ADH4/5 rs4699726 4 100318536 SLCO1B1/1A2 rs2857468 12 21383204 
ADH6 rs2051428 4 100342209 SLCO1B1/1A2 rs7301895 12 21389159 
ADH6 rs1893883 4 100343739 SLCO1B1/1A2 rs12818296 12 21413821 
ADH6 rs3857224 4 100348708 SLCO1B1/1A2 rs12319824 12 21417918 
ADH6 rs17219837 4 100350769 SLCO1B1/1A2 rs10770804 12 21431936 
ADH6 rs4699734 4 100358389 SLCO1B1/1A2 rs11831407 12 21435078 
ADH6 rs12510722 4 100366124 SLCO1B1/1A2 rs17681288 12 21436279 
ADH1A/B/C rs2173199 4 100390402 SLCO1B1/1A2 rs7316461 12 21437894 
ADH6 rs7684914 4 100393567 ABCC9 rs16924332 12 21865495 
ADH1A/B/C rs1497379 4 100395093 ABCC9 rs829074 12 21868202 
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ADH1A/B/C rs13142106 4 100397174 ABCC9 rs1283809 12 21871885 
ADH1A/B/C rs1618572 4 100414144 ABCC9 rs11046202 12 21873857 
ADH1A/B/C rs12512110 4 100414838 ABCC9 rs11046205 12 21883593 
ADH1A/B/C rs3819197 4 100419532 ABCC9 rs11046211 12 21894989 
ADH1A/B/C rs1229966 4 100432456 ABCC9 rs12230539 12 21904480 
ADH1A/B/C rs12507573 4 100445347 ABCC9 rs11046217 12 21908424 
ADH1A/B/C rs13133908 4 100451647 ABCC9 rs11046232 12 21952954 
ADH1A/B/C rs4147536 4 100458135 ABCC9 rs2277405 12 21970105 
ADH1A/B/C rs1159918 4 100462032 ABCC9 rs11046238 12 21984188 
ADH1A/B/C rs1229982 4 100462955   rs10844647 12 33632437 
ADH1A/B/C rs3811802 4 100463244 SLCO2B1 rs2306168  12 74585230 
ADH1A/B/C rs9307239 4 100465960   rs10846743 12 123876258 
ADH1A/B/C rs2173201 4 100469993   rs12018394 13 19867210 
ADH1A/B/C rs1229864 4 100470483   rs945177 13 26519985 
ADH1A/B/C rs1229863 4 100471409 ABCC4 rs4148546 13 94478286 
ADH1A/B/C rs3846448 4 100473958 ABCC4 rs6492764 13 94482932 
ADH1A/B/C rs1229980 4 100474298 ABCC4 rs17268038 13 94485672 
ADH1A/B/C rs1614972 4 100477178 ABCC4 rs9302043 13 94498996 
ADH1A/B/C rs1662060 4 100478864 ABCC4 rs12868708 13 94506945 
ADH1A/B/C rs283410 4 100483422 ABCC4 rs1189442 13 94507396 
ADH1A/B/C rs1631460 4 100483643 ABCC4 rs4148536 13 94515499 
ADH1A/B/C rs3762896 4 100487154 ABCC4 rs2619311 13 94520683 
ADH1A/B/C rs17586163 4 100493594 ABCC4 rs3782949 13 94527455 
ADH1A/B/C rs4699741 4 100497720 ABCC4 rs1751051 13 94529769 
ADH1A/B/C rs17586246 4 100498124 ABCC4 rs2698243 13 94546726 
ADH7 rs17587689 4 100543094 ABCC4 rs4148527 13 94550690 
ADH7 rs1348276 4 100544653 ABCC4 rs9561784 13 94560006 
ADH7 rs1442490 4 100545426 ABCC4 rs11070109 13 94561827 
ADH7 rs994772 4 100546687 ABCC4 rs4148524 13 94565334 
ADH7 rs7663410 4 100548609 ABCC4 rs1751064 13 94575749 
ADH7 rs284792 4 100549332 ABCC4 rs1751070 13 94582292 
ADH7 rs729147 4 100552290 ABCC4 rs3782958 13 94591872 
ADH7 rs3805331 4 100552955 ABCC4 rs1189470 13 94599733 
ADH7 rs284784 4 100554897 ABCC4 rs7988595 13 94606919 
ADH7 rs1154454 4 100557365 ABCC4 rs12429339 13 94619492 
ADH7 rs1154460 4 100560666 ABCC4 rs1189459 13 94623392 
ADH7 rs971074 4 100560884 ABCC4 rs4148494 13 94627520 
ADH7 rs17529530 4 100574513 ABCC4 rs2009772 13 94627589 
ADH7 rs1154473 4 100578935 ABCC4 rs1678405 13 94627682 
ADH7 rs1154476 4 100579750 ABCC4 rs1564352 13 94636047 
ADH7 rs1154477 4 100580792 ABCC4 rs3864997 13 94643974 
ADH7 rs1154481 4 100583295 ABCC4 rs1751025 13 94649688 
ADH7 rs7668420 4 100584723 ABCC4 rs17189467 13 94662967 
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SLCO4C1 rs12658856 5 101592492 ABCC4 rs4773850 13 94674544 
SLCO4C1 rs1469104 5 101597444 ABCC4 rs4773856 13 94678484 
SLCO4C1 rs7719298 5 101599589 ABCC4 rs9524848 13 94678621 
SLCO4C1 rs10072122 5 101615830 ABCC4 rs9524849 13 94680597 
SLCO4C1 rs10067049 5 101616094 ABCC4 rs9524855 13 94683559 
SLCO4C1 rs2600834 5 101633540 ABCC4 rs9561817 13 94690296 
SLCO4C1 rs709369 5 101652235 ABCC4 rs10508021 13 94692121 
SLCO6A1 rs9327842 5 101725737 ABCC4 rs2892715 13 94692330 
SLCO6A1 rs13355600 5 101730099 ABCC4 rs16950829 13 94692386 
SLCO6A1 rs1901509 5 101810829 ABCC4 rs4148440 13 94696429 
SLCO6A1 rs981988 5 101847880 ABCC4 rs9556466 13 94698072 
SLCO6A1 rs6860730 5 101859422 ABCC4 rs4148434 13 94701436 
SLCO6A1 rs6883528 5 101864039 ABCC4 rs9590220 13 94704695 
ALDH7A1 rs11750167 5 125901308 ABCC4 rs7322029 13 94706426 
ALDH7A1 rs17597355 5 125902185 ABCC4 rs9590222 13 94707786 
ALDH7A1 rs2408700 5 125902424 ABCC4 rs17268268 13 94708018 
ALDH7A1 rs2035471 5 125905534 ABCC4 rs9516551 13 94708727 
ALDH7A1 rs1060856 5 125908008 ABCC4 rs7984157 13 94709901 
ALDH7A1 rs2775 5 125908488 ABCC4 rs17268275 13 94710845 
ALDH7A1 rs4240406 5 125910724 ABCC4 rs4148432 13 94711083 
ALDH7A1 rs11241901 5 125911127 ABCC4 rs4148431 13 94711124 
ALDH7A1 rs4836272 5 125911240 ABCC4 rs870004 13 94716064 
ALDH7A1 rs13179664 5 125912833 ABCC4 rs8002180 13 94720766 
ALDH7A1 rs1038380 5 125913702 ABCC4 rs4148426 13 94723712 
ALDH7A1 rs1038381 5 125913970 ABCC4 rs7336051 13 94724432 
ALDH7A1 rs4379190 5 125915395 ABCC4 rs9524873 13 94725387 
ALDH7A1 rs12513847 5 125918458 ABCC4 rs9524875 13 94725760 
ALDH7A1 rs7713264 5 125919415 ABCC4 rs17300935 13 94725857 
ALDH7A1 rs4835913 5 125923408 ABCC4 rs4773866 13 94727327 
ALDH7A1 rs4626334 5 125925126 ABCC4 rs9524879 13 94730011 
ALDH7A1 rs4626335 5 125925310 ABCC4 rs7324283 13 94731671 
ALDH7A1 rs2035472 5 125928620 ABCC4 rs34665760 13 94732706 
ALDH7A1 rs4836277 5 125929340 ABCC4 rs9524885 13 94733590 
ALDH7A1 rs6898430 5 125934667 ABCC4 rs7330673 13 94740493 
ALDH7A1 rs7709115 5 125935989 ABCC4 rs4771912 13 94741886 
ALDH7A1 rs13171814 5 125943931 ABCC4 rs4773875 13 94744827 
ALDH7A1 rs6595719 5 125949667 ABCC4 rs871052 13 94748741 
ALDH7A1 rs3736171 5 125959275 ABCC4 rs17189561 13 94749594 
ALDH7A1 rs900646 5 125973910 ABCC4 rs868853 13 94753077 
SLC22A4/5 rs4594848 5 131614497 ABCC4 rs2992907 13 94757902 
SLC22A4/5 rs162889 5 131652285 ABCC4 rs9524901 13 94760121 
SLC22A4/5 rs2662314 5 131653068 ABCC4 rs12019639 13 94761519 
SLC22A4/5 rs272893 5 131690961 SLC15A1 rs9557022 13 98119574 
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SLC22A4/5 rs10479002 5 131699561 SLC15A1 rs7986109 13 98133429 
SLC22A4/5 rs1050152 5 131704219 SLC15A1 rs1289389 13 98134291 
SLC22A4/5 rs17622208 5 131744949 SLC15A1 rs4646234 13 98134381 
SLC22A4/5 rs2073643 5 131751187 SLC15A1 rs8187840 13 98136532 
SLC22A4/5 rs7705826 5 131760355 SLC15A1 rs950905 13 98138038 
GPX3 rs3763015 5 150377358 SLC15A1 rs4608199 13 98140444 
GPX3 rs2042235 5 150378107 SLC15A1 rs3783001 13 98140532 
GPX3 rs3828599 5 150381989 SLC15A1 rs2802390 13 98140631 
GPX3 rs8177433 5 150384504 SLC15A1 rs9557033 13 98141095 
GPX3 rs8177447 5 150387649 SLC15A1 rs2390106 13 98141892 
GPX3 rs10463312 5 150391087 SLC15A1 rs8001466 13 98153602 
GPX3 rs2233302 5 150395291 SLC15A1 rs1782672 13 98157304 
GPX3 rs2161359 5 150406727 SLC15A1 rs2297319 13 98159960 
GPX3 rs3792794 5 150414915 SLC15A1 rs7997477 13 98170633 
TPMT rs12199316 6 18231481 SLC15A1 rs4646219 13 98172307 
TPMT rs4716223 6 18233923 SLC15A1 rs7324010 13 98172873 
TPMT rs1142345 6 18238897 SLC15A1 rs9584921 13 98181773 
TPMT rs1800584 6 18238991 SLC15A1 rs4646215 13 98182318 
TPMT rs2842946 6 18239812 SLC15A1 rs4646213 13 98182599 
TPMT rs12201199 6 18247781 SLC15A1 rs4772128 13 98183554 
TPMT rs2842936 6 18248229 SLC15A1 rs9582259 13 98183991 
TPMT rs2842938 6 18249309 SLC15A1 rs9517424 13 98184762 
TPMT rs4449636 6 18255998 SLC15A1 rs9513474 13 98186808 
TPMT rs9396834 6 18272052 SLC15A1 rs9513475 13 98189347 
TPMT rs7744164 6 18278503 SLC15A1 rs7983644 13 98189610 
ALDH5A1 rs2817227 6 24572122 SLC15A1 rs1331251 13 98190905 
ALDH5A1 rs9358768 6 24579372 SLC15A1 rs4646212 13 98192572 
ALDH5A1 rs9467190 6 24582750 SLC15A1 rs4772131 13 98195537 
ALDH5A1 rs2760139 6 24589278 SLC15A1 rs4772132 13 98195913 
ALDH5A1 rs13218564 6 24589521 SLC15A1 rs12853199 13 98196843 
ALDH5A1 rs2076317 6 24598126 SLC15A1 rs3782993 13 98201612 
ALDH5A1 rs2817219 6 24611877 SLC15A1 rs7320943 13 98206110 
ALDH5A1 rs2817220 6 24613200 SLC15A1 rs9557045 13 98211704 
ALDH5A1 rs2328824 6 24615740 SLC10A2 rs9514085 13 102484763 
ALDH5A1 rs1569579 6 24621615 SLC10A2 rs994720 13 102485582 
ALDH5A1 rs2252525 6 24622548 SLC10A2 rs1571513 13 102487470 
ALDH5A1 rs807515 6 24627865 SLC10A2 rs16961116 13 102490843 
ALDH5A1 rs11751325 6 24630773 SLC10A2 rs6491729 13 102492286 
ALDH5A1 rs807516 6 24631696 SLC10A2 rs3803258 13 102494988 
ALDH5A1 rs807518 6 24634222 SLC10A2 rs279942 13 102496111 
ALDH5A1 rs809419 6 24634969 SLC10A2 rs279941 13 102496169 
ALDH5A1 rs2267539 6 24638913 SLC10A2 rs2301157 13 102496364 
ALDH5A1 rs12199955 6 24639429 SLC10A2 rs183965 13 102502105 
225 
 
 
ALDH5A1 rs2744601 6 24641484 SLC10A2 rs182195 13 102502829 
ALDH5A1 rs1054899 6 24642172 SLC10A2 rs1854519 13 102504282 
ALDH5A1 rs12190214 6 24643187 SLC10A2 rs1886925 13 102505233 
ALDH5A1 rs2744603 6 24645844 SLC10A2 rs183963 13 102505285 
ALDH5A1 rs1091031 6 24647118 SLC10A2 rs9518913 13 102511540 
ALDH5A1 rs2744604 6 24648518 SLC10A2 rs3783238 13 102511959 
ALDH5A1 rs2817239 6 24649347 SLC10A2 rs9514091 13 102512255 
ALDH5A1 rs807528 6 24652461 SLC10A2 rs16961268 13 102513784 
ALDH5A1 rs16889440 6 24652946 SLC10A2 rs16961271 13 102514693 
ALDH5A1 rs12196913 6 24653286 SLC10A2 rs16961277 13 102514824 
ALDH5A1 rs807530 6 24653918 SLC10A2 rs7987433 13 102517057 
CYP21A2 rs396458 6 32113628 SLC10A2 rs16961311 13 102525295 
CYP21A2 rs12525076 6 32115438 SLC10A2 rs279922 13 102544627 
CYP21A2 rs7756934 6 32117354 SLC10A2 rs7999460 13 102557895 
CYP21A2 rs433061 6 32122806 SLC22A17 rs4981470 14 22881104 
CYP21A2 rs2269429 6 32137161 SLC22A17 rs12882406 14 22882077 
CYP21A2 rs2071295 6 32146678 SLC22A17 rs4982753 14 22884409 
TAP1 rs4148871 6 32911294 SLC22A17 rs11625724 14 22884835 
TAP1 rs241429 6 32911818 SLC22A17 rs12896494 14 22886838 
TAP1 rs3819714 6 32912195 SLC22A17 rs17090828 14 22889653 
TAP1 rs3819717 6 32912277 SLC22A17 rs7148564 14 22893753 
TAP1 rs241427 6 32912392 SLC22A17 rs10162489 14 22894376 
TAP1 rs3819720 6 32912548 SLC22A17 rs4671 14 22895553 
TAP1 rs3819721 6 32912776 GPX2 rs8016174 14 64440234 
TAP1 rs241424 6 32912912 GPX2 rs7143764 14 64449036 
TAP1 rs2239701 6 32913027 GPX2 rs2296327 14 64480300 
TAP1 rs4148869 6 32914554 GPX2 rs1886506 14 64485119 
TAP1 rs9357155 6 32917826 GPX2 rs942625 14 64492395 
TAP1 rs2071463 6 32920506 SLC10A1 rs4646296 14 69313258 
TAP1 rs2071541 6 32920836 SLC10A1 rs11626135 14 69316202 
TAP1 rs3198005 6 32921192 SLC10A1 rs17556915 14 69318111 
TAP1 rs1057373 6 32921257 SLC10A1 rs7154439 14 69335581 
TAP1 rs13215 6 32921830 SLC10A1 rs12882299 14 69337547 
TAP1 rs4148882 6 32924936 SLC10A1 rs11628423 14 69351423 
TAP1 rs12529313 6 32925108 ALDH6A1 rs7153587 14 73579413 
TAP1 rs2071481 6 32927843 ALDH6A1 rs1536 14 73594282 
TAP1 rs991760 6 32931545 ALDH6A1 rs1476748 14 73621801 
TAP1 rs9276826 6 32938546 ALDH6A1 rs17096314 14 73637705 
TAP1 rs1383268 6 32941344 ALDH6A1 rs1468507 14 73641851 
TAP1 rs1383266 6 32942710 ALDH6A1 rs4903189 14 73667602 
TAP1 rs6912492 6 32977687 ALDH6A1 rs8003130 14 73670602 
PPARD rs707969 6 35397424 GSTZ1 rs4899651 14 76854215 
PPARD rs6901410 6 35438008 GSTZ1 rs8177539 14 76857512 
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PPARD rs9658119 6 35473945 GSTZ1 rs8004558 14 76861793 
PPARD rs9470015 6 35477062 GSTZ1 rs7972 14 76862990 
PPARD rs2076169 6 35496457 GSTZ1 rs2287396 14 76863945 
PPARD rs9462085 6 35512415 GSTZ1 rs1046428 14 76864036 
SLC22A7 rs2651189 6 43353352 GSTZ1 rs8177569 14 76865421 
SLC22A7 rs2651204 6 43367065 GSTZ1 rs731346 14 76866394 
SLC22A7 rs4149178 6 43380166 GSTZ1 rs6637 14 76871184 
SLC22A7 rs2254303 6 43384368 GSTZ1 rs3759732 14 76873305 
SLC22A7 rs11965886 6 43389745 GSTZ1 rs2287398 14 76879072 
SLC22A7 rs4714675 6 43395871 ALDH1A2 rs12593414 15 56024390 
SLC22A7 rs2279087 6 43407036 ALDH1A2 rs7169289 15 56030975 
SLC22A7 rs12190755 6 43430209 ALDH1A2 rs4646636 15 56038326 
ABCC10 rs2185631 6 43515983 ALDH1A2 rs4646615 15 56048887 
ABCC10 rs2487663 6 43517396 ALDH1A2 rs1964429 15 56058994 
ABCC10 rs1214748 6 43526669 ALDH1A2 rs16977883 15 56068327 
CYP39A1 rs12208360 6 46629208 ALDH1A2 rs12903202 15 56094085 
CYP39A1 rs1090735 6 46632941 ALDH1A2 rs11858606 15 56095942 
CYP39A1 rs699945 6 46649220 CYP11A1 rs2277603 15 72409586 
CYP39A1 rs1738311 6 46657935 CYP11A1 rs2959003 15 72415944 
CYP39A1 rs1157157 6 46659702 CYP11A1 rs16968477 15 72449440 
CYP39A1 rs2206926 6 46667962 CYP11A1 rs16968478 15 72449864 
CYP39A1 rs7761731 6 46671776 CYP11A1 rs9806234 15 72450086 
CYP39A1 rs12208873 6 46677049 CYP11A1 rs4886595 15 72450318 
CYP39A1 rs6458511 6 46678742 CYP11A1 rs3803463 15 72454562 
CYP39A1 rs7758684 6 46690115 CYP11A1 rs7163158 15 72456436 
CYP39A1 rs9463225 6 46700267 CYP1A1 rs1800031 15 72799288 
CYP39A1 rs3799866 6 46704245 CYP1A1 rs1799814 15 72800040 
CYP39A1 rs9472810 6 46707146 CYP1A1 rs56313657 15 72800857 
CYP39A1 rs6924295 6 46711646 CYP1A1/2 rs4646421 15 72803245 
CYP39A1 rs3736737 6 46711959 CYP1A1/2 rs2470893 15 72806502 
CYP39A1 rs639434 6 46714287 CYP1A1/2 rs4886605 15 72813041 
CYP39A1 rs2277119 6 46717864 CYP1A2 rs2069514 15 72825273 
CYP39A1 rs952884 6 46721042 CYP1A2 rs12720461 15 72828404 
CYP39A1 rs12215229 6 46722398 CYP1A2 rs762551 15 72828970 
CYP39A1 rs10498769 6 46725277 CYP1A2 rs56107638 15 72832665 
CYP39A1 rs12192544 6 46728211 CYP1A1/2 rs2470890 15 72834479 
CYP39A1 rs953062 6 46734312 CYP1A1/2 rs2301249 15 72879437 
CYP39A1 rs6904373 6 46736026 SLCO3A1 rs8033392 15 90189998 
CYP39A1 rs9472817 6 46748951 SLCO3A1 rs7165398 15 90195099 
GSTA1/2/3/4/5 rs2180312 6 52712013 SLCO3A1 rs12907294 15 90198898 
GSTA1/2/3/4/5 rs2224198 6 52713868 SLCO3A1 rs7162027 15 90200661 
GSTA1/2/3/4/5 rs2608615 6 52717623 SLCO3A1 rs8028382 15 90214312 
GSTA1/2/3/4/5 rs6904935 6 52721018 SLCO3A1 rs12904318 15 90216359 
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GSTA1/2/3/4/5 rs2180314 6 52725690 SLCO3A1 rs4537992 15 90217425 
GSTA1/2/3/4/5 rs2608624 6 52730434 SLCO3A1 rs12898512 15 90222292 
GSTA1/2/3/4/5 rs2144698 6 52731766 SLCO3A1 rs4583214 15 90223072 
GSTA1/2/3/4/5 rs2608632 6 52735657 SLCO3A1 rs4360905 15 90224667 
GSTA1/2/3/4/5 rs2608668 6 52758481 SLCO3A1 rs4619375 15 90225123 
GSTA1/2/3/4/5 rs4715326 6 52765511 SLCO3A1 rs12592577 15 90226127 
GSTA1/2/3/4/5 rs9395826 6 52787649 SLCO3A1 rs4932582 15 90227531 
GSTA1/2/3/4/5 rs7739421 6 52805363 SLCO3A1 rs10152168 15 90230674 
GSTA1/2/3/4/5 rs10484409 6 52939744 SLCO3A1 rs7175096 15 90231631 
GSTA1/2/3/4/5 rs396216 6 52941397 SLCO3A1 rs8031901 15 90232161 
GSTA1/2/3/4/5 rs1032419 6 52942801 SLCO3A1 rs8036437 15 90232801 
GSTA1/2/3/4/5 rs7496 6 52950798 SLCO3A1 rs8035436 15 90232929 
GSTA1/2/3/4/5 rs367836 6 52951090 SLCO3A1 rs12437999 15 90246586 
GSTA1/2/3/4/5 rs2274760 6 52958114 SLCO3A1 rs4327025 15 90247687 
GSTA1/2/3/4/5 rs3756980 6 52959938 SLCO3A1 rs7181019 15 90252895 
GSTA1/2/3/4/5 rs13197674 6 52968366 SLCO3A1 rs11636676 15 90253857 
GSTA1/2/3/4/5 rs2397136 6 52973873 SLCO3A1 rs4294800 15 90261698 
SLC22A16 rs3757351 6 110842323 SLCO3A1 rs4244910 15 90270698 
SLC22A16 rs6933664 6 110843077 SLCO3A1 rs4598887 15 90272693 
SLC22A16 rs2207356 6 110848304 SLCO3A1 rs7170211 15 90274770 
SLC22A16 rs7756222 6 110853219 SLCO3A1 rs4932515 15 90279601 
SLC22A16 rs9320331 6 110853761 SLCO3A1 rs4932516 15 90280347 
SLC22A16 rs17578180 6 110856841 SLCO3A1 rs11635541 15 90286015 
SLC22A16 rs9481067 6 110857245 SLCO3A1 rs8034107 15 90287430 
SLC22A16 rs761590 6 110858177 SLCO3A1 rs7164216 15 90288287 
SLC22A16 rs221712 6 110869519 SLCO3A1 rs4306482 15 90288762 
SLC22A16 rs723685 6 110870568 SLCO3A1 rs12917237 15 90292162 
SLC22A16 rs2428192 6 110894064 SLCO3A1 rs9635404 15 90302076 
SLC22A16 rs7740547 6 110897601 SLCO3A1 rs10852166 15 90311153 
SLC22A16 rs17579009 6 110897677 SLCO3A1 rs975721 15 90313978 
SLC22A16 rs10214672 6 110898003 SLCO3A1 rs12905744 15 90319455 
SLC22A16 rs17071722 6 110900785 SLCO3A1 rs8041020 15 90326650 
SLC22A16 rs916719 6 110902242 SLCO3A1 rs12906515 15 90328534 
SLC22A16 rs3806970 6 110906241 SLCO3A1 rs8032914 15 90329368 
ALDH8A1 rs9373116 6 135266062 SLCO3A1 rs7163369 15 90334918 
ALDH8A1 rs9494115 6 135277227 SLCO3A1 rs1517621 15 90336085 
ALDH8A1 rs2072827 6 135295296 SLCO3A1 rs12439765 15 90336606 
ALDH8A1 rs3817776 6 135298449 SLCO3A1 rs4932598 15 90338849 
ALDH8A1 rs4646870 6 135313021 SLCO3A1 rs8037790 15 90343835 
SLC22A1/2 rs456598 6 160458911 SLCO3A1 rs4932599 15 90344382 
SLC22A1/2 rs1867351 6 160463113 SLCO3A1 rs8025658 15 90345228 
SLC22A1/2 rs683369 6 160471194 SLCO3A1 rs17644210 15 90346288 
SLC22A1/2 rs3777392 6 160476632 SLCO3A1 rs12443009 15 90346469 
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SLC22A1 rs4646278 6 160477261 SLCO3A1 rs17695281 15 90347083 
SLC22A1/2 rs6937722 6 160479432 SLCO3A1 rs12593984 15 90347416 
SLC22A1/2 rs3798168 6 160479797 SLCO3A1 rs7182304 15 90348663 
SLC22A1 rs628031 6 160480835 SLCO3A1 rs17644254 15 90349509 
SLC22A1/2 rs9457843 6 160480923 SLCO3A1 rs1983351 15 90349598 
SLC22A1/2 rs3798167 6 160487918 SLCO3A1 rs12148487 15 90350469 
SLC22A1/2 rs2197296 6 160488987 SLCO3A1 rs12439818 15 90351969 
SLC22A1/2 rs1382785 6 160493397 SLCO3A1 rs2030207 15 90352917 
SLC22A1/2 rs650284 6 160494525 SLCO3A1 rs10468146 15 90354385 
SLC22A1/2 rs651164 6 160501364 SLCO3A1 rs12903900 15 90354493 
SLC22A1/2 rs4646283 6 160501492 SLCO3A1 rs17644334 15 90354701 
SLC22A1/2 rs6455682 6 160501901 SLCO3A1 rs7178378 15 90357808 
SLC22A1/2 rs9456505 6 160502330 SLCO3A1 rs7498017 15 90358807 
SLC22A1/2 rs2083867 6 160503038 SLCO3A1 rs2387400 15 90359238 
SLC22A1/2 rs3101826 6 160504843 SLCO3A1 rs12905905 15 90364079 
SLC22A1/2 rs791190 6 160533697 SLCO3A1 rs8043469 15 90365186 
SLC22A1/2 rs2450975 6 160557965 SLCO3A1 rs12906289 15 90365510 
SLC22A2 rs8177517 6 160583410 SLCO3A1 rs7174192 15 90366030 
SLC22A2 rs8177516 6 160584675 SLCO3A1 rs12913189 15 90366611 
SLC22A1/2 rs3912161 6 160589708 SLCO3A1 rs6496888 15 90367418 
SLC22A2 rs316019 6 160590272 SLCO3A1 rs7165226 15 90368450 
SLC22A1/2 rs3127572 6 160602208 SLCO3A1 rs4984325 15 90370621 
SLC22A1/2 rs316029 6 160606658 SLCO3A1 rs7181178 15 90370961 
SLC22A1/2 rs643960 6 160612097 SLCO3A1 rs12905838 15 90372480 
SLC22A3 rs3106170 6 160649914 SLCO3A1 rs11854488 15 90373513 
SLC22A3 rs569919 6 160687173 SLCO3A1 rs4984341 15 90374822 
SLC22A3 rs512077 6 160694918 SLCO3A1 rs925874 15 90376845 
SLC22A3 rs9364554 6 160753654 SLCO3A1 rs1400786 15 90387143 
SLC22A3 rs2665355 6 160757358 SLCO3A1 rs1878556 15 90396051 
SLC22A3 rs4708867 6 160762715 SLCO3A1 rs8040836 15 90401014 
SLC22A3 rs2292334 6 160778178 SLCO3A1 rs908652 15 90402367 
SLC22A3 rs2504926 6 160796280 SLCO3A1 rs995002 15 90403747 
AHR rs10452776 7 17293268 SLCO3A1 rs9989291 15 90414978 
AHR rs4719497 7 17301424 SLCO3A1 rs4247079 15 90416789 
AHR rs713150 7 17306682 SLCO3A1 rs8031518 15 90424349 
AHR rs17722841 7 17310119 SLCO3A1 rs12910142 15 90424507 
AHR rs2282885 7 17312139 SLCO3A1 rs7178811 15 90433957 
AHR rs17779352 7 17316151 SLCO3A1 rs207975 15 90438027 
AHR rs1476080 7 17324398 SLCO3A1 rs2048945 15 90443405 
AHR rs4236290 7 17330093 SLCO3A1 rs2853650 15 90450210 
AHR rs7811989 7 17337888 SLCO3A1 rs2238360 15 90457120 
AHR rs2066853 7 17345635 SLCO3A1 rs207955 15 90458287 
AHR rs7780687 7 17372243 SLCO3A1 rs12439582 15 90461841 
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AHR rs2053998 7 17373586 SLCO3A1 rs6496892 15 90464500 
ABCB5 rs1476485 7 20636154 SLCO3A1 rs11632723 15 90466778 
ABCB5 rs2106563 7 20646974 SLCO3A1 rs12443458 15 90467297 
ABCB5 rs1108864 7 20660067 SLCO3A1 rs2238359 15 90468381 
ABCB5 rs1972525 7 20676834 SLCO3A1 rs8033892 15 90470188 
ABCB5 rs13240297 7 20679020 SLCO3A1 rs3815318 15 90472923 
ABCB5 rs11764760 7 20687609 SLCO3A1 rs11853311 15 90478448 
ABCB5 rs10230205 7 20693357 SLCO3A1 rs7175217 15 90478521 
ABCB5 rs7805806 7 20693853 SLCO3A1 rs8035166 15 90479382 
ABCB5 rs2190411 7 20695352 SLCO3A1 rs4777789 15 90485746 
ABCB5 rs12700229 7 20696456 SLCO3A1 rs2238357 15 90486370 
ABCB5 rs17143272 7 20703102 SLCO3A1 rs7495740 15 90486835 
ABCB5 rs7459042 7 20706661 SLCO3A1 rs2238354 15 90486934 
ABCB5 rs2158854 7 20711088 SLCO3A1 rs2283458 15 90490116 
ABCB5 rs10239567 7 20713167 SLCO3A1 rs2215084 15 90493950 
ABCB5 rs10488577 7 20713600 SLCO3A1 rs11630759 15 90498521 
ABCB5 rs12673841 7 20715815 SLCO3A1 rs960440 15 90499647 
ABCB5 rs10266338 7 20728263 SLCO3A1 rs768882 15 90499688 
ABCB5 rs1023541 7 20728349 SLCO3A1 rs7181257 15 90501413 
ABCB5 rs10255466 7 20729569 SLCO3A1 rs3169130 15 90508974 
ABCB5 rs6461513 7 20730432 SLCO3A1 rs2108601 15 90509272 
ABCB5 rs10950831 7 20730899 SLCO3A1 rs1060206 15 90509554 
ABCB5 rs10254317 7 20734538 SLCO3A1 rs7172018 15 90512095 
ABCB5 rs6959944 7 20740616 SLCO3A1 rs2240589 15 90515883 
ABCB5 rs9638774 7 20743775 SLCO3A1 rs1053909 15 90516575 
ABCB5 rs10231520 7 20748619 SLCO3A1 rs11633815 15 90517577 
ABCB5 rs12669866 7 20748999 ALDH1A3 rs3803435 15 99231085 
ABCB5 rs17220780 7 20755720 ALDH1A3 rs12906432 15 99231690 
ABCB5 rs2108258 7 20758523 ALDH1A3 rs3809523 15 99236205 
POR rs3898649 7 75384828 ALDH1A3 rs9944290 15 99242258 
POR rs4728533 7 75424472 ALDH1A3 rs7182884 15 99256385 
POR rs7796654 7 75433906 ALDH1A3 rs1130738 15 99273363 
POR rs13240755 7 75444045 ALDH1A3 rs14226 15 99273840 
POR rs10954732 7 75449085 ALDH1A3 rs4072820 15 99293837 
POR rs6952753 7 75460747 ABCC1/6 rs504348 16 15950675 
ABCB4 rs31644 7 86859960 ABCC1/6 rs762775 16 15955658 
ABCB4 rs31652 7 86867623 ABCC1/6 rs7190484 16 15959420 
ABCB4 rs1526090 7 86869745 ABCC1/6 rs215101 16 15960474 
ABCB4 rs4148828 7 86886466 ABCC1/6 rs215099 16 15962195 
ABCB4 rs31666 7 86890204 ABCC1/6 rs12923345 16 15962583 
ABCB4 rs31668 7 86891142 ABCC1/6 rs129116 16 15973541 
ABCB4 rs31670 7 86897100 ABCC1/6 rs7188722 16 15978280 
ABCB4 rs17651890 7 86903623 ABCC1/6 rs215064 16 15985473 
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ABCB4 rs1202283 7 86920228 ABCC1/6 rs17501011 16 15988624 
ABCB1 rs4148815 7 86925770 ABCC1/6 rs152023 16 15992737 
ABCB1 rs17064 7 86971406 ABCC1/6 rs152022 16 15994167 
ABCB1 rs1045642 7 86976581 ABCC1/6 rs12928602 16 15994997 
ABCB1 rs4437575 7 86977252 ABCC1/6 rs246218 16 15995066 
ABCB1 rs12720066 7 87007638 ABCC1/6 rs17501331 16 15996942 
ABCB1 rs1922242 7 87011603 ABCC1/6 rs4781708 16 16003138 
ABCB1 rs2235013 7 87016562 ABCC1/6 rs6498595 16 16003453 
ABCB1 rs1128503 7 87017537 ABCC1/6 rs4781709 16 16005663 
ABCB1 rs2235015 7 87037500 ABCC1/6 rs2014800 16 16007467 
ABCB1 rs10264990 7 87040551 ABCC1/6 rs8187843 16 16009376 
ABCB1 rs1989831 7 87043415 ABCC1/6 rs4781718 16 16012258 
ABCB1 rs4148733 7 87051168 ABCC1/6 rs1967120 16 16016395 
ABCB1 rs17327624 7 87054753 ABCC1/6 rs3784863 16 16018456 
ABCB1 rs9282564 7 87067376 ABCC1/6 rs8059648 16 16018938 
ABCB1 rs4148732 7 87071985 ABCC1/6 rs246214 16 16022393 
ABCB1 rs13233308 7 87082896 ABCC1/6 rs152033 16 16024772 
ABCB1 rs10246878 7 87113577 ABCC1/6 rs875740 16 16030549 
ABCB1 rs6465118 7 87168359 ABCC1/6 rs246234 16 16036243 
CYP51A1 rs3750111 7 91566859 ABCC1/6 rs11075293 16 16037497 
CYP51A1 rs7797834 7 91581086 ABCC1/6 rs246232 16 16038025 
PON1 rs705377 7 94752793 ABCC1/6 rs8054670 16 16039635 
PON1 rs854541 7 94758416 ABCC1/6 rs171583 16 16039833 
PON1 rs11764692 7 94758928 ABCC1/6 rs246227 16 16043648 
PON1 rs17773605 7 94762474 ABCC1/6 rs17205859 16 16049239 
PON1 rs854549 7 94764521 ABCC1/6 rs4148343 16 16049859 
PON1 rs854551 7 94765613 ABCC1/6 rs35593 16 16056126 
PON1 rs854552 7 94765860 ABCC1/6 rs35596 16 16060441 
PON1 rs854555 7 94768327 ABCC1/6 rs17287570 16 16062604 
PON1 rs3917550 7 94772509 ABCC1/6 rs35597 16 16065535 
PON1 rs2269829 7 94774065 ABCC1/6 rs35600 16 16067129 
PON1 rs3917541 7 94775560 ABCC1/6 rs4148348 16 16069429 
PON1 rs3917538 7 94775829 ABCC1/6 rs8187858 16 16069540 
PON1 rs3917527 7 94778194 ABCC1/6 rs4148349 16 16069839 
PON1 rs2074354 7 94778523 ABCC1/6 rs35610 16 16070774 
PON1 rs2299257 7 94780701 ABCC1/6 rs35625 16 16077067 
PON1 rs854560 7 94784020 ABCC1/6 rs4148350 16 16077978 
PON1 rs2074351 7 94785735 ABCC1/6 rs35629 16 16078943 
PON1 rs854565 7 94786280 ABCC1/6 rs10852377 16 16084325 
PON1 rs2272365 7 94786562 ABCC1/6 rs2074086 16 16088643 
PON1 rs3917490 7 94786777 ABCC1/6 rs2889517 16 16089457 
PON1 rs2049649 7 94787265 ABCC1/6 rs7498870 16 16090081 
PON1 rs2299260 7 94787473 ABCC1/6 rs3888565 16 16090546 
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PON1 rs2299261 7 94787599 ABCC1/6 rs2239995 16 16100066 
PON1 rs854568 7 94787737 ABCC1/6 rs2074085 16 16103399 
PON1 rs2299262 7 94787864 ABCC1/6 rs8053266 16 16104334 
PON1 rs854569 7 94787991 ABCC1/6 rs16967755 16 16106756 
PON1 rs2237583 7 94788113 ABCC1/6 rs11864374 16 16109386 
PON1 rs2237584 7 94788773 ABCC1/6 rs3784867 16 16110846 
PON1 rs3917478 7 94789505 ABCC1/6 rs4780591 16 16112480 
PON1 rs854573 7 94792799 ABCC1/6 rs3887893 16 16113002 
PON1 rs705382 7 94793157 ABCC1/6 rs9673292 16 16113242 
PON1 rs757158 7 94793464 ABCC1/6 rs212079 16 16127627 
PON1 rs13236941 7 94793756 ABCC1/6 rs2283512 16 16127703 
PON1 rs17166818 7 94796564 ABCC1/6 rs13332486 16 16128191 
PON1 rs13228784 7 94798761 ABCC1/6 rs212081 16 16133472 
PON2/3 rs2057682 7 94828700 ABCC1/6 rs212084 16 16136708 
PON2/3 rs7787187 7 94835296 ABCC1/6 rs4148380 16 16143932 
PON2/3 rs11768074 7 94838527 ABCC1/6 rs212091 16 16144151 
PON2/3 rs1053275 7 94839491 ABCC1/6 rs212093 16 16145255 
PON2/3 rs6977389 7 94857291 ABCC1/6 rs2066738 16 16156182 
PON2/3 rs10487132 7 94858241 ABCC1/6 rs169845 16 16158099 
PON2/3 rs13226149 7 94863536 ABCC1/6 rs2238472 16 16159100 
PON2/3 rs11977702 7 94867703 ABCC1/6 rs16967488 16 16160197 
PON2/3 rs9641164 7 94872757 ABCC1/6 rs169844 16 16162267 
PON2/3 rs2237585 7 94887754 ABCC1/6 rs2376957 16 16162706 
PON2/3 rs2286233 7 94892193 ABCC1/6 rs3213473 16 16164268 
PON2/3 rs12534274 7 94895446 ABCC1/6 rs2283509 16 16166331 
PON2/3 rs4729189 7 94895895 ABCC1/6 rs4781732 16 16170073 
PON2/3 rs7802018 7 94898249 ABCC1/6 rs9924755 16 16178910 
PON2/3 rs2299267 7 94899857 ABCC1/6 rs212077 16 16188277 
PON2/3 rs43037 7 94904942 ABCC1/6 rs3851722 16 16189808 
PON2/3 rs43038 7 94905247 ABCC1/6 rs2238469 16 16190572 
PON2/3 rs6978425 7 94906620 ABCC1/6 rs2239322 16 16191766 
PON2/3 rs12535571 7 94907602 ABCC1/6 rs7186601 16 16196257 
PON2/3 rs10953147 7 94910552 ABCC1/6 rs8056397 16 16197033 
PON2/3 rs43044 7 94910683 ABCC1/6 rs4781735 16 16197743 
PON2/3 rs43047 7 94913570 ABCC1/6 rs4780599 16 16197878 
CYP3A5 rs10264272 7 99100771 ABCC1/6 rs9930886 16 16199484 
CYP3A rs4646450 7 99104254 SULT1A1/2 rs4787456 16 28467074 
CYP3A5 rs776746 7 99108475 SULT1A1/2 rs151228 16 28470527 
CYP3A rs2687079 7 99142554 SULT1A1/2 rs9924471 16 28499031 
CYP3A rs4646437 7 99203019 SULT1A1/2 rs12445705 16 28517197 
CYP3A rs2246709 7 99203655 SULT1A1/2 rs11074904 16 28523209 
CYP3A rs533486 7 99278630 SULT1A1 rs1801030 16 28524986 
CYP3A rs800667 7 99285177 ABCC11/12 rs7193955 16 46680083 
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CYP3A rs472660 7 99298043 ABCC11/12 rs12149826 16 46722278 
SLC13A1 rs4288315 7 122495785 ABCC11/12 rs8046826 16 46730882 
SLC13A1 rs13245959 7 122579092 ABCC11/12 rs16945874 16 46732736 
SLC13A1 rs10265711 7 122615738 ABCC11/12 rs16945894 16 46737611 
GSTK1 rs7780478 7 142623691 ABCC11/12 rs6500338 16 46747886 
GSTK1 rs10256011 7 142646365 ABCC11/12 rs8050306 16 46754604 
ABCB8 rs2303922 7 150356655 ABCC11/12 rs17743256 16 46757031 
ABCB8 rs2303924 7 150362631 ABCC11/12 rs12443685 16 46783980 
ABCB8 rs4148850 7 150369557 ABCC11/12 rs11866251 16 46785363 
ABCB8 rs2069459 7 150382523 ABCC11/12 rs7203695 16 46790037 
NAT1 rs10888150 8 18110406 ABCC11/12 rs8050120 16 46793078 
NAT1 rs7017402 8 18112354 ABCC11/12 rs10521168 16 46803255 
NAT1 rs5030839 8 18124395 ABCC11/12 rs17822931 16 46815699 
NAT1 rs9650592 8 18126109 ABCC11/12 rs16945988 16 46823278 
NAT1 rs13277177 8 18130376 ABCC11/12 rs11076560 16 46837905 
NAT2 rs7013253 8 18287748 CES1 rs1814268 16 54410560 
NAT2 rs1390358 8 18297035 CES1 rs12443580 16 54423838 
NAT2 rs1805158 8 18301983 CES1 rs6499786 16 54426736 
NAT2 rs1801280 8 18302134 CES1 rs35918553 16 54428636 
NAT2 rs1799929 8 18302274 CES1 rs6499788 16 54429338 
NAT2 rs1799930 8 18302383 CES1 rs6499789 16 54433814 
NAT2 rs1799931 8 18302650 CES2 rs11568314 16 65528062 
EPHX2 rs6558000 8 27395271 CES2 rs11568311 16 65528758 
EPHX2 rs11780471 8 27400636   rs11646004 16 85946502 
EPHX2 rs2741334 8 27420704 SLC2A4 rs2654189 17 7118596 
EPHX2 rs7816586 8 27425251 SLC2A4 rs2654185 17 7124086 
EPHX2 rs721619 8 27437913 SLC2A4 rs5418 17 7125816 
EPHX2 rs12547188 8 27446163 SLC2A4 rs5435 17 7127847 
EPHX2 rs13269963 8 27456521 SLC2A4 rs222842 17 7132815 
EPHX2 rs1042064 8 27458049 SLC2A4 rs3744405 17 7133979 
EPHX2 rs2565050 8 27460271 ALDH3A2 rs1004490 17 19496317 
EPHX2 rs2640726 8 27461726 ALDH3A1 rs12948881 17 19578132 
GSR rs3594 8 30655202 ALDH3A1 rs2072327 17 19592074 
GSR rs2250192 8 30659165 ALDH3A1 rs7221211 17 19593268 
GSR rs2551715 8 30666178 ALDH3A1 rs2052052 17 19600341 
GSR rs8190996 8 30673548 ALDH3A1 rs7225305 17 19601711 
GSR rs3779647 8 30680429 SLC13A2 rs11654702 17 23818922 
GSR rs2978663 8 30685487 SLC13A2 rs3764866 17 23824331 
GSR rs8190893 8 30703446 SLC13A2 rs1558220 17 23833095 
GSR rs12543000 8 30708027 SLC13A2 rs1990287 17 23843192 
GSR rs12543324 8 30716145 SLC13A2 rs2191090 17 23852624 
CYP7A1 rs10087499 8 59557523 SLC13A2 rs12453704 17 23860572 
CYP7A1 rs10957057 8 59562894 SLC13A2 rs4332786 17 23861649 
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CYP7A1 rs8192879 8 59566130 PNMT rs881844 17 35063744 
CYP7A1 rs8192877 8 59566995 PNMT rs2934963 17 35074518 
CYP7A1 rs8192871 8 59574525 PNMT rs1053651 17 35075837 
CYP7A1 rs7833904 8 59580216 PNMT rs876493 17 35078071 
SLCO5A1 rs4738017 8 70738684 PNMT rs903501 17 35093019 
SLCO5A1 rs4738020 8 70742250 ABCC3 rs17717246 17 46060685 
SLCO5A1 rs10103580 8 70746282 ABCC3 rs7212045 17 46061023 
SLCO5A1 rs11989109 8 70746932 ABCC3 rs2412332 17 46062521 
SLCO5A1 rs16936279 8 70747363 ABCC3 rs757421 17 46062767 
SLCO5A1 rs10448034 8 70751432 ABCC3 rs2189595 17 46063948 
SLCO5A1 rs2933067 8 70766287 ABCC3 rs8073706 17 46064940 
SLCO5A1 rs2380572 8 70780229 ABCC3 rs2412333 17 46070270 
SLCO5A1 rs6472477 8 70781403 ABCC3 rs739922 17 46074614 
SLCO5A1 rs17728769 8 70782967 ABCC3 rs1541392 17 46074888 
SLCO5A1 rs16936356 8 70786926 ABCC3 rs12051822 17 46078584 
SLCO5A1 rs2380585 8 70787140 ABCC3 rs4794174 17 46080603 
SLCO5A1 rs17729279 8 70788128 ABCC3 rs4793666 17 46082252 
SLCO5A1 rs2959561 8 70788310 ABCC3 rs4794175 17 46083582 
SLCO5A1 rs2380584 8 70790206 ABCC3 rs4148411 17 46088744 
SLCO5A1 rs2380580 8 70790837 ABCC3 rs4148412 17 46088814 
SLCO5A1 rs2933029 8 70795078 ABCC3 rs739923 17 46090773 
SLCO5A1 rs16936388 8 70809484 ABCC3 rs733392 17 46091402 
SLCO5A1 rs10096220 8 70839611 ABCC3 rs1978153 17 46092860 
SLCO5A1 rs12542317 8 70877797 ABCC3 rs4148413 17 46095797 
SLCO5A1 rs7833221 8 70879693 ABCC3 rs879459 17 46101134 
SLCO5A1 rs2380601 8 70879888 ABCC3 rs8075406 17 46104521 
SLCO5A1 rs2380602 8 70881936 ABCC3 rs16949207 17 46104919 
SLCO5A1 rs10504460 8 70886578 ABCC3 rs4148416 17 46108422 
SLCO5A1 rs1873547 8 70887465 ABCC3 rs967935 17 46110387 
SLCO5A1 rs3750266 8 70907366 ABCC3 rs3785912 17 46111936 
CYP11B2 rs5283 8 143957599 ABCC3 rs2277624 17 46116104 
CYP11B2 rs3097 8 143990317 ABCC3 rs1051640 17 46123485 
CYP11B2 rs11781082 8 143996903 ABCC3 rs17563146 17 46124328 
CYP11B2 rs6988985 8 144004106 ABCC3 rs4148418 17 46125516 
ALDH1B1 rs10973774 9 38373193 ABCC3 rs11651060 17 46141215 
ALDH1B1 rs11790480 9 38374578   rs1451280 18 20714450 
ALDH1B1 rs1555480 9 38376351   rs726155 18 68359526 
ALDH1B1 rs13285234 9 38376975 CYP4F11 rs7259345 19 15876099 
ALDH1B1 rs4878802 9 38381218 CYP4F11 rs12610962 19 15884377 
ALDH1B1 rs4242647 9 38383209 CYP4F11 rs1060467 19 15885538 
ALDH1B1 rs7846941 9 38384563 CYP4F11 rs12971888 19 15887204 
ALDH1B1 rs4646771 9 38384806 CYP4F11 rs8104361 19 15895714 
ALDH1B1 rs2228093 9 38386002 CYP4F11 rs7249167 19 15898359 
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ALDH1B1 rs2073478 9 38386065 CYP4F11 rs2305804 19 15899365 
ALDH1B1 rs3043 9 38387355 CYP4F11 rs12460831 19 15908758 
ALDH1B1 rs7859877 9 38387915 CYP4F11 rs1025500 19 15911931 
ALDH1B1 rs4646774 9 38388826 CYP4F11 rs2116952 19 15913255 
ALDH1B1 rs7853954 9 38389721 CYP4F11 rs10775621 19 15918677 
ALDH1B1 rs4878202 9 38391860 CYP4F11 rs10500211 19 15919348 
ALDH1B1 rs4878805 9 38394105 CYP4F11 rs4239627 19 15935673 
ALDH1B1 rs7865905 9 38394352 CYP2A6/7 rs7251570 19 46033590 
ALDH1B1 rs6476703 9 38394520 CYP2A6/7 rs8110214 19 46036048 
ALDH1B1 rs911758 9 38395580 CYP2A6/7 rs4343391 19 46036208 
ALDH1B1 rs11791018 9 38396458 CYP2A6 rs5031017 19 46041590 
ALDH1B1 rs1475102 9 38397090 CYP2A6 rs28399454 19 46043107 
ALDH1B1 rs7021469 9 38397767 CYP2A6 rs28399447 19 46044781 
ALDH1A1 rs3905336 9 74660180 CYP2A6 rs28399444 19 46046280 
ALDH1A1 rs660519 9 74687834 CYP2A6/7 rs1801272 19 46046373 
ALDH1A1 rs10869198 9 74697590 CYP2A6 rs4986891 19 46046469 
ALDH1A1 rs4646548 9 74705366 CYP2A6 rs28399433 19 46048219 
ALDH1A1 rs168351 9 74707131 CYP2A6/7 rs4570984 19 46066942 
ALDH1A1 rs1888202 9 74709071 CYP2A6/7 rs2261144 19 46074993 
ALDH1A1 rs348472 9 74710880 CYP2A6/7 rs10411264 19 46086176 
ALDH1A1 rs10781106 9 74712742 CYP2A6/7 rs8103444 19 46089501 
ALDH1A1 rs8187950 9 74724858 CYP2A6/7 rs11878463 19 46093764 
ALDH1A1 rs7043217 9 74732715 CYP2B6 rs2054675 19 46187595 
ALDH1A1 rs2017362 9 74734211 CYP2B6 rs8192709 19 46189114 
ALDH1A1 rs348462 9 74736989 CYP2B6 rs2099361 19 46190188 
ALDH1A1 rs8187910 9 74739630 CYP2B6 rs8100458 19 46192053 
ALDH1A1 rs1330286 9 74742773 CYP2B6 rs8192712 19 46192140 
ALDH1A1 rs8187890 9 74749669 CYP2B6 rs2279342 19 46201967 
ALDH1A1 rs1424482 9 74753377 CYP2B6 rs12721655 19 46202122 
ALDH1A1 rs348447 9 74765983 CYP2B6 rs3745274 19 46204681 
ABCA1 rs4149338 9 106585724 CYP2B6 rs2279343 19 46207103 
ABCA1 rs1331924 9 106587443 CYP2B6 rs2306606 19 46208022 
ABCA1 rs4149336 9 106590460 CYP2B6 rs28399499 19 46210061 
ABCA1 rs2740484 9 106591001 CYP2B6 rs34097093 19 46210210 
ABCA1 rs2297406 9 106591359 CYP2B6 rs7255374 19 46212191 
ABCA1 rs2740479 9 106603258 CYP2B6 rs7260329 19 46213478 
ABCA1 rs2066716 9 106608526 CYP2B6 rs10853744 19 46213779 
ABCA1 rs2297409 9 106616067 CYP2B6 rs1042389 19 46215993 
ABCA1 rs3818688 9 106620478 CYP2B6 rs2113103 19 46220507 
ABCA1 rs4149316 9 106621128 CYP2B6 rs11666982 19 46223208 
ABCA1 rs2254884 9 106621570 CYP2B6 rs11670865 19 46223362 
ABCA1 rs3818689 9 106624837 CYP2B6 rs3745277 19 46223755 
ABCA1 rs4149313 9 106626574 CYP2B6 rs4803421 19 46229802 
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ABCA1 rs2515629 9 106634185 CYP2B6 rs10425407 19 46232125 
ABCA1 rs2065412 9 106638561 CYP2A13/2F1 rs16974961 19 46291894 
ABCA1 rs2472386 9 106641362 CYP2A13/2F1 rs1709081 19 46292640 
ABCA1 rs2274873 9 106642499 CYP2A13/2F1 rs305985 19 46305025 
ABCA1 rs4149291 9 106649297 CYP2A13/2F1 rs305968 19 46314029 
ABCA1 rs2472384 9 106658502 CYP2A13/2F1 rs305975 19 46320517 
ABCA1 rs2230805 9 106663850 CYP2A13/2F1 rs1631814 19 46327661 
ABCA1 rs4149281 9 106666210 CYP2A13/2F1 rs10408019 19 46330169 
ABCA1 rs4743764 9 106668925 CYP2A13/2F1 rs13382161 19 46333808 
ABCA1 rs1929842 9 106673444 CYP2A13/2F1 rs16974549 19 46334140 
ABCA1 rs1929841 9 106673546 CYP2A13/2F1 rs1645675 19 46334647 
ABCA1 rs2000069 9 106675690 CYP2A13/2F1 rs7247759 19 46334720 
ABCA1 rs4149275 9 106678328 CYP2A13/2F1 rs1709128 19 46334906 
ABCA1 rs3858075 9 106684651 CYP2A13/2F1 rs1709127 19 46335220 
ABCA1 rs2275542 9 106684901 CYP2A13/2F1 rs1631931 19 46335684 
ABCA1 rs2482424 9 106705572 SULT2A1 rs296381 19 53062914 
ABCA1 rs2740486 9 106706334 SULT2A1 rs188440 19 53063945 
ABCA1 rs3905001 9 106707885 SULT2A1 rs296364 19 53067510 
ABCA1 rs2777795 9 106712186 SULT2A1 rs4149452 19 53069331 
ABCA1 rs4149265 9 106712319 SULT2A1 rs2547238 19 53074292 
ABCA1 rs4149263 9 106717110 SULT2A1 rs4149448 19 53078169 
ABCA1 rs2515618 9 106718618 SULT2A1 rs7508610 19 53083388 
ABCA1 rs2515616 9 106721816 SULT2A1 rs2910397 19 53089929 
ABCA1 rs2472510 9 106722943 SULT2B1 rs12611321 19 53745060 
ABCA1 rs2472508 9 106724074 SULT2B1 rs279451 19 53745118 
ABCA1 rs2515614 9 106724139 SULT2B1 rs3848542 19 53753536 
ABCA1 rs2487052 9 106726226 SULT2B1 rs12611137 19 53756771 
ABCA1 rs2472377 9 106726925 SULT2B1 rs2665605 19 53762686 
ABCA1 rs1800977 9 106730271 SULT2B1 rs2544796 19 53767089 
ABCA1 rs2472493 9 106735669 SULT2B1 rs2544795 19 53768273 
ABCA1 rs3887137 9 106738433 SULT2B1 rs3760802 19 53768499 
ABCA1 rs2437819 9 106739017 SULT2B1 rs3826827 19 53768735 
ABCA1 rs2487038 9 106739755 SULT2B1 rs3760804 19 53768869 
RXRA rs11185644 9 136350684 SULT2B1 rs2665579 19 53769264 
RXRA rs12339187 9 136369148 SULT2B1 rs3760808 19 53769479 
RXRA rs10881582 9 136395899 SULT2B1 rs2544794 19 53771058 
RXRA rs10776909 9 136428567 SULT2B1 rs8108904 19 53774218 
RXRA rs1805352 9 136439770 SULT2B1 rs2431141 19 53775135 
RXRA rs4240705 9 136451221 SULT2B1 rs6509396 19 53775305 
RXRA rs3118571 9 136457999 SULT2B1 rs10416980 19 53780734 
RXRA rs3132294 9 136463941 SULT2B1 rs2665581 19 53781607 
RXRA rs1045570 9 136472132 SULT2B1 rs11880831 19 53782621 
RXRA rs4842196 9 136473049 SULT2B1 rs10426377 19 53784046 
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RXRA rs3118523 9 136475342 SULT2B1 rs10426628 19 53784242 
CYP26A1 rs7073161 10 94816455 SULT2B1 rs3745726 19 53786668 
CYP26A1 rs2068888 10 94829632 SULT2B1 rs2302948 19 53787877 
CYP26A1 rs7905501 10 94830706 SULT2B1 rs10417472 19 53789699 
CYP26A1 rs10786068 10 94832467 SULT2B1 rs12460535 19 53790562 
CYP26A1 rs12359135 10 94833525 SULT2B1 rs4149455 19 53793768 
CYP26A1 rs7080494 10 94836083 SULT2B1 rs1132054 19 53794211 
CYP26A1 rs913422 10 94837105 SULT2B1 rs1052131 19 53794325 
CYP2C8 rs7087256 10 96785514 SULT2B1 rs2617805 19 53804107 
CYP2C8 rs1058932 10 96786851 SULT2B1 rs454715 19 53806048 
CYP2C8 rs1934952 10 96787490 SLC13A3 rs6017911 20 44609961 
CYP2C8 rs10509681 10 96788739 SLC13A3 rs12479924 20 44610310 
CYP2C8 rs1341164 10 96790863 SLC13A3 rs6066021 20 44613799 
CYP2C8 rs2275620 10 96792588 SLC13A3 rs85022 20 44614659 
CYP2C8 rs1058930 10 96808109 SLC13A3 rs202377 20 44614848 
CYP2C8 rs11572080 10 96817020 SLC13A3 rs847059 20 44618164 
CYP2C8 rs7909236 10 96819420 SLC13A3 rs10218 20 44620912 
CYP2C8 rs17110453 10 96819519 SLC13A3 rs847066 20 44627212 
ABCC2 rs4148388 10 101539755 SLC13A3 rs847067 20 44629751 
ABCC2 rs2804398 10 101548624 SLC13A3 rs847069 20 44630622 
ABCC2 rs2756109 10 101548736 SLC13A3 rs436978 20 44631938 
ABCC2 rs2273697 10 101553805 SLC13A3 rs6090518 20 44640412 
ABCC2 rs11190291 10 101556000 SLC13A3 rs202385 20 44641355 
ABCC2 rs2002042 10 101577921 SLC13A3 rs6124817 20 44641655 
ABCC2 rs3740065 10 101595683 SLC13A3 rs761218 20 44642391 
ABCC2 rs8187710 10 101601284 SLC13A3 rs6094382 20 44643277 
ABCC2 rs11190297 10 101608093 SLC13A3 rs2064342 20 44644956 
CYP17A1 rs284860 10 104562953 SLC13A3 rs12625158 20 44647459 
CYP17A1 rs10883782 10 104573922 SLC13A3 rs13039165 20 44648328 
CYP17A1 rs4919682 10 104574320 SLC13A3 rs3092473 20 44649321 
CYP17A1 rs1004467 10 104584497 SLC13A3 rs3091805 20 44649420 
CYP17A1 rs6162 10 104586971 SLC13A3 rs3752270 20 44650535 
CYP17A1 rs2486758 10 104587470 SLC13A3 rs85024 20 44655758 
CYP17A1 rs7089422 10 104595318 SLC13A3 rs847095 20 44656557 
CYP17A1 rs17724534 10 104595511 SLC13A3 rs431072 20 44657045 
GSTO1/O2 rs966645 10 106000529 SLC13A3 rs6063009 20 44657882 
GSTO1/O2 rs568526 10 106023429 SLC13A3 rs10854171 20 44660852 
GSTO1/O2 rs10491045 10 106023893 SLC13A3 rs451595 20 44663217 
CYP2E1 rs6413420 10 135190819 SLC13A3 rs847058 20 44666164 
CYP2E1 rs915906 10 135193728 SLC13A3 rs847057 20 44666440 
CYP2E1 rs8192772 10 135194701 SLC13A3 rs6124828 20 44669529 
CYP2E1 rs915908 10 135196949 SLC13A3 rs3091733 20 44670376 
CYP2E1 rs2149617 10 135218315 SLC13A3 rs383551 20 44671619 
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SLC22A18 rs400643 11 2869522 SLC13A3 rs4810535 20 44682123 
SLC22A18 rs2283231 11 2873291 SLC13A3 rs742594 20 44690385 
SLC22A18 rs365605 11 2877242 SLC13A3 rs16991650 20 44691134 
SLC22A18 rs367035 11 2880402 SLC13A3 rs2425884 20 44691699 
SLC22A18 rs413781 11 2882197 SLC13A3 rs3091520 20 44692047 
SLC22A18 rs389646 11 2882337 SLC13A3 rs2425885 20 44693038 
SLC22A18 rs4930028 11 2889641 SLC13A3 rs2425886 20 44693250 
SLC22A18 rs3782067 11 2891879 SLC13A3 rs941206 20 44694448 
SLC22A18 rs3764895 11 2902521 SLC13A3 rs2425887 20 44695530 
ABCC8 rs2285676 11 17364601 SLC13A3 rs3091556 20 44696189 
ABCC8 rs5215 11 17365206 SLC13A3 rs17481569 20 44698593 
ABCC8 rs8192690 11 17371146 SLC13A3 rs2694903 20 44700354 
ABCC8 rs8192691 11 17373913 SLC13A3 rs6017949 20 44702963 
ABCC8 rs739689 11 17374080 SLC13A3 rs11699754 20 44707758 
ABCC8 rs1799859 11 17375855 SLC13A3 rs6090536 20 44708393 
ABCC8 rs2074311 11 17378436 SLC13A3 rs2757524 20 44709070 
ABCC8 rs12422139 11 17378973 SLC13A3 rs11907381 20 44710186 
ABCC8 rs2077654 11 17384477 SLC13A3 rs1004571 20 44711576 
ABCC8 rs7926934 11 17389664 SLC13A3 rs2757523 20 44715003 
ABCC8 rs2355017 11 17391179 SLC13A3 rs6066043 20 44721860 
ABCC8 rs2074309 11 17391790 SLC13A3 rs13038390 20 44726581 
ABCC8 rs2237991 11 17396805 CYP24A1 rs2762920 20 52183230 
ABCC8 rs916829 11 17397049 CYP24A1 rs873216 20 52192413 
ABCC8 rs2299639 11 17397961 CYP24A1 rs2762926 20 52195825 
ABCC8 rs929235 11 17399036 CYP24A1 rs2585413 20 52195887 
ABCC8 rs2237988 11 17400710 CYP24A1 rs2762927 20 52196373 
ABCC8 rs2237984 11 17402597 CYP24A1 rs2031343 20 52197270 
ABCC8 rs2074308 11 17409156 CYP24A1 rs6022985 20 52199020 
ABCC8 rs4148618 11 17410019 CYP24A1 rs2762929 20 52199602 
ABCC8 rs11024286 11 17415683 CYP24A1 rs8124792 20 52200214 
ABCC8 rs7950189 11 17424893 CYP24A1 rs6068810 20 52202758 
ABCC8 rs722341 11 17429722 CYP24A1 rs6097807 20 52202862 
ABCC8 rs1048099 11 17453092 CYP24A1 rs2762933 20 52203310 
ABCC8 rs3758949 11 17457639 CYP24A1 rs4809957 20 52204578 
ABCC8 rs12278956 11 17464789 CYP24A1 rs2762934 20 52204668 
SLC22A6/8 rs6591722 11 62506256 CYP24A1 rs927650 20 52206148 
SLC22A6/8 rs10897312 11 62508234 CYP24A1 rs1570669 20 52207834 
SLC22A6/8 rs955434 11 62513689 CYP24A1 rs2209314 20 52212368 
SLC22A6/8 rs4149183 11 62522445 CYP24A1 rs6127118 20 52212459 
SLC22A6/8 rs2276299 11 62523007 CYP24A1 rs6068816 20 52214498 
SLC22A6/8 rs2187383 11 62532474 CYP24A1 rs2762939 20 52214658 
SLC22A6/8 rs948979 11 62540402 CYP24A1 rs3787554 20 52216087 
SLC22A6/8 rs10792369 11 62543011 CYP24A1 rs2244719 20 52216265 
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SLC22A6/8 rs10897315 11 62545707 CYP24A1 rs3787557 20 52216542 
SLC22A6/8 rs10897316 11 62546339 CYP24A1 rs2762941 20 52217059 
SLC22A9 rs556730 11 62899453 CYP24A1 rs2181874 20 52217885 
SLC22A9 rs604285 11 62925353 CYP24A1 rs4809959 20 52219266 
SLC22A9 rs630759 11 62933285 CYP24A1 rs4809960 20 52219480 
SLC22A11 rs693591 11 64081645 CYP24A1 rs2245153 20 52219813 
SLC22A11 rs1783811 11 64089872 CYP24A1 rs13038432 20 52220709 
SLC22A12 rs475688 11 64120867 CYP24A1 rs6022999 20 52221420 
SLC22A12 rs17146121 11 64143102 CYP24A1 rs2248359 20 52224925 
GSTP1 rs612020 11 67102017 CYP24A1 rs2426498 20 52230088 
GSTP1 rs614080 11 67103863 CYP24A1 rs2208588 20 52230378 
GSTP1 rs1695 11 67109265 CYP24A1 rs2585424 20 52231986 
ALDH3B2 rs10736660 11 67176431 CYP24A1 rs6023012 20 52239980 
ALDH3B2 rs1551886 11 67187338 SLCO4A1 rs6089917 20 60734665 
ALDH3B2 rs11603033 11 67205316 SLCO4A1 rs6062918 20 60741383 
ALDH3B1 rs11228120 11 67525372 SLCO4A1 rs2427364 20 60751170 
ALDH3B1 rs12418774 11 67530807 SLCO4A1 rs17311216 20 60757617 
ALDH3B1 rs479763 11 67531704 SLCO4A1 rs3195701 20 60758800 
ALDH3B1 rs3763941 11 67532938 SLCO4A1 rs2236553 20 60760188 
ALDH3B1 rs1003777 11 67548543 SLCO4A1 rs2258022 20 60769411 
ALDH3B1 rs105147 11 67549590 SLCO4A1 rs12481701 20 60772300 
ALDH3B1 rs3794176 11 67551219 SLCO4A1 rs6062771 20 60772955 
ALDH3B1 rs4147779 11 67561383 SLCO4A1 rs3787538 20 60773449 
ALDH3B1 rs884826 11 67562705 SLCO4A1 rs1055196 20 60774011 
SLCO2B1 rs4944991 11 74538434 SLCO4A1 rs3787537 20 60774187 
SLCO2B1 rs2851071 11 74543364 SLCO4A1 rs6010817 20 60774260 
SLCO2B1 rs4944993 11 74543488 SLCO4A1 rs13037524 20 60775645 
SLCO2B1 rs1789694 11 74559330 SLCO4A1 rs2427372 20 60775725 
SLCO2B1 rs12422149 11 74561225 SLCO4A1 rs6062400 20 60776381 
SLCO2B1 rs7947726 11 74563722 SLCO4A1 rs4809480 20 60777875 
SLCO2B1 rs1676881 11 74564506 SLCO4A1 rs7266121 20 60780515 
SLCO2B1 rs11823030 11 74584852 SLCO4A1 rs2427374 20 60781847 
SLCO2B1 rs7116044 11 74589602 SLCO4A1 rs2313152 20 60782438 
NNMT rs2244175 11 113667731 SLCO4A1 rs2427377 20 60784589 
NNMT rs2852432 11 113669214 SLCO4A1 rs2427378 20 60784723 
NNMT rs4646335 11 113672152 SLCO4A1 rs2105161 20 60788376 
NNMT rs3819100 11 113672686   rs6011368 20 62356948 
NNMT rs2301128 11 113673209 CBR1 rs2835235 21 36319470 
NNMT rs1941404 11 113674248 CBR1 rs7275820 21 36331284 
NNMT rs10891645 11 113676457 CBR1 rs1005696 21 36365350 
NNMT rs2155806 11 113677720 CBR1 rs9024 21 36367183 
NNMT rs1941398 11 113683266 CBR1 rs4239798 21 36368322 
NNMT rs949370 11 113693674 CBR1 rs2835268 21 36371006 
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NNMT rs1941396 11 113695631 CBR3 rs2242801 21 36424820 
NNMT rs7929497 11 113697342 CBR3 rs2239566 21 36428636 
NNMT rs11214958 11 113717478 CBR3 rs2835286 21 36440232 
SLCO1B3/1C1 rs3809208 12 20739263 CBR3 rs8129031 21 36445883 
SLCO1B3/1C1 rs10770704 12 20747028 CBR3 rs726271 21 36447405 
SLCO1B3/1C1 rs11045399 12 20754206 CBR3 rs2835288 21 36447699 
SLCO1B3/1C1 rs1515777 12 20754840 ABCG1 rs748319 21 42486126 
SLCO1B3/1C1 rs952658 12 20756568 ABCG1 rs8131660 21 42488628 
SLCO1B3/1C1 rs10841596 12 20759021 ABCG1 rs1378577 21 42492734 
SLCO1B3/1C1 rs2056136 12 20759160 ABCG1 rs1117640 21 42498343 
SLCO1B3/1C1 rs2417862 12 20761532 ABCG1 rs221948 21 42506262 
SLCO1B3/1C1 rs2203494 12 20766653 ABCG1 rs4148095 21 42509025 
SLCO1B3/1C1 rs16923154 12 20777198 ABCG1 rs3787968 21 42523456 
SLCO1B3/1C1 rs974453 12 20781209 ABCG1 rs225440 21 42526122 
SLCO1B3/1C1 rs17379695 12 20794062 ABCG1 rs225448 21 42532899 
SLCO1B3/1C1 rs11045505 12 20840713 ABCG1 rs4148117 21 42539134 
SLCO1B3/1C1 rs1515766 12 20854402 ABCG1 rs12329683 21 42542679 
SLCO1B3/1C1 rs12228798 12 20855824 ABCG1 rs9982242 21 42544189 
SLCO1B3/1C1 rs7310629 12 20876554 ABCG1 rs225374 21 42544702 
SLCO1B3/1C1 rs2900474 12 20901315 ABCG1 rs225376 21 42547191 
SLCO1B3 rs4149117 12 20902747 ABCG1 rs7279750 21 42547753 
SLCO1B3 rs7311358 12 20907027 ABCG1 rs183436 21 42550900 
SLCO1B3/1C1 rs3764006 12 20945636 ABCG1 rs3787986 21 42551877 
SLCO1B3/1C1 rs2117032 12 20965389 ABCG1 rs225385 21 42555755 
SLCO1B1/1A2 rs704166 12 21171109 ABCG1 rs17767083 21 42557390 
SLCO1B1/1A2 rs3829307 12 21183473 ABCG1 rs225391 21 42557737 
SLCO1B1/1A2 rs2417954 12 21187611 ABCG1 rs225398 21 42561663 
SLCO1B1/1A2 rs7489119 12 21196565 ABCG1 rs691687 21 42562939 
SLCO1B1/1A2 rs4149023 12 21200724 ABCG1 rs2298689 21 42569902 
SLCO1B1/1A2 rs4149026 12 21206682 ABCG1 rs2234718 21 42570264 
SLCO1B1/1A2 rs4149033 12 21209077 ABCG1 rs4148123 21 42571320 
SLCO1B1/1A2 rs4149035 12 21209532 ABCG1 rs182694 21 42571884 
SLCO1B1/1A2 rs2291073 12 21217081 ABCG1 rs3787997 21 42572165 
SLCO1B1/1A2 rs964614 12 21220657 ABCG1 rs225406 21 42572299 
SLCO1B1 RS2306283 12 21221005 ABCG1 rs2839482 21 42573501 
SLCO1B1/1A2 rs4149057 12 21222866 ABCG1 rs225410 21 42573976 
SLCO1B1/1A2 rs6487213 12 21224533 ABCG1 rs3788007 21 42579845 
SLCO1B1/1A2 rs11045834 12 21232363 ABCG1 rs450808 21 42580013 
SLCO1B1/1A2 rs4149061 12 21241935 ABCG1 rs425215 21 42580170 
SLCO1B1/1A2 rs4149064 12 21242128 ABCG1 rs7277991 21 42582751 
SLCO1B1/1A2 rs11045889 12 21280304 ABCG1 rs4148137 21 42583121 
SLCO1B1/1A2 rs2199763 12 21280975 ABCG1 rs914189 21 42583978 
SLCO1B1/1A2 rs12371604 12 21282603 ABCG1 rs9975333 21 42587586 
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SLCO1B1 rs55737008 12 21283314 ABCG1 rs1541290 21 42591552 
SLCO1B1/1A2 rs2199680 12 21306763 ABCG1 rs3746917 21 42591941 
SLCO1B1/1A2 rs11045913 12 21307680 ABCG1 rs15661 21 42597422 
SLCO1B1/1A2 rs11045945 12 21340335 ABCG1 rs225434 21 42597810 
SLCO1B1/1A2 rs16923647 12 21342662 SLC19A1 rs3753019 21 45749213 
SLCO1B1/1A2 rs3751270 12 21348518 SLC19A1 rs2236483 21 45750482 
SLCO1B1/1A2 rs4115170 12 21366230 SLC19A1 rs2838950 21 45750725 
SLCO1B1/1A2 rs7958005 12 21369104 SLC19A1 rs7278425 21 45750979 
SLCO1B1/1A2 rs4762818 12 21384796 SLC19A1 rs2838951 21 45754148 
SLCO1B1/1A2 rs11837182 12 21393223 SLC19A1 rs17004785 21 45757046 
SLCO1B1/1A2 rs4762699 12 21395335 SLC19A1 rs2838956 21 45769452 
SLCO1B1/1A2 rs17333533 12 21396583 SLC19A1 rs3788205 21 45788806 
SLCO1B1/1A2 rs10743413 12 21398341 GSTT2 rs575959 22 22619365 
SLCO1B1/1A2 rs11045994 12 21398969 GSTT2 rs113413 22 22622264 
SLCO1B1/1A2 rs10841798 12 21403464 GSTT2 rs2858908 22 22625776 
SLCO1B1/1A2 rs2045938 12 21411619 CYB5R3 rs137043 22 41295611 
SLCO1B1/1A2 rs7137767 12 21416873 CYB5R3 rs137049 22 41298166 
SLCO1B1/1A2 rs5486 12 21423367 CYB5R3 rs1540311 22 41337538 
SLCO1B1/1A2 rs2417977 12 21424435 CYB5R3 rs137111 22 41338048 
SLCO1B1/1A2 rs7967902 12 21434482 CYB5R3 rs137116 22 41341618 
SLCO1B1/1A2 rs11046012 12 21436623 CYB5R3 rs137124 22 41345660 
ABCC9 rs4148679 12 21857968 CYB5R3 rs743887 22 41348531 
ABCC9 rs4148677 12 21867695 CYB5R3 rs137126 22 41349196 
ABCC9 rs2112080 12 21874187 CYB5R3 rs137127 22 41349576 
ABCC9 rs1517284 12 21879355 CYB5R3 rs2071846 22 41353883 
ABCC9 rs704175 12 21882887 CYB5R3 rs137138 22 41353924 
ABCC9 rs704179 12 21884887 CYB5R3 rs137139 22 41354354 
ABCC9 rs829080 12 21891130 CYB5R3 rs2267452 22 41355414 
ABCC9 rs1283822 12 21893150 CYB5R3 rs737733 22 41356240 
ABCC9 rs4148674 12 21894811 CYB5R3 rs2071847 22 41357574 
ABCC9 rs704189 12 21903614 CYB5R3 rs6002829 22 41357768 
ABCC9 rs697252 12 21909431 CYB5R3 rs3091344 22 41358425 
ABCC9 rs704205 12 21921432 CYB5R3 rs5751318 22 41365737 
ABCC9 rs4148666 12 21923258 CYB5R3 rs6002850 22 41371489 
ABCC9 rs7301876 12 21925887 CYB5R3 rs9611830 22 41382080 
ABCC9 rs4148665 12 21926514 CYB5R3 rs1009433 22 41383757 
ABCC9 rs1914361 12 21937120   rs2106806 X 15557622 
ABCC9 rs4148649 12 21961498   rs2227144 X 18018148 
ABCC9 rs2277404 12 21969823   rs1927286 X 55300517 
ABCC9 rs10841914 12 21986068   rs1386582 X 63901233 
ALDH2 rs737280 12 110679359   rs10217898 X 63965932 
ALDH2 rs2238151 12 110696216   rs1932206 X 64132368 
ALDH2 rs968529 12 110718751   rs10126240 X 64176284 
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ALDH2 rs4646778 12 110720166   rs6625400 X 68270595 
ALDH2 rs16941667 12 110728796 ABCB7 rs5937937 X 74185882 
ALDH2 rs16941669 12 110730020   rs1023465 X 78104115 
ABCC4 rs7321486 13 94462890   rs2499043 X 118257334 
ABCC4 rs4148551 13 94471519   rs1541341 X 118893264 
ABCC4 rs4274307 13 94478310   rs6637326 X 126819324 
ABCC4 rs6492763 13 94482701   
   ABCC4 rs17189299 13 94483795   
   ABCC4 rs2182262 13 94489513   
   ABCC4 rs1151471 13 94495881   
   ABCC4 rs1189446 13 94505114   
   ABCC4 rs9561773 13 94505835   
   ABCC4 rs1750190 13 94507073   
   ABCC4 rs12854072 13 94507444   
   ABCC4 rs1189457 13 94517495   
   ABCC4 rs1189465 13 94524074   
   ABCC4 rs1751045 13 94528093   
   ABCC4 rs943290 13 94529059   
   ABCC4 rs1751052 13 94531379   
   ABCC4 rs12864844 13 94533730   
   ABCC4 rs4148530 13 94534997   
   ABCC4 rs1751059 13 94554024   
   ABCC4 rs1729775 13 94555944   
   ABCC4 rs4773840 13 94568426   
   ABCC4 rs1189428 13 94578020   
   ABCC4 rs1729741 13 94582157   
   ABCC4 rs2766482 13 94583722   
   ABCC4 rs4148514 13 94587147   
   ABCC4 rs4148512 13 94589729   
   ABCC4 rs3852616 13 94591375   
   ABCC4 rs9590190 13 94600527   
   ABCC4 rs1729788 13 94606004   
   ABCC4 rs1750996 13 94609600   
   ABCC4 rs1038138 13 94615397   
   ABCC4 rs9561797 13 94618853   
   ABCC4 rs11568663 13 94620762   
   ABCC4 rs1729786 13 94621240   
   ABCC4 rs17189376 13 94622104   
   ABCC4 rs1887162 13 94633634   
   ABCC4 rs3843689 13 94636242   
   ABCC4 rs1557069 13 94637297   
   ABCC4 rs4773843 13 94637496   
   ABCC4 rs1611822 13 94640070   
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ABCC4 rs9524821 13 94641435   
   ABCC4 rs2487566 13 94643273   
   ABCC4 rs4148482 13 94643632   
   ABCC4 rs1678384 13 94646394   
   ABCC4 rs1678386 13 94647177   
   ABCC4 rs1751022 13 94647911   
   ABCC4 rs17268163 13 94651236   
   ABCC4 rs1678388 13 94651781   
   ABCC4 rs1751027 13 94651871   
   ABCC4 rs4773844 13 94653501   
   ABCC4 rs1617844 13 94656136   
   ABCC4 rs2274405 13 94656979   
   ABCC4 rs873706 13 94660388   
   ABCC4 rs1926657 13 94672957   
   ABCC4 rs9561811 13 94681672   
   ABCC4 rs4148455 13 94686278   
   ABCC4 rs9634642 13 94686672   
   ABCC4 rs4148454 13 94687506   
   ABCC4 rs9524858 13 94690357   
   ABCC4 rs4148450 13 94693667   
   ABCC4 rs7320375 13 94709934   
   SLC15A1 rs4646214 13 98182341   
   SLC10A2 rs9586056 13 102511975   
   SLC10A2 rs9557997 13 102514832   
   CYP1A1 rs1048943 15 72800038   
   SLCO3A1 rs9989284 15 90414958   
   ABCC1/6 rs903880 16 16038015   
   SULT1A1 rs9282861 16 28525015   
   ABCC3 rs739921 17 46074589   
   CYP4F11 rs17641483 19 15919371   
   CYP2A6 rs28399468 19 46041572   
   CYP2A6 rs5031016 19 46041614   
   CYP2A13/2F1 rs1645674 19 46334111   
   CYP24A1 rs3787555 20 52216098   
   SLC19A1 rs12483553 21 45750521   
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Appendix4: Primers and Oligos for Spike in Assays. 
Table1: PCR Primers for Spike in Products 
Name F Primer R Primer Amp 
Size 
Chr Start End 
2D6_1 CACTGGCTCCAAGCATGGCAG CCGGATTCCAGCTGGGAAATG 3167 22 40855423 40858590 
2D6_2 CTGGAATCCGGTGTCGAAGTGG CGGCCCTGACACTCCTTCTTG 1807 22 40853626 40855433 
2D6_deletion GCTAATTGGTGCATGCACGAACC GCATGAGCTAAGGCACCCAGAC 3650 22 na na 
2D6_duplication CACCATGGTGTCTTTGCTTTCCTGG AGCACCTCAGGTCAGTCACG 3900 22 na na 
2C19_1 ATGTCTGGAGGAGACCAGGA CGAAGATTAGGAGACTTTGTCCTT 678 10 96511316 96511994 
2C19_2 GCTTCAACCTAGTACAATGAAACCA AATCTCTAATAACAAACACTTCCCTTACTG 752 10 96512205 96512957 
2C19_3 CTGTATTTTGGCCTGGAACG TCTCAGCTTCAAACCCTGCT 594 10 96524835 96525429 
2C19_4 CAGCTAGGCTGTAATTGTTAATTCG AGGGCTTTGGAGTTTAGTGGA 619 10 96530044 96530663 
2C19_5 GGCTTGTCCTTCAATTCACAC TTTTACATTTTCTATGATGCTTACTGG 1160 10 96530755 96531915 
2C19_6 AGATCTGAAGATAGGTGAAGAGTAAGC TCAATGTAACTATTATAGAGTATGGGGAAT 643 10 96602225 96602868 
2C9_1 ATGGGGAGGATGGAAAACAGAGACTT AGTAGAGAAGATAGTAGTCCAGTAAGGTCAGTGATATG 335 10 96691807 96692142 
2C9_2 AGAATCAATGGACATGAACAACCCTCA AGTTAAACATCCTTAGTAAACACAGAACTAGTCAACA 151 10 96698968 96699119 
2C9_3 CTAAAGTCCAGGAAGAGATTGAACGTGTG GGAGAAACAAACTTACCTTGGGAATGAGA 203 10 96730930 96731133 
 
Table1 contains PCR primers to amplify specific regions in CYP2C9, CYP2D6 and CYP2C19. The 2D6_deltion and 2D6_duplication 
primers only produce a PCR product when either the deletion or duplication is present respectively. The PCR product can then be 
spiked into the GoldenGate process in place of genomic DNA. 
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Table2: Custom GoldenGate Oligos Designed for the PCR ProductVariants 
Haplotype Gene Chr Position Variation Oligos 
*7 CYP2D6 22 40853802 T/G ACTTCGTCAGTAACGGACCTCACGCTGCACATCCGGAT 
GAGTCGAGGTCATATCGTCTCACGCTGCACATCCGGAG 
TAGGATCATGAGCAGGAGGTGGACGGTGCTGAACATCCAGTGTCTGCCTATAGTGAGTC 
*5 CYP2C19 10 96602485 A/G ACTTCGTCAGTAACGGACGCCCTCTCCCACACAAATCCA 
GAGTCGAGGTCATATCGTGCCCTCTCCCACACAAATCCG 
TTTCCTGAAAATAACAAACATAGGGCCCCATTCGATGTACCTGAGAGTCTGCCTATAGTGAGTC 
*4 CYP2C9 10 96731044 A/G ACTTCGTCAGTAACGGACGGCTGGTGGGGAGAAGGTCAA 
GAGTCGAGGTCATATCGTGGCTGGTGGGGAGAAGGTCAG 
GTATCTCTGGACCTCGTGCCGAGCGGCAGTTAGTCATGTCGGTCTGCCTATAGTGAGTC 
*14 CYP2D6 22 40854979 A/G ACTTCGTCAGTAACGGACGGCCTTCGCCAACCACTCCA 
GAGTCGAGGTCATATCGTGGCCTTCGCCAACCACTCCG 
TGGGTGATGGGCAGAAGAGACCTTCGGCTCTTATGCCCAGTCTGCCTATAGTGAGTC 
*12 CYP2D6 22 40856614 T/C ACTTCGTCAGTAACGGACCAGCAGGTTGCCCAGCCT 
GAGTCGAGGTCATATCGTCAGCAGGTTGCCCAGCCC 
CTGGTGGGTAGCGTGCAGGGCGGCCTATCAAATCACTGGCGTCTGCCTATAGTGAGTC 
*11 CYP2D6 22 40855856 G/C ACTTCGTCAGTAACGGACCCCTGACCCTCCCTCTGCAG 
GAGTCGAGGTCATATCGTCCCTGACCCTCCCTCTGCAC 
CTTCGGGGACGTGTTCAGGAATTTAGCCCGCATCCTACCTGGTCTGCCTATAGTGAGTC 
*8 CYP2D6 22 40854979 T/G ACTTCGTCAGTAACGGACGGCCTTCGCCAACCACTCCT 
GAGTCGAGGTCATATCGTGGCCTTCGCCAACCACTCCG 
TGGGTGATGGGCAGAAGCCTGTCCGAAGTGTGTGCCAAAGTCTGCCTATAGTGAGTC 
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*3 CYP2D6 22 40854188 T/G ACTTCGTCAGTAACGGACGCTGGGTCCCAGGTCATCCT 
GAGTCGAGGTCATATCGTGCTGGGTCCCAGGTCATCCG 
TCAGTTAGCAGCTCATCCAGTGAATCCCCTACATACTGCGCGGTCTGCCTATAGTGAGTC 
*12 CYP2C19 10 96602661 T/G ACTTCGTCAGTAACGGACCAGCCAGACCATCTGTGCTTCTT 
GAGTCGAGGTCATATCGTCAGCCAGACCATCTGTGCTTCTG 
AGACAGGAATGAAGCACAGCCGCAGACTGGAGGACTCGGTATGTCTGCCTATAGTGAGTC 
*9 CYP2D6 22 40848676 A/G ACTTCGTCAGTAACGGACGCCTTCCTGGCAGAGATGGAGA 
GAGTCGAGGTCATATCGTGCCTTCCTGGCAGAGATGGAGG 
GAGTGGCTGCCACGGTTCTATGAGGGCGAAGGAGCCTAGTCTGCCTATAGTGAGTC 
*17 CYP2C19 10 96511647 T/C ACTTCGTCAGTAACGGACGTCAAATTTGTGTCTTCTGTTCTCAAAGT 
GAGTCGAGGTCATATCGTGTCAAATTTGTGTCTTCTGTTCTCAAAGC 
TCTCTGATGTAAGAGATAATGCGAGCGTACTCGACCGATCCCTGGGTCTGCCTATAGTGAGTC 
*4 CYP2C19 10 96512453 T/C ACTTCGTCAGTAACGGACCACAAGGACCACAAAAGGATCCAT 
GAGTCGAGGTCATATCGTCACAAGGACCACAAAAGGATCCAC 
GAAGCCTTCTCCTCTTGTTAAGTCCCAGCGGAGATAATCCCGTCGTCTGCCTATAGTGAGTC 
*17 CYP2C19 10 96592613 T/C ACTTCGTCAGTAACGGACGGCTCCGGTTTCTGCCAAT 
GAGTCGAGGTCATATCGTGGCTCCGGTTTCTGCCAAC 
ACACGTTCAATCTCTTCCTGACGACTTCGTATAGGCTGGCAGGTCTGCCTATAGTGAGTC 
*8 CYP2C19 10 96525163 A/G ACTTCGTCAGTAACGGACAGAAACGCCGGATCTCCTTCCA 
GAGTCGAGGTCATATCGTAGAAACGCCGGATCTCCTTCCG 
CTCTTTCCATTGCTGAAAACGTTCCCGCAACAGGAGGGATTCGTCTGCCTATAGTGAGTC 
*2 CYP2C19 10 96531606 T/C ACTTCGTCAGTAACGGACGGTTTTTAAGTAATTTGTTATGGGTTCCT 
GAGTCGAGGTCATATCGTGGTTTTTAAGTAATTTGTTATGGGTTCCC 
GGAAATAATCAATGATAGTGGGAACAAGCTCCACAGTCATCCGGTGTCTGCCTATAGTGAGTC 
*3 CYP2C19 10 96530400 A/G ACTTCGTCAGTAACGGACTCAGGATTGTAAGCACCCCCTGA 
GAGTCGAGGTCATATCGTTCAGGATTGTAAGCACCCCCTGG 
TCCAGGTAAGGCCAAGTTTTGGCGCTTTCAAGAGGCGTAACTGTCTGCCTATAGTGAGTC 
*3 CYP2C9 10 96731043 T/G ACTTCGTCAGTAACGGACGCTGGTGGGGAGAAGGTCAAT 
GAGTCGAGGTCATATCGTGCTGGTGGGGAGAAGGTCAAG 
CACCACAGCATCTGTGTAGGGTGCCTCCATACAAACGCTGGGGTCTGCCTATAGTGAGTC 
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*2 CYP2C9 10 96692037 T/C ACTTCGTCAGTAACGGACGGGGGAAGAGGAGCATTGAGGACT 
GAGTCGAGGTCATATCGTGGGGGAAGAGGAGCATTGAGGACC 
CCTTGTGGAGGAGTTGAGAAGTATTTACCCCTGAGCCGGTCAGTCTGCCTATAGTGAGTC 
*9 CYP2C9 10 96698964 T/C ACTTCGTCAGTAACGGACTTGTTCATGTCCATTGATTCTTGGT 
GAGTCGAGGTCATATCGTTTGTTCATGTCCATTGATTCTTGGC 
TTCTTTTACTTTTTCCAAAATATAATGAGGTGACGCATCCCTCCATTGTCTGCCTATAGTGAGTC 
*11 CYP2C9 10 96730971 A/G ACTTCGTCAGTAACGGACGGTCTTGCATGCAGGGGCTCCA 
GAGTCGAGGTCATATCGTGGTCTTGCATGCAGGGGCTCCG 
TTTCTGCCAATCACACGTTGAAGTCAGGTCAATCGTCGCGCGTCTGCCTATAGTGAGTC 
*5 CYP2C9 10 96731048 G/C ACTTCGTCAGTAACGGACGCAGGCTGGTGGGGAGAAGG 
GAGTCGAGGTCATATCGTGCAGGCTGGTGGGGAGAAGC 
CAATGTATCTCTGGACCTCGTAGAAATTACGGTCCTCCACCGACGTCTGCCTATAGTGAGTC 
*8 CYP2C9 10 96692056 T/C ACTTCGTCAGTAACGGACGTTCTCAACTCCTCCACAAGGCAGT 
GAGTCGAGGTCATATCGTGTTCTCAACTCCTCCACAAGGCAGC 
GGCTTCCTCTTGAACACGGGATGCTGGGAGACGTTCACATGTCTGCCTATAGTGAGTC 
*10 CYP2C9 10 96699027 A/G ACTTCGTCAGTAACGGACTTGATTGCTTCCTGATGAAAATGGA 
GAGTCGAGGTCATATCGTTTGATTGCTTCCTGATGAAAATGGG 
AAGGTAAAATGTAAACAAAAGCTTTCGATACCGCAAGGTCATTGGCGTCTGCCTATAGTGAGTC 
*12 CYP2C9 10 96738767 A/G ACTTCGTCAGTAACGGACGGCCATCTGCTCTTCTTCAGACAGA 
GAGTCGAGGTCATATCGTGGCCATCTGCTCTTCTTCAGACAGG 
ATGAAGCACAGCTGGTAGAAGATCGTCCCATCGCAAGCCTGAGGTCTGCCTATAGTGAGTC 
*10 CYP2D6 22 40856638 A/G ACTTCGTCAGTAACGGACGAGTGGCAGGGGGCCTGGTGA 
GAGTCGAGGTCATATCGTGAGTGGCAGGGGGCCTGGTGG 
TAGCGTGCAGCCCAGCTCCCCAGTAGAGTACGGCGGTCGTCTGCCTATAGTGAGTC 
*2a CYP2D6 22 40858326 C/G ACTTCGTCAGTAACGGACGCCTGGACAACTTGGAAGAACCC 
GAGTCGAGGTCATATCGTGCCTGGACAACTTGGAAGAACCG 
AAATTAGCTGGGATTGGGTCGTAAGCTCGACTGTAGACGATGGTCTGCCTATAGTGAGTC 
*2 CYP2D6 22 40852557 G/C ACTTCGTCAGTAACGGACGACAAAGCTCATAGGGGGATGGGG 
GAGTCGAGGTCATATCGTGACAAAGCTCATAGGGGGATGGGC 
CACCAGGAAAGCAAAGACACGGTAGTCGTTCACAGGGCAAGCGTCTGCCTATAGTGAGTC 
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Table2 contains the custom designed GoldenGate oligos to assay variants in the PCR amplicons for CYP2D6, CYP2C9 and 
CYP2C19. The three oligos in order are the two allele specific oligos and the locus specific oligo. For the CYP2D6 deletion (*5) and 
the CYP2D6 duplication (XN), signal is generated if the deletion or duplication is present respectively. 
 
 
 
 
 
 
 
*17 CYP2D6 22 40855716 T/C ACTTCGTCAGTAACGGACCCCGCCTGTGCCCATCAT 
GAGTCGAGGTCATATCGTCCCGCCTGTGCCCATCAC 
CAGATCCTGGGTTTCGGAGAATTACCCGCTCGCTACGGAGTCTGCCTATAGTGAGTC 
*41 CYP2D6 22 40853749 T/C ACTTCGTCAGTAACGGACGCCCCCGCCTGTACCCTTT 
GAGTCGAGGTCATATCGTGCCCCCGCCTGTACCCTTC 
CTGCACTGTTTCCCAGATGACATAGGTGCGGCTGGGCTTACGTCTGCCTATAGTGAGTC 
*4 CYP2D6 22 40854891 A/G ACTTCGTCAGTAACGGACGCGCATCTCCCACCCCCAA 
GAGTCGAGGTCATATCGTGCGCATCTCCCACCCCCAG 
CAACGGTCTCTTGGACAAAGGGGTTAGGTGATACACCGAGCTGTCTGCCTATAGTGAGTC 
*5 CYP2D6    ACTTCGTCAGTAACGGACTTGGTGCATATACAATCCTCTG 
ACTTCGTCAGTAACGGACTTGGTGCATATACAATCCTCTG 
GTGGGGACTTGGAGAACTTTACTCTAAGGCGGGTCTGCTCGAGTCTGCCTATAGTGAGTC 
XN CYP2D6    ACTTCGTCAGTAACGGACCCAGGCACCTAAGGAACTCT 
ACTTCGTCAGTAACGGACCCAGGCACCTAAGGAACTCT 
ATTAGCTGACCACTGCCGTACGATCTCTTGGTCGCAAGTATCCGTCTGCCTATAGTGAGTC 
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Appendix 5: Additional Phenotypes in IKP liver samples 
 
The following two tables contain enzymatic activity and protein expression data for selected ADME enzymes. Each phenotype was 
tested for association with each SNP on the ADME panel. Each phenotype was treated as both a continuous and dichotomous trait. 
Table 1: Enzymatic Activities (Enzyme name and probe drug measured) 
Sample 1A2 
Phenacetin 
2A6 
Coumarin 
2B6   
OH-
Bup 
2C8 
Amodiaquine 
2C9   
LucH 
2C19             
4OH-S-Meph 
2D6        
5OH-PPF-5 
2E1 
Chlorzoxazone 
3A4   
oOH-
ATV 
POR  
cycOx 
16 1353.05 879.33 81.73 1722.83 40.26 179.24 91.39 86.36 193.21 0.12 
18 1211.76 848.69   1448.47 50.73 40.09 67.62 99.50 110.79 0.14 
19 1988.03 1424.92   965.81 88.85 39.27 20.40 196.93 188.81 0.15 
21 1092.03 682.30 49.47 1333.47 14.96 13.53 45.89 362.83 128.35 0.12 
22 1618.64 573.17 74.10 1972.39 64.39 59.03 68.23 186.18 430.54 0.23 
25 1315.44 96.80 47.47 1442.71 27.28 51.26   67.99 543.58 0.18 
28 1312.56 2081.04 218.73 2115.54 27.39 67.63 45.71 75.23 275.30 0.13 
29 2390.98 1050.06 ###### 2578.11 24.65 27.85 56.52 310.74 447.50 0.18 
36 1138.77 1366.55 107.87 1762.00 23.20 69.61 111.89 109.79 216.16 0.16 
38 1517.34 1642.33 118.73 1788.39 22.16 171.63 95.63 175.36 346.74 0.13 
39 2902.26 2244.92 137.73 3117.21 43.80 188.06 86.55 110.06 283.21 0.20 
40 1612.33 1658.45 74.06 1182.79 22.68 45.39 109.87 76.68 460.64 0.15 
41 2354.26 1405.47 163.13 1034.97 31.93 78.93 39.59 196.30 484.30 0.18 
42 2752.73 1356.23 158.33 1503.19 24.77 43.61 78.58 83.29 196.08 0.15 
43 1381.62 1751.77 131.33 1034.86 10.35 52.12 166.95 87.57 310.31 0.15 
44 616.01 1673.39 39.33 1276.35 5.09 11.93 46.13 53.95 116.91 0.13 
47 250.92 300.70 232.46 756.53 22.28 11.95 41.02 79.72 4.99 0.12 
54 813.42 1601.73 194.13 1158.87 20.75 51.25 175.41 113.83 224.24 0.16 
58 3069.27 1333.97 161.80 2666.28 20.00 65.65 143.75 114.70 410.75 0.19 
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59 2101.52 598.04 290.66 1857.96 31.41 90.11 59.85 69.70 292.91 0.14 
61 1589.13 1088.41 122.73 1325.51 38.95 50.78 31.11 69.16 166.30 0.11 
63 1642.44 771.89 65.73 1352.33 40.61 53.40 111.46 93.67 215.09 0.17 
64 701.49 1115.30 105.47 1316.53 24.96 57.08 91.93 54.46 140.01 0.13 
69 1123.23 1746.74 331.47 1251.53 29.72 12.19 63.27 180.85 484.15 0.15 
70 2526.26 639.03 70.80 958.41 17.15 18.07 0.07 93.44 169.57 0.09 
72 664.50 779.09 280.67 659.31 30.20 1.58 128.12 38.52 115.70 0.20 
76 1513.27 1113.03 32.27 1284.42 13.03 9.56   86.55 263.12 0.12 
79 460.51 142.52 93.40 426.68 16.67 1.24 5.28 52.50 53.49 0.11 
80 2193.28 1612.83 102.00 2007.76 42.99 94.26 12.72 149.57 519.43 0.16 
81 2014.08 867.93 143.49 1553.63 64.69 64.39 182.96 183.44 242.50 0.22 
82 2355.42 383.70 119.60 847.90 58.11 60.00 56.18 123.87 262.40 0.16 
85 598.17 1088.23 67.93 694.60 27.36 35.01   65.45 169.85 0.10 
87 1919.99 841.68 76.40 1744.91 59.77 1.58   97.70 188.76 0.14 
96 1435.50 1081.36 154.93 1547.65 39.63 125.68   98.23 341.37 0.13 
98 3383.42 1167.49 74.00 1470.88 29.50 87.65 35.14 71.30 121.97 0.10 
102 3423.65 2360.95 197.00 2018.22 30.36 37.56   138.45 416.03 0.19 
103 1269.51 525.94 193.33 1620.43 43.75 24.37 56.65 121.33 88.00 0.12 
104 981.51 639.50 114.80 1278.64 74.05 55.04 0.00 56.84 251.75 0.12 
106 1446.92 379.13 45.30 973.83 79.38 41.85 63.60 112.23 349.59 0.15 
118 2751.06 1999.95 273.00 2233.55 53.98 79.33 17.48 69.54 192.84 0.14 
120 1338.91 1176.56 29.47 1874.92 10.84 52.27 75.15 64.34 140.60 0.11 
121 4422.95 1967.03 98.27 427.81 43.50 118.58   179.77 263.98 0.16 
122 2352.98 2657.17 285.00 2436.65 73.21 49.19   258.80 358.52 0.17 
123 194.85 298.11 49.53 2137.41 9.10 1.07   82.37 60.50 0.12 
124 4447.98 1245.11 94.87 1031.02 45.08 24.97   155.67 169.83 0.19 
126 1951.60 1545.58 79.67 1896.28 76.71 107.21 171.42 84.38 137.86 0.14 
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127 825.30 374.14 19.60 1281.53 45.67 2.42 109.58 175.80 208.39 0.10 
129 2871.86 1965.47 57.00 2287.46 51.58 93.63 258.03 519.90 248.06 0.17 
132 1986.58 996.79 98.48 1382.51 45.60 1.53 32.48 158.52 63.86 0.12 
133 4536.21 680.98 129.63 1843.28 74.37 66.27 87.06 157.60 267.89 0.18 
134 4022.85 2516.59 139.08 1773.66 91.16 80.22 135.25 301.39 401.26 0.14 
135 1219.50 1501.34 71.01 1048.84 33.26 186.76 344.50 166.44 147.32 0.11 
136 1554.11 2887.51 335.62 2428.11 147.53 115.65 49.76 242.26 286.77 0.22 
137 194.85 310.74 129.81 294.88 16.63 0.76 99.38 127.85 8.88 0.19 
139 1169.32 631.21 79.22 1414.91 16.91 112.55 110.13 578.85 279.17 0.16 
140 2823.66 2010.07 211.06 1680.26 37.55 120.44 157.07 306.10 454.83 0.14 
143 2580.92 2118.18 265.24 1902.42 42.38 180.80 66.84 286.81 249.71 0.21 
144 875.06 1927.53 199.35 1705.11 20.97 106.07 115.05 166.63 87.69 0.10 
145 1919.91 687.56 75.24 912.30 15.26 6.99 123.45 196.91 195.18 0.13 
150 1044.93 1452.49 7.10 850.66 17.43 102.89 114.14 286.90 164.17 0.14 
153 3488.63 639.95 5.95 771.43 20.78 25.74 154.82 358.34 271.30 0.18 
156 852.12 1409.23 51.91 700.57 29.39 48.79 71.42 173.04 177.86 0.14 
157 1852.14 2276.89 5.56 1130.98 59.09 138.24 66.86 269.92 264.06 0.15 
159 579.39 663.85 76.72 710.41 5.31 59.60 106.78 383.07 103.73 0.11 
163 2348.01 940.91 8.95 1023.53 25.00 108.51 4.26 396.29 333.46 0.21 
164 1141.04 881.10 87.40 1323.71 14.95 40.89 148.21 203.77 237.88 0.12 
165 2668.28 2811.31 9.40 1800.82 30.33 60.40 24.97 310.70 287.60 0.12 
166 1993.35 1347.39 147.61 1428.39 20.88 38.05 186.79 404.59 163.62 0.14 
168 1365.05 3624.26 ###### 2632.33 47.72 159.45 38.85 513.34 1397.27 0.26 
169 130.12 450.91 123.74 326.27 8.86 0.85 66.03 79.74 23.10 0.14 
170 1476.75 1615.53 92.70 1316.78 41.71 23.77 187.09 166.56 156.67 0.15 
171 4071.72 1282.09 41.36 960.23 22.76 91.79 125.55 340.79 173.18 0.18 
178 197.32 416.15 31.73 444.79 16.96 0.63 87.03 86.72 24.91 0.14 
251 
 
 
179 2382.71 574.95 38.46 847.68 44.69 10.49 370.69 442.18 271.81 0.20 
181 1079.21 771.58 97.19 927.62 21.94 6.61 47.86 146.25 146.32 0.12 
182 751.48 1130.89 281.97 944.90 37.24 12.41 53.47 165.94 231.08 0.14 
183 1610.88 736.77 23.61 860.85 24.62 17.06 13.58 150.73 122.59 0.11 
186 390.98 1386.59 37.72 616.57 11.91 2.08 72.17 118.47 34.07 0.09 
187 2650.17 1309.10 83.59 861.14 20.17 2.51 433.00 422.57 134.47 0.18 
188 1555.72 1258.90 35.56 1086.43 15.60 22.23 48.72 266.25 153.72 0.14 
189 3383.39 1172.69 193.22 1188.58 12.91 39.49 121.36 242.17 314.78 0.13 
190 1702.59 1649.02 95.15 760.23 11.61 151.32 129.12 227.87 387.69 0.15 
191 707.42 1411.72 616.92 1307.24 22.36 63.70 54.65 330.12 572.73 0.21 
192 1210.21 679.16 56.74 1285.66 16.61 49.54 50.75 122.79 82.49 0.13 
193 1437.13 558.33 137.80 1474.70 12.03 118.79 67.41 402.17 243.61 0.12 
194 1374.47 2609.83 249.61 1402.22 20.35 45.68 170.60 491.22 266.20 0.13 
195 2262.50 653.45 29.30 869.63 16.02 16.46 5.50 192.72 159.32 0.08 
199 1157.70 1060.03 61.56 1082.79 20.19 150.25 61.77 327.23 86.35 0.11 
202 998.26 761.52 79.97 504.92 18.46 1.19 168.84 187.15 57.42 0.20 
205 1082.55 1234.09 89.03 1120.00 19.86 1.79 79.33 140.82 66.18 0.11 
209 1974.15 1780.73 163.78 1098.57 26.66 8.68 88.09 209.55 342.34 0.11 
210 1316.11 638.96 63.62 693.90 11.28 39.36 167.64 142.39 182.56 0.12 
212 1977.90 799.68 59.45 442.80 27.58 58.47 55.19 62.67 115.00 0.10 
213 1487.63 202.09 96.69 603.20 19.28 32.89 108.21 321.85 44.92 0.11 
214 442.32 849.13 83.42 850.87 16.45 2.41 97.68 135.37 85.75 0.08 
218 1957.19 1642.52 152.23 1199.14 22.00 19.36 1.90 258.17 0.31 0.13 
221 716.32 449.63 73.10 1276.12   8.18 94.10 272.50 55.88 0.09 
222 784.77 760.56 39.16 902.47 21.19 48.35 81.31 210.18 127.84 0.10 
223 1842.98 2144.77 160.50 1151.56 14.46 57.58 209.16 441.17 192.35 0.13 
224 2024.86 939.00 125.60 1153.95 18.96 70.48 108.76 484.84 71.00 0.10 
252 
 
 
225 2535.70 2076.01 116.34 776.49 13.22 22.52 56.46 609.20 303.49 0.19 
226 1013.93 1033.19 91.86 911.02   43.11 82.76 115.07 190.19 0.20 
227 1345.76 1381.38 79.32 927.14   81.20 4.69 269.61 122.26 0.11 
229 1810.89 1438.89 54.54 1863.82 36.27 133.09 106.47 376.89 306.60 0.15 
230 1500.86 893.00 58.00 1041.85 15.15 43.78 118.52 94.60 131.09 0.10 
231 1537.38 819.06 143.35 1413.37 22.56 11.49 254.82 329.51 73.71 0.17 
232 1635.49 468.07 62.56 995.64 15.82 11.44 247.44 860.36 33.37 0.21 
234 562.53 166.00 65.43 734.23 16.21 8.88 129.89 190.45 104.60 0.15 
235 965.14 2214.72 56.18 1062.24 31.70 4.10 166.62 248.96 240.28 0.22 
236 2566.76 2062.08 116.62 1226.01 24.09 153.39 168.78 454.32 397.41 0.19 
237 2486.96 1552.35 66.67 1476.83 41.74 9.72 99.26 510.92 176.46 0.19 
238 1183.16 1776.29 101.71 1292.91 22.47 11.34 84.37 137.76 448.01 0.13 
239 2549.68 623.54 52.75 1186.91 26.91 117.86 99.28 86.33 187.69 0.15 
240 2209.16 1880.78 179.93 1680.19 36.94 84.43 101.29 226.16 373.55 0.19 
242 1612.07 857.99 50.46 1150.03 13.04 106.11 54.61 118.49 103.98 0.09 
243 1464.46 827.81 92.70 1470.46 27.20 31.64 125.48 160.21 180.88 0.13 
244 1144.77 1267.00 175.13 1402.79 36.54 273.92 77.02 174.34 430.44 0.15 
246 2073.81 1875.58 124.41 1023.18 21.52 67.16 164.66 291.26 243.94 0.16 
248 1238.43 580.77 69.80 1182.61 26.31 60.15 152.44 211.48 213.24 0.15 
249 918.35 527.05 138.35 1098.77 12.32 44.88   188.89 89.70 0.12 
250 1281.31 635.10 45.66 918.39 7.14 14.20 55.38 147.42 130.12 0.14 
251 973.89 634.62 148.60 1114.44 26.25 65.24 160.53 123.62 131.51 0.15 
254 1250.92 1238.17 18.96 1280.76 17.02 58.37 49.81 160.95 248.49 0.15 
255 671.37 643.46 82.71 970.54 23.07 52.04   177.85 109.81 0.09 
259 1017.83 1778.66 168.76 1512.00 15.99 46.56   222.24 134.61 0.13 
260 677.91 570.12 110.77 603.05 21.57 3.96 121.01 146.47 139.69 0.11 
261 1556.73 1372.83 175.25 1158.13 17.91 56.77 123.36 129.77 329.99 0.14 
253 
 
 
264 718.06 758.45 84.19 722.90 16.93 13.32 61.68 121.71 62.01 0.10 
266 1781.20 786.76 92.24 1674.87 27.14 116.97 68.20 235.69 184.17 0.14 
268 768.80 251.99 43.40 204.23 6.27 2.40 81.49 139.85 171.60 0.13 
269 1706.87 780.73 170.45 1838.28 13.22 238.62   214.48 336.40 0.14 
270 2232.52 1922.35 211.50 1332.24 7.43 64.58 132.10 184.17 354.11 0.13 
271 1460.91 1197.54 88.40 938.57 14.34 53.23 30.43 119.84 63.34 0.09 
272 1323.21 727.22 301.13 1332.69 34.01 91.93 78.68 206.38 240.62 0.14 
273 1447.72 1217.73 179.30 1618.45 17.24 15.05 152.87 130.15 150.07 0.11 
274 878.18 379.12 152.30 831.51 21.91 3.03 1.44 200.53 96.09 0.14 
275 1357.18 690.21 106.98 1230.85 44.07 97.57 177.06 185.70 222.71 0.25 
279 1554.56 1419.84 86.22 552.79 56.59 126.76 187.20 127.47 203.65 0.18 
281 235.45 1629.32 87.41 342.81 25.04 1.97 57.34 69.36 62.71 0.20 
282 458.45 1218.33 86.07 786.77 28.65 25.97 126.99 21.51 94.59 0.20 
283 284.01 604.45 14.70 645.33 26.20 17.37 53.90 45.69 53.30 0.10 
285 961.16 1080.48 39.30 1130.88 18.47 53.37 270.46 103.20 141.16 0.12 
288 1588.94 2834.02 671.54 3212.17 56.98 93.43 43.60 121.91 599.18 0.17 
293 1232.60 2179.83 866.69 2871.21 31.86 34.31 84.38 178.13 841.09 0.25 
295 837.51 1713.79 94.66 1300.11 18.91 26.05 240.65 113.01 83.64 0.15 
296 309.09 474.27 34.65 1055.53 44.74 2.80 90.61 67.43 96.31 0.18 
297 1426.83 926.68 72.66 1548.36 36.65 33.09 56.62 106.66 104.49 0.12 
298 1018.17 654.69 88.53 1307.97 37.80 49.01 77.87 114.55 208.36 0.12 
299 2645.70 768.38 139.99 1235.82 20.78 165.56 116.56 203.15 247.60 0.13 
300 1314.20 1115.09 96.95 1257.18 15.23 85.90 157.41 114.51 145.15 0.12 
 
 
 
254 
 
 
 
Table 2: Protein Expression of Selected ADME Proteins 
Sampl
e 
1A1 1A2 2A6 2B6  2C8  2C9 2C19 2D6  2E1  3A4 3A5  P450 POR UGT1A
1  
UGT1A
3  
16 0.65 23.00 12.21 11.76 22.46 47.73 61.06 39.00 45.26 47.56 1.53 387.37 15.00 0.7 95.98 
18 0.36 52.80 11.17 18.18 78.50 114.83 4.45 39.60 69.26 83.65 0.90 240.96 27.00 3.63 31.88 
19 2.39 76.20 16.45 28.31 63.81 160.84 15.45 12.70 82.24 99.46 1.74 314.41 35.40   76.65 
21 1.83 76.58 17.19 7.86 50.19 168.79 4.27 57.90 205.92 60.86 2.70 314.38 22.50 0.53 162.41 
22 3.81 128.16 12.79 7.24 172.6
3 
66.44 10.41 34.40 149.27 456.95 2.66 328.42 116.50 4.49 23.53 
25 0.95 70.86 1.47 4.05 54.75 169.40 7.56 19.85 33.74 233.92 2.18 314.90 139.00 1.96 15.94 
28 2.69 73.53 49.05 8.40 283.3
1 
158.56 9.19 23.35 25.91 155.68 3.21 445.26 41.00 0.57 236.79 
29 2.69 93.48 26.09 43.85 59.54 83.76 7.78 46.50 169.29 206.65 2.01 543.27 55.50 3.8 42.50 
36 3.30 42.93 44.39 16.05 160.0
0 
151.09 14.69 51.00 28.04 121.12 2.56 377.38 44.33 1.35 18.97 
38 6.19 135.92 40.85 20.92 67.14 251.11 26.78 31.20 49.88 150.84 2.76 397.29 49.00 2.42 47.81 
39 7.89 106.67 42.58 12.65 236.4
0 
91.91 46.08 18.15 71.54 104.99 3.02 440.00 121.50 2.62 69.66 
40 3.60 127.16 43.97 33.27 157.0
4 
138.18 18.34 40.40 24.32 370.65 21.41 480.17 58.00 2.17 31.12 
41 5.40 81.60 27.13 30.58 95.88 47.15 26.32 14.80 66.18 244.56 16.29 548.57 43.40 1.85 104.73 
42 7.78 196.90 45.98 44.26 186.7
0 
80.75 34.50 21.00 44.92 100.26 1.42 370.35 50.00 2.84 201.12 
43 3.73 95.63 45.56 32.39 158.1
1 
50.69 35.71 54.00 70.38 174.34 1.76 345.25 47.00 0.95 40.98 
44 0.81 56.51 57.24 6.89 152.0
9 
21.14 8.93 19.70 36.27 53.31 1.14 201.31 24.75 0.28 66.79 
47 0.15 8.86 7.08 22.94 23.34 91.01 3.40 14.15 119.53 7.22 0.73 183.95 47.67 2.72 55.40 
54 0.47 25.74 22.06 8.00 46.58 103.23 13.23 55.57 94.99 101.29 1.72 339.17 58.50 0.88 153.16 
255 
 
 
58 4.26 135.43 33.32 12.01 394.6
1 
96.89 50.65 37.00 93.92 179.32 2.43 597.39 74.33 1.19 271.33 
59 2.26 143.97 20.55 39.64 119.0
1 
233.93 34.45 18.20 28.87 356.95 0.68 304.15 69.00 0.73 232.18 
61 3.85 95.82 22.01 32.14 59.56 216.55 15.12 26.95 13.14 62.50 16.84 311.34 44.33 0.7 216.56 
63 1.31 183.66 18.77 9.65 114.3
0 
321.38 5.07 78.05 114.61 139.40 1.59 324.52 84.00 1.81 109.89 
64 6.14 50.55 23.93 17.31 71.54 100.82 13.96 14.90 21.95 50.14 1.68 302.07 40.50 0.59 332.13 
69 0.58 46.08 37.38 21.80 121.1
8 
78.37 3.40 38.00 167.15 137.64 2.96 355.68 102.00 1.48 48.46 
70 8.32 117.54 12.25 11.24 49.52 72.11 9.57 0.50 57.76 116.68 2.10 311.07 31.00 1.69 117.04 
72 0.48 20.54 16.55 28.28 50.39 162.51 5.76 34.00 11.19 44.22 1.54 204.84 83.50 2.55 192.73 
76 2.12 67.29 21.14 4.06 42.29 24.31 4.37 12.10 49.11 75.11 1.73 290.02 33.00 0.73 38.09 
79 0.84 21.75 1.57 12.00 32.98 131.28 4.67 7.40 68.24 13.02 1.32 185.34 18.00 1.29 34.11 
80 0.33 157.76 51.26 19.71 226.7
0 
455.36 37.94 13.90 115.57 85.74 1.51 569.69 54.50 0.88 57.91 
81 5.13 119.93 16.82 3.83 332.7
4 
281.66 22.70 42.50 72.04 95.76 3.22 338.95 161.00 0.68 485.36 
82 2.04 93.36 8.38 17.36 75.07 321.98 6.99 21.60 167.14 123.13 3.68 193.87 43.00 0.92 209.89 
85 0.73 21.10 17.14 11.85 140.9
9 
108.38 14.66 36.50 42.26 111.44 22.97 246.67 31.00 0.39 38.09 
87 9.90 77.84 18.92 19.05 73.95 192.38 9.83 32.40 62.83 46.02 3.71 456.57 71.67 1.25 65.04 
96 2.25 85.00 19.94 19.06 98.05 392.66 36.57 50.00 66.89 133.95 1.54 355.19 39.00 0.63 229.90 
98 8.32 126.40 23.53 9.90 43.48 187.88 21.41 48.90 27.27 71.68 2.76 387.64 55.00 0.09 210.52 
102 10.97 194.76 56.03 26.90 251.5
8 
81.37 14.90 24.90 70.25 157.19 4.23 634.05 124.00 1.26 88.08 
103 3.04 77.09 17.18 15.69 74.09 263.98 5.96 49.70 200.30 71.54 2.14 288.21 63.00 0.18 121.55 
104 3.50 73.15 16.35 13.34 93.77 525.63 18.44 4.60 87.10 158.35 2.91 369.44 44.50 0 318.86 
106 0.47 31.71 8.16 3.51 93.16 162.87 6.07 36.70 73.31 227.19 1.76 350.57 95.00 0.29 199.64 
118 13.66 90.13 34.10 26.37 187.7
1 
175.04 21.21 11.40 28.97 72.55 1.38 476.68 56.00 0.58 57.25 
120 2.44 51.72 32.91 1.79 82.80 14.59 21.38 39.10 32.48 61.95 2.30 216.22 33.00 0.13 119.79 
256 
 
 
121 9.73 176.82 46.67 7.32 110.2
8 
141.94 81.23 7.95 86.48 168.81 3.40 500.64 82.67 0.35 58.13 
122 2.74 123.07 58.21 15.49 210.2
9 
220.39 7.10 14.25 98.47 249.44 3.30 611.52 88.50 0.48 53.73 
123 0.21 4.94 8.40 1.69 18.61 4.52 4.24 13.00 81.81 15.57 0.59 158.31 59.50 3.93 12.33 
124 10.32 81.06 16.70 11.74 259.3
8 
190.68 5.81 14.75 94.01 72.00 3.09 527.59 65.00 0.66 51.09 
126 3.88 67.07 25.25 17.77 110.3
1 
156.41 35.60 61.30 37.36 83.58 2.37 454.33 59.50 0.82 59.02 
127 0.37 19.76 5.56 3.18 48.29 83.30 1.01 18.60 56.04 60.65 1.64 254.05 43.50 0.29 103.94 
129 6.61 54.72 45.46 3.17 132.6
6 
71.10 32.64 59.80 79.54 118.94 2.34 482.61 51.50 1.08 76.63 
132 1.77 81.52 19.18 5.10 76.45 119.72 0.10 27.40 29.48 34.65 1.40 268.32 37.00 1.94 95.13 
133 6.20 120.05 15.72 10.24 70.00 284.11 14.14 23.00 58.26 81.06 3.00 495.24 18.00 1.31 118.91 
134 24.36 207.10 63.44 11.12 136.7
7 
287.22 26.27 69.50 109.69 169.02 1.99 548.59 53.00 1.05 837.67 
135 2.63 64.81 39.30 18.36 100.1
7 
82.73 63.51 43.20 46.32 121.18 2.38 334.30 43.33 0.87 116.82 
136 1.07 62.24 76.46 61.30 190.6
3 
330.20 16.12 23.80 44.87 295.09 18.20 555.64 87.00 2.7 28.20 
137 0.26 7.20 3.19 9.66 33.77 28.68 2.09 35.00 18.13 4.38 1.38 539.87 36.50 0.47 91.04 
139 1.49 64.95 30.22 6.01 120.3
9 
298.36 59.98 57.50 316.46 236.18 2.65 292.81 138.50 0.4 175.64 
140 6.25 141.73 56.22 19.56 149.7
4 
438.77 48.20 59.90 68.14 120.47 2.82 488.31 42.50 1.14 313.41 
143 2.72 173.16 66.06 29.89 141.6
5 
176.15 35.36 35.20 51.30 153.40 2.79 507.25 47.50 1.34 28.20 
144 3.32 54.31 23.30 7.60 269.6
7 
72.55 23.20 58.60 47.55 75.12 2.29 211.17 35.33 0.51 93.46 
145 2.30 80.10 11.63 2.50 48.40 70.36 2.65 47.50 63.88 101.37 1.03 262.64 39.00 0.34 87.01 
150 0.86 39.67 34.89 9.45 130.7
4 
35.06 25.82 44.50 65.49 147.70 1.99 320.58 31.00 0.11 37.95 
153 6.36 278.74 14.17 15.93 255.7
8 
173.16 7.84 47.00 170.62 343.18 2.99 491.65 47.67 1.47 136.16 
156 1.42 54.83 30.65 6.00 76.29 203.66 12.20 26.70 20.02 109.22 3.29 390.40 36.00 0.65 52.37 
257 
 
 
157 3.56 118.50 37.04 13.97 143.8
0 
323.11 25.21 17.00 65.87 172.12 2.66 428.42 83.00 4.18 153.08 
159 0.71 31.65 11.36 4.19 54.86 87.57 21.82 32.70 178.06 79.19 1.64 310.10 40.50 0.63 43.51 
163 4.19 187.66 24.08 25.69 65.55 160.43 38.20 0.65 94.61 313.08 2.49 455.60 78.50 1.33 27.14 
164 0.80 104.80 27.75 13.78 88.02 178.92 11.18 30.60 73.37 245.71 2.64 352.94 45.00 0.4 186.11 
165 6.35 190.48 73.39 26.56 172.7
3 
96.36 7.95 4.60 62.56 171.42 3.05 500.86 59.50 2.62 369.00 
166 6.15 148.17 29.87 6.78 97.46 65.12 10.12 18.90 108.51 124.57 18.94 367.88 43.50 0.93 91.85 
168 13.17 56.61 114.37 209.5
3 
492.2
3 
170.92 53.56 25.90 144.56 1034.42 2.03 693.75 96.75 1.86 385.12 
169 0.45 3.62 4.22 6.14 39.51 11.97 0.47 14.30 13.74 1.54 2.17 79.29 22.00 0.41 88.59 
170 3.25 98.38 31.92 9.94 178.3
2 
158.48 8.41 41.40 31.83 160.83 2.02 329.72 54.50 1.27 173.99 
171 5.30 208.16 23.32 2.57 94.46 74.87 18.08 47.90 55.00 232.12 2.41 337.29 73.50 1.23 35.92 
178 0.50 7.74 3.99 3.30 31.60 38.10 6.11 27.00 4.26 5.80 1.74 79.00 36.00 0.3 17.56 
179 3.39 90.53 9.46 7.59 69.37 156.10 3.35 46.20 115.47 128.06 1.12 294.83 76.67 0.86 86.20 
181 3.08 22.98 10.18 9.50 45.55 20.08 3.15 20.60 25.99 69.68 1.35 246.58 11.00 0.03 79.81 
182 0.68 23.56 21.92 20.20 71.46 201.66 3.28 17.65 52.56 203.59 2.68 255.71 36.00 2.96 42.30 
183 9.57 91.14 20.67 12.10 85.77 181.04 7.57 0.40 33.40 78.03 1.14 251.54 22.00 0.79 39.11 
186 0.46 20.55 23.00 3.40 64.40 74.01 2.07 36.15 37.80 36.88 1.26 179.47 20.00 1.32 22.35 
187 5.81 145.30 24.53 20.63 74.91 47.93 2.51 41.10 98.65 78.03 1.68 276.40 64.00 1.36 170.80 
188 4.40 46.95 25.43 5.01 70.28 76.62 8.78 16.45 50.80 82.69 0.96 211.43 36.00 0.33 170.80 
189 2.71 157.05 30.93 19.40 123.6
6 
120.36 13.31 14.90 44.10 207.08 2.92 399.75 46.00 1.23 464.51 
190 9.46 94.41 46.86 21.80 91.36 47.96 53.53 39.10 50.18 204.94 3.36 380.72 50.33 0.86 273.14 
191 0.72 25.67 30.85 74.25 119.0
3 
27.36 9.06 24.10 100.12 394.14 24.44 352.48 81.50 1.57 168.38 
192 2.85 62.47 21.92 7.80 134.6
4 
150.46 13.82 18.75 22.70 76.86 2.37 252.61 48.50 0.37 243.43 
193 6.18 53.51 12.46 7.20 81.46 143.95 22.25 20.65 124.37 272.36 1.84 233.36 50.00   158.03 
194 1.09 32.63 60.37 17.80 387.7
4 
26.81 18.70 43.80 133.94 263.68 1.91 410.35 73.33 0.95 277.75 
258 
 
 
195 1.45 26.87 6.75 4.10 94.46 5.29 8.13 1.20 22.75 58.49 1.71 166.24 15.00 0.21 469.49 
199 2.99 79.18 25.85 7.80 44.03 15.27 44.65 28.00 101.10 88.02 2.71 305.25 49.50 0.55 21.94 
202 1.10 42.53 17.07 7.90 51.87 36.09 8.80 46.80 33.08 39.01 1.75 190.94 97.00 0.57 118.12 
205 2.71 34.49 17.65 5.00 34.60 49.66 2.19 29.60 30.71 38.18 3.33 215.06 27.00 0.17 81.17 
209 3.19 110.88 46.47 23.60 140.4
3 
150.21 22.12 71.90 52.76 256.75 2.26 392.72 111.00 0.58 52.92 
210 3.30 65.94 14.02 15.20 81.86 84.96 6.10 79.05 28.66 260.36 2.19 267.09 64.50 0.23 84.09 
212 9.33 73.07 16.31 2.01 37.95 139.63 20.83 19.55 1.88 94.05 5.88 237.04 31.50 0.24 218.93 
213 0.48 64.98 3.61 5.17 57.13 108.76 6.24 20.60 68.64 52.98 0.59 174.75 22.00 0.19 80.47 
214 0.86 22.93 19.88 6.07 70.96 129.64 3.08 41.20 28.15 78.18 1.14 166.46 42.00 0.05 60.90 
218 7.54 67.04 51.76 17.75 107.9
7 
192.98 2.71 3.54 29.34 92.78 3.02 322.39 84.33   18.65 
221 0.63 24.24 5.75 6.30 65.57 157.40 4.75 9.50 52.78 36.26 1.35 166.89 45.33 0.19 108.02 
222 1.22 37.81 19.07 1.60 63.43 163.58 5.42 8.10 15.40 94.96 1.71 163.89 62.33 0.07 172.54 
223 4.02 125.53 61.10 11.72 90.22 216.03 18.43 62.20 17.87 279.42 2.96 403.40 62.67 0.81 61.62 
224 9.60 155.10 8.58 11.31 72.25 154.56 11.90 16.80 93.15 90.13 1.65 236.11 65.50 2.5 216.76 
225 6.75 84.45 74.01 11.32 118.6
2 
107.74 4.63 11.10 56.23 288.31 1.22 513.97 97.67 2.22 79.02 
226 1.22 37.93 25.34 2.86 61.83 110.56 12.25 59.20 12.06 177.76 2.89 233.18 100.00 0.13 446.57 
227 2.03 57.03 30.33 2.80 120.0
5 
204.99 13.89 0.40 72.26 148.25 12.52 274.84 40.00 0.03 184.14 
229 5.86 113.73 31.75 4.20 133.8
9 
296.11 23.26 43.40 24.68 292.06 1.86 323.02 99.33 1.08 76.84 
230 1.70 39.57 17.50 6.10 65.23 107.94 7.39 36.75 8.20 132.76 2.09 213.55 42.67 0.48 25.37 
231 1.66 37.25 19.63 7.75 92.07 114.21 1.14 66.35 56.16 55.12 15.74 336.36 71.67 0.48 31.90 
232 0.17 38.00 6.67 5.39 55.64 81.12 4.58 82.40 129.57 17.48 0.24 235.19 122.00 0.42 73.94 
234 0.09 13.64 5.33 1.20 50.96 108.70 5.57 30.20 33.29 52.20 0.30 218.04 86.50 1.41 101.47 
235 1.82 31.34 56.42 5.00 88.81 223.55 3.43 69.00 7.05 165.36 5.26 318.85 181.00 0.32 225.97 
236 6.78 134.24 63.01 7.90 106.3
6 
311.42 45.10 82.00 58.73 459.14 1.80 496.68 76.33 0.65 333.47 
237 6.10 94.90 27.05 3.77 154.1 257.76 1.55 27.40 97.85 168.27 8.84 404.47 84.33 0.54 314.82 
259 
 
 
1 
238 1.51 54.20 71.76 12.70 212.4
0 
194.80 3.93 30.60 6.20 271.83 4.95 425.69 77.50 0.25 161.52 
239 3.99 83.08 18.85 4.70 200.4
9 
231.04 7.43 54.40 9.22 100.91 4.78 302.58 74.00 0.95 219.67 
240 1.59 166.15 36.80 9.80 145.4
4 
297.56 20.35 48.00 33.66 129.03 1.25 424.20 83.00 0.93 197.46 
242 13.34 108.22 34.42 6.10 138.0
3 
101.92 22.49 16.20 10.44 88.30 1.80 162.55 37.00 0.86 21.81 
243 3.06 47.91 21.28 10.30 188.5
5 
233.34 3.78 61.80 34.37 63.08 4.62 291.64 71.50   68.24 
244 3.20 28.50 17.29 8.41 103.8
6 
161.95 50.19 34.00 89.00 68.36 1.46 376.27 71.00 4.63 24.63 
246 7.37 64.60 19.58 7.33 74.45 90.98 3.31 55.20 84.30 53.87 4.46 365.68 81.50 1.62 233.40 
248 2.00 44.69 27.14 6.06 33.64 152.93 4.00 43.10 54.13 85.56 1.19 180.29 77.50 1.36 17.36 
249 0.85 31.19 14.07 8.09 51.65 102.45 5.73 24.80 84.60 44.52 2.02 222.95 49.50 1.79 21.00 
250 9.48 70.72 27.93 18.93 60.86 44.92 0.31 14.05 19.73 109.99 1.56 252.74 31.00 1.55 79.55 
251 2.99 36.03 22.83 12.53 51.88 192.02 12.11 72.80 7.44 81.22 2.63 354.06 40.50 0.88 178.48 
254 4.06 74.56 67.44 8.85 91.26 223.98 26.54 19.00 36.05 332.46 1.30 284.39 68.75 1.08 166.37 
255 1.01 53.87 27.10 9.70 61.75 132.49 13.96 82.40 41.74 133.79 2.85 259.58 52.00 2.15 23.82 
259 1.42 74.99 88.60 7.91 56.32 26.68 1.14 14.45 45.41 93.08 1.38 309.58 78.00 0.86 65.42 
260 0.76 15.78 17.35 6.95 107.7
0 
44.45 1.50 23.90 25.42 117.51 0.89 224.08 46.50 0.3 62.19 
261 1.94 52.41 29.00 13.87 77.79 202.82 13.67 39.80 28.88 170.53 2.02 287.13 38.50 1.12 114.68 
264 0.76 24.34 18.68 25.79 67.43 221.72 2.47 19.70 55.28 64.26 1.26 153.13 22.50 0.26 1.58 
266 8.26 78.84 26.00 9.18 94.56 173.61 14.34 17.00 144.81 169.89 1.47 341.64 22.50 1.32 41.91 
268 0.42 32.12 14.62 6.26 29.09 159.04 0.45 12.60 59.89 132.37 1.19 210.38 27.00 0.87 74.72 
269 2.35 61.03 20.41 13.40 123.9
0 
165.13 24.12 16.80 89.58 119.07 1.49 381.76 34.33 0.1 346.33 
270 6.01 61.67 74.93 6.30 151.2
1 
149.06 8.20 33.20 80.94 197.62 2.32 352.41 23.00 0.95 126.12 
271 2.72 56.31 28.36 5.55 113.8
0 
220.67 6.81 12.70 53.71 62.40 1.48 221.41 26.50 2.14 22.61 
260 
 
 
272 1.56 42.35 25.11 20.66 60.75 237.24 12.42 19.90 216.50 202.38 1.61 269.15 44.00 1.79 15.81 
273 2.80 59.40 32.51 17.95 181.5
4 
91.34 4.50 23.20 96.70 52.94 2.90 261.64 29.50 1.53 22.14 
274 0.24 24.52 9.66 8.30 53.40 123.58 3.32 0.70 210.23 74.81 1.33 169.58 39.00 0.6 49.81 
275 2.34 50.55 26.97 13.89 57.87 164.17 6.99 66.80 51.22 161.48 1.35 253.60 69.00 4.33 48.23 
279 1.03 92.76 44.77 6.22 67.68 171.75 32.50 45.15 47.10 241.26 1.78 365.43 65.75 1.77 307.58 
281 0.40 3.73 20.37 6.33 7.52 150.88 1.94 19.00 6.75 21.19 2.54 343.80 14.50 0.2 44.28 
282 0.47 9.80 20.00 1.84 37.38 59.20 4.41 34.50 2.92 49.05 2.45 146.70 20.50 0.4 125.05 
283 0.40 3.65 8.47 1.50 44.82 210.55 3.30 23.20 9.74 18.69 2.91 167.72 19.50 0.38 3.84 
285 1.95 46.41 40.43 9.08 53.45 119.09 12.71 74.50 34.65 88.55 1.46 276.73 19.00 1.56 31.63 
288 3.11 89.90 40.86 63.30 452.3
8 
514.96 25.70 20.40 73.70 1425.86 2.75 670.88 46.00 2 737.33 
293 3.53 57.50 35.42 45.93 232.7
5 
774.53 6.52 52.80 72.20 760.60 2.83 521.90 71.40 1.26 124.50 
295 0.43 12.31 32.18 23.25 93.39 560.10 7.43 120.20 44.75 44.30 1.15 289.06 43.33 0.46 9.88 
296 0.35 8.97 12.01 3.17 9.18 231.43 5.30 27.93 8.26 18.57 2.92 169.34 20.00 0.58 64.72 
297 4.66 33.85 5.56 4.47 103.3
3 
414.61 5.89 22.60 70.05 59.90 1.32 309.21 30.00 0.19 14.63 
298 3.79 23.09 42.95 6.90 31.10 365.27 13.86 31.70 49.02 116.28 42.01 341.50 46.50 0.26 35.58 
299 7.05 70.01 20.42 12.70 43.15 82.80 33.92 26.50 99.64 123.30 2.50 440.76 62.00 0.84 28.47 
300 5.43 32.53 42.84 6.70 111.7
4 
75.92 34.21 48.60 57.90 63.70 1.47 328.23 32.50 0.32 44.43 
 
